N-Acylethanolamine: Difference between revisions
→Mood: Cite |
m Typo fixing, replaced: efciently → efficiently, of 17th century → of the 17th century |
||
(47 intermediate revisions by 23 users not shown) | |||
Line 1: | Line 1: | ||
{{Short description|Class of chemical compounds}} |
{{Short description|Class of chemical compounds}} |
||
{{DISPLAYTITLE:''N''-Acylethanolamine}} |
{{DISPLAYTITLE:''N''-Acylethanolamine}} |
||
{{Use dmy dates|date=January 2024}} |
|||
[[File:N-acylethanolamine.png|thumb|right|General chemical structure of ''N''-acylethanolamines]] |
[[File:N-acylethanolamine.png|thumb|right|General chemical structure of ''N''-acylethanolamines]] |
||
An '''''N''-acylethanolamine''' ('''NAE''') is a type of [[fatty acid amide]] where one of several types of [[acyl group]]s is linked to the nitrogen atom of [[ethanolamine]], and highly [[Metabolism|metabolic]] formed by intake of [[essential fatty acid]]s through [[Diet (nutrition)|diet]] by 20:4, n-6 and 22:6, n-3 fatty acids,<ref name=":25" /><ref name=":26">{{cite journal | vauthors = Galasso I, Russo R, Mapelli S, Ponzoni E, Brambilla IM, Battelli G, Reggiani R | title = Variability in Seed Traits in a Collection of Cannabis sativa L. Genotypes | journal = Frontiers in Plant Science | volume = 7 | pages = 688 | date = |
An '''''N''-acylethanolamine''' ('''NAE''') is a type of [[fatty acid amide]] where one of several types of [[acyl group]]s is linked to the nitrogen atom of [[ethanolamine]], and highly [[Metabolism|metabolic]] formed by intake of [[essential fatty acid]]s through [[Diet (nutrition)|diet]] by 20:4, n-6 and 22:6, n-3 fatty acids,<ref name=":25" /><ref name=":26">{{cite journal | vauthors = Galasso I, Russo R, Mapelli S, Ponzoni E, Brambilla IM, Battelli G, Reggiani R | title = Variability in Seed Traits in a Collection of Cannabis sativa L. Genotypes | journal = Frontiers in Plant Science | volume = 7 | pages = 688 | date = 20 May 2016 | pmid = 27242881 | pmc = 4873519 | doi = 10.3389/fpls.2016.00688 | doi-access = free }}</ref> and when the body is physically and psychologically active,.<ref name=":27">{{cite journal | vauthors = Charytoniuk T, Zywno H, Berk K, Bzdega W, Kolakowski A, Chabowski A, Konstantynowicz-Nowicka K | title = The Endocannabinoid System and Physical Activity-A Robust Duo in the Novel Therapeutic Approach against Metabolic Disorders | journal = International Journal of Molecular Sciences | volume = 23 | issue = 6 | pages = 3083 | date = March 2022 | pmid = 35328503 | pmc = 8948925 | doi = 10.3390/ijms23063083 | doi-access = free }}</ref><ref name=":1" /> The [[Endocannabinoid system|endocannabinoid signaling]] system (ECS) is the major pathway by which NAEs exerts its physiological effects in animal cells with similarities in plants, and the metabolism of NAEs is an integral part of the ECS,<ref>{{cite book | vauthors = Blancaflor EB, Chapman KD | chapter = Similarities Between Endocannabinoid Signaling in Animal Systems and N-Acylethanolamine Metabolism in Plants |date=2006 | title = Communication in Plants: Neuronal Aspects of Plant Life |pages=205–219 | veditors = Baluška F, Mancuso S, Volkmann D |place=Berlin, Heidelberg |publisher=Springer |language=en |doi=10.1007/978-3-540-28516-8_14 |isbn=978-3-540-28516-8 }}</ref> a very ancient signaling system, being clearly present from the [[Divergent evolution|divergence]] of the [[Protostome|protostomian]]/[[Deuterostome|deuterostomian]],<ref>{{Cite journal |last1=Fasano |first1=Silvia |last2=Meccariello |first2=Rosaria |last3=Cobellis |first3=Gilda |last4=Chianese |first4=Rosanna |last5=Cacciola |first5=Giovanna |last6=Chioccarelli |first6=Teresa |last7=Pierantoni |first7=Riccardo |date=April 2009 |title=The Endocannabinoid System: An Ancient Signaling Involved in the Control of Male Fertility |journal=Annals of the New York Academy of Sciences |language=en |volume=1163 |issue=1 |pages=112–124 |doi=10.1111/j.1749-6632.2009.04437.x|pmid=19456333 |bibcode=2009NYASA1163..112F |s2cid=6304998 |doi-access=free }}</ref><ref>{{Citation |last1=Elphick |first1=M. R. |title=The Phylogenetic Distribution and Evolutionary Origins of Endocannabinoid Signalling |date=2005 |work=Cannabinoids |pages=283–297 |editor-last=Pertwee |editor-first=Roger G. |series=Handbook of Experimental Pharmacology |place=Berlin, Heidelberg |publisher=Springer |language=en |doi=10.1007/3-540-26573-2_9 |isbn=978-3-540-26573-3 |last2=Egertová |first2=M.|issue=168 |pmid=16596778 |doi-access=free }}</ref> and even further back in time, to the very beginning of bacteria, the oldest organisms on Earth known to express [[phosphatidylethanolamine]], the precursor to endocannabinoids, in their [[cytoplasm]]ic [[Cell membrane|membranes]]. Fatty acid metabolites with affinity for [[Cannabinoid receptor|CB receptors]] are produced by [[cyanobacteria]], which [[Divergent evolution|diverged]] from [[eukaryote]]s at least 2000 Million years ago (MYA), by [[brown algae]] which diverged about 1500 MYA, by [[sponge]]s, which diverged from [[eumetazoa]]ns about 930 MYA, and a lineages that predate the evolution of CB receptors, as [[Cannabinoid receptor type 1|CB1]] – [[Cannabinoid receptor type 2|CB2]] duplication event may have occurred prior to the [[lophotrochozoa]]n-deuterostome divergence 590 MYA. [[Fatty acid amide hydrolase]] (FAAH) evolved relatively recently, either after the evolution of [[Evolution of fish|fish]] 400 MYA, or after the appearance of [[Evolution of mammals|mammals]] 300 MYA, but after the appearance of [[vertebrate]]s. Linking FAAH, [[TRPV1|vanilloid receptors]] (VR1) and [[anandamide]] (NAE 20:4) implies a coupling among the remaining ‘‘older’’ parts of the endocannabinoid system, [[Diacylglycerol lipase|monoglyceride lipase]] (MGL), CB receptors, that evolved prior to the [[Animal|metazoan]]–[[bilateria]]n divergence (ie, between extant [[Hydra (genus)|Hydra]] and [[leech]]), but were secondarily lost in the [[Ecdysozoa]], and [[2-Arachidonoylglycerol]] (2-AG).<ref>{{Cite journal |last=McPartland |first=John M |date=1 April 2004 |title=Phylogenomic and chemotaxonomic analysis of the endocannabinoid system |url=https://www.sciencedirect.com/science/article/pii/S0165017304000037 |journal=Brain Research Reviews |language=en |volume=45 |issue=1 |pages=18–29 |doi=10.1016/j.brainresrev.2003.11.005 |pmid=15063097 |s2cid=25038370 |issn=0165-0173}}</ref> |
||
These [[amide]]s conceptually can be formed from a [[fatty acid]] and ethanolamine with the release of a molecule of |
These [[amide]]s conceptually can be formed from a [[fatty acid]] and ethanolamine with the release of a molecule of water, but the known biological synthesis uses a [[N-acyl phosphatidylethanolamine-specific phospholipase D|specific phospholipase D]] to cleave the [[phospholipid]] unit from [[N-acylphosphatidylethanolamines|''N''-acylphosphatidylethanolamines]].<ref>{{cite journal | vauthors = Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N | title = Molecular characterization of a phospholipase D generating anandamide and its congeners | journal = The Journal of Biological Chemistry | volume = 279 | issue = 7 | pages = 5298–5305 | date = February 2004 | pmid = 14634025 | doi = 10.1074/jbc.M306642200 | doi-access = free }}</ref> Another route relies on the [[transesterification]] of acyl groups from [[phosphatidylcholine]] by an [[N-acyltransferase|''N''-acyltransferase]] (NAT) activity.{{citation needed|date=September 2012}} The suffixes ''-[[amine]]'' and ''-[[amide]]'' in these names each refer to the single nitrogen atom of ethanolamine that links the compound together: it is termed "amine" in ethanolamine because it is considered as a free terminal nitrogen in that subunit, while it is termed "amide" when it is considered in association with the adjacent [[carbonyl group]] of the acyl subunit. Names for these compounds may be encountered with either "amide" or "amine" varying by author.<ref>For example, note synonyms in PubChem for [https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5283454 oleoylethanolamine].</ref> |
||
''N''-acylethanolamines (NAEs) are broken down, or [[Hydrolysis|hydrolysed]], by [[fatty acid amide hydrolase]] (FAAH) to [[ethanolamine]] (MEA) and their corresponding [[fatty acid]], [[arachidonic acid]]. FAAH is activated during [[Stress (biology)|stress]] exposure circumstances, which also raises the [[Neural circuit|neuronal]] [[Membrane potential|excitability]] in the [[amygdala]], a critical brain area that mediates [[anxiety]], and the [[anxiolytic]] outcome of [[Cannabinoid receptor type 1|CB1 receptor]] activation.<ref name=":40">{{Cite journal |last1=Silva |first1=Hugo-Henrique |last2=Tavares |first2=Valéria |last3=Silva |first3=Maria-Raquel G. |last4=Neto |first4=Beatriz Vieira |last5=Cerqueira |first5=Fátima |last6=Medeiros |first6=Rui |date= |
''N''-acylethanolamines (NAEs) are broken down, or [[Hydrolysis|hydrolysed]], by [[fatty acid amide hydrolase]] (FAAH) to [[ethanolamine]] (MEA) and their corresponding [[fatty acid]], [[arachidonic acid]]. FAAH is activated during [[Stress (biology)|stress]] exposure circumstances, which also raises the [[Neural circuit|neuronal]] [[Membrane potential|excitability]] in the [[amygdala]], a critical brain area that mediates [[anxiety]], and the [[anxiolytic]] outcome of [[Cannabinoid receptor type 1|CB1 receptor]] activation.<ref name=":40">{{Cite journal |last1=Silva |first1=Hugo-Henrique |last2=Tavares |first2=Valéria |last3=Silva |first3=Maria-Raquel G. |last4=Neto |first4=Beatriz Vieira |last5=Cerqueira |first5=Fátima |last6=Medeiros |first6=Rui |date=26 March 2023 |title=Association of FAAH rs324420 (C385A) Polymorphism with High-Level Performance in Volleyball Players |journal=Genes |language=en |volume=14 |issue=6 |pages=1164 |doi=10.3390/genes14061164 |pmid=37372343 |pmc=10298391 |issn=2073-4425 |doi-access=free }}{{Creative Commons text attribution notice|cc=by4|from this source=yes}}</ref> Inhibition of FAAH has been shown to increase the levels of NAEs ''[[in vivo]]'' and to produce desirable phenotypes, that produce [[analgesic]], [[anxiolytic]], [[Neuroprotection|neuroprotective]], and [[anti-inflammatory]] effects,<ref>{{Cite journal |last=Hayes |first=Alexander C. |date=2013 |title=Identification of N-acylethanolamines in Dictyostelium discoideum and confirmation of their hydrolysis by fatty acid amide hydrolase |journal=J. Lipid Res. |volume=54 |issue=2 |pages=457–466|doi=10.1194/jlr.M032219 |doi-access=free |pmid=23187822 |pmc=3588872 }}</ref> like in [[High-performance sport|high-level performance athletes]] (i.e., elite athletes) that present an extraordinary interindividual variability of [[Physical fitness|physical]], but also [[Brain training|mental traits]], that greatly influence their sports accomplishments and their career longevity, by an FAAH [[Gene polymorphism|genetic polymorphism]] that produce the [[SNP genotyping|SNP]] rs324420 (C385A [[allele]]), associated with a higher sensitivity of FAAH to [[Proteolysis|proteolytic]] degradation and a shorter [[half-life]], as compared to the C variant, as the A variant displays normal [[Catalysis|catalytic]] properties, but an enhanced sensitivity to degradation, leading to increased NAE and [[anandamide]] (AEA) signaling.<ref name=":40" /> Activation of the [[cannabinoid receptor]] [[Cannabinoid receptor 1|CB1]] or [[Cannabinoid receptor type 2|CB2]] in different [[Tissue (biology)|tissues]], including skin, inhibit FAAH, and thereby increases [[endocannabinoid]] levels.<ref name=":39" /> |
||
== Examples == |
== Examples == |
||
Examples of ''N''-acylethanolamines include:<ref name="pmid14634025">The list and references provided are based on background discussion in {{cite journal | vauthors = Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N | title = Molecular characterization of a phospholipase D generating anandamide and its congeners | journal = The Journal of Biological Chemistry | volume = 279 | issue = 7 | pages = 5298–305 | date = February 2004 | pmid = 14634025 | doi = 10.1074/jbc.M306642200 | doi-access = free }}</ref> |
Examples of ''N''-acylethanolamines include:<ref name="pmid14634025">The list and references provided are based on background discussion in {{cite journal | vauthors = Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N | title = Molecular characterization of a phospholipase D generating anandamide and its congeners | journal = The Journal of Biological Chemistry | volume = 279 | issue = 7 | pages = 5298–305 | date = February 2004 | pmid = 14634025 | doi = 10.1074/jbc.M306642200 | doi-access = free }}</ref> |
||
* [[Anandamide]] (''N''-arachidonoylethanolamine; NAE) or arachidonoylethanolamine (AEA: [[Carbon|C]]<sub>22</sub>[[Hydrogen|H]]<sub>37</sub>[[Biological functions of nitric oxide|NO]]<sub>2</sub>; 20:[[Double bond|4]], [[Omega-6 fatty acid|ω-6]]) is the [[amide]] of [[arachidonic acid]] (C<sub>20</sub>H<sub>32</sub>[[Oxygen|O]]<sub>2</sub>; 20:4, ω-6) and [[ethanolamine]] (MEA: C<sub>2</sub>H<sub>7</sub>NO).<ref>{{Cite web |last=PubChem |title=Anandamide |url=https://pubchem.ncbi.nlm.nih.gov/compound/5281969 |access-date=2023-06-29 |website=pubchem.ncbi.nlm.nih.gov |language=en}}</ref> It is the ligand of both [[cannabinoid receptor]]s and [[TRPV1|vanilloid receptor]] that attenuates [[pain]] sensation.<ref name="Isolation and structure of a brain">{{cite journal | vauthors = Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R | display-authors = 6 | title = Isolation and structure of a brain constituent that binds to the cannabinoid receptor | journal = Science | volume = 258 | issue = 5090 | pages = 1946–9 | date = December 1992 | pmid = 1470919 | doi = 10.1126/science.1470919 | bibcode = 1992Sci...258.1946D }}</ref><ref>{{cite journal | vauthors = Di Marzo V | title = 'Endocannabinoids' and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance | journal = Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism | volume = 1392 | issue = 2–3 | pages = 153–75 | date = June 1998 | pmid = 9630590 | doi = 10.1016/s0005-2760(98)00042-3 }}</ref><ref>{{cite journal | vauthors = Di Marzo V, De Petrocellis L, Fezza F, Ligresti A, Bisogno T | title = Anandamide receptors | journal = Prostaglandins, Leukotrienes, and Essential Fatty Acids | volume = 66 | issue = 2–3 | pages = 377–91 | year = 2002 | pmid = 12052051 | doi = 10.1054/plef.2001.0349 }}</ref><ref name="Calignano">{{cite journal | vauthors = Calignano A, La Rana G, Giuffrida A, Piomelli D | title = Control of pain initiation by endogenous cannabinoids | journal = Nature | volume = 394 | issue = 6690 | pages = 277–81 | date = July 1998 | pmid = 9685157 | doi = 10.1038/28393 | s2cid = 4418082 | bibcode = 1998Natur.394..277C | url = http://www.escholarship.org/uc/item/8kz9z53h }}</ref> Where binding to cannabinoid receptors is coupled to [[nitric oxide]] (NO) release in the [[central nervous system]] of [[invertebrate]]s and in peripheral [[White blood cell|immune cells]] of both invertebrates and humans.<ref name=":24">{{cite journal | vauthors = Maccarrone M, van der Stelt M, Rossi A, Veldink GA, Vliegenthart JF, Agrò AF | title = Anandamide hydrolysis by human cells in culture and brain | language = English | journal = The Journal of Biological Chemistry | volume = 273 | issue = 48 | pages = 32332–32339 | date = November 1998 | pmid = 9822713 | doi = 10.1074/jbc.273.48.32332 | doi-access = free }}</ref> |
* [[Anandamide]] (''N''-arachidonoylethanolamine; NAE) or arachidonoylethanolamine (AEA: [[Carbon|C]]<sub>22</sub>[[Hydrogen|H]]<sub>37</sub>[[Biological functions of nitric oxide|NO]]<sub>2</sub>; 20:[[Double bond|4]], [[Omega-6 fatty acid|ω-6]]) is the [[amide]] of [[arachidonic acid]] (C<sub>20</sub>H<sub>32</sub>[[Oxygen|O]]<sub>2</sub>; 20:4, ω-6) and [[ethanolamine]] (MEA: C<sub>2</sub>H<sub>7</sub>NO).<ref>{{Cite web |last=PubChem |title=Anandamide |url=https://pubchem.ncbi.nlm.nih.gov/compound/5281969 |access-date=2023-06-29 |website=pubchem.ncbi.nlm.nih.gov |language=en}}</ref> It is the ligand of both [[cannabinoid receptor]]s and [[TRPV1|vanilloid receptor]] that attenuates [[pain]] sensation.<ref name="Isolation and structure of a brain">{{cite journal | vauthors = Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R | display-authors = 6 | title = Isolation and structure of a brain constituent that binds to the cannabinoid receptor | journal = Science | volume = 258 | issue = 5090 | pages = 1946–9 | date = December 1992 | pmid = 1470919 | doi = 10.1126/science.1470919 | bibcode = 1992Sci...258.1946D }}</ref><ref>{{cite journal | vauthors = Di Marzo V | title = 'Endocannabinoids' and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance | journal = Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism | volume = 1392 | issue = 2–3 | pages = 153–75 | date = June 1998 | pmid = 9630590 | doi = 10.1016/s0005-2760(98)00042-3 }}</ref><ref>{{cite journal | vauthors = Di Marzo V, De Petrocellis L, Fezza F, Ligresti A, Bisogno T | title = Anandamide receptors | journal = Prostaglandins, Leukotrienes, and Essential Fatty Acids | volume = 66 | issue = 2–3 | pages = 377–91 | year = 2002 | pmid = 12052051 | doi = 10.1054/plef.2001.0349 }}</ref><ref name="Calignano">{{cite journal | vauthors = Calignano A, La Rana G, Giuffrida A, Piomelli D | title = Control of pain initiation by endogenous cannabinoids | journal = Nature | volume = 394 | issue = 6690 | pages = 277–81 | date = July 1998 | pmid = 9685157 | doi = 10.1038/28393 | s2cid = 4418082 | bibcode = 1998Natur.394..277C | url = http://www.escholarship.org/uc/item/8kz9z53h }}</ref> Where binding to cannabinoid receptors is coupled to [[nitric oxide]] (NO) release in the [[central nervous system]] of [[invertebrate]]s and in peripheral [[White blood cell|immune cells]] of both invertebrates and humans.<ref name=":24">{{cite journal | vauthors = Maccarrone M, van der Stelt M, Rossi A, Veldink GA, Vliegenthart JF, Agrò AF | title = Anandamide hydrolysis by human cells in culture and brain | language = English | journal = The Journal of Biological Chemistry | volume = 273 | issue = 48 | pages = 32332–32339 | date = November 1998 | pmid = 9822713 | doi = 10.1074/jbc.273.48.32332 | doi-access = free | hdl = 1887/50863 | hdl-access = free }}</ref> |
||
* ''N''-[[Palmitoylethanolamide|Palmitoylethanolamine]] (PEA: C<sub>18</sub>H<sub>37</sub>NO<sub>2</sub>; 16:0) is the amide of [[palmitic acid]] (C<sub>16</sub>H<sub>32</sub>O<sub>2</sub>; 16:0) and ethanolamine. It is a ligand at [[Cannabinoid receptor type 2|CB2]] receptors,<ref name=":2">{{cite journal | vauthors = Walter L, Franklin A, Witting A, Moller T, Stella N | title = Astrocytes in culture produce anandamide and other acylethanolamides | journal = The Journal of Biological Chemistry | volume = 277 | issue = 23 | pages = 20869–76 | date = June 2002 | pmid = 11916961 | doi = 10.1074/jbc.M110813200 | doi-access = free }}</ref><ref name=":4">{{cite journal | vauthors = Kamlekar RK, Swamy MJ | title = Molecular packing and intermolecular interactions in two structural polymorphs of N-palmitoylethanolamine, a type 2 cannabinoid receptor agonist | journal = Journal of Lipid Research | volume = 47 | issue = 7 | pages = 1424–33 | date = July 2006 | pmid = 16609146 | doi = 10.1194/jlr.M600043-JLR200 | doi-access = free }}</ref> and [[Peroxisome proliferator-activated receptor alpha|PPAR-α]].<ref>{{Cite journal |last1=Verme |first1=Jesse Lo |last2=Fu |first2=Jin |last3=Astarita |first3=Giuseppe |last4=Rana |first4=Giovanna La |last5=Russo |first5=Roberto |last6=Calignano |first6=Antonio |last7=Piomelli |first7=Daniele |date=2005 |
* ''N''-[[Palmitoylethanolamide|Palmitoylethanolamine]] (PEA: C<sub>18</sub>H<sub>37</sub>NO<sub>2</sub>; 16:0) is the amide of [[palmitic acid]] (C<sub>16</sub>H<sub>32</sub>O<sub>2</sub>; 16:0) and ethanolamine. It is a ligand at [[Cannabinoid receptor type 2|CB2]] receptors,<ref name=":2">{{cite journal | vauthors = Walter L, Franklin A, Witting A, Moller T, Stella N | title = Astrocytes in culture produce anandamide and other acylethanolamides | journal = The Journal of Biological Chemistry | volume = 277 | issue = 23 | pages = 20869–76 | date = June 2002 | pmid = 11916961 | doi = 10.1074/jbc.M110813200 | doi-access = free }}</ref><ref name=":4">{{cite journal | vauthors = Kamlekar RK, Swamy MJ | title = Molecular packing and intermolecular interactions in two structural polymorphs of N-palmitoylethanolamine, a type 2 cannabinoid receptor agonist | journal = Journal of Lipid Research | volume = 47 | issue = 7 | pages = 1424–33 | date = July 2006 | pmid = 16609146 | doi = 10.1194/jlr.M600043-JLR200 | doi-access = free }}</ref> and [[Peroxisome proliferator-activated receptor alpha|PPAR-α]].<ref>{{Cite journal |last1=Verme |first1=Jesse Lo |last2=Fu |first2=Jin |last3=Astarita |first3=Giuseppe |last4=Rana |first4=Giovanna La |last5=Russo |first5=Roberto |last6=Calignano |first6=Antonio |last7=Piomelli |first7=Daniele |date=1 January 2005 |title=The Nuclear Receptor Peroxisome Proliferator-Activated Receptor-α Mediates the Anti-Inflammatory Actions of Palmitoylethanolamide |url=https://molpharm.aspetjournals.org/content/67/1/15 |journal=Molecular Pharmacology |language=en |volume=67 |issue=1 |pages=15–19 |doi=10.1124/mol.104.006353 |issn=0026-895X |pmid=15465922|s2cid=12671741 }}</ref> It has [[anti-inflammatory]] activity and also attenuates [[pain]] sensation in [[mammal]]s, whose levels are increased following [[Neuroinflammation|neuroinflammatory]] or [[Neuropathic pain|neuropathic]] conditions in both animals and humans, possibly to exert a local anti-inflammatory and [[analgesic]] action.<ref name="Calignano"/><ref>{{cite journal | vauthors = Lambert DM, Vandevoorde S, Jonsson KO, Fowler CJ | title = The palmitoylethanolamide family: a new class of anti-inflammatory agents? | journal = Current Medicinal Chemistry | volume = 9 | issue = 6 | pages = 663–74 | date = March 2002 | pmid = 11945130 | doi = 10.2174/0929867023370707 }}</ref><ref>{{cite journal | vauthors = Rahman IA, Tsuboi K, Uyama T, Ueda N | title = New players in the fatty acyl ethanolamide metabolism | journal = Pharmacological Research | volume = 86 | pages = 1–10 | date = August 2014 | pmid = 24747663 | doi = 10.1016/j.phrs.2014.04.001 | series = Lipid amide signaling: regulation, physiological roles and pathological implications }}</ref><ref>{{Cite journal |last1=Darmani |first1=Nissar A. |last2=Izzo |first2=Angelo A. |last3=Degenhardt |first3=Brian |last4=Valenti |first4=Marta |last5=Scaglione |first5=Giuseppe |last6=Capasso |first6=Raffaele |last7=Sorrentini |first7=Italo |last8=Di Marzo |first8=Vincenzo |date=1 June 2005 |title=Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: Review of the available pre-clinical data, and first human studies |url=https://www.sciencedirect.com/science/article/pii/S0028390805000298 |journal=Neuropharmacology |series=Future Directions in Cannabinoid Therapeutics: “From the Bench to the Clinic” |language=en |volume=48 |issue=8 |pages=1154–1163 |doi=10.1016/j.neuropharm.2005.01.001 |pmid=15910891 |s2cid=14828175 |issn=0028-3908}}</ref> NAE 16:0 has also been identified in plants including corn, and seeds of cotton, okra, tomato, castor bean, soya bean and peanuts,<ref name=":0">{{cite journal | vauthors = Chapman KD, Venables B, Markovic R, Bettinger C | title = N-Acylethanolamines in seeds. Quantification Of molecular species and their degradation upon imbibition | journal = Plant Physiology | volume = 120 | issue = 4 | pages = 1157–64 | date = August 1999 | pmid = 10444099 | pmc = 59349 | doi = 10.1104/pp.120.4.1157 }}</ref> but its physiological functions remain unknown,<ref>{{cite journal | vauthors = Motes CM, Pechter P, Yoo CM, Wang YS, Chapman KD, Blancaflor EB | title = Differential effects of two phospholipase D inhibitors, 1-butanol and N-acylethanolamine, on in vivo cytoskeletal organization and Arabidopsis seedling growth | journal = Protoplasma | volume = 226 | issue = 3–4 | pages = 109–23 | date = December 2005 | pmid = 16333570 | doi = 10.1007/s00709-005-0124-4 | s2cid = 19838345 }}</ref> |
||
* ''N''-alpha-Linoleoylethanolamide (ALEA: C<sub>20</sub>H<sub>35</sub>NO<sub>2</sub>; 18:3, ω-3) or Anandamide (18:3, n-3),<ref name=":41">{{Cite web |last=PubChem |title=Alpha-Linolenoyl ethanolamide |url=https://pubchem.ncbi.nlm.nih.gov/compound/5283449 |access-date=2023-08-03 |website=pubchem.ncbi.nlm.nih.gov |language=en}}</ref> is a metabolic product of the omega-3 fat [[Α-Linolenic acid|α-linoleic acid]] (ALA: C<sub>18</sub>H<sub>30</sub>O<sub>2</sub>; 18:3, ω-3) and [[ethanolamine]] (MEA: C<sub>2</sub>H<sub>7</sub>NO).<ref name=":42">{{Cite journal |last1=Jones |first1=Peter J. H. |last2=Lin |first2=Lin |last3=Gillingham |first3=Leah G. |last4=Yang |first4=Haifeng |last5=Omar |first5=Jaclyn M. |date=2014 |
* ''N''-alpha-Linoleoylethanolamide (ALEA: C<sub>20</sub>H<sub>35</sub>NO<sub>2</sub>; 18:3, ω-3) or Anandamide (18:3, n-3),<ref name=":41">{{Cite web |last=PubChem |title=Alpha-Linolenoyl ethanolamide |url=https://pubchem.ncbi.nlm.nih.gov/compound/5283449 |access-date=2023-08-03 |website=pubchem.ncbi.nlm.nih.gov |language=en}}</ref> is a metabolic product of the omega-3 fat [[Α-Linolenic acid|α-linoleic acid]] (ALA: C<sub>18</sub>H<sub>30</sub>O<sub>2</sub>; 18:3, ω-3) and [[ethanolamine]] (MEA: C<sub>2</sub>H<sub>7</sub>NO).<ref name=":42">{{Cite journal |last1=Jones |first1=Peter J. H. |last2=Lin |first2=Lin |last3=Gillingham |first3=Leah G. |last4=Yang |first4=Haifeng |last5=Omar |first5=Jaclyn M. |date=1 December 2014 |title=Modulation of plasma N-acylethanolamine levels and physiological parameters by dietary fatty acid composition in humans |journal=Journal of Lipid Research |language=en |volume=55 |issue=12 |pages=2655–2664 |doi=10.1194/jlr.P051235 |doi-access=free |pmid=25262934 |pmc=4242457 |issn=0022-2275}}</ref> |
||
* ''N''-[[Oleoylethanolamine]] (OEA: C<sub>20</sub>H<sub>39</sub>NO<sub>2</sub>; 18:1, [[Omega-9 fatty acid|ω-9]]) |
* ''N''-[[Oleoylethanolamine]] (OEA: C<sub>20</sub>H<sub>39</sub>NO<sub>2</sub>; 18:1, [[Omega-9 fatty acid|ω-9]]) is the amide of [[oleic acid]] (C<sub>18</sub>H<sub>34</sub>O<sub>2</sub>; 18:1) and ethanolamine. It has [[anorexic]] effects and enables [[Fatty acid degradation|fat breakdown]] by stimulating [[PPAR-alpha]].<ref name="De Fonseca">{{cite journal | vauthors = Rodríguez de Fonseca F, Navarro M, Gómez R, Escuredo L, Nava F, Fu J, Murillo-Rodríguez E, Giuffrida A, LoVerme J, Gaetani S, Kathuria S, Gall C, Piomelli D | display-authors = 6 | title = An anorexic lipid mediator regulated by feeding | journal = Nature | volume = 414 | issue = 6860 | pages = 209–212 | date = November 2001 | pmid = 11700558 | doi = 10.1038/35102582 | s2cid = 4430005 | bibcode = 2001Natur.414..209R | url = https://escholarship.org/uc/item/67p148qt }}</ref> In plants, NAE 18:1 is present abundantly in dry seeds and levels decline during seed imbibition,<ref name=":0" /><ref>{{cite journal | vauthors = Kilaru A, Tamura P, Isaac G, Welti R, Venables BJ, Seier E, Chapman KD | title = Lipidomic analysis of N-acylphosphatidylethanolamine molecular species in Arabidopsis suggests feedback regulation by N-acylethanolamines | journal = Planta | volume = 236 | issue = 3 | pages = 809–824 | date = September 2012 | pmid = 22673881 | pmc = 3579225 | doi = 10.1007/s00425-012-1669-z | bibcode = 2012Plant.236..809K }}</ref> but its physiological functions are yet to be elucidated. In humans, plasma OEA levels are also found positively correlated with positive [[Positive mood|mood]] and [[emotion]]s.<ref name=":1">{{cite journal | vauthors = Stone NL, Millar SA, Herrod PJ, Barrett DA, Ortori CA, Mellon VA, O'Sullivan SE | title = An Analysis of Endocannabinoid Concentrations and Mood Following Singing and Exercise in Healthy Volunteers | journal = Frontiers in Behavioral Neuroscience | volume = 12 | pages = 269 | date = 26 November 2018 | pmid = 30534062 | pmc = 6275239 | doi = 10.3389/fnbeh.2018.00269 | doi-access = free }} [[File:CC-BY icon.svg|50px]] Material was copied from this source, which is available under a [https://creativecommons.org/licenses/by/4.0/ Creative Commons Attribution 4.0 International License].</ref> OEA acting mostly at [[Peroxisome proliferator-activated receptor alpha|peroxisome proliferator‐activated receptor‐α]] (PPAR‐α) [[nuclear receptor]]s and, to some extent, [[TRPV1]] channels.<ref>{{cite journal | vauthors = Di Marzo V, Piscitelli F | title = Gut feelings about the endocannabinoid system | journal = Neurogastroenterology and Motility | volume = 23 | issue = 5 | pages = 391–398 | date = May 2011 | pmid = 21481098 | doi = 10.1111/j.1365-2982.2011.01689.x | doi-access = free }}</ref> |
||
* ''N-''[[Stearoylethanolamide|Stearoylethanolamine]] (SEA: C<sub>20</sub>H<sub>41</sub>NO<sub>2</sub>; 18:0) is the amide of [[stearic acid]] (C<sub>18</sub>H<sub>36</sub>O<sub>2</sub>) and ethanolamine (MEA: C<sub>2</sub>H<sub>7</sub>NO). It has pro-[[apoptotic]] activity. It operates independently of the known cannabinoid and vanilloid receptors targeted by anandamide.<ref name="De Fonseca" /> It is an inhibitor of the [[sphingolipid]] signaling pathway, via specific [[ceramidase]] inhibition (ceramidase converts [[ceramide]] to [[sphingosine]]) and blocks the effects of [[Tumor necrosis factor superfamily|TNF]]- and arachidonic acid on intracellular [[Calcium in biology|Ca<sup>2+</sup>]] concentration.<ref name=":3">{{cite journal | vauthors = Tripathy S, Kleppinger-Sparace K, Dixon RA, Chapman KD | title = N-acylethanolamine signaling in tobacco is mediated by a membrane-associated, high-affinity binding protein | journal = Plant Physiology | volume = 131 | issue = 4 | pages = 1781–91 | date = April 2003 | pmid = 12692337 | pmc = 166934 | doi = 10.1104/pp.102.014936 }}</ref><ref>{{cite journal | vauthors = Hofmann U, Domeier E, Frantz S, Laser M, Weckler B, Kuhlencordt P, Heuer S, Keweloh B, Ertl G, Bonz AW | display-authors = 6 | title = Increased myocardial oxygen consumption by TNF-alpha is mediated by a sphingosine signaling pathway | journal = American Journal of Physiology. Heart and Circulatory Physiology | volume = 284 | issue = 6 | pages = H2100-5 | date = June 2003 | pmid = 12560208 | doi = 10.1152/ajpheart.00888.2002 }}</ref><ref>{{cite journal | vauthors = Amadou A, Nawrocki A, Best-Belpomme M, Pavoine C, Pecker F | title = Arachidonic acid mediates dual effect of TNF-alpha on Ca2+ transients and contraction of adult rat cardiomyocytes | journal = American Journal of Physiology. Cell Physiology | volume = 282 | issue = 6 | pages = C1339-47 | date = June 2002 | pmid = 11997249 | doi = 10.1152/ajpcell.00471.2001 }}</ref> |
* ''N-''[[Stearoylethanolamide|Stearoylethanolamine]] (SEA: C<sub>20</sub>H<sub>41</sub>NO<sub>2</sub>; 18:0) is the amide of [[stearic acid]] (C<sub>18</sub>H<sub>36</sub>O<sub>2</sub>) and ethanolamine (MEA: C<sub>2</sub>H<sub>7</sub>NO). It has pro-[[apoptotic]] activity. It operates independently of the known cannabinoid and vanilloid receptors targeted by anandamide.<ref name="De Fonseca" /> It is an inhibitor of the [[sphingolipid]] signaling pathway, via specific [[ceramidase]] inhibition (ceramidase converts [[ceramide]] to [[sphingosine]]) and blocks the effects of [[Tumor necrosis factor superfamily|TNF]]- and arachidonic acid on intracellular [[Calcium in biology|Ca<sup>2+</sup>]] concentration.<ref name=":3">{{cite journal | vauthors = Tripathy S, Kleppinger-Sparace K, Dixon RA, Chapman KD | title = N-acylethanolamine signaling in tobacco is mediated by a membrane-associated, high-affinity binding protein | journal = Plant Physiology | volume = 131 | issue = 4 | pages = 1781–91 | date = April 2003 | pmid = 12692337 | pmc = 166934 | doi = 10.1104/pp.102.014936 }}</ref><ref>{{cite journal | vauthors = Hofmann U, Domeier E, Frantz S, Laser M, Weckler B, Kuhlencordt P, Heuer S, Keweloh B, Ertl G, Bonz AW | display-authors = 6 | title = Increased myocardial oxygen consumption by TNF-alpha is mediated by a sphingosine signaling pathway | journal = American Journal of Physiology. Heart and Circulatory Physiology | volume = 284 | issue = 6 | pages = H2100-5 | date = June 2003 | pmid = 12560208 | doi = 10.1152/ajpheart.00888.2002 }}</ref><ref>{{cite journal | vauthors = Amadou A, Nawrocki A, Best-Belpomme M, Pavoine C, Pecker F | title = Arachidonic acid mediates dual effect of TNF-alpha on Ca2+ transients and contraction of adult rat cardiomyocytes | journal = American Journal of Physiology. Cell Physiology | volume = 282 | issue = 6 | pages = C1339-47 | date = June 2002 | pmid = 11997249 | doi = 10.1152/ajpcell.00471.2001 }}</ref> |
||
* N-Linoleoyl ethanolamide (MEA: C<sub>20</sub>H<sub>37</sub>NO<sub>2</sub>; 18:2, ω-6) or Anandamide (18:2, n-6) is the [[ethanolamide]] of [[linoleic acid]] (LA: [[Carbon|C]]<sub>18</sub>[[Hydrogen|H]]<sub>32</sub>[[Oxygen|O]]<sub>2</sub>; 18:[[Double bond|2]], [[Omega-6 fatty acid|ω-6]]) and its metabolized incorporated [[ethanolamine]] (MEA: C<sub>2</sub>H<sub>7</sub>NO),<ref>{{Cite web |title=Linoleoyl ethanolamide |url=https://pubchem.ncbi.nlm.nih.gov/compound/5283446 |access-date=2022-10-29 | work = PubChem | publisher = U.S. National Library of Medicine |language=en}}</ref> is the first natural inhibitor of [[fatty acid amide hydrolase]] (FAAH) discovered, also derives from [[hydroperoxide]]s of NAE 20:4 (AEA) or its [[Linoleyl alcohol|linoleoyl]] analogues by [[lipoxygenase]] action.<ref name=":24" /> |
* N-Linoleoyl ethanolamide (MEA: C<sub>20</sub>H<sub>37</sub>NO<sub>2</sub>; 18:2, ω-6) or Anandamide (18:2, n-6) is the [[ethanolamide]] of [[linoleic acid]] (LA: [[Carbon|C]]<sub>18</sub>[[Hydrogen|H]]<sub>32</sub>[[Oxygen|O]]<sub>2</sub>; 18:[[Double bond|2]], [[Omega-6 fatty acid|ω-6]]) and its metabolized incorporated [[ethanolamine]] (MEA: C<sub>2</sub>H<sub>7</sub>NO),<ref>{{Cite web |title=Linoleoyl ethanolamide |url=https://pubchem.ncbi.nlm.nih.gov/compound/5283446 |access-date=2022-10-29 | work = PubChem | publisher = U.S. National Library of Medicine |language=en}}</ref> is the first natural inhibitor of [[fatty acid amide hydrolase]] (FAAH) discovered, also derives from [[hydroperoxide]]s of NAE 20:4 (AEA) or its [[Linoleyl alcohol|linoleoyl]] analogues by [[lipoxygenase]] action.<ref name=":24" /> |
||
* ''N-''[[Docosahexaenoylethanolamine|Docosahexaenoyl ethanolamine]] (DHEA: C<sub>24</sub>H<sub>37</sub>NO<sub>2</sub>; 22:6, ω-3), or Anandamide (22:6, n-3) "synaptamide", is the non-[[Oxidative phosphorylation|oxidative]] produced amide of the mainly [[fish oil]] derived, [[docosahexaenoic acid]] (DHA: C<sub>22</sub>H<sub>32</sub>O<sub>2</sub>; 22:6, [[Omega-3 fatty acid|ω-3]]) and ethanolamine (MEA: C<sub>2</sub>H<sub>7</sub>NO).<ref name=":44">{{Cite web | work = PubChem |title=Docosahexaenoyl Ethanolamide |url=https://pubchem.ncbi.nlm.nih.gov/compound/5283451 |access-date=2022-11-19 | publisher = U.S. National Library of Medicine |language=en}}</ref> It can act at CB1 and CB2 receptors,<ref name=":10" /><ref name=":43">{{Cite journal |last1=Brown |first1=Iain |last2=Cascio |first2=Maria G. |last3=Rotondo |first3=Dino |last4=Pertwee |first4=Roger G. |last5=Heys |first5=Steven D. |last6=Wahle |first6=Klaus W. J. |date=2013 |
* ''N-''[[Docosahexaenoylethanolamine|Docosahexaenoyl ethanolamine]] (DHEA: C<sub>24</sub>H<sub>37</sub>NO<sub>2</sub>; 22:6, ω-3), or Anandamide (22:6, n-3) "synaptamide", is the non-[[Oxidative phosphorylation|oxidative]] produced amide of the mainly [[fish oil]] derived, [[docosahexaenoic acid]] (DHA: C<sub>22</sub>H<sub>32</sub>O<sub>2</sub>; 22:6, [[Omega-3 fatty acid|ω-3]]), that is the most abundant [[Polyunsaturated fat|polyunsaturated fatty acid]] (PUFA) in the brain and the [[retina]],<ref name=":55" /> and ethanolamine (MEA: C<sub>2</sub>H<sub>7</sub>NO).<ref name=":44">{{Cite web | work = PubChem |title=Docosahexaenoyl Ethanolamide |url=https://pubchem.ncbi.nlm.nih.gov/compound/5283451 |access-date=2022-11-19 | publisher = U.S. National Library of Medicine |language=en}}</ref> It can act at CB1 and CB2 receptors,<ref name=":10" /><ref name=":43">{{Cite journal |last1=Brown |first1=Iain |last2=Cascio |first2=Maria G. |last3=Rotondo |first3=Dino |last4=Pertwee |first4=Roger G. |last5=Heys |first5=Steven D. |last6=Wahle |first6=Klaus W. J. |date=1 January 2013 |title=Cannabinoids and omega-3/6 endocannabinoids as cell death and anticancer modulators |url=https://www.sciencedirect.com/science/article/pii/S0163782712000537 |journal=Progress in Lipid Research |language=en |volume=52 |issue=1 |pages=80–109 |doi=10.1016/j.plipres.2012.10.001 |pmid=23103355 |issn=0163-7827}}</ref> and have anti-proliferative effects on prostate cancer cell lines and promotes [[synaptogenesis]], [[neurogenesis]] and [[Neurite|neuritogenesis]],<ref name="pmid20660502">{{cite journal | vauthors = Brown I, Cascio MG, Wahle KW, Smoum R, Mechoulam R, Ross RA, Pertwee RG, Heys SD | display-authors = 6 | title = Cannabinoid receptor-dependent and -independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines | journal = Carcinogenesis | volume = 31 | issue = 9 | pages = 1584–91 | date = September 2010 | pmid = 20660502 | pmc = 2930808 | doi = 10.1093/carcin/bgq151 }}</ref><ref name="pmid21810478">{{cite journal | vauthors = Kim HY, Spector AA, Xiong ZM | title = A synaptogenic amide N-docosahexaenoylethanolamide promotes hippocampal development | journal = Prostaglandins & Other Lipid Mediators | volume = 96 | issue = 1–4 | pages = 114–20 | date = November 2011 | pmid = 21810478 | pmc = 3215906 | doi = 10.1016/j.prostaglandins.2011.07.002 }}</ref> and as an endogenous [[metabolite]] of DHA, it promotes [[Development of the nervous system|brain development]] and function.<ref>{{cite journal | vauthors = Lee JW, Huang BX, Kwon H, Rashid MA, Kharebava G, Desai A, Patnaik S, Marugan J, Kim HY | display-authors = 6 | title = Orphan GPR110 (ADGRF1) targeted by N-docosahexaenoylethanolamine in development of neurons and cognitive function | journal = Nature Communications | volume = 7 | pages = 13123 | date = October 2016 | issue = 1 | pmid = 27759003 | pmc = 5075789 | doi = 10.1038/ncomms13123 | bibcode = 2016NatCo...713123L }}</ref> |
||
*''N''-[[Docosatetraenoylethanolamide|Docosatetraenoylethanolamine]] (DEA: C<sub>24</sub>H<sub>41</sub>NO<sub>2</sub>; 22:4,ω-6) act on the CB1 receptor,<ref name=":2" /> and possible CB2.<ref name=":3" /> |
*''N''-[[Docosatetraenoylethanolamide|Docosatetraenoylethanolamine]] (DEA: C<sub>24</sub>H<sub>41</sub>NO<sub>2</sub>; 22:4,ω-6) act on the CB1 receptor,<ref name=":2" /> and possible CB2.<ref name=":3" /> |
||
*''N''-[[Eicosapentaenoylethanolamide]] (EPEA: C<sub>22</sub>H<sub>35</sub>NO<sub>2</sub>; 20:5, ω-3) or Anandamide (20:5, n-3). It is the amide of [[eicosapentaenoic acid]] (EPA: C<sub>20</sub>H<sub>30</sub>O<sub>2</sub>; 20:5, n-3),<ref name=":45">{{Cite web |last=PubChem |title=Eicosapentaenoyl Ethanolamide |url=https://pubchem.ncbi.nlm.nih.gov/compound/5283450 |access-date=2023-08-05 |website=pubchem.ncbi.nlm.nih.gov |language=en}}</ref> that can act on CB1 and CB2 receptors in combination with [[Peroxisome proliferator-activated receptor gamma|PPAR-gamma]] to decrease [[Lipopolysaccharide|LPS]] induced [[adipocyte]] [[Interleukin 6|IL-6]] and [[MCP-1]] levels.<ref name=":10">{{cite journal | vauthors = Balvers MG, Verhoeckx KC, Plastina P, Wortelboer HM, Meijerink J, Witkamp RF | title = Docosahexaenoic acid and eicosapentaenoic acid are converted by 3T3-L1 adipocytes to N-acyl ethanolamines with anti-inflammatory properties | journal = Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids | volume = 1801 | issue = 10 | pages = 1107–14 | date = October 2010 | pmid = 20601112 | doi = 10.1016/j.bbalip.2010.06.006 }}</ref><ref name=":43" /> |
*''N''-[[Eicosapentaenoylethanolamide]] (EPEA: C<sub>22</sub>H<sub>35</sub>NO<sub>2</sub>; 20:5, ω-3) or Anandamide (20:5, n-3). It is the amide of [[eicosapentaenoic acid]] (EPA: C<sub>20</sub>H<sub>30</sub>O<sub>2</sub>; 20:5, n-3),<ref name=":45">{{Cite web |last=PubChem |title=Eicosapentaenoyl Ethanolamide |url=https://pubchem.ncbi.nlm.nih.gov/compound/5283450 |access-date=2023-08-05 |website=pubchem.ncbi.nlm.nih.gov |language=en}}</ref> that can act on CB1 and CB2 receptors in combination with [[Peroxisome proliferator-activated receptor gamma|PPAR-gamma]] to decrease [[Lipopolysaccharide|LPS]] induced [[adipocyte]] [[Interleukin 6|IL-6]] and [[MCP-1]] levels.<ref name=":10">{{cite journal | vauthors = Balvers MG, Verhoeckx KC, Plastina P, Wortelboer HM, Meijerink J, Witkamp RF | title = Docosahexaenoic acid and eicosapentaenoic acid are converted by 3T3-L1 adipocytes to N-acyl ethanolamines with anti-inflammatory properties | journal = Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids | volume = 1801 | issue = 10 | pages = 1107–14 | date = October 2010 | pmid = 20601112 | doi = 10.1016/j.bbalip.2010.06.006 }}</ref><ref name=":43" /> |
||
*''N''-[[homo-gamma-linolenoylethanolamine]], or Anandamide (20:3,n-6) (HGLEA: C<sub>22</sub>H<sub>39</sub>NO<sub>2</sub>; 20:3,ω-6).<ref>{{cite journal | vauthors = Walter L, Franklin A, Witting A, Wade C, Xie Y, Kunos G, Mackie K, Stella N | display-authors = 6 | title = Nonpsychotropic cannabinoid receptors regulate microglial cell migration | journal = The Journal of Neuroscience | volume = 23 | issue = 4 | pages = 1398–405 | date = February 2003 | pmid = 12598628 | pmc = 6742252 | doi = 10.1523/JNEUROSCI.23-04-01398.2003 }}</ref> |
*''N''-[[homo-gamma-linolenoylethanolamine]], or Anandamide (20:3,n-6) (HGLEA: C<sub>22</sub>H<sub>39</sub>NO<sub>2</sub>; 20:3,ω-6).<ref>{{cite journal | vauthors = Walter L, Franklin A, Witting A, Wade C, Xie Y, Kunos G, Mackie K, Stella N | display-authors = 6 | title = Nonpsychotropic cannabinoid receptors regulate microglial cell migration | journal = The Journal of Neuroscience | volume = 23 | issue = 4 | pages = 1398–405 | date = February 2003 | pmid = 12598628 | pmc = 6742252 | doi = 10.1523/JNEUROSCI.23-04-01398.2003 }}</ref> |
||
These bioactive lipid amides are generated by the membrane enzyme [[NAPE-PLD]], and natural [[bile acids]] regulate this essential process.<ref name="Garau">{{cite journal | vauthors = Magotti P, Bauer I, Igarashi M, Babagoli M, Marotta R, Piomelli D, Garau G | title = Structure of human N-acylphosphatidylethanolamine-hydrolyzing phospholipase D: regulation of fatty acid ethanolamide biosynthesis by bile acids | journal = Structure | volume = 23 | issue = 3 | pages = 598–604 | date = March 2015 | pmid = 25684574 | pmc = 4351732 | doi = 10.1016/j.str.2014.12.018 }}</ref> An ''in vivo'' active NAPE-PLD inhibitor called LEI-401 was found to be [[Central nervous system|CNS]]-active |
These bioactive lipid amides are generated by the membrane enzyme [[NAPE-PLD]], and natural [[bile acids]] regulate this essential process.<ref name="Garau">{{cite journal | vauthors = Magotti P, Bauer I, Igarashi M, Babagoli M, Marotta R, Piomelli D, Garau G | title = Structure of human N-acylphosphatidylethanolamine-hydrolyzing phospholipase D: regulation of fatty acid ethanolamide biosynthesis by bile acids | journal = Structure | volume = 23 | issue = 3 | pages = 598–604 | date = March 2015 | pmid = 25684574 | pmc = 4351732 | doi = 10.1016/j.str.2014.12.018 }}</ref> An ''in vivo'' active NAPE-PLD inhibitor called LEI-401 was found to be [[Central nervous system|CNS]]-active and modulated NAE [[biosynthesis]]. It had similar effects as a cannabinoid [[Cannabinoid receptor type 1|CB1]] receptor [[Cannabinoid receptor antagonist|antagonist]], which could be reversed by co-treatment with a [[Fatty acid amide hydrolase|FAAH]] inhibitor.<ref name=":7">{{cite journal | vauthors = Mock ED, Mustafa M, Gunduz-Cinar O, Cinar R, Petrie GN, Kantae V, Di X, Ogasawara D, Varga ZV, Paloczi J, Miliano C, Donvito G, van Esbroeck AC, van der Gracht AM, Kotsogianni I, Park JK, Martella A, van der Wel T, Soethoudt M, Jiang M, Wendel TJ, Janssen AP, Bakker AT, Donovan CM, Castillo LI, Florea BI, Wat J, van den Hurk H, Wittwer M, Grether U, Holmes A, van Boeckel CA, Hankemeier T, Cravatt BF, Buczynski MW, Hill MN, Pacher P, Lichtman AH, van der Stelt M | display-authors = 6 | title = Discovery of a NAPE-PLD inhibitor that modulates emotional behavior in mice | journal = Nature Chemical Biology | volume = 16 | issue = 6 | pages = 667–675 | date = June 2020 | pmid = 32393901 | doi = 10.1038/s41589-020-0528-7 | pmc = 7468568 }}</ref> |
||
At least two pathways distinct from NAPE-PLD have been proposed as metabolic pathways for NAE 20:4 (AEA) formation. One pathway involves the double-''O''-[[Acylation|deacylation]] of [[NAPEs]] by [[Alpha/beta hydrolase superfamily|α,β-hydrolase]] (ABHD4) to form [[Glycerophospholipid|glycerophospho]]-''N''-acylethanolamines (GP-NAEs),<ref>{{cite journal | vauthors = Tsuboi K, Okamoto Y, Ikematsu N, Inoue M, Shimizu Y, Uyama T, Wang J, Deutsch DG, Burns MP, Ulloa NM, Tokumura A, Ueda N | display-authors = 6 | title = Enzymatic formation of N-acylethanolamines from N-acylethanolamine plasmalogen through N-acylphosphatidylethanolamine-hydrolyzing phospholipase D-dependent and -independent pathways | journal = Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids | volume = 1811 | issue = 10 | pages = 565–577 | date = October 2011 | pmid = 21801852 | doi = 10.1016/j.bbalip.2011.07.009 }}</ref> followed by conversion of these intermediates to NAEs by glycero[[Phosphodiesterase I|phosphodiesterase]]-1 (GDE1). Another pathway |
At least two pathways distinct from NAPE-PLD have been proposed as metabolic pathways for NAE 20:4 (AEA) formation. One pathway involves the double-''O''-[[Acylation|deacylation]] of [[NAPEs]] by [[Alpha/beta hydrolase superfamily|α,β-hydrolase]] (ABHD4) to form [[Glycerophospholipid|glycerophospho]]-''N''-acylethanolamines (GP-NAEs),<ref>{{cite journal | vauthors = Tsuboi K, Okamoto Y, Ikematsu N, Inoue M, Shimizu Y, Uyama T, Wang J, Deutsch DG, Burns MP, Ulloa NM, Tokumura A, Ueda N | display-authors = 6 | title = Enzymatic formation of N-acylethanolamines from N-acylethanolamine plasmalogen through N-acylphosphatidylethanolamine-hydrolyzing phospholipase D-dependent and -independent pathways | journal = Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids | volume = 1811 | issue = 10 | pages = 565–577 | date = October 2011 | pmid = 21801852 | doi = 10.1016/j.bbalip.2011.07.009 }}</ref> followed by conversion of these intermediates to NAEs by glycero[[Phosphodiesterase I|phosphodiesterase]]-1 (GDE1). Another pathway uses a [[phospholipase C]] (PLC) to produce phopho-''N''-arachidonoylethanolamine (pAEA) from NAPE, widely found in [[phospholipid]]s,<ref>{{cite journal | vauthors = Wellner N, Diep TA, Janfelt C, Hansen HS | title = N-acylation of phosphatidylethanolamine and its biological functions in mammals | journal = Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids | volume = 1831 | issue = 3 | pages = 652–662 | date = March 2013 | pmid = 23000428 | doi = 10.1016/j.bbalip.2012.08.019 }}</ref> followed by conversion of pAEA into NAE 20:4 (AEA) by [[phosphatase]]s such as [[PTPN22]] and [[SHIP1]].<ref>{{cite journal | vauthors = Serrano A, Parsons LH | title = Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors | journal = Pharmacology & Therapeutics | volume = 132 | issue = 3 | pages = 215–241 | date = December 2011 | pmid = 21798285 | pmc = 3209522 | doi = 10.1016/j.pharmthera.2011.06.005 }}</ref> |
||
The effects of NAE 20:4 (AEA) and another [[Endocannabinoid system|endocannabinoid]] [[2-Arachidonoylglycerol]] (2-AG: C<sub>23</sub>H<sub>38</sub>O<sub>4</sub>; 20:4, ω-6), with [[Tissue (biology)|tissue]] levels of 2-AG usually several tens to several hundreds of times those of AEA,<ref name=":37">{{Cite journal |last=Oka |first=Saori |date=2006 |title=Involvement of the Cannabinoid CB2 Receptor and Its Endogenous Ligand 2-Arachidonoylglycerol in Oxazolone-Induced Contact Dermatitis in Mice |url=https://journals.aai.org/jimmunol/article/177/12/8796/74027/Involvement-of-the-Cannabinoid-CB2-Receptor-and |access-date=2023-03-24 |journal=Journal of Immunology |volume=177 |issue=12 |pages=8796–9505 |doi=10.4049/jimmunol.177.12.8796 |pmid=17142782 |s2cid=11946479 |doi-access=free }}</ref> is found to be enhanced by |
The effects of NAE 20:4 (AEA) and another [[Endocannabinoid system|endocannabinoid]] [[2-Arachidonoylglycerol]] (2-AG: C<sub>23</sub>H<sub>38</sub>O<sub>4</sub>; 20:4, ω-6), with [[Tissue (biology)|tissue]] levels of 2-AG usually several tens to several hundreds of times those of AEA,<ref name=":37">{{Cite journal |last=Oka |first=Saori |date=2006 |title=Involvement of the Cannabinoid CB2 Receptor and Its Endogenous Ligand 2-Arachidonoylglycerol in Oxazolone-Induced Contact Dermatitis in Mice |url=https://journals.aai.org/jimmunol/article/177/12/8796/74027/Involvement-of-the-Cannabinoid-CB2-Receptor-and |access-date=2023-03-24 |journal=Journal of Immunology |volume=177 |issue=12 |pages=8796–9505 |doi=10.4049/jimmunol.177.12.8796 |pmid=17142782 |s2cid=11946479 |doi-access=free }}</ref> is found to be enhanced by "[[Entourage effect|entourage compounds]]", NAEs that inhibit their [[hydrolysis]] via substrate competition, and thereby prolong their action. These compounds include ''N''-palmitylethanolamide (PEA, NAE 16:0), ''N''-oleoylethanolamide (SEA, NAE 18:0), and ''cis''-9-octadecenoamide (OEA, oleamide, NAE 18:1).<ref name=":9">{{cite journal | vauthors = McPartland JM, Guy GW, Di Marzo V | title = Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system | journal = PLOS ONE | volume = 9 | issue = 3 | pages = e89566 | date = 12 March 2014 | pmid = 24622769 | pmc = 3951193 | doi = 10.1371/journal.pone.0089566 | bibcode = 2014PLoSO...989566M | doi-access = free }} [[File:CC-BY icon.svg|50px]] Text was copied from this source, which is available under a [https://creativecommons.org/licenses/by/4.0/ Creative Commons Attribution 4.0 International License].</ref> |
||
All are members of the endocannabinoidome, a complex [[lipid]] signaling system composed of more than 100 of fatty acid-derived mediators and their receptors, its [[Anabolism|anabolic]] and [[Catabolism|catabolic]] [[enzyme]]s of more than 50 [[protein]]s, which are deeply involved in the control of [[Bioenergetics|energy metabolism]] and its [[Pathology|pathological]] deviations,<ref>{{cite journal | vauthors = Di Marzo V, Silvestri C | title = Lifestyle and Metabolic Syndrome: Contribution of the Endocannabinoidome | journal = Nutrients | volume = 11 | issue = 8 | date = August 2019 | pmid = 31434293 | pmc = 6722643 | doi = 10.3390/nu11081956 | at = 1956 | doi-access = free }}</ref> as well as [[immunosuppression]],<ref name=":5">{{cite journal | vauthors = Surowiec I, Gouveia-Figueira S, Orikiiriza J, Lindquist E, Bonde M, Magambo J, Muhinda C, Bergström S, Normark J, Trygg J | display-authors = 6 | title = The oxylipin and endocannabidome responses in acute phase Plasmodium falciparum malaria in children | journal = Malaria Journal | volume = 16 | issue = 1 | pages = 358 | date = September 2017 | pmid = 28886714 | pmc = 5591560 | doi = 10.1186/s12936-017-2001-y }}</ref> and some NAE members, do not activate the CB1 and CB2 receptors |
All are members of the endocannabinoidome, a complex [[lipid]] signaling system composed of more than 100 of fatty acid-derived mediators and their receptors, its [[Anabolism|anabolic]] and [[Catabolism|catabolic]] [[enzyme]]s of more than 50 [[protein]]s, which are deeply involved in the control of [[Bioenergetics|energy metabolism]] and its [[Pathology|pathological]] deviations,<ref>{{cite journal | vauthors = Di Marzo V, Silvestri C | title = Lifestyle and Metabolic Syndrome: Contribution of the Endocannabinoidome | journal = Nutrients | volume = 11 | issue = 8 | date = August 2019 | pmid = 31434293 | pmc = 6722643 | doi = 10.3390/nu11081956 | at = 1956 | doi-access = free }}</ref> as well as [[immunosuppression]],<ref name=":5">{{cite journal | vauthors = Surowiec I, Gouveia-Figueira S, Orikiiriza J, Lindquist E, Bonde M, Magambo J, Muhinda C, Bergström S, Normark J, Trygg J | display-authors = 6 | title = The oxylipin and endocannabidome responses in acute phase Plasmodium falciparum malaria in children | journal = Malaria Journal | volume = 16 | issue = 1 | pages = 358 | date = September 2017 | pmid = 28886714 | pmc = 5591560 | doi = 10.1186/s12936-017-2001-y | doi-access = free }}</ref> and some NAE members, do not activate the CB1 and CB2 receptors efficiently, but instead activate other receptors (e.g. [[peroxisome proliferator-activated receptor]]s (PPAR)-[[Peroxisome proliferator-activated receptor alpha|α]]/[[Peroxisome proliferator-activated receptor gamma|γ]], [[G protein-coupled receptor|G-protein coupled receptors]] (GPR) [[GPR55|55]], [[GPR110|110]], [[NAGly receptor|118]], [[GPR119|119]], [[TRPV1]] channels), known to counteract metabolic disorders in animal models, by [[Gut microbiota|gut bacterial]] families (e.g. [[Veillonellaceae]], [[Peptostreptococcaceae]] and [[Akkermansia]]<nowiki/>ceae) associated with variations in most NAEs and omega3-derived 2-[[monoacylglycerols]] (2‑MAGs), congeners of 2-AG, as gut microbiota communities and the host endocannabinoidome also seem to be interrelated in a mutual crosstalk controlling whole body metabolism,<ref>{{Cite journal | vauthors = Lacroix S |date=2020 |title=Dietary fatty acid intake and gut microbiota determine circulating endocannabinoidome signaling beyond the effect of body fat |url=https://www.nature.com/articles/s41598-020-72861-3.pdf?origin=ppub |journal=Scientific Reports|volume=10 |issue=1 |page=15975 |doi=10.1038/s41598-020-72861-3 |pmid=32994521 |pmc=7524791 |bibcode=2020NatSR..1015975C }}</ref><ref>{{Cite journal |last=Manca |first=Claudia |date=2020 |title=Germ-free mice exhibit profound gut microbiota-dependent alterations of intestinal endocannabinoidome signaling |journal=J Lipid Res |volume=61 |issue=1 |pages=70–85 |doi=10.1194/jlr.RA119000424 |doi-access=free |pmid=31690638 |pmc=6939599 }}</ref> and onset and development of chronic [[Gastrointestinal tract|intestinal]] inflammation.<ref>{{Cite journal |last=Venneri |first=Tommaso |date=15 May 2023 |title=Altered endocannabinoidome bioactive lipid levels accompany reduced DNBS-induced colonic inflammation in germ-free mice |journal=Lipids in Health and Disease |volume=22|issue=1 |page=63 |doi=10.1186/s12944-023-01823-1 |pmid=37189092 |pmc=10186685 |doi-access=free }}</ref> |
||
NAE's are also involved in modulation of different physiological processes such as [[pain]], [[Stress (biology)|stress]], [[anxiety]], [[appetite]], [[Circulatory system|cardiovascular]] function and [[inflammation]]. A study |
NAE's are also involved in modulation of different physiological processes such as [[pain]], [[Stress (biology)|stress]], [[anxiety]], [[appetite]], [[Circulatory system|cardiovascular]] function and [[inflammation]]. A study suggests the presence of an endogenous NAE tone control [[emotion]]al [[behavior]].<ref name=":7" /> |
||
[[Raphael Mechoulam]] that described and named Anandamide in 1992. He said: |
[[Raphael Mechoulam]] that described and named Anandamide in 1992. He said: |
||
{{blockquote|Look, I believe there are 8 |
{{blockquote|Look, I believe there are 8 billion people on this planet, and I believe there are 8 billion different personalities. One way of explaining it is, there are several hundred compounds, endocannabinoid-like compounds. They are like anandamide in their chemical structure, that are present in the brain, and it is quite possible that each one of us, has a different, slightly different level of these compounds. And it is quite possible that differences in the endocannabinoid system, endocannabinoid-like system, can have something to do with the different personalities, and that ratios of 10 of these to 10 of others and so on will cause that.<ref name="Isolation and structure of a brain" /> in the YouTube video The Scientist, released in 2015.<ref>{{Citation|title=The Scientist| date=23 July 2015 |url=https://www.youtube.com/watch?v=csbJnBKqwIw |archive-url=https://ghostarchive.org/varchive/youtube/20211215/csbJnBKqwIw |archive-date=2021-12-15 |url-status=live|language=en|access-date=2021-03-14}}{{cbignore}}</ref>}} |
||
Beyond [[vertebrate]]s NAEs are also found to have signaling roles in more primitive [[organism]], implicated as [[Metabolism|metabolic]] signals that coordinate [[nutrient]] status and [[Life expectancy|lifespan]] determination in ''[[Caenorhabditis elegans]]'', and detected in organisms as diverse as [[yeast]] (''[[Saccharomyces cerevisiae]]''), [[freshwater fish]] (''[[Esox lucius]]'' and ''[[Common carp|Cyprinus carpio]]''), [[Bivalvia|bivalve mollusc]] (''[[Mediterranean mussel|Mytilus galloprovincialis]]''), [[protist]]s (''[[Tetrahymena|Tetrahymena thermophila]]''), [[slime mold]] (''[[Dictyostelium discoideum]]''), [[Microorganism|microbes]] such as |
Beyond [[vertebrate]]s NAEs are also found to have signaling roles in more primitive [[organism]], implicated as [[Metabolism|metabolic]] signals that coordinate [[nutrient]] status and [[Life expectancy|lifespan]] determination in ''[[Caenorhabditis elegans]]'', and detected in organisms as diverse as [[yeast]] (''[[Saccharomyces cerevisiae]]''), [[freshwater fish]] (''[[Esox lucius]]'' and ''[[Common carp|Cyprinus carpio]]''), [[Bivalvia|bivalve mollusc]] (''[[Mediterranean mussel|Mytilus galloprovincialis]]''), [[protist]]s (''[[Tetrahymena|Tetrahymena thermophila]]''), [[slime mold]] (''[[Dictyostelium discoideum]]''), [[Microorganism|microbes]] such as bacteria, [[Fungus|fungi]], and viruses, are all organisms that appear to regulate their endogenous NAE levels via similar enzymatic machinery as [[mammal]]ian vertebrates, show a widespread occurrence of NAEs, from [[Unicellular organism|single-celled]] organisms to humans, and a highly conserved role for this group of [[Lipid signaling|lipids]] in [[cell signaling]].<ref>{{cite journal | vauthors = Blancaflor EB, Kilaru A, Keereetaweep J, Khan BR, Faure L, Chapman KD | title = N-Acylethanolamines: lipid metabolites with functions in plant growth and development | journal = The Plant Journal | volume = 79 | issue = 4 | pages = 568–83 | date = August 2014 | pmid = 24397856 | doi = 10.1111/tpj.12427 | doi-access = free }}</ref><ref name=":4" /> Studies in [[amphibian]]s and birds show that endocannabinoid signaling may function as a [[behavior]]al switch, allowing redirection from less- to more-essential behaviors in response to [[Climate change|emergent]] [[environmental change]]s,<ref name=":12">{{cite journal | vauthors = Sorrentino G | title = Introduction to emerging industrial applications of cannabis (''Cannabis sativa'' L''.'') | journal = Rendiconti Lincei. Scienze Fisiche e Naturali | pages = 233–243 | date = March 2021 | volume = 32 | issue = 2 | pmid = 33777341 | pmc = 7978457 | doi = 10.1007/s12210-021-00979-1 }}</ref><ref name=":17">{{Cite journal| vauthors = Rockström J, Steffen W, Noone K, Persson Å, Chapin III FS, Lambin E, Lenton TM, Scheffer M, Folke C, Schellnhuber HJ, Nykvist B | display-authors = 6 |date=18 November 2009|title=Planetary Boundaries: Exploring the Safe Operating Space for Humanity|url=http://www.ecologyandsociety.org/vol14/iss2/art32/|journal=Ecology and Society|language=en|volume=14|issue=2|doi=10.5751/ES-03180-140232|issn=1708-3087|doi-access=free|hdl=10535/5421|hdl-access=free}}</ref> and provide evidence of cannabinoid modulation of [[aggression]], [[Vomiting|emesis]], [[List of feeding behaviours|feeding behavior]], [[Animal locomotion|locomotor activity]], reproductive behaviors, [[vocal learning]], [[Perception|sensory perception]] and [[stress response]]s.<ref>{{cite book | vauthors = Soderstrom K | title = Behavioral Neurobiology of the Endocannabinoid System | chapter = Lessons from Nonmammalian Species | volume = 1 | pages = 173–98 | date = 2009 | pmid = 21104384 | doi = 10.1007/978-3-540-88955-7_7 | publisher = Springer | isbn = 978-3-540-88955-7 | series = Current Topics in Behavioral Neurosciences | veditors = Kendall D, Alexander S | place = Berlin, Heidelberg }}</ref><ref>{{cite journal | vauthors = DeVries MS, Cordes MA, Rodriguez JD, Stevenson SA, Riters LV | title = Neural endocannabinoid CB1 receptor expression, social status, and behavior in male European starlings | journal = Brain Research | volume = 1644 | pages = 240–8 | date = August 2016 | pmid = 27206544 | pmc = 4904780 | doi = 10.1016/j.brainres.2016.05.031 }}</ref> |
||
== NAE and the reproductive system == |
== NAE and the reproductive system == |
||
Several |
Several researchers have found, that NAE, and especially 20:4 anandamide (AEA: [[Carbon|C]]<sub>22</sub>[[Hydrogen|H]]<sub>37</sub>[[Biological functions of nitric oxide|NO]]<sub>2</sub>; 20:[[Double bond|4]], [[Omega-6 fatty acid|ω-6]]), is a part of the [[reproductive system]],<ref name=":11">{{cite journal | vauthors = Melamede R | title = Harm reduction—the cannabis paradox | journal = Harm Reduction Journal | volume = 2 | issue = 1 | pages = 17 | date = September 2005 | pmid = 16179090 | pmc = 1261530 | doi = 10.1186/1477-7517-2-17 | doi-access = free }} [[File:CC-BY icon.svg|50px]] Text was copied from this source, which is available under a [https://creativecommons.org/licenses/by/2.0/ Creative Commons Attribution 2.0 Generic (CC BY 2.0)] license.</ref> and play a fundamental role for a healthy and successful pregnancy. |
||
A 2006 report from the Pediatrics Department at [[Vanderbilt University]] characterized NAE 20:4 (AEA) as |
A 2006 report from the Pediatrics Department at [[Vanderbilt University]] characterized NAE 20:4 (AEA) as "an emerging concept in [[Female reproductive system|female reproduction]]", because they found a "cannabinoid sensor" mechanism to influence several crucial steps during early pregnancy. |
||
The Vanderbilt research team termed this |
The Vanderbilt research team termed this "endocannabinoid signaling in preimplantation embryo development and activation", because one of the first things the [[Fertilisation|fertilized]] [[embryo]] must do, is to attach itself to the lining of the [[uterus]], and without becoming attached to the [[Uterus#Layers|uterine wall]], which forms the [[umbilical cord]], there will be no pregnancy. NAE 20:4 (AEA) plays a key role, because, for the embryo to become attached to the lining of the uterus, a particular amount (temporary reduction by high [[Fatty acid amide hydrolase]] FAAH) of NAE 20:4 (AEA),<ref>{{cite journal | vauthors = Wang H, Matsumoto H, Guo Y, Paria BC, Roberts RL, Dey SK | title = Differential G protein-coupled cannabinoid receptor signaling by anandamide directs blastocyst activation for implantation | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 100 | issue = 25 | pages = 14914–14919 | date = December 2003 | pmid = 14645706 | pmc = 299852 | doi = 10.1073/pnas.2436379100 | doi-access = free | bibcode = 2003PNAS..10014914W }}</ref> present at the [[Uterine epithelium|uterine lining]] (uterine epithelium), is necessary for the fertilized embryo can attach itself to the uterine wall, i.e. [[Implantation (embryology)|implantation]]. NAE 20:4 (AEA) uses the CB1 receptors, that are at high levels on the [[blastocyst]] (fertilized egg), to this attachment. So, the amount of NAE 20:4 (AEA) directs the outcome of the attachment to the uterine wall via CB1, and thereby, the outcome to pregnancy,<ref>{{cite journal | vauthors = Wang H, Xie H, Dey SK | title = Endocannabinoid signaling directs periimplantation events | journal = The AAPS Journal | volume = 8 | issue = 2 | pages = E425–E432 | date = 2006 | pmid = 16808046 | pmc = 3231559 | doi = 10.1007/BF02854916 }}</ref><ref name=":8">{{cite journal | vauthors = Fride E | title = The endocannabinoid-CB(1) receptor system in pre- and postnatal life | journal = European Journal of Pharmacology | volume = 500 | issue = 1–3 | pages = 289–297 | date = October 2004 | pmid = 15464041 | doi = 10.1016/j.ejphar.2004.07.033 | series = SPECIAL CELEBRATORY VOLUME 500 Dedicated to Professor David de Wied Honorary and Founding Editor }}</ref> by [[Synchronization|synchronizing]] [[trophoblast]] differentiation and uterine preparation to the receptive state. |
||
However, low FAAH expression and high NAE 20:4 (AEA) levels at the interimplantation sites, prior to successful implantation, have been reported, and a later possible [[miscarriage]], as AEA levels are inversely correlated with FAAH levels in [[peripheral blood mononuclear cell]]s (PMNCs) and FAAH levels are found lower in women who consequently miscarry compared with those who progress beyond the [[Pregnancy|first trimester]]. A consequence also |
However, low FAAH expression and high NAE 20:4 (AEA) levels at the interimplantation sites, prior to successful implantation, have been reported, and a later possible [[miscarriage]], as AEA levels are inversely correlated with FAAH levels in [[peripheral blood mononuclear cell]]s (PMNCs) and FAAH levels are found lower in women who consequently miscarry compared with those who progress beyond the [[Pregnancy|first trimester]]. A consequence also found in women undergoing ''in vitro'' [[In vitro fertilisation|fertilization]] and [[embryo transfer]], as low activity of FAAH in PMNCs and high plasma AEA levels after embryo transfer show failure to achieve a successful pregnancy. As well, high AEA level also inhibits [[C19MC miRNA cluster|BeWo]] trophoblast cell proliferation, in a dose-dependent manner, ''via'' the [[Cannabinoid receptor type 2|CB2 receptor]], suggest that FAAH acts as a barrier to the AEA [[Mother|maternal]]-[[Fetus|fetal]] transfer. So, high plasma AEA levels can be used as a marker of early pregnancy loss in patients with threatened miscarriage, as altered modulation of the ECS contribute to the [[Spontaneous abortion|spontaneous pregnancy loss]].<ref name=":31">{{cite journal | vauthors = Trabucco E, Acone G, Marenna A, Pierantoni R, Cacciola G, Chioccarelli T, Mackie K, Fasano S, Colacurci N, Meccariello R, Cobellis G, Cobellis L | display-authors = 6 | title = Endocannabinoid system in first trimester placenta: low FAAH and high CB1 expression characterize spontaneous miscarriage | journal = Placenta | volume = 30 | issue = 6 | pages = 516–522 | date = June 2009 | pmid = 19419760 | doi = 10.1016/j.placenta.2009.03.015 }}</ref> |
||
This is in line with a study of 50 women, where NAE 20:4 (AEA) [[hydrolase]] activity was lower in the seven women who [[Miscarriage|miscarried]] than in the 43 who did not (60.43 pmol/min per mg protein [SD 29.34] vs 169.60 pmol/min per mg protein [30.20], and another study showing that all 15 women in the low AEA hydrolase group had miscarriages, compared with one of the 105 women with high concentrations at or above the threshold of hydrolase.<ref>{{cite journal | vauthors = Maccarrone M, Valensise H, Bari M, Lazzarin N, Romanini C, Finazzi-Agrò A | title = Relation between decreased anandamide hydrolase concentrations in human lymphocytes and miscarriage | journal = Lancet | volume = 355 | issue = 9212 | pages = 1326–1329 | date = April 2000 | pmid = 10776746 | doi = 10.1016/S0140-6736(00)02115-2 | s2cid = 39733100 }}</ref> |
This is in line with a study of 50 women, where NAE 20:4 (AEA) [[hydrolase]] activity was lower in the seven women who [[Miscarriage|miscarried]] than in the 43 who did not (60.43 pmol/min per mg protein [SD 29.34] vs 169.60 pmol/min per mg protein [30.20], and another study showing that all 15 women in the low AEA hydrolase group had miscarriages, compared with one of the 105 women with high concentrations at or above the threshold of hydrolase.<ref>{{cite journal | vauthors = Maccarrone M, Valensise H, Bari M, Lazzarin N, Romanini C, Finazzi-Agrò A | title = Relation between decreased anandamide hydrolase concentrations in human lymphocytes and miscarriage | journal = Lancet | volume = 355 | issue = 9212 | pages = 1326–1329 | date = April 2000 | pmid = 10776746 | doi = 10.1016/S0140-6736(00)02115-2 | s2cid = 39733100 }}</ref> |
||
An earlier 2004 research |
An earlier 2004 research into the course of [[ectopic pregnancy]], a result of embryo retention in the [[fallopian tube]], found that decoupled cannabinoid receptor CB1, can cause retention of embryos in the mouse [[Oviducal|oviduct]], and lead to pregnancy failure, as either silencing or amplification of NAE 20:4 (AEA) signaling ''via'' CB1 receptors causes oviductal retention or blastocyst incompetence for implantation. The report estimates that aberrant cannabinoid signaling impedes coordinated oviductal [[smooth muscle]] [[Muscle contraction|contraction]] and relaxation, which are crucial to normal oviductal embryo transport. This was also seen in wild-type mice treated with [[methanandamide]] (AM-356; C<sub>23</sub>H<sub>39</sub>NO<sub>2</sub>, 20:4, n6), and thereby concluded, that a colocalization of CB1 in the oviduct muscularis implicate a basal endocannabinoid tone of NAE 20:4 (AEA) is needed for oviductal [[motility]] and for normal journey of embryos into the uterus.<ref>{{cite journal | vauthors = Wang H, Guo Y, Wang D, Kingsley PJ, Marnett LJ, Das SK, DuBois RN, Dey SK | display-authors = 6 | title = Aberrant cannabinoid signaling impairs oviductal transport of embryos | journal = Nature Medicine | volume = 10 | issue = 10 | pages = 1074–80 | date = October 2004 | pmid = 15378054 | doi = 10.1038/nm1104 | s2cid = 29106466 }}</ref> |
||
Another 2004 study published in the ''[[American Journal of Obstetrics and Gynecology]]'' find NAE 20:4 (AEA) and the [[phytocannabinoid]] [[Tetrahydrocannabinol|Δ<sup>9</sup>-tetrahydrocannabinol]] (THC: [[Carbon|C]]<sub>21</sub>[[Hydrogen|H]]<sub>30</sub>[[Oxygen|O]]<sub>2</sub>), that can mimic NAE 20:4 (AEA) by direct activation at [[Cannabinoid receptor type 1|CB1]], as the CB1 [[C-terminus|carboxyl-terminus]] have critical structures important for CB1 activity and regulation in the [[Receptor (biochemistry)|receptor]] life cycle including activation, [[Desensitization (receptor)|desensitization]], and [[Receptor-mediated endocytosis|internalization]],<ref>{{Cite journal |last1=Stadel |first1=Rebecca |last2=Ahn |first2=Kwang H. |last3=Kendall |first3=Debra A. |date=2011 |title=The Cannabinoid Type-1 Receptor Carboxyl-Terminus, More Than Just a Tail |journal=Journal of Neurochemistry |volume=117 |issue=1 |pages=1–18 |doi=10.1111/j.1471-4159.2011.07186.x |issn=0022-3042 |pmc=3055937 |pmid=21244428}}</ref> the [[Cannabinoid receptor type 2|CB2]] receptors,<ref>{{cite journal | vauthors = Pertwee RG | title = The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin | journal = British Journal of Pharmacology | volume = 153 | issue = 2 | pages = 199–215 | date = January 2008 | pmid = 17828291 | pmc = 2219532 | doi = 10.1038/sj.bjp.0707442 }}</ref><ref>{{cite |
Another 2004 study published in the ''[[American Journal of Obstetrics and Gynecology]]'' find NAE 20:4 (AEA) and the [[phytocannabinoid]] [[Tetrahydrocannabinol|Δ<sup>9</sup>-tetrahydrocannabinol]] (THC: [[Carbon|C]]<sub>21</sub>[[Hydrogen|H]]<sub>30</sub>[[Oxygen|O]]<sub>2</sub>), that can mimic NAE 20:4 (AEA) by direct activation at [[Cannabinoid receptor type 1|CB1]], as the CB1 [[C-terminus|carboxyl-terminus]] have critical structures important for CB1 activity and regulation in the [[Receptor (biochemistry)|receptor]] life cycle including activation, [[Desensitization (receptor)|desensitization]], and [[Receptor-mediated endocytosis|internalization]],<ref>{{Cite journal |last1=Stadel |first1=Rebecca |last2=Ahn |first2=Kwang H. |last3=Kendall |first3=Debra A. |date=2011 |title=The Cannabinoid Type-1 Receptor Carboxyl-Terminus, More Than Just a Tail |journal=Journal of Neurochemistry |volume=117 |issue=1 |pages=1–18 |doi=10.1111/j.1471-4159.2011.07186.x |issn=0022-3042 |pmc=3055937 |pmid=21244428}}</ref> the [[Cannabinoid receptor type 2|CB2]] receptors,<ref>{{cite journal | vauthors = Pertwee RG | title = The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin | journal = British Journal of Pharmacology | volume = 153 | issue = 2 | pages = 199–215 | date = January 2008 | pmid = 17828291 | pmc = 2219532 | doi = 10.1038/sj.bjp.0707442 }}</ref><ref>{{cite book | vauthors = Morales P, Hurst DP, Reggio PH | title = Phytocannabinoids | chapter = Molecular Targets of the Phytocannabinoids: A Complex Picture | series = Progress in the Chemistry of Organic Natural Products | volume = 103 | pages = 103–131 | date = 2017 | publisher = Springer | location = Cham | pmid = 28120232 | pmc = 5345356 | doi = 10.1007/978-3-319-45541-9_4 | isbn = 978-3-319-45539-6 }}</ref> and markedly lowering AEA content levels,<ref name=":21">{{cite journal |display-authors=6 |vauthors=Thieme U, Schelling G, Hauer D, Greif R, Dame T, Laubender RP, Bernhard W, Thieme D, Campolongo P, Theiler L |date=2014 |title=Quantification of anandamide and 2-arachidonoylglycerol plasma levels to examine potential influences of tetrahydrocannabinol application on the endocannabinoid system in humans |journal=Drug Testing and Analysis |volume=6 |issue=1–2 |pages=17–23 |doi=10.1002/dta.1561 |pmid=24424856}}</ref> enhance the function of [[glycine receptor]]s (GlyRs),<ref name=":36">{{Cite journal |last=Xiong |first=Wei |date=2011 |title=Cannabinoid potentiation of glycine receptors contributes to cannabis-induced analgesia |journal=Nature Chemical Biology |volume=7 |issue=5 |pages=296–303 |doi=10.1038/nchembio.552 |pmid=21460829 |pmc=3388539 }}</ref> activate the [[nuclear receptor]] family, [[peroxisome proliferator-activated receptor]]s (PPARs),<ref>{{Cite journal |last=O'Sullivan |first=S E |date=2007 |title=Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors |journal=British Journal of Pharmacology |volume=152 |issue=5 |pages=576–582 |doi=10.1038/sj.bjp.0707423 |issn=0007-1188 |pmc=2190029 |pmid=17704824}}</ref> able to switch from [[Agonist-antagonist|agonist]] to [[Cannabinoid receptor antagonist|antagonist]] depending on firing rate,<ref>{{cite journal | vauthors = Roloff AM, Thayer SA | title = Modulation of excitatory synaptic transmission by Delta 9-tetrahydrocannabinol switches from agonist to antagonist depending on firing rate | journal = Molecular Pharmacology | volume = 75 | issue = 4 | pages = 892–900 | date = April 2009 | pmid = 19118122 | pmc = 2684930 | doi = 10.1124/mol.108.051482 }}</ref> and to protect [[neonatal]] [[cardiac cell]]s against [[Hypoxia (medical)|hypoxia]] via CB2 receptor activation by induction of [[Biological functions of nitric oxide|NO]] production,<ref>{{Cite journal |last=Lipina |first=Christopher |date=24 January 2017 |title=The endocannabinoid system: 'NO' longer anonymous in the control of nitrergic signalling? |url=https://academic.oup.com/jmcb/article/9/2/91/2959911 |journal=J Mol Cell Biol. |volume=9 |issue=2 |pages=91–103|doi=10.1093/jmcb/mjx008 |pmid=28130308 |pmc=5439392 }}</ref><ref name=":38">{{Cite journal |last1=Shmist |first1=Yelena A. |last2=Goncharov |first2=Igor |last3=Eichler |first3=Maor |last4=Shneyvays |first4=Vladimir |last5=Isaac |first5=Ahuva |last6=Vogel |first6=Zvi |last7=Shainberg |first7=Asher |date=1 February 2006 |title=Delta-9-tetrahydrocannabinol protects cardiac cells from hypoxia via CB2 receptor activation and nitric oxide production |url=https://doi.org/10.1007/s11010-006-2346-y |journal=Molecular and Cellular Biochemistry |language=en |volume=283 |issue=1 |pages=75–83 |doi=10.1007/s11010-006-2346-y |pmid=16444588 |s2cid=24074568 |issn=1573-4919}}</ref> to exert a direct relaxant effect on human pregnant [[myometrium]] ''[[in vitro]]'', with equal potency for both compounds, which was mediated through the CB1 receptor. This means that the middle layer of the [[uterine wall]], where also CB2 reseptors are expressed, is modulated by NAE 20:4 (AEA) as well.<ref>{{cite journal |vauthors=Dennedy MC, Friel AM, Houlihan DD, Broderick VM, Smith T, Morrison JJ |date=January 2004 |title=Cannabinoids and the human uterus during pregnancy |url=https://www.drugsandalcohol.ie/6737/1/2313-2422_Elesevier_Cannabinoids_and_the_human_uterus.pdf |journal=American Journal of Obstetrics and Gynecology |language=English |volume=190 |issue=1 |pages=2–9; discussion 3A |doi=10.1016/j.ajog.2003.07.013 |pmid=14749627}}</ref> |
||
Likewise, there is also demonstrated CB1 expression in the first trimester [[placenta]] characterized by a |
Likewise, there is also demonstrated CB1 expression in the first trimester [[placenta]] characterized by a spatial-temporal modulation. But, at term, there is found lack of FAAH and high CB1 expression at placental [[Chorionic villi|villous]] tissue of non-laboring compared with laboring.<ref name=":31" /> |
||
After birth, CB1 receptors appears to be critical for [[Breastfeeding|milk sucking]] by [[Infant|newborn]], as it apparently activate [[Mouth|oral]]-motor musculature, by [[2-Arachidonoylglycerol|2-AG]] (C<sub>23</sub>H<sub>38</sub>O<sub>4</sub>; 20:4 ω-6) in the [[breast milk]], activation, as elevated levels of 2-AG modulate infant [[appetite]] and health,<ref>{{cite journal | vauthors = Datta P, Melkus MW, Rewers-Felkins K, Patel D, Bateman T, Baker T, Hale TW | title = Human Milk Endocannabinoid Levels as a Function of Obesity and Diurnal Rhythm | journal = Nutrients | volume = 13 | issue = 7 | pages = 2297 | date = July 2021 | pmid = 34371807 | pmc = 8308542 | doi = 10.3390/nu13072297 | doi-access = free }}</ref> as well as NAE 20:4 (AEA) act as a [[Neuroprotection|neuroprotectant]], also by providing [[retrograde signaling]] in the developing [[Postpartum period|postnatal]] brain, with observations suggest that children may be less prone to psychoactive side effects of Δ<sup>9</sup>-tetrahydrocannabinol (THC: C<sub>21</sub>H<sub>30</sub>O<sub>2</sub>) or endocannabinoids than adults, as very low [[density]] of CB1, and neonatal cardiac cells express CB2, but not CB1 receptors,<ref name=":38" /> suggest a promising future for [[cannabinoid]]s in [[Pediatrics|pediatric]] medicine for conditions including non-organic [[Failure to thrive|failure-to-thrive]] and [[cystic fibrosis]].<ref name=":8" /><ref>{{cite journal | vauthors = Fride E, Suris R, Weidenfeld J, Mechoulam R | title = Differential response to acute and repeated stress in cannabinoid CB1 receptor knockout newborn and adult mice | language = en-US | journal = Behavioural Pharmacology | volume = 16 | issue = 5–6 | pages = 431–440 | date = September 2005 | pmid = 16148448 | doi = 10.1097/00008877-200509000-00016 | s2cid = 25548954 }}</ref> |
After birth, CB1 receptors appears to be critical for [[Breastfeeding|milk sucking]] by [[Infant|newborn]], as it apparently activate [[Mouth|oral]]-motor musculature, by [[2-Arachidonoylglycerol|2-AG]] (C<sub>23</sub>H<sub>38</sub>O<sub>4</sub>; 20:4 ω-6) in the [[breast milk]], activation, as elevated levels of 2-AG modulate infant [[appetite]] and health,<ref>{{cite journal | vauthors = Datta P, Melkus MW, Rewers-Felkins K, Patel D, Bateman T, Baker T, Hale TW | title = Human Milk Endocannabinoid Levels as a Function of Obesity and Diurnal Rhythm | journal = Nutrients | volume = 13 | issue = 7 | pages = 2297 | date = July 2021 | pmid = 34371807 | pmc = 8308542 | doi = 10.3390/nu13072297 | doi-access = free }}</ref> as well as NAE 20:4 (AEA) act as a [[Neuroprotection|neuroprotectant]], also by providing [[retrograde signaling]] in the developing [[Postpartum period|postnatal]] brain, with observations suggest that children may be less prone to psychoactive side effects of Δ<sup>9</sup>-tetrahydrocannabinol (THC: C<sub>21</sub>H<sub>30</sub>O<sub>2</sub>) or endocannabinoids than adults, as very low [[density]] of CB1, and neonatal cardiac cells express CB2, but not CB1 receptors,<ref name=":38" /> suggest a promising future for [[cannabinoid]]s in [[Pediatrics|pediatric]] medicine for conditions including non-organic [[Failure to thrive|failure-to-thrive]] and [[cystic fibrosis]].<ref name=":8" /><ref>{{cite journal | vauthors = Fride E, Suris R, Weidenfeld J, Mechoulam R | title = Differential response to acute and repeated stress in cannabinoid CB1 receptor knockout newborn and adult mice | language = en-US | journal = Behavioural Pharmacology | volume = 16 | issue = 5–6 | pages = 431–440 | date = September 2005 | pmid = 16148448 | doi = 10.1097/00008877-200509000-00016 | s2cid = 25548954 }}</ref> |
||
== Mood == |
== Mood == |
||
As the [[Euphoria|euphoric]] [[feeling]] described after |
As the [[Euphoria|euphoric]] [[feeling]] described after running, called the "[[Neurobiological effects of physical exercise|runners high]]" is, at least in part, due to increased circulating endocannabinoids (eCBs), and these lipid signaling molecules are involved in [[Reward system|reward]], appetite, [[Mood (psychology)|mood]], [[memory]] and [[neuroprotection]], an analysis of endocannabinoid concentrations and moods after singing, dancing, exercise and reading in healthy volunteers, showed that singing increased plasma levels of anandamide (AEA) by 42%, palmitoylethanolamine (PEA) by 53% and oleoylethanolamine (OEA) by 34%, and improved [[positive mood]] and [[Broaden-and-build|emotions]]. Dancing did not affect eCB levels but decreased negative mood and emotions. Cycling increased OEA levels by 26% and reading increased OEA levels by 28%. All the ethanolamines were positively correlated with [[heart rate]]. As so, the plasma OEA levels were positively correlated with positive mood and emotions, and AEA levels were seen positively correlated with [[Hunger (motivational state)|satiation]].<ref name=":1" /> |
||
However in [[Post-traumatic stress disorder|posttraumatic stress disorder]] (PTSD), circulating NAE 20:4 (AEA) are found associated with overall mood states and |
However in [[Post-traumatic stress disorder|posttraumatic stress disorder]] (PTSD), circulating NAE 20:4 (AEA) are found associated with overall mood states and exercise-induced improvements in women with and without PTSD, as AEA significantly increased following aerobic exercise for both groups, whereas the circulation of the endocannabinoid [[2-Arachidonoylglycerol|2-AG]] only increased in women without PTSD, thereby AEA was associated with lower [[Depressive mood|depressive]] mood, [[confusion]], and total [[Mood disorder|mood disturbance]] within the PTSD group and consistent with the discovery of a greater eCB tone, and particularly AEA, following [[Pharmacology|pharmacological]] and/or non-pharmacological manipulations that may be beneficial for improving psychological outcomes, as mood and [[cognition]] among PTSD and possibly other [[Psychiatric rehabilitation|psychiatric]] populations.<ref>{{Cite journal |last1=Botsford |first1=Chloe |last2=Brellenthin |first2=Angelique G. |last3=Cisler |first3=Josh M. |last4=Hillard |first4=Cecilia J. |last5=Koltyn |first5=Kelli F. |last6=Crombie |first6=Kevin M. |date=1 January 2023 |title=Circulating endocannabinoids and psychological outcomes in women with PTSD |journal=Journal of Anxiety Disorders |language=en |volume=93 |pages=102656 |doi=10.1016/j.janxdis.2022.102656 |pmid=36469982 |pmc=9839585 |issn=0887-6185 }}</ref> |
||
NAE and endocannabinoids is an integral component of [[Stress (biology)|stress]] recovery, both centrally and peripherally, through regulation of the [[Hypothalamic–pituitary–adrenal axis|HPA axis]], and reduction in circulating NAE 20:4 (AEA) content in [[Major depressive disorder|major depression]], and exposure to stress, is found to increase inflammatory markers by down-regulating the circulating content of the endogenous anti-inflammatory molecules, through their activation of [[Peroxisome proliferator-activated receptor alpha|PPAR-α]], palmitoylethanolamine (PEA: C<sub>18</sub>H<sub>37</sub>NO<sub>2</sub>; 16:0) and [[Oleoylethanolamine]] (OEA: C<sub>20</sub>H<sub>39</sub>NO<sub>2</sub>; 18:1, [[Omega-9 fatty acid|ω-9]]), as NAE [[catabolism]] is accelerated by stress and by the same [[Fatty acid amide hydrolase|FAAH]] catabolic pathway.<ref name=":35">{{Cite journal |last=Hill |first=Matthew N. |date=2009 |title=Circulating Endocannabinoids and N-Acyl Ethanolamines Are Differentially Regulated in Major Depression and Following Exposure to Social Stress |journal=Psychoneuroendocrinology |volume=34 |issue=8 |pages=1257–1262 |doi=10.1016/j.psyneuen.2009.03.013 |pmid=19394765 |pmc=2716432 }}</ref> |
NAE and endocannabinoids is an integral component of [[Stress (biology)|stress]] recovery, both centrally and peripherally, through regulation of the [[Hypothalamic–pituitary–adrenal axis|HPA axis]], and reduction in circulating NAE 20:4 (AEA) content in [[Major depressive disorder|major depression]], and exposure to stress, is found to increase inflammatory markers by down-regulating the circulating content of the endogenous anti-inflammatory molecules, through their activation of [[Peroxisome proliferator-activated receptor alpha|PPAR-α]], palmitoylethanolamine (PEA: C<sub>18</sub>H<sub>37</sub>NO<sub>2</sub>; 16:0) and [[Oleoylethanolamine]] (OEA: C<sub>20</sub>H<sub>39</sub>NO<sub>2</sub>; 18:1, [[Omega-9 fatty acid|ω-9]]), as NAE [[catabolism]] is accelerated by stress and by the same [[Fatty acid amide hydrolase|FAAH]] catabolic pathway.<ref name=":35">{{Cite journal |last=Hill |first=Matthew N. |date=2009 |title=Circulating Endocannabinoids and N-Acyl Ethanolamines Are Differentially Regulated in Major Depression and Following Exposure to Social Stress |journal=Psychoneuroendocrinology |volume=34 |issue=8 |pages=1257–1262 |doi=10.1016/j.psyneuen.2009.03.013 |pmid=19394765 |pmc=2716432 }}</ref> |
||
Administration of CB<sub>1</sub> [[receptor antagonist]]s to humans has been found to increase indices of |
Administration of CB<sub>1</sub> [[receptor antagonist]]s to humans has been found to increase indices of depression and [[anxiety]]. Accordingly, the deficit in circulating endocannabinoids and activation of CB1, documented in individuals with [[Major depressive disorder|major depression]], may contribute to the [[emotion]]al [[sequela]]e associated with this disease. And it is therefore speculated, that this reduction in circulating endocannabinoid and NAE content in depression may be associated with the increased rates of [[inflammation]], [[cardiovascular disease]] and [[autoimmune dysfunction]] seen in this disease.<ref name=":35" /> And in other [[Stress (biology)|stress]]-associated [[Mental disorder|psychiatric disorders]], like [[Post-traumatic stress disorder|posttraumatic stress disorder]] (PTSD) and [[borderline personality disorder]] (BPD), characterized by intense and rapidly changing [[Mood (psychology)|mood]] states as well as chronic [[feeling]]s of [[emptiness]], [[impulsivity]], [[fear]] of [[Abandonment (emotional)|abandonment]], unstable [[Interpersonal relationship|relationships]], and unstable [[self-image]], showing significantly and cronically reduced content of the NAE 20:4 (AEA) that attenuate depressive and anxious symptoms, by elevated [[Fatty-acid amide hydrolase 1|fatty acid amide hydrolase]] (FAAH) in the [[amygdala]]-[[prefrontal cortex]] (PFC), that subserves [[Emotional self-regulation|emotion regulation]] and used to measures of [[hostility]] and [[aggression]], provide preliminary evidence of elevated FAAH binding in PFC in any [[Mental disorder|psychiatric condition]],<ref>{{Cite journal |last1=Wingenfeld |first1=Katja |last2=Dettenborn |first2=Lucia |last3=Kirschbaum |first3=Clemens |last4=Gao |first4=Wei |last5=Otte |first5=Christian |last6=Roepke |first6=Stefan |date=4 July 2018 |title=Reduced levels of the endocannabinoid arachidonylethanolamide (AEA) in hair in patients with borderline personality disorder – a pilot study |url=https://www.tandfonline.com/doi/full/10.1080/10253890.2018.1451837 |journal=Stress |language=en |volume=21 |issue=4 |pages=366–369 |doi=10.1080/10253890.2018.1451837 |pmid=29546791 |s2cid=3929753 |issn=1025-3890}}</ref> may be of great therapeutic interest to psychiatry.<ref name=":49">{{Cite journal |last1=Crippa |first1=José |last2=Zuardi |first2=Antonio |last3=Hallak |first3=Jaime |date=2010 |title=Therapeutical use of the cannabinoids in psychiatry |url=https://pubmed.ncbi.nlm.nih.gov/20512271/ |journal=Braz J Psychiatry |volume=32 |pages=56–66 |pmid=20512271 |via=PubMed Central}}</ref><ref>{{Cite journal |last1=Cousens |first1=Kenneth |last2=DiMascio |first2=Alberto |date=1 December 1973 |title=(−)δ9 THC as an hypnotic |url=https://doi.org/10.1007/BF00437513 |journal=Psychopharmacologia |language=en |volume=33 |issue=4 |pages=355–364 |doi=10.1007/BF00437513 |pmid=4776660 |s2cid=8775767 |issn=1432-2072}}</ref> And consistent with the model that lower endocannabinoid tone could perturb PFC circuitry that regulates [[emotion]] and aggression,<ref name=":47" /> and the feeling of [[loneliness]], as [[Social relation|social]] [[Meeting|contact]] increases, whereas [[Social isolation|isolation]] decreases, the production of the [[Endogeny (biology)|endogenous]] [[Cannabis (drug)|marijuanna]]-like [[neurotransmitter]], NAE 20:4 (AEA) in [[nucleus accumbens]] (NAc), where activation of CB1 are necessary and sufficient to express the [[Reward system|rewarding]] properties of social interactions, i.e. [[Interpersonal relationship|social contact]] reward.<ref name=":48" /> |
||
And possible why cannabinoids are seen highly used in the |
And possible why cannabinoids are seen highly used in the prison [[Prisoner|population]], and among those who have been imprisoned, and is clearly involved in [[Everyday life|daily life]] in prison, where [[Detention (imprisonment)|detainees]] in some prisons estimated the current use of [[Cannabis (drug)|cannabis]]/[[hashish]] to be as high as 80%, and staff estimate 50%, described [[analgesic]], [[Calmness|calming]], self-help to go through the prison [[experience]], relieve [[Stress management|stress]], facilitate [[sleep]], prevent violence, and a social peacemaker, where the introduction of a more restrictive regulation induced fear of violence, increased [[Smuggling|trafficking]] and a shift to other drug use.<ref>{{Cite journal |last1=Ritter |first1=Catherine |last2=Broers |first2=Barbara |last3=Elger |first3=Bernice S. |date=1 November 2013 |title=Cannabis use in a Swiss male prison: Qualitative study exploring detainees' and staffs' perspectives |url=https://www.sciencedirect.com/science/article/pii/S0955395913000753 |journal=International Journal of Drug Policy |language=en |volume=24 |issue=6 |pages=573–578 |doi=10.1016/j.drugpo.2013.05.001 |pmid=23773686 |issn=0955-3959}}</ref><ref>{{Cite journal |last=Jiménez-Vinaja |first=R. |date=31 March 2022 |title=Jailhouse rock: Health status, patterns of use, and subjective benefits of cannabis use in a sample of inmates in Spanish prisons |journal=Rev Esp Sanid Penit. |volume=24 |issue=1 |pages=9–14 |doi=10.18176/resp.00044 |pmid=35411912 |pmc=9017606 }}</ref> As seen in the Danish prisons that reflect a ‘treatment guarantee’ embedded in a policy of [[zero tolerance]] and intensified [[Solitary confinement|disciplinary sanctions]], launched by the [[Cabinet of Denmark|Danish Government]] ([[Anders Fogh Rasmussen I Cabinet|Regeringen, 2003]]) and inspired by [[Federal drug policy of the United States|US drug policy]] called ''The Fight against Drugs'', with introduction of better [[fence]] systems, more [[Detection dog|sniffer-dogs]], and [[Prison cell|cell]] and [[Frisking|body search]] of inmates, with an increasingly repressive response to drugs, including [[zero tolerance]] and harsher [[punishment]] like [[Isolation cell|isolation]], that reflects the same chain of destruction as the steps seen to [[the Holocaust]],<ref>{{Citation |title=Excerpt: The House I Live In – The Chain of Destruction | date=24 January 2013 |url=https://www.youtube.com/watch?v=c8N0TDsjpkE |access-date=2023-08-15 |language=en}}</ref> to make clients drug free and preparing them for a life without crime.<ref>{{Cite journal |last1=Kolind |first1=Torsten |last2=Frank |first2=Vibeke Asmussen |last3=Dahl |first3=Helle |date=1 January 2010 |title=Drug treatment or alleviating the negative consequences of imprisonment? A critical view of prison-based drug treatment in Denmark |url=https://www.sciencedirect.com/science/article/pii/S0955395909000589 |journal=International Journal of Drug Policy |language=en |volume=21 |issue=1 |pages=43–48 |doi=10.1016/j.drugpo.2009.03.002 |pmid=19427186 |issn=0955-3959}}</ref> |
||
[[Released convicts aftercare|Released]] to a daily life environment, where the highest scores for [[quality of life]] is observed among [[Habitual offender|habitual]] cannabis users, followed by occasional users, whereas both non-users and dysfunctional users present less favorable score, and non-users reported more |
[[Released convicts aftercare|Released]] to a daily life environment, where the highest scores for [[quality of life]] is observed among [[Habitual offender|habitual]] cannabis users, followed by occasional users, whereas both non-users and dysfunctional users present less favorable score, and non-users reported more depression or [[anxiety]] symptoms and a lower quality of life, than occasional and habitual users, found in a Brazilian [[cross-sectional study]] involving more than 7400 adults (6620 recreational cannabis users and 785 non-users), even [[Criminal law|illegal]].<ref>{{Cite journal |last=de Lima e Silva Surjus |first=Luciana Togni |date=5 April 2023 |title=Use of Marijuana to Promote Well-Being: Effects of Use and Prohibition in the Daily Lives of Brazilian Adults |journal=Subst Abuse |volume=17 |doi=10.1177/11782218231162469 |pmid=37051015 |pmc=10084564 }}</ref><ref name=":53" /> And other findings imply that a causal link between marijuana use and violence is primarily due to its illegality, and thus would not exist in an environment in which marijuana use, at least [[Medical cannabis|medicinally]] (MML), as a first choice in any situation, is [[Legality of cannabis|legalized]], to correct the [[injustice]]s of [[Legality of cannabis|cannabis prohibition]], as the legalization of cannabis for adult use is found being increasingly embraced in several countries and local entities, coursed by the economic and [[Suffering|human suffering]] of cannabis prohibition, which have fallen most heavily upon disadvantaged minority populations, and for countries, in which cannabis consumption before constituted a traditional habit, also in [[Cannabis and religion|religion]], and [[History of cannabis|practiced]] for hundreds or thousands of years,<ref>{{Cite web |last=His Majesty's |first=Government of Nepal |date=8 August 1975 |title=CHAPTER VI NARCOTIC DRUGS AND PSYCHOTROPIC SUBSTANCES – Declarations and Reservations for Nepal |url=https://treaties.un.org/pages/ShowMTDSGDetails.aspx?src=UNTSONLINE&tabid=2&mtdsg_no=VI-18&chapter=6&lang=en#EndDec |website=un.org}}</ref><ref>{{Cite journal |last1=Hamayun |first1=Muhammad |last2=Shinwari |first2=Zabta Khan |date=22 December 2004 |title=Folk Methodology of Charas (Hashish) Production and Its Marketing at Afridi Tirah, Federally Administered Tribal Areas (FATA), Pakistan |url=http://www.tandfonline.com/doi/abs/10.1300/J237v09n02_04 |journal=Journal of Industrial Hemp |language=en |volume=9 |issue=2 |pages=41–50 |doi=10.1300/J237v09n02_04 |s2cid=85423253 |issn=1537-7881}}</ref><ref>{{Cite journal |date=23 February 2009 |title=The Science of Marijuana, 2nd edn |journal=British Journal of Clinical Pharmacology |language=en |volume=67 |issue=2 |pages=268 |doi=10.1111/j.1365-2125.2008.03355.x |pmc=2670388}}</ref> without being subject to any social [[Shame|opprobrium]], as no correlation between Marijuana use and criminal behavior are found, correlates with a reduction in [[homicide]] and assault rates, after introduction of state MML.<ref>{{Cite journal |last1=Adinoff |first1=Bryon |last2=Reiman |first2=Amanda |date=2 November 2019 |title=Implementing social justice in the transition from illicit to legal cannabis |url=https://www.tandfonline.com/doi/full/10.1080/00952990.2019.1674862 |journal=The American Journal of Drug and Alcohol Abuse |language=en |volume=45 |issue=6 |pages=673–688 |doi=10.1080/00952990.2019.1674862 |pmid=31634005 |s2cid=204834660 |issn=0095-2990}}</ref><ref>{{Cite web |last1=Iōakeimoglou |first1=Geōrgios |last2=Wolstenholme |first2=G. E. W. |last3=Knight |first3=Julie |date=1965 |title=Hashish its chemistry and pharmacology. In honor of Professor Dr. G. Joachimoglu {{!}} WorldCat.org |url=https://www.worldcat.org/title/599717800 |access-date=2023-08-13 |website=www.worldcat.org |language=en}}</ref><ref>{{Cite journal |last1=Morris |first1=Robert G. |last2=TenEyck |first2=Michael |last3=Barnes |first3=J. C. |last4=Kovandzic |first4=Tomislav V. |date=26 March 2014 |title=The Effect of Medical Marijuana Laws on Crime: Evidence from State Panel Data, 1990–2006 |journal=PLOS ONE |volume=9 |issue=3 |pages=e92816 |doi=10.1371/journal.pone.0092816 |pmid=24671103 |pmc=3966811 |bibcode=2014PLoSO...992816M |doi-access=free }}</ref> Followed by an almost 5% estimated reduction in the total [[List of countries by suicide rate|suicide rate]], for the period 1990 through 2007, with an 11% percent reduction for 20- through 29-year-old males, and a 9% reduction in the suicide rate of 30- through 39-year-old males.<ref name=":54">{{Cite web|vauthors = Anderson DM, Rees DI, Sabia JJ |date=January 2012|title=High on Life? Medical Marijuana Laws and Suicide|url=http://ftp.iza.org/dp6280.pdf|website=Institute for the Study of Labor (IZA)}}</ref> And the secondary [[Death|mortality]] attributing to herbal cannabis is found extremely rare, and usually associated with [[Accident|misadventures]] with [[law enforcement]], and the prison [[experience]] and of [[solitary confinement]]s.<ref>{{Cite journal |last=Russo |first=Ethan B. |date=2 January 2023 |title=When The Pharmacopoeia Fails: Cannabis for Pain |url=https://academic.oup.com/painmedicine/article-abstract/24/7/912/6967039 |access-date=2023-08-13 |journal=Pain Medicine (Malden, Mass.)|volume=24 |issue=7 |pages=912–913 |doi=10.1093/pm/pnac208 |pmid=36592031 }}</ref><ref>{{Cite web |last=Bojesen |first=Bo |date=6 April 1979 |title=Title: Tremmeværk/latticework - Situation: Prisoner in solitary confinement gets a visit, where the official visits the prisoner, who sits alone in the dark – Subtitle: The Human Rights Commission must now take a closer look at the long-term isolation of Danish remand prisoners.- Dialogue: You can try to talk to him, but he's been so strangely withdrawn over the last seven months. – Digitale samlinger |url=http://www5.kb.dk/images/billed/2010/okt/billeder/object327102/da/ |access-date=2023-08-13 |website=www5.kb.dk}}</ref> |
||
== Longevity == |
== Longevity == |
||
A study of 42 eighty years old ([[Ageing|octogenarians]]) humans living in the east-central mountain area of [[Sardinia]], a High-Longevity Zone (HLZ) in |
A study of 42 eighty years old ([[Ageing|octogenarians]]) humans living in the east-central mountain area of [[Sardinia]], a High-Longevity Zone (HLZ) in Italy, have found, that the endocannabinoidome related circulating NAEs and familiar fatty acids are associated with a [[Maximum life span|longer]] human life or [[longevity]], as increased [[conjugated linoleic acid]] (CLA: C<sub>18</sub>H<sub>32</sub>O<sub>2</sub>; 18:[[Double bond|2]], n-6) and [[heptadecanoic acid]] (C<sub>17</sub>H<sub>34</sub>O<sub>2</sub>; 17:0), elevated [[palmitoleic acid]] (POA; C<sub>16</sub>H<sub>30</sub>O<sub>2</sub>; 16:1, n-7), a [[conjugate acid]] of a palmitoleate (C<sub>16</sub>H<sub>29</sub>O<sub>2</sub>; 16:1, n-7),<ref>{{cite journal | vauthors = Subramanian C, Frank MW, Batte JL, Whaley SG, Rock CO | title = Oleate hydratase from ''Staphylococcus aureus'' protects against palmitoleic acid, the major antimicrobial fatty acid produced by mammalian skin | journal = The Journal of Biological Chemistry | volume = 294 | issue = 23 | pages = 9285–9294 | date = June 2019 | pmid = 31018965 | pmc = 6556589 | doi = 10.1074/jbc.RA119.008439 | doi-access = free }}</ref> where n-7 fatty acids are precursors for the production of omega-4 fatty acids like palmitolinoleic acid (16:2),<ref>{{Cite web| vauthors = Vanhoutte K, Vanhoutte J |date=22 June 2009|title=Composition comprising omega-7 and/or omega-4 fatty acids|url=https://patents.google.com/patent/WO2010149662A1/en|website=Google Patents}}</ref> and a significantly increased level of NAE 22:6 (DHEA: C<sub>24</sub>H<sub>37</sub>NO<sub>2</sub>; 22:6, n-3), the metabolite of [[Docosahexaenoic acid|DHA]] (C<sub>22</sub>H<sub>32</sub>O<sub>2</sub>; 22:6, n-3), and the two endocannabinoids NAE 20:4 (AEA: [[Carbon|C]]<sub>22</sub>[[Hydrogen|H]]<sub>37</sub>[[Biological functions of nitric oxide|NO]]<sub>2</sub>; 20:[[Double bond|4]], [[Omega-6 fatty acid|ω-6]]) and [[2-Arachidonoylglycerol|2-arachidonoyl-glycerol]] (2-AG: C<sub>23</sub>H<sub>38</sub>O<sub>4</sub>; 20:4, n-6), as well of increased NAE 18:1 (OEA: C<sub>20</sub>H<sub>39</sub>NO<sub>2</sub>; 18:1, [[Omega-9 fatty acid|ω-9]]), the amide of [[palmitic acid]] (C<sub>16</sub>H<sub>32</sub>O<sub>2</sub>; 16:0) and [[ethanolamine]] (MEA: C<sub>2</sub>H<sub>7</sub>NO), and increase of 2-linoleoyl-glycerol (2-LG; C<sub>21</sub>H<sub>38</sub>O<sub>4</sub>; 18:2, n-6),<ref>{{cite journal| vauthors = Compton DL, Laszlo JA, Appell M, Vermillion KE, Evans KO |date=2012|title=Influence of Fatty Acid Desaturation on Spontaneous Acyl Migration in 2-Monoacylglycerols|url=https://aocs.onlinelibrary.wiley.com/doi/abs/10.1007/s11746-012-2113-z|journal=Journal of the American Oil Chemists' Society|language=en|volume=89|issue=12|pages=2259–2267|doi=10.1007/s11746-012-2113-z|s2cid=83629022|issn=1558-9331}}</ref> derived from [[linoleic acid]] (LA: C<sub>18</sub>H<sub>32</sub>O<sub>2</sub>; 18:2, n-6), can indicate a metabolic pattern potentially protective from adverse chronic conditions, and show a suitable [[physiological]] metabolic pattern, that may counteract the adverse stimuli leading to age-related disorders such as neurodegenerative and metabolic diseases.<ref>{{cite journal | vauthors = Manca C, Carta G, Murru E, Abolghasemi A, Ansar H, Errigo A, Cani PD, Banni S, Pes GM | display-authors = 6 | title = Circulating fatty acids and endocannabinoidome-related mediator profiles associated to human longevity | journal = GeroScience | date = March 2021 | volume = 43 | issue = 4 | pages = 1783–1798 | pmid = 33650014 | doi = 10.1007/s11357-021-00342-0 | pmc = 8492808 | doi-access = free }}</ref> |
||
It is found that [[3T3-L1]] [[adipocyte]]s [[Bioconversion|convert]] [[eicosapentaenoic acid]] (EPA: C<sub>20</sub>H<sub>30</sub>O<sub>2</sub>; 20:5, ω-3) to NAE 20:5 (EPEA: C<sub>22</sub>H<sub>35</sub>NO<sub>2</sub>; 20:5, ω-3) or Anandamide (20:5, n-3) and [[docosahexaenoic acid]] (DHA: C<sub>22</sub>H<sub>32</sub>O<sub>2</sub>; 22:6, ω-3) to NAE 22:6 (DHEA: C<sub>24</sub>H<sub>37</sub>NO<sub>2</sub>; 22:6, ω-3), or Anandamide (22:6, n-3). This conversion to EPEA and DHEA decrease [[Interleukin 6|IL-6]] and [[MCP-1]] levels, and the combined incubations with [[Peroxisome proliferator-activated receptor gamma|PPAR-gamma]] and [[Cannabinoid receptor type 2|CB2]] antagonists, suggest a role of these receptors in mediating the reduction of IL-6 by DHEA. These results are in line with the hypothesis, that in addition to other pathways, this formation of NAEs may contribute to the biological activity of n-3 [[Polyunsaturated fatty acid|PUFAs]], and different targets, including the endocannabinoid system, may be involved in the [[Immunotherapy|immune-modulating]] activity of [[Fish oil|fish-oil]] derived NAEs.<ref name=":10" /> |
It is found that [[3T3-L1]] [[adipocyte]]s [[Bioconversion|convert]] [[eicosapentaenoic acid]] (EPA: C<sub>20</sub>H<sub>30</sub>O<sub>2</sub>; 20:5, ω-3) to NAE 20:5 (EPEA: C<sub>22</sub>H<sub>35</sub>NO<sub>2</sub>; 20:5, ω-3) or Anandamide (20:5, n-3) and [[docosahexaenoic acid]] (DHA: C<sub>22</sub>H<sub>32</sub>O<sub>2</sub>; 22:6, ω-3) to NAE 22:6 (DHEA: C<sub>24</sub>H<sub>37</sub>NO<sub>2</sub>; 22:6, ω-3), or Anandamide (22:6, n-3). This conversion to EPEA and DHEA decrease [[Interleukin 6|IL-6]] and [[MCP-1]] levels, and the combined incubations with [[Peroxisome proliferator-activated receptor gamma|PPAR-gamma]] and [[Cannabinoid receptor type 2|CB2]] antagonists, suggest a role of these receptors in mediating the reduction of IL-6 by DHEA. These results are in line with the hypothesis, that in addition to other pathways, this formation of NAEs may contribute to the biological activity of n-3 [[Polyunsaturated fatty acid|PUFAs]], and different targets, including the endocannabinoid system, may be involved in the [[Immunotherapy|immune-modulating]] activity of [[Fish oil|fish-oil]] derived NAEs.<ref name=":10" /> |
||
== The importance of a low ratio of omega-6 to omega-3 essential fatty acids == |
== The importance of a low ratio of omega-6 to omega-3 essential fatty acids == |
||
Studies have found |
Studies have found that humans [[Human evolution|evolved]] on a [[Food|diet]] with a ratio of [[Omega-6 fatty acid|omega-6]] (n-6) to [[Omega-3 fatty acid|omega-3]] (n-3) [[essential fatty acid]]s (EFA) of about 1:1, whereas in today's [[Western pattern diet|Western diets]] the ratio is 15/1–16.7/1, or even more. The excessive amounts of n-6 [[polyunsaturated fatty acid]]s (PUFA) and a very high n-6/n-3 ratio, promote the [[pathogenesis]] of many diseases, including [[Cardiovascular disease|cardiovascular]] disease, cancer, and [[Inflammatory disease|inflammatory]] and [[Autoimmune disease|autoimmune]] diseases, whereas a low n-6/n-3 ratio exert suppressive effects. However, it is found impotent, that this low ratio, should change a bit, depending on disease, as the ratio of 2.5/1 reduce [[Rectum|rectal]] cell [[Cell proliferation|proliferation]] in patients with [[colorectal cancer]], and 2–3/1 suppress inflammation in patients with [[rheumatoid arthritis]], 4/1 is optimum for prevention of cardiovascular disease, showing a 70% decrease in total [[Death|mortality]], and 5/1 have a beneficial effect on patients with [[asthma]], whereas 10/1 have adverse consequences, indicate, that the optimal ‘low ratio’, may vary with the specific disease.<ref>{{cite journal | vauthors = Simopoulos AP | title = The importance of the ratio of omega-6/omega-3 essential fatty acids | journal = Biomedicine & Pharmacotherapy | volume = 56 | issue = 8 | pages = 365–379 | date = October 2002 | pmid = 12442909 | doi = 10.1016/S0753-3322(02)00253-6 }}</ref><ref name=":12" /> |
||
The [[World Health Organization]] (WHO) estimate [[hemp]], a culture [[Carbon dioxide|CO<sub>2</sub>]] negative, - a crop that is capable in the [[carbon cycle]] of removing more CO<sub>2</sub> from the ambient than it emits, where production of [[biomass]] produce between 8 and 12 tons of CO<sub>2</sub>, but seize between 10 and 15 tons per |
The [[World Health Organization]] (WHO) estimate [[hemp]], a culture [[Carbon dioxide|CO<sub>2</sub>]] negative, - a crop that is capable in the [[carbon cycle]] of removing more CO<sub>2</sub> from the ambient than it emits, where production of [[biomass]] produce between 8 and 12 tons of CO<sub>2</sub>, but seize between 10 and 15 tons per hectare, with the possibility to sequester up to 22 tons of CO<sub>2</sub> from the increased dry matter of the stem, where 80% of atmospheric carbon is sequestered and stored, by a [[nitrogen]] [[Fertilizer|fertilization]] between 0 and 120 kg per hectare,<ref name=":12" /> with [[root]]s that by various physicians and [[Herbal medicine|herbalists]] in the latter part of the 17th century, was recommended to treat fever, [[inflammation]], [[gout]], [[arthritis]], and [[Arthralgia|joint pain]], as well as [[Burn|skin burns]] and hard [[Neoplasm|tumors]], beside more,<ref>{{Cite journal |last1=Ryz |first1=Natasha R. |last2=Remillard |first2=David J. |last3=Russo |first3=Ethan B. |date=1 August 2017 |title=Cannabis Roots: A Traditional Therapy with Future Potential for Treating Inflammation and Pain |journal=Cannabis and Cannabinoid Research |volume=2 |issue=1 |pages=210–216 |doi=10.1089/can.2017.0028 |issn=2378-8763 |pmc=5628559 |pmid=29082318}}</ref> as well as to have modest [[antimicrobial]] activity against [[Cryptococcus neoformans]] by ergost-5-en-3-ol,<ref>{{Cite web |last=PubChem |title=Ergost-5-en-3-ol |url=https://pubchem.ncbi.nlm.nih.gov/compound/18660356 |access-date=2023-03-26 |website=pubchem.ncbi.nlm.nih.gov |language=en}}</ref> and potent antimicrobial activity against [[Escherichia coli]] by p-coumaroyltyramine,<ref>{{Cite web |last=PubChem |title=p-Coumaroyltyramine |url=https://pubchem.ncbi.nlm.nih.gov/compound/5372945 |access-date=2023-03-26 |website=pubchem.ncbi.nlm.nih.gov |language=en}}</ref><ref>{{Cite journal |last1=Elhendawy |first1=Mostafa A. |last2=Wanas |first2=Amira S. |last3=Radwan |first3=Mohamed M. |last4=Azzaz |first4=Nabil A. |last5=Toson |first5=ElShahat S. |last6=ElSohly |first6=Mahmoud A. |date=2018 |title=Chemical and Biological Studies of Cannabis sativa Roots |url=https://www.karger.com/Article/FullText/495582 |journal=Medical Cannabis and Cannabinoids |language=english |volume=1 |issue=2 |pages=104–111 |doi=10.1159/000495582 |issn=2504-3889 |pmid=32296742|pmc=7158750 }}</ref> as having what is considered to be an optimal 3:1 balance of omega 6 to omega 3 essential fatty acids, and where [[Hemp oil|hempseed oil]], of which 80% are [[polyunsaturated fatty acid]]s, of which 60% are omega-6 [[linoleic acid]] (LA: C<sub>18</sub>H<sub>32</sub>O<sub>2</sub>), the precursor of NAE 20:4 (AEA) and other NAEs, and 20% are omega-3 [[alpha-linolenic acid]] (ALA: C<sub>18</sub>H<sub>30</sub>O<sub>2</sub>), the precursor of NAE 18:3 (ALEA: C<sub>20</sub>H<sub>35</sub>NO<sub>2</sub>; 18:3, ω-3) or Anandamide (18:3, n-3),<ref name=":41" /><ref name=":42" /> is the only one that is in perfect balance according to what the human body needs – 3:1, and a [[Pound (mass)|pound]] (454 gram) of [[Hemp protein|hemp seed]], of which 43% are [[protein]], can provide all the protein, [[essential fatty acid]]s, and [[dietary fiber]] necessary for human survival for two weeks, or 33 gram a day.<ref name=":26" /><ref>{{Cite journal |last=Iftikhar |first=Amna |date=20 December 2021 |title=Applications of Cannabis Sativa L. in Food and Its Therapeutic Potential: From a Prohibited Drug to a Nutritional Supplement |journal=Molecules |volume=26 |issue=24 |page=7699 |doi=10.3390/molecules26247699 |pmid=34946779 |pmc=8708517 |doi-access=free }}</ref><ref>{{Cite web |title=Hemp Seed Protein |url=https://innvista.com/health/foods/hemp/hemp-seed-protein/ |access-date=2022-10-31 |website=Innvista |language=en-US}}</ref><ref>{{Cite web |title=Omega Oils |url=https://innvista.com/health/nutrition/fats/omega-oils/ |access-date=2022-10-31 |website=Innvista |language=en-US}}</ref><ref>{{Cite web |title=Hampefrøolie |url=https://www.nyborggaard.dk/shop/19-hampefroeolie/ |access-date=2023-07-22 |website=www.nyborggaard.dk |language=da}}</ref><ref>{{Cite web |title=Hampeprotein |url=https://www.nyborggaard.dk/shop/7-hampeprotein/ |access-date=2023-08-20 |website=www.nyborggaard.dk |language=da}}</ref> |
||
And their absence has been found responsible for the development of a wide range of diseases such as [[metabolic disorder]]s,<ref name=":27" /> [[Cardiovascular disease|cardiovascular disorders]], [[Inflammation|inflammatory]] processes, [[Viral disease|viral infections]], certain types of |
And their absence has been found responsible for the development of a wide range of diseases such as [[metabolic disorder]]s,<ref name=":27" /> [[Cardiovascular disease|cardiovascular disorders]], [[Inflammation|inflammatory]] processes, [[Viral disease|viral infections]], certain types of cancer and [[Autoimmune disease|autoimmune disorders]],<ref>{{Cite journal | vauthors = Guil-Guerrero JL, Rincón-Cervera MÁ, Venegas-Venegas E |date=2010 |title=Gamma-linolenic and stearidonic acids: Purification and upgrading of C18-PUFA oils |journal=European Journal of Lipid Science and Technology |language=en |volume=112 |issue=10 |pages=1068–1081 |doi=10.1002/ejlt.200900294 |issn=1438-7697}}</ref> as well as [[Skin condition|skin disorders]], as [[Skin|cutaneous]] cannabinoid ("c[ut]annabinoid") signaling is deeply involved in the maintenance of skin homeostasis, [[Innate immune system|barrier formation]] and [[Regeneration (biology)|regeneration]], and its dysregulation is implicated to contribute to several diseases and disorders, e.g., [[atopic dermatitis]], [[psoriasis]], [[scleroderma]], [[acne]], [[hair growth]] and [[Pigmentation disorder|pigmentation]] disorders, [[Keratin disease|keratin]] diseases, various tumors, and [[itch]], as the endocannabinoids (eCBs; e.g., NAE 20:4; AEA), the eCB-responsive receptors (e.g., CB<sub>1</sub>, CB<sub>2</sub>), as well as the complex enzyme and transporter apparatus involved in the metabolism of the [[ligand]]s, show to be expressed in several [[Tissue (biology)|tissues]], including the skin,<ref>{{Cite journal |last1=Tóth |first1=Kinga Fanni |last2=Ádám |first2=Dorottya |last3=Bíró |first3=Tamás |last4=Oláh |first4=Attila |date=6 March 2019 |title=Cannabinoid Signaling in the Skin: Therapeutic Potential of the "C(ut)annabinoid" System |journal=Molecules |volume=24 |issue=5 |pages=918 |doi=10.3390/molecules24050918 |issn=1420-3049 |pmc=6429381 |pmid=30845666 |doi-access=free }}</ref> where 18 [[prostanoid]]s, 12 [[Hydroxy group|hydroxy]]-[[fatty acid]]s, 9 endocannabinoids and ''N''-acyl ethanolamides (NAEs), and 21 non-[[Hydroxylation|hydroxylated]] [[ceramide]]s and [[Sphingolipid|sphingoid]] bases, of which several demonstrating significantly different expression in the tissues assayed, demonstrate the diversity of [[lipid]] mediators involved in maintaining tissue homeostasis in resting skin and hint at their contribution to signaling, cross-support, and functions of different skin compartments.<ref>{{Cite journal |last1=Kendall |first1=Alexandra C. |last2=Pilkington |first2=Suzanne M. |last3=Massey |first3=Karen A. |last4=Sassano |first4=Gary |last5=Rhodes |first5=Lesley E. |last6=Nicolaou |first6=Anna |date=1 June 2015 |title=Distribution of Bioactive Lipid Mediators in Human Skin |url=https://www.jidonline.org/article/S0022-202X(15)37264-X/fulltext |journal=Journal of Investigative Dermatology |language=English |volume=135 |issue=6 |pages=1510–1520 |doi=10.1038/jid.2015.41 |issn=0022-202X |pmid=25668241|s2cid=2385238 |doi-access=free }}</ref> |
||
The NAE substitutes, the phytocannabinoids from the flowers and |
The NAE substitutes, the phytocannabinoids from the flowers and fruits, like the [[Psychoactive drug|psychoactive]] compound Δ<sup>9</sup>-tetrahydrocannabinol (THC: C<sub>21</sub>H<sub>30</sub>O<sub>2</sub>) and the nonpsychotropic compounds [[cannabidiol]] (CBD: C<sub>21</sub>H<sub>30</sub>O<sub>2</sub>), and [[Leaf|leaves]] ([[Tetrahydrocannabinolic acid|THCA]]/[[Cannabidiolic acid synthase|CBDA]]: C<sub>22</sub>H<sub>30</sub>O<sub>4</sub>),<ref name=":16">{{Cite web |date=2008 |title=Marijuana Symposium Mendocino Sept 11 '08 |url=https://www.youtube.com/watch?v=GQMgQUo-1ng |url-status=live |archive-url=https://ghostarchive.org/varchive/youtube/20211215/GQMgQUo-1ng |archive-date=2021-12-15 |website=YouTube |vauthors=Courtney W}}{{cbignore}}</ref> from the plant, are also potent [[Peroxisome proliferator-activated receptor gamma|PPARγ]] agonist with [[Neuroprotection|neuroprotective]] activity,<ref>{{Cite web |last=PubChem |title=(6aR,10aR)-1-Hydroxy-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-dibenzo[b,d]pyran-4-carboxylic acid |url=https://pubchem.ncbi.nlm.nih.gov/compound/46889976 |access-date=2023-03-24 |website=pubchem.ncbi.nlm.nih.gov |language=en}}</ref><ref>{{Cite web |last=PubChem |title=Cannabidiolic acid |url=https://pubchem.ncbi.nlm.nih.gov/compound/160570 |access-date=2023-03-24 |website=pubchem.ncbi.nlm.nih.gov |language=en}}</ref><ref>{{Cite journal |last1=Nadal |first1=Xavier |last2=del Río |first2=Carmen |last3=Casano |first3=Salvatore |last4=Palomares |first4=Belén |last5=Ferreiro-Vera |first5=Carlos |last6=Navarrete |first6=Carmen |last7=Sánchez-Carnerero |first7=Carolina |last8=Cantarero |first8=Irene |last9=Bellido |first9=Maria Luz |last10=Meyer |first10=Stefan |last11=Morello |first11=Gaetano |last12=Appendino |first12=Giovanni |last13=Muñoz |first13=Eduardo |date=December 2017 |title=Tetrahydrocannabinolic acid is a potent PPARγ agonist with neuroprotective activity |journal=British Journal of Pharmacology |volume=174 |issue=23 |pages=4263–4276 |doi=10.1111/bph.14019 |issn=0007-1188 |pmc=5731255 |pmid=28853159}}</ref> and found to modulate inflammatory responses by regulating the production of [[cytokine]]s from [[keratinocyte]]s in several experimental models of skin inflammation, by [[CB2 receptor|CB<sub>2</sub>]] and [[TRPV1]] activation, where CBD dose-dependently elevates the levels of NAE 20:4 (AEA) and inhibits [[Polyinosinic:polycytidylic acid|poly-(I:C)]]-induced release of [[CCL8|MCP-2]], [[Interleukin 6|interleukin-6]] (IL-6), [[Interleukin 8|IL-8]], and [[Tumor necrosis factor α|tumor necrosis factor-''α'']]'','' in [[allergic contact dermatitis]] (ACD),<ref>{{Cite journal |last1=Petrosino |first1=Stefania |last2=Verde |first2=Roberta |last3=Vaia |first3=Massimo |last4=Allarà |first4=Marco |last5=Iuvone |first5=Teresa |last6=Marzo |first6=Vincenzo Di |date=1 June 2018 |title=Anti-inflammatory Properties of Cannabidiol, a Nonpsychotropic Cannabinoid, in Experimental Allergic Contact Dermatitis |url=https://jpet.aspetjournals.org/content/365/3/652 |journal=Journal of Pharmacology and Experimental Therapeutics |language=en |volume=365 |issue=3 |pages=652–663 |doi=10.1124/jpet.117.244368 |issn=0022-3565 |pmid=29632236|s2cid=4739468 |doi-access=free }}</ref> through the endocannabinoid system (ECS), and where FAAH–deficient mice, which have increased levels of NAE 20:4, displayed reduced [[allergic response]]s in the skin,<ref>{{Cite journal |last=Karsak |first=Meliha |date=8 June 2007 |title=Attenuation of Allergic Contact Dermatitis Through the Endocannabinoid System |url=https://www.science.org/doi/10.1126/science.1142265?keytype2=tf_ipsecsha&ijkey=b4545151147d6fac41003eb7d1599e43b4c87289 |journal=Science |volume=316 |issue=5830 |pages=1494–1497|doi=10.1126/science.1142265 |pmid=17556587 |bibcode=2007Sci...316.1494K |s2cid=37611370 }}</ref> as the activation of CB1 or CB2 increases endocannabinoid levels by inhibiting [[fatty acid amide hydrolase]] (FAAH) or [[adenylyl cyclase]], and activation of CB1 is tightly associated with the generation of [[Cell membrane|cellular]] [[ceramide]]s.<ref name=":39">{{Cite journal |last=Shin |first=Kyong-Oh |date=2 August 2021 |title=N-Palmitoyl Serinol Stimulates Ceramide Production through a CB1-Dependent Mechanism in In Vitro Model of Skin Inflammation |journal=Int J Mol Sci |volume=22 |issue=15|page=8302 |doi=10.3390/ijms22158302 |pmid=34361066 |pmc=8348051 |doi-access=free }}{{Creative Commons text attribution notice|cc=by4|from this source=yes}} |
||
</ref> |
</ref> |
||
Beside the CB1 receptors being triggers of the generation of [[ |
Beside the CB1 receptors being triggers of the generation of [[ceramide]]s that mediate [[neuron]]al [[Cell membrane|cell]] fate, the skin CB1 receptor aktivation also increases ceramides, with long-chain fatty acids (FAs) (C22–C24), which mainly account for the formation of the [[Epidermis|epidermal]] barrier, through activation of [[Sphingosine N-acyltransferase|ceramide synthase]], [[Ceramide synthase 2|CerS 2]] and [[Ceramide synthase 3|CerS 3]], thereby resulting in the enhancement of epidermal permeability barrier function in [[Interleukin 4|IL-4]] inflamed skin.<ref name=":39" /> |
||
[[Biosynthesis|Synthesis]] of [[PUFA|LC-PUFAs]] in |
[[Biosynthesis|Synthesis]] of [[PUFA|LC-PUFAs]] in humans and many other [[eukaryote]]s starts with: |
||
<nowiki>*</nowiki> [[Linoleic acid]] (LA: [[Carbon|C]]<sub>18</sub>[[Hydrogen|H]]<sub>32</sub>[[Oxygen|O]]<sub>2</sub>; 18:[[Double bond|2]]-n6) → [[Linoleoyl-CoA desaturase|Δ6-desaturation]] (removing two hydrogen atoms, creating a [[double bond]] and a bend in the fatty acid) → [[Gamma-Linolenic acid|''γ''-linolenic acid]] (GLA: C<sub>18</sub>H<sub>30</sub>O<sub>2</sub>; 18:3-n6) → Δ6-specific [[elongase]] (introducing two carbons and four hydrogens) → [[Dihomo-γ-linolenic acid|Dihomo-gamma-linolenic acid]] DGLA: C<sub>20</sub>H<sub>34</sub>O<sub>2</sub>; 20:3-n6) → [[FADS1|Δ5-desaturase]] → [[arachidonic acid]] (AA: C<sub>20</sub>H<sub>32</sub>O<sub>2</sub>; 20:4-n6) → also endocannabinoids. |
<nowiki>*</nowiki> [[Linoleic acid]] (LA: [[Carbon|C]]<sub>18</sub>[[Hydrogen|H]]<sub>32</sub>[[Oxygen|O]]<sub>2</sub>; 18:[[Double bond|2]]-n6) → [[Linoleoyl-CoA desaturase|Δ6-desaturation]] (removing two hydrogen atoms, creating a [[double bond]] and a bend in the fatty acid) → [[Gamma-Linolenic acid|''γ''-linolenic acid]] (GLA: C<sub>18</sub>H<sub>30</sub>O<sub>2</sub>; 18:3-n6) → Δ6-specific [[elongase]] (introducing two carbons and four hydrogens) → [[Dihomo-γ-linolenic acid|Dihomo-gamma-linolenic acid]] DGLA: C<sub>20</sub>H<sub>34</sub>O<sub>2</sub>; 20:3-n6) → [[FADS1|Δ5-desaturase]] → [[arachidonic acid]] (AA: C<sub>20</sub>H<sub>32</sub>O<sub>2</sub>; 20:4-n6) → also endocannabinoids. |
||
<nowiki>*</nowiki> [[Alpha-Linolenic acid|α-Linolenic acid]] (ALA: C<sub>18</sub>H<sub>30</sub>O<sub>2</sub>; 18:3-n3) → Δ6-desaturation → [[stearidonic acid]] (SDA: C<sub>18</sub>H<sub>28</sub>O<sub>2</sub>; 18:4-n3) and/or → Δ6-specific elongase → [[eicosatetraenoic acid]] (ETA: C<sub>20</sub>H<sub>32</sub>O<sub>2</sub>; 20:4-n3) → Δ5-desaturase → [[eicosapentaenoic acid]] (EPA: C<sub>20</sub>H<sub>30</sub>O<sub>2</sub>; 20:5-n3). |
<nowiki>*</nowiki> [[Alpha-Linolenic acid|α-Linolenic acid]] (ALA: C<sub>18</sub>H<sub>30</sub>O<sub>2</sub>; 18:3-n3) → Δ6-desaturation → [[stearidonic acid]] (SDA: C<sub>18</sub>H<sub>28</sub>O<sub>2</sub>; 18:4-n3) and/or → Δ6-specific elongase → [[eicosatetraenoic acid]] (ETA: C<sub>20</sub>H<sub>32</sub>O<sub>2</sub>; 20:4-n3) → Δ5-desaturase → [[eicosapentaenoic acid]] (EPA: C<sub>20</sub>H<sub>30</sub>O<sub>2</sub>; 20:5-n3) → elongation and Δ6-desaturation ([[FADS2]]) → [[docosahexaenoic acid]] (DHA: C<sub>22</sub>H<sub>32</sub>O<sub>2</sub>; 22:6-n3) → + ethanolamine (MEA: C<sub>2</sub>H<sub>7</sub>NO) → ''N-''Docosahexaenoyl ethanolamine (DHEA: C<sub>24</sub>H<sub>37</sub>NO<sub>2</sub>; 22:6, ω-3), or Anandamide (22:6, n-3) "synaptamide", is the non-[[Oxidative phosphorylation|oxidative]] produced amide, NAE 22:6.<ref>{{Cite journal |last1=Mukerjee |first1=Souvik |last2=Saeedan |first2=Abdulaziz S. |last3=Ansari |first3=Mohd Nazam |last4=Singh |first4=Manjari |date=2021 |title=Polyunsaturated Fatty Acids Mediated Regulation of Membrane Biochemistry and Tumor Cell Membrane Integrity |journal=Membranes |language=en |volume=11 |issue=7 |pages=479 |doi=10.3390/membranes11070479 |doi-access=free |pmid=34203433 |pmc=8304949 |issn=2077-0375}}</ref><ref name=":55">{{Cite journal |last1=Simón |first1=María Victoria |last2=Agnolazza |first2=Daniela L. |last3=German |first3=Olga Lorena |last4=Garelli |first4=Andrés |last5=Politi |first5=Luis E. |last6=Agbaga |first6=Martin-Paul |last7=Anderson |first7=Robert E. |last8=Rotstein |first8=Nora P. |date=2016 |title=Synthesis of docosahexaenoic acid from eicosapentaenoic acid in retina neurons protects photoreceptors from oxidative stress |journal=Journal of Neurochemistry |language=en |volume=136 |issue=5 |pages=931–946 |doi=10.1111/jnc.13487 |issn=0022-3042 |pmc=4755815 |pmid=26662863}}</ref><ref name=":44" /> |
||
By a Δ17-desaturase, [[gamma-Linolenic acid]] (GLA: C<sub>18</sub>H<sub>30</sub>O<sub>2</sub>; 18:3-n6) can be further converted to [[stearidonic acid]] (SDA: C<sub>18</sub>H<sub>28</sub>O<sub>2</sub>; 18:4-n3), [[Dihomo-γ-linolenic acid|dihomo-gamma-linolenic acid]] (DHGLA/DGLA: C<sub>20</sub>H<sub>34</sub>O<sub>2</sub>; 20:3-n6) to [[eicosatetraenoic acid]] (ETA: C<sub>20</sub>H<sub>32</sub>O<sub>2</sub>; 20:4-n3; omega-3 Arachidonic acid)<ref>{{Cite web | work = PubChem |title=8,11,14,17-Eicosatetraenoic acid |url=https://pubchem.ncbi.nlm.nih.gov/compound/3080584 |access-date=2022-11-28 | publisher = U.S. National Library of Medicine |language=en}}</ref> and [[arachidonic acid]] (AA: C<sub>20</sub>H<sub>32</sub>O<sub>2</sub>; 20:4-n6) to [[eicosapentaenoic acid]] (EPA: C<sub>20</sub>H<sub>30</sub>O<sub>2</sub>; 20:5-n3), respectively.<ref>{{cite journal | vauthors = Abedi E, Sahari MA | title = Long-chain polyunsaturated fatty acid sources and evaluation of their nutritional and functional properties | journal = Food Science & Nutrition | volume = 2 | issue = 5 | pages = 443–463 | date = September 2014 | pmid = 25473503 | pmc = 4237475 | doi = 10.1002/fsn3.121 }}</ref> |
By a Δ17-desaturase, [[gamma-Linolenic acid]] (GLA: C<sub>18</sub>H<sub>30</sub>O<sub>2</sub>; 18:3-n6) can be further converted to [[stearidonic acid]] (SDA: C<sub>18</sub>H<sub>28</sub>O<sub>2</sub>; 18:4-n3), [[Dihomo-γ-linolenic acid|dihomo-gamma-linolenic acid]] (DHGLA/DGLA: C<sub>20</sub>H<sub>34</sub>O<sub>2</sub>; 20:3-n6) to [[eicosatetraenoic acid]] (ETA: C<sub>20</sub>H<sub>32</sub>O<sub>2</sub>; 20:4-n3; omega-3 Arachidonic acid)<ref>{{Cite web | work = PubChem |title=8,11,14,17-Eicosatetraenoic acid |url=https://pubchem.ncbi.nlm.nih.gov/compound/3080584 |access-date=2022-11-28 | publisher = U.S. National Library of Medicine |language=en}}</ref> and [[arachidonic acid]] (AA: C<sub>20</sub>H<sub>32</sub>O<sub>2</sub>; 20:4-n6) to [[eicosapentaenoic acid]] (EPA: C<sub>20</sub>H<sub>30</sub>O<sub>2</sub>; 20:5-n3), respectively.<ref>{{cite journal | vauthors = Abedi E, Sahari MA | title = Long-chain polyunsaturated fatty acid sources and evaluation of their nutritional and functional properties | journal = Food Science & Nutrition | volume = 2 | issue = 5 | pages = 443–463 | date = September 2014 | pmid = 25473503 | pmc = 4237475 | doi = 10.1002/fsn3.121 }}</ref> |
||
* [[Fatty acid]]s with at least 20 carbons (C<sub>20</sub>) and three double bonds (20:3) bind to [[Cannabinoid receptor type 1|CB1]] receptors.<ref name=":25" /> |
* [[Fatty acid]]s with at least 20 carbons (C<sub>20</sub>) and three double bonds (20:3) bind to [[Cannabinoid receptor type 1|CB1]] receptors.<ref name=":25" /> |
||
* [[Arachidonic acid]] (AA) is also the catalyst to the formation of the two main [[Endocannabinoid system|endocannabinoids]], [[Anandamide]] (AEA) and [[2-Arachidonoylglycerol |
* [[Arachidonic acid]] (AA) is also the catalyst to the formation of the two main [[Endocannabinoid system|endocannabinoids]], [[Anandamide]] (AEA) and [[2-Arachidonoylglycerol]] (2-AG). |
||
<nowiki>*</nowiki> [[Anandamide]] (AEA: C<sub>22</sub>H<sub>37</sub>[[Biological functions of nitric oxide|NO]]<sub>2</sub>; 20:4,n-6) is an ''N''-acylethanolamine resulting from the formal [[Condensation reaction|condensation]] of the [[Carboxylic acid|carboxy]] group of arachidonic acid (AA: C<sub>20</sub>H<sub>32</sub>O<sub>2</sub>; 20:4-n6) with the [[Amino acid|amino]] group of [[ethanolamine]] (C<sub>2</sub>H<sub>7</sub>[[Biological functions of nitric oxide|NO]]), bind preferably to [[Cannabinoid receptor type 1|CB1]] receptors.<ref>{{Cite web | work = PubChem |title=Anandamide |url=https://pubchem.ncbi.nlm.nih.gov/compound/5281969 |access-date=2022-11-28 | publisher = U.S. National Library of Medicine |language=en}}</ref> |
<nowiki>*</nowiki> [[Anandamide]] (AEA: C<sub>22</sub>H<sub>37</sub>[[Biological functions of nitric oxide|NO]]<sub>2</sub>; 20:4,n-6) is an ''N''-acylethanolamine resulting from the formal [[Condensation reaction|condensation]] of the [[Carboxylic acid|carboxy]] group of arachidonic acid (AA: C<sub>20</sub>H<sub>32</sub>O<sub>2</sub>; 20:4-n6) with the [[Amino acid|amino]] group of [[ethanolamine]] (C<sub>2</sub>H<sub>7</sub>[[Biological functions of nitric oxide|NO]]), bind preferably to [[Cannabinoid receptor type 1|CB1]] receptors.<ref>{{Cite web | work = PubChem |title=Anandamide |url=https://pubchem.ncbi.nlm.nih.gov/compound/5281969 |access-date=2022-11-28 | publisher = U.S. National Library of Medicine |language=en}}</ref> |
||
<nowiki>*</nowiki> [[2-Arachidonoylglycerol |
<nowiki>*</nowiki> [[2-Arachidonoylglycerol]] (2-AG: C<sub>23</sub>H<sub>38</sub>O<sub>4</sub>; 20:4-n6) is an endogenous [[agonist]] of the [[cannabinoid receptor]]s (CB1 and CB2), and the physiological [[Ligand (biochemistry)|ligand]] for the cannabinoid [[CB2 receptor]].<ref name=":28" /> It is an [[ester]] formed from omega-6-arachidonic acid (AA: C<sub>20</sub>H<sub>32</sub>O<sub>2</sub>; 20:4-n6) and [[glycerol]] (C<sub>3</sub>H<sub>8</sub>O<sub>3</sub>),<ref>{{Cite web |work =PubChem |title=2-Arachidonoylglycerol |url=https://pubchem.ncbi.nlm.nih.gov/compound/5282280 |access-date=2022-11-28 | publisher = U.S. National Library of Medicine |language=en}}</ref> and [[Tissue (biology)|tissue]] levels of 2-AG is usually several tens to several hundreds of times those of AEA.<ref name=":37" /> |
||
The N-acylethanolamine synthesis pathway is one of the non-oxidative pathways in which the mainly [[fish oil]] derived n−3 long-chain [[ |
The N-acylethanolamine synthesis pathway is one of the non-oxidative pathways in which the mainly [[fish oil]] derived n−3 long-chain [[polyunsaturated fatty acid]]s ([[Omega-3 polyunsaturated fatty acid|n−3 LCPUFA]], [[Carbon|C]]<sub>18</sub> to C<sub>22</sub>), [[Omega-3 fatty acid|ω-3]] [[Fatty acid|FAs]] [[docosahexaenoic acid]] (DHA: [[Carbon|C]]<sub>22</sub>[[Hydrogen|H]]<sub>32</sub>[[Oxygen|O]]<sub>2</sub>; 22:[[Double bond|6]], n-3) and [[eicosapentaenoic acid]] (EPA: C<sub>20</sub>H<sub>30</sub>O<sub>2</sub>; 20:5, n-3) are converted to NAE 22:6 docosahexaenoyl ethanolamide (DHEA: C<sub>24</sub>H<sub>37</sub>[[Biological functions of nitric oxide|NO]]<sub>2</sub>; 22:6, ω-3)<ref name=":44" /> and NAE 20:5 eicosapentaenoyl ethanolamide (EPEA: C<sub>22</sub>H<sub>35</sub>NO<sub>2</sub>; 20:5, ω-3), or Anandamid (20:5, n-3),<ref name=":45" /> by incorporated [[ethanolamine]] (MEA: C<sub>2</sub>H<sub>7</sub>NO), respectively. On common diseases including cancers, this conversion show beneficial [[Synergy|synergistic]] effect, when administered with the NAE-[[fatty acid]] familiar<!--Please do not link this to family, which is about domestic groups of people--> [[cannabinoid]]s,<ref name=":43" /> like [[Tetrahydrocannabinol|delta(9)-tetrahydrocannabinol]] (THC: C<sub>21</sub>H<sub>30</sub>O<sub>2</sub>), – a [[metabolite]] of [[Tetrahydrocannabinolic acid|delta9-tetrahydrocannabinolic acid]] (THCA: C<sub>22</sub>H<sub>30</sub>O<sub>4</sub>), a [[Diterpene|diterpenoid]], with a [[carboxyl group]] (–COOH) at one end, like [[11-Nor-9-carboxy-THC]] (THC-COOH: C<sub>21</sub>H<sub>28</sub>O<sub>4</sub>), the secondary [[metabolite]] of THC, which is formed in the body after [[Cannabis (drug)|cannabis]] is consumed, that has a role as an [[anti-inflammatory]] and a [[Neuroprotection|neuroprotective]] agent,<ref>{{Cite web |last=PubChem |title=delta9-Tetrahydrocannabinolic acid |url=https://pubchem.ncbi.nlm.nih.gov/compound/98523 |access-date=2023-08-05 |website=pubchem.ncbi.nlm.nih.gov |language=en}}</ref> – and a non-[[narcotic]] [[analgesic]], a [[hallucinogen]], a [[cannabinoid receptor]] agonist and an [[epitope]].<ref name=":50">{{Cite web |last=PubChem |title=Dronabinol |url=https://pubchem.ncbi.nlm.nih.gov/compound/16078 |access-date=2023-08-05 |website=pubchem.ncbi.nlm.nih.gov |language=en}}</ref> As ''[[Cannabis sativa]]'' and their derivatives act in the [[organism]] by mimicking endogenous substances, the endocannabinoids, that activate specific cannabinoid receptors, is why cannabinoids are found to be selective [[Chemotherapy|antitumour]] compounds, that can kill [[Neoplasm|tumour cells]], by growth arrest or [[apoptosis]], without affecting their non-transformed counterparts, is probably because, cannabinoid receptors regulate cell-survival and [[Cell death|cell-death]] pathways differently in tumour and non-tumour cells.<ref>{{Cite journal |last=Guzmán |first=Manuel |date=2003 |title=Cannabinoids: potential anticancer agents |url=https://www.nature.com/articles/nrc1188 |journal=Nature Reviews Cancer |language=en |volume=3 |issue=10 |pages=745–755 |doi=10.1038/nrc1188 |pmid=14570037 |s2cid=7868655 |issn=1474-1768}}</ref><ref>{{Cite journal |last1=Guzmán |first1=Manuel |last2=Sánchez |first2=Cristina |last3=Galve-Roperh |first3=Ismael |date=1 January 2001 |title=Control of the cell survival/death decision by cannabinoids |url=https://doi.org/10.1007/s001090000177 |journal=Journal of Molecular Medicine |language=en |volume=78 |issue=11 |pages=613–625 |doi=10.1007/s001090000177 |pmid=11269508 |s2cid=12278192 |issn=1432-1440}}</ref><ref>{{Cite journal |last1=Munson |first1=A. E. |last2=Harris |first2=L. S. |last3=Friedman |first3=M. A. |last4=Dewey |first4=W. L. |last5=Carchman |first5=R. A. |date=1 September 1975 |title=Antineoplastic Activity of Cannabinoids |url=https://academic.oup.com/jnci/article-abstract/55/3/597/912322 |journal=Journal of the National Cancer Institute |volume=55 |issue=3 |pages=597–602|doi=10.1093/jnci/55.3.597 |pmid=1159836 }}</ref><ref name=":46" /><ref>{{Cite journal |last=Clark |first=Thomas M. |date=13 October 2021 |title=Scoping Review and Meta-Analysis Suggests that Cannabis Use May Reduce Cancer Risk in the United States |journal=Cannabis Cannabinoid Res. |volume=6 |issue=5 |pages=413–434 |doi=10.1089/can.2019.0095 |pmid=33998861 |pmc=8612444 }}</ref> |
||
== Metabolic production of NAEs == |
== Metabolic production of NAEs == |
||
Line 110: | Line 111: | ||
The major COX-2 derived prostanoid product from NAE 20:4 (AEA) are [[prostaglandin E2]] (PGE<sub>2</sub>) ethanolamide (PGE<sub>2</sub>-EA; prostamide E2) and [[Prostaglandin D2|PGD<sub>2</sub>]] ethanolamide (PGD<sub>2</sub>-EA; prostamide D2), might have many important functions,<ref>{{cite journal | vauthors = Yu M, Ives D, Ramesha CS | title = Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2 | journal = The Journal of Biological Chemistry | volume = 272 | issue = 34 | pages = 21181–6 | date = August 1997 | pmid = 9261124 | doi = 10.1074/jbc.272.34.21181 | doi-access = free }}</ref> as PGE<sub>2</sub> and PGD<sub>2</sub> are pro-inflammatory mediators responsible for the induction of [[inflammation]],<ref name="Dyall 2017 885–900"/> PGE<sub>2</sub>-EA and PGD<sub>2</sub>-EA are contrary both growth inhibitory and can induce [[apoptosis]],<ref>{{cite journal | vauthors = Patsos HA, Hicks DJ, Dobson RR, Greenhough A, Woodman N, Lane JD, Williams AC, Paraskeva C | display-authors = 6 | title = The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2 | journal = Gut | volume = 54 | issue = 12 | pages = 1741–50 | date = December 2005 | pmid = 16099783 | pmc = 1774787 | doi = 10.1136/gut.2005.073403 }}</ref> as well as that NAE 20:4 (AEA) and/or its prostamide metabolites in the [[renal medulla]], may represent [[medullipin]] and function as a regulator of [[body fluid]] and the [[mean arterial pressure]] (MAP).<ref>{{cite journal | vauthors = Ritter JK, Li C, Xia M, Poklis JL, Lichtman AH, Abdullah RA, Dewey WL, Li PL | display-authors = 6 | title = Production and actions of the anandamide metabolite prostamide E2 in the renal medulla | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 342 | issue = 3 | pages = 770–9 | date = September 2012 | pmid = 22685343 | pmc = 3422528 | doi = 10.1124/jpet.112.196451 }}</ref> |
The major COX-2 derived prostanoid product from NAE 20:4 (AEA) are [[prostaglandin E2]] (PGE<sub>2</sub>) ethanolamide (PGE<sub>2</sub>-EA; prostamide E2) and [[Prostaglandin D2|PGD<sub>2</sub>]] ethanolamide (PGD<sub>2</sub>-EA; prostamide D2), might have many important functions,<ref>{{cite journal | vauthors = Yu M, Ives D, Ramesha CS | title = Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2 | journal = The Journal of Biological Chemistry | volume = 272 | issue = 34 | pages = 21181–6 | date = August 1997 | pmid = 9261124 | doi = 10.1074/jbc.272.34.21181 | doi-access = free }}</ref> as PGE<sub>2</sub> and PGD<sub>2</sub> are pro-inflammatory mediators responsible for the induction of [[inflammation]],<ref name="Dyall 2017 885–900"/> PGE<sub>2</sub>-EA and PGD<sub>2</sub>-EA are contrary both growth inhibitory and can induce [[apoptosis]],<ref>{{cite journal | vauthors = Patsos HA, Hicks DJ, Dobson RR, Greenhough A, Woodman N, Lane JD, Williams AC, Paraskeva C | display-authors = 6 | title = The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2 | journal = Gut | volume = 54 | issue = 12 | pages = 1741–50 | date = December 2005 | pmid = 16099783 | pmc = 1774787 | doi = 10.1136/gut.2005.073403 }}</ref> as well as that NAE 20:4 (AEA) and/or its prostamide metabolites in the [[renal medulla]], may represent [[medullipin]] and function as a regulator of [[body fluid]] and the [[mean arterial pressure]] (MAP).<ref>{{cite journal | vauthors = Ritter JK, Li C, Xia M, Poklis JL, Lichtman AH, Abdullah RA, Dewey WL, Li PL | display-authors = 6 | title = Production and actions of the anandamide metabolite prostamide E2 in the renal medulla | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 342 | issue = 3 | pages = 770–9 | date = September 2012 | pmid = 22685343 | pmc = 3422528 | doi = 10.1124/jpet.112.196451 }}</ref> |
||
Fatty acid amide hydrolase (FAAH) is the main degrading enzyme of NAE 20:4 (AEA) and NAE 18:1 (OEA), which have opposite effects on food intake and [[Energy homeostasis|energy balance]]. AEA, an endogenous ligand of CB1 cannabinoid receptors, enhances food intake and energy storage, whereas OEA binds to [[Peroxisome proliferator-activated receptor|peroxisome proliferator-activated receptors-α]] to reduce food intake and promoting [[lipolysis]], thereby FAAH deficiency promotes [[energy storage]] and enhances the [[motivation]] for |
Fatty acid amide hydrolase (FAAH) is the main degrading enzyme of NAE 20:4 (AEA) and NAE 18:1 (OEA), which have opposite effects on food intake and [[Energy homeostasis|energy balance]]. AEA, an endogenous ligand of CB1 cannabinoid receptors, enhances food intake and energy storage, whereas OEA binds to [[Peroxisome proliferator-activated receptor|peroxisome proliferator-activated receptors-α]] to reduce food intake and promoting [[lipolysis]], thereby FAAH deficiency promotes [[energy storage]] and enhances the [[motivation]] for food, through the enhancement of AEA levels rather than promoting the [[Anorectic|anorexic]] effects of OEA.<ref>{{cite journal | vauthors = Touriño C, Oveisi F, Lockney J, Piomelli D, Maldonado R | title = FAAH deficiency promotes energy storage and enhances the motivation for food | journal = International Journal of Obesity | volume = 34 | issue = 3 | pages = 557–568 | date = March 2010 | pmid = 20029375 | pmc = 3709605 | doi = 10.1038/ijo.2009.262 | doi-access = free }}</ref> Tetrahydrocannabinol (THC: [[Carbon|C]]<sub>21</sub>[[Hydrogen|H]]<sub>30</sub>[[Oxygen|O]]<sub>2</sub>) is found to lower production of NAE 20:4 (AEA) and 2-AG, that is synthesized in an on-demand manner when needed for activation,<ref>{{cite journal | vauthors = Filipiuc LE, Ababei DC, Alexa-Stratulat T, Pricope CV, Bild V, Stefanescu R, Stanciu GD, Tamba BI | display-authors = 6 | title = Major Phytocannabinoids and Their Related Compounds: Should We Only Search for Drugs That Act on Cannabinoid Receptors? | journal = Pharmaceutics | volume = 13 | issue = 11 | pages = 1823 | date = November 2021 | pmid = 34834237 | pmc = 8625816 | doi = 10.3390/pharmaceutics13111823 | doi-access = free }}</ref> by a [[Phase (pharmacology)|biphasic]] response after THC injection reaching maximal values at 30 min., where AEA increased slightly from 0.58 ± 0.21 ng/ml at baseline to 0.64 ± 0.24 ng/ml, and 2-AG from 7,60 ± 4,30 ng/ml to 9,50 ± 5,90 ng/ml, and after reaching maximal concentrations, EC plasma levels decreased markedly to a nadir of 300 min after THC administration to 0.32 ± 0.15 ng/ml for AEA, and 5,50 ± 3,01 ng/ml for 2-AG, and returned to near baseline levels until 48 hours after the experiment, in 25 healthy volunteers who received a large intravenous dose of THC (0.10 mg/kg).<ref name=":21" /> |
||
[[Insulin (medication)|Insulin medication]] and [[intraoperative]] doses of [[insulin]] is also found, but not recognized by companies [[Novo Nordisk|producing]] and selling medication to general public also as a slimming formula like [[Semaglutide|Wegovy]], to get its [[anorectic]] effect by the |
[[Insulin (medication)|Insulin medication]] and [[intraoperative]] doses of [[insulin]] is also found, but not recognized by companies [[Novo Nordisk|producing]] and selling medication to general public also as a slimming formula like [[Semaglutide|Wegovy]], to get its [[anorectic]] effect by the involvement of [[Fatty acid amide hydrolase|FAAH]] activity, which, beside of other NAE's, degrade NAE 20:4 (AEA),<ref name=":29">{{cite journal | vauthors = Weis F, Beiras-Fernandez A, Hauer D, Hornuss C, Sodian R, Kreth S, Briegel J, Schelling G | display-authors = 6 | title = Effect of anaesthesia and cardiopulmonary bypass on blood endocannabinoid concentrations during cardiac surgery | language = English | journal = British Journal of Anaesthesia | volume = 105 | issue = 2 | pages = 139–144 | date = August 2010 | pmid = 20525978 | doi = 10.1093/bja/aeq117 | doi-access = free }}</ref> suggest that insulin may play a key role in the obesity-linked dysregulation of the adipose ECS at the [[gene]] level.<ref name=":30">{{cite journal | vauthors = Murdolo G, Kempf K, Hammarstedt A, Herder C, Smith U, Jansson PA | title = Insulin differentially modulates the peripheral endocannabinoid system in human subcutaneous abdominal adipose tissue from lean and obese individuals | journal = Journal of Endocrinological Investigation | volume = 30 | issue = 8 | pages = RC17–RC21 | date = September 2007 | pmid = 17923791 | doi = 10.1007/BF03347440 | s2cid = 39337082 }}</ref> And is possible why the [[European Medicines Agency]] (EMA) in 2023 are investigating several reports from European countries about [[Suicidal ideation|suicidal thoughts]] and thoughts of [[self-harm]] in patients, who have been treated with [[Novo Nordisk]]'s popular [[Diabetes medication|medicines]] for [[obesity]] and [[diabetes]].<ref>{{Cite web |last1=Journalist |first1=Vibeke Lyngklip Svansø |last2=Journalist |first2=Signe Westermann Kühn |date=23 June 2023 |title=Ny bekymring om populære Novo Nordisk-lægemidler – undersøger om de kan give selvmordstanker |url=https://www.berlingske.dk/content/item/1735511 |access-date=2023-07-04 |website=Berlingske.dk |language=da}}</ref> An outcome also seen in the CB1 receptor blocker [[rimonabant]], an [[anorectic]] [[Anti-obesity|antiobesity drug]] that was first approved in Europe in 2006 but was withdrawn worldwide in 2008 due to serious psychiatric side effects,<ref name=":16" /><ref name=":49" /> and happening at the same time as EMA, has raised a [[Pharmacovigilance|safety alert]] for Wegovy, that also applies to the companies diabetes medication [[Semaglutide|Ozempic]], based on a study that suggests that the active substance in the two preparations, can increase the risk of [[thyroid cancer]] in patients with [[type 2 diabetes]].<ref>{{Cite web |last=Weber |first=Cordelia |date=21 June 2023 |title=Novo Nordisk-slankemiddel undersøges for at øge kræftrisiko |url=https://www.bt.dk/content/item/1700794 |access-date=2023-07-04 |website=www.bt.dk |language=da}}</ref> |
||
FAAH expression, that metabolizes NAE 20:4 (AEA) involved in the regulation of [[emotion]]al reactivity, into [[ethanolamine]] and [[arachidonic acid]], is found significantly increased in [[Depression (mood)|depressive]]-like phenotypes, where [[Knockout mouse|knockout]] or pharmacological inhibition of FAAH effectively reduces depressive-like behavior, with a dose-dependent effect, that elicits [[anxiolytic]] and [[antidepressant]]-like effects, like the NAE 20:4 (AEA) substitutes [[Tetrahydrocannabinol|∆<sup>9</sup>-THC]] and other [[ |
FAAH expression, that metabolizes NAE 20:4 (AEA) involved in the regulation of [[emotion]]al reactivity, into [[ethanolamine]] and [[arachidonic acid]], is found significantly increased in [[Depression (mood)|depressive]]-like phenotypes, where [[Knockout mouse|knockout]] or pharmacological inhibition of FAAH effectively reduces depressive-like behavior, with a dose-dependent effect, that elicits [[anxiolytic]] and [[antidepressant]]-like effects, like the NAE 20:4 (AEA) substitutes [[Tetrahydrocannabinol|∆<sup>9</sup>-THC]] and other [[cannabinoid]]s that may contribute to the overall [[Mood (psychology)|mood]]-elevating properties of [[Cannabis (drug)|cannabis]],<ref name=":53">{{Cite journal |last=El-Alfy |first=Abir T. |date=21 March 2010 |title=Antidepressant-like effect of Δ9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L |journal=Pharmacol Biochem Behav |volume=95 |issue=4 |pages=434–442|doi=10.1016/j.pbb.2010.03.004 |pmid=20332000 |pmc=2866040 }}</ref><ref>{{Cite journal |last1=Fokos |first1=S. |last2=Panagis |first2=G. |date=2010 |title=Effects of delta9-tetrahydrocannabinol on reward and anxiety in rats exposed to chronic unpredictable stress |url=https://pubmed.ncbi.nlm.nih.gov/19406854/ |journal=Journal of Psychopharmacology |volume=24 |issue=5 |pages=767–777 |doi=10.1177/0269881109104904 |issn=1461-7285 |pmid=19406854|s2cid=8855238 }}</ref><ref>{{Cite journal |last1=Sharpe |first1=Lara |last2=Sinclair |first2=Justin |last3=Kramer |first3=Andrew |last4=de Manincor |first4=Michael |last5=Sarris |first5=Jerome |date=2 October 2020 |title=Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties |journal=Journal of Translational Medicine |volume=18 |issue=1 |pages=374 |doi=10.1186/s12967-020-02518-2 |issn=1479-5876 |pmc=7531079 |pmid=33008420 |doi-access=free }}</ref> and differences in FAAH expression in depressive-like phenotypes were largely localized to animal [[prefrontal cortex]] (PFC), [[hippocampus]] and [[striatum]], containing high densities of [[Cannabinoid receptor type 1|CB1]] receptors.<ref>{{Cite journal |last1=Rafiei |first1=Dorsa |last2=Kolla |first2=Nathan J. |date=21 January 2021 |title=Elevated Brain Fatty Acid Amide Hydrolase Induces Depressive-Like Phenotypes in Rodent Models: A Review |journal=International Journal of Molecular Sciences |volume=22 |issue=3 |pages=1047 |doi=10.3390/ijms22031047 |issn=1422-0067 |pmc=7864498 |pmid=33494322 |doi-access=free }}</ref><ref>{{Cite journal |last1=Viveros |first1=M. P. |last2=Marco |first2=Eva M. |last3=File |first3=Sandra E. |date=2005 |title=Endocannabinoid system and stress and anxiety responses |url=https://pubmed.ncbi.nlm.nih.gov/15927244/ |journal=Pharmacology, Biochemistry, and Behavior |volume=81 |issue=2 |pages=331–342 |doi=10.1016/j.pbb.2005.01.029 |issn=0091-3057 |pmid=15927244|s2cid=25052842 }}</ref> As well as FAAH levels in [[amygdala]] and PFC are elevated in [[borderline personality disorder]], which relates to the [[hostility]] and [[aggression]], are consistent with the model, that lower endocannabinoid tone perturb PFC circuitry that regulates emotion and aggression, provide preliminary evidence of elevated PFC FAAH binding in any [[Mental disorder|psychiatric condition]].<ref name=":47">{{Cite journal |last=Kolla |first=Nathan J. |date=10 June 2020 |title=Elevated fatty acid amide hydrolase in the prefrontal cortex of borderline personality disorder: a [11C]CURB positron emission tomography study |journal=Neuropsychopharmacology |volume=45 |issue=11 |pages=1834–1841 |doi=10.1038/s41386-020-0731-y |pmid=32521537 |pmc=7608329 }}</ref> |
||
A FAAH 385A mutant alleles have been found to have a direct effect on elevated plasma levels of NAE 20:4 (AEA) and related NAEs in humans, and biomarkers that may indicate risk for severe [[obesity]] that suggest novel [[Endocannabinoid system|ECS]] obesity treatment strategies,<ref>{{cite journal | vauthors = Sipe JC, Scott TM, Murray S, Harismendy O, Simon GM, Cravatt BF, Waalen J | title = Biomarkers of endocannabinoid system activation in severe obesity | journal = PLOS ONE | volume = 5 | issue = 1 | pages = e8792 | date = January 2010 | pmid = 20098695 | pmc = 2808340 | doi = 10.1371/journal.pone.0008792 | doi-access = free | bibcode = 2010PLoSO...5.8792S }}</ref> as [[leptin]] increases the FAAH activity and reduces NAE 20:4 (AEA) signaling, particularly within the [[hypothalamus]], to promote a suppression of [[Eating|food intake]], a mechanism that is lost in diet-induced obesity and modulated by a human genetic variant (C385A) of the ''FAAH'' [[gene]].<ref>{{cite journal | vauthors = Balsevich G, Sticht M, Bowles NP, Singh A, Lee TT, Li Z, Chelikani PK, Lee FS, Borgland SL, Hillard CJ, McEwen BS, Hill MN | display-authors = 6 | title = Role for fatty acid amide hydrolase (FAAH) in the leptin-mediated effects on feeding and energy balance | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 115 | issue = 29 | pages = 7605–7610 | date = July 2018 | pmid = 29967158 | pmc = 6055171 | doi = 10.1073/pnas.1802251115 | doi-access = free | bibcode = 2018PNAS..115.7605B }}</ref> The cannabinoid type 1 receptors (CB1) and their endogenous ligands, the endocannabinoids, present in peripheral organs, such as [[liver]], [[white adipose tissue]], [[muscle]], and [[pancreas]], where it regulate [[Lipid signaling|lipid]] and [[glucose]] [[homeostasis]], and dysregulation of it, has been associated with the development of obesity, characterized by chronic mild [[inflammation]],<ref>{{cite journal | vauthors = Trayhurn P, Bing C, Wood IS | title = Adipose tissue and |
A FAAH 385A mutant alleles have been found to have a direct effect on elevated plasma levels of NAE 20:4 (AEA) and related NAEs in humans, and biomarkers that may indicate risk for severe [[obesity]] that suggest novel [[Endocannabinoid system|ECS]] obesity treatment strategies,<ref>{{cite journal | vauthors = Sipe JC, Scott TM, Murray S, Harismendy O, Simon GM, Cravatt BF, Waalen J | title = Biomarkers of endocannabinoid system activation in severe obesity | journal = PLOS ONE | volume = 5 | issue = 1 | pages = e8792 | date = January 2010 | pmid = 20098695 | pmc = 2808340 | doi = 10.1371/journal.pone.0008792 | doi-access = free | bibcode = 2010PLoSO...5.8792S }}</ref> as [[leptin]] increases the FAAH activity and reduces NAE 20:4 (AEA) signaling, particularly within the [[hypothalamus]], to promote a suppression of [[Eating|food intake]], a mechanism that is lost in diet-induced obesity and modulated by a human genetic variant (C385A) of the ''FAAH'' [[gene]].<ref>{{cite journal | vauthors = Balsevich G, Sticht M, Bowles NP, Singh A, Lee TT, Li Z, Chelikani PK, Lee FS, Borgland SL, Hillard CJ, McEwen BS, Hill MN | display-authors = 6 | title = Role for fatty acid amide hydrolase (FAAH) in the leptin-mediated effects on feeding and energy balance | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 115 | issue = 29 | pages = 7605–7610 | date = July 2018 | pmid = 29967158 | pmc = 6055171 | doi = 10.1073/pnas.1802251115 | doi-access = free | bibcode = 2018PNAS..115.7605B }}</ref> The cannabinoid type 1 receptors (CB1) and their endogenous ligands, the endocannabinoids, present in peripheral organs, such as [[liver]], [[white adipose tissue]], [[muscle]], and [[pancreas]], where it regulate [[Lipid signaling|lipid]] and [[glucose]] [[homeostasis]], and dysregulation of it, has been associated with the development of obesity, characterized by chronic mild [[inflammation]],<ref>{{cite journal | vauthors = Trayhurn P, Bing C, Wood IS | title = Adipose tissue and adipokines—energy regulation from the human perspective | journal = The Journal of Nutrition | volume = 136 | issue = 7 Suppl | pages = 1935S–1939S | date = July 2006 | pmid = 16772463 | doi = 10.1093/jn/136.7.1935S | doi-access = free }}</ref> and its sequelae, such as [[dyslipidemia]] and [[diabetes]], are involved in modulating food intake and the motivation to consume [[Palatability|palatable]] food.<ref>{{cite book | vauthors = Cota D | title = Obesity and Metabolism | chapter = Role of the endocannabinoid system in energy balance regulation and obesity | language = english | volume = 36 | pages = 135–145 | date = 2008 | pmid = 18230900 | doi = 10.1159/000115362 | isbn = 978-3-8055-8429-6 | series = Frontiers of Hormone Research | publisher = KARGER | location = Basel }}</ref> |
||
NAE 20:4 related THC treatment have shown to increase culture protein content and reduced methyl-(3)H-thymidine incorporation, and cells treated with THC underwent [[adipogenesis]] shown by the expression of [[PPARγ]] and had increased [[lipid accumulation]]. Basal and IP-stimulated [[Lipolysis|lipolyses]] were also inhibited by THC, and the effects on methyl-(3)H-thymidine incorporation and lipolysis seem to be mediated through CB1- and CB2-dependent pathways. THC did also decrease NAPE-PLD, the [[enzyme]] that catalyzes and converts ordinary [[lipid]]s into chemical signals like NAE 20:4 (AEA) and NAE 18:1 (OEA), in preadipocytes and increased [[adiponectin]] and [[TGFβ]] transcription in [[adipocyte]]s, results that show the ECS interferes with adipocyte biology and may contribute to adipose [[Tissue remodeling|tissue (AT) remodeling]]. And this stimulation of adiponectin production and inhibition of lipolysis from THC may be in favor of improved [[insulin]] sensitivity under cannabinoid influence.<ref>{{cite journal | vauthors = Teixeira D, Pestana D, Faria A, Calhau C, Azevedo I, Monteiro R | title = Modulation of adipocyte biology by δ(9)-tetrahydrocannabinol | journal = Obesity | volume = 18 | issue = 11 | pages = 2077–2085 | date = November 2010 | pmid = 20467421 | doi = 10.1038/oby.2010.100 | doi-access = free }}</ref> |
NAE 20:4 related THC treatment have shown to increase culture protein content and reduced methyl-(3)H-thymidine incorporation, and cells treated with THC underwent [[adipogenesis]] shown by the expression of [[PPARγ]] and had increased [[lipid accumulation]]. Basal and IP-stimulated [[Lipolysis|lipolyses]] were also inhibited by THC, and the effects on methyl-(3)H-thymidine incorporation and lipolysis seem to be mediated through CB1- and CB2-dependent pathways. THC did also decrease NAPE-PLD, the [[enzyme]] that catalyzes and converts ordinary [[lipid]]s into chemical signals like NAE 20:4 (AEA) and NAE 18:1 (OEA), in preadipocytes and increased [[adiponectin]] and [[TGFβ]] transcription in [[adipocyte]]s, results that show the ECS interferes with adipocyte biology and may contribute to adipose [[Tissue remodeling|tissue (AT) remodeling]]. And this stimulation of adiponectin production and inhibition of lipolysis from THC may be in favor of improved [[insulin]] sensitivity under cannabinoid influence.<ref>{{cite journal | vauthors = Teixeira D, Pestana D, Faria A, Calhau C, Azevedo I, Monteiro R | title = Modulation of adipocyte biology by δ(9)-tetrahydrocannabinol | journal = Obesity | volume = 18 | issue = 11 | pages = 2077–2085 | date = November 2010 | pmid = 20467421 | doi = 10.1038/oby.2010.100 | doi-access = free }}</ref> |
||
A [[WIN 55,212-2|full agonist]] at the [[CB1 receptor|CB<sub>1</sub>]] receptor is found able to up-regulate [[Peroxisome proliferator-activated receptor gamma|PPARy]], and increased (+50%) [[glucose uptake]], the [[Protein targeting|translocation]] of [[glucose transporter]] 4, and intracellular [[Calcium in biology|calcium]] in [[Adipocyte|fat cells]], that indicate a role for the local endocannabinoids in the regulation of [[Carbohydrate metabolism|glucose metabolism]] in human adipocytes and suggest a role in channelling excess |
A [[WIN 55,212-2|full agonist]] at the [[CB1 receptor|CB<sub>1</sub>]] receptor is found able to up-regulate [[Peroxisome proliferator-activated receptor gamma|PPARy]], and increased (+50%) [[glucose uptake]], the [[Protein targeting|translocation]] of [[glucose transporter]] 4, and intracellular [[Calcium in biology|calcium]] in [[Adipocyte|fat cells]], that indicate a role for the local endocannabinoids in the regulation of [[Carbohydrate metabolism|glucose metabolism]] in human adipocytes and suggest a role in channelling excess energy fuels to [[adipose tissue]] in obese humans.<ref>{{cite journal | vauthors = Pagano C, Pilon C, Calcagno A, Urbanet R, Rossato M, Milan G, Bianchi K, Rizzuto R, Bernante P, Federspil G, Vettor R | display-authors = 6 | title = The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms | journal = The Journal of Clinical Endocrinology and Metabolism | volume = 92 | issue = 12 | pages = 4810–4819 | date = December 2007 | pmid = 17785353 | doi = 10.1210/jc.2007-0768 | doi-access = free }}</ref> This is consistent with the decreased prevalence of diabetes seen in marijuana users,<ref>{{cite journal | vauthors = Rajavashisth TB, Shaheen M, Norris KC, Pan D, Sinha SK, Ortega J, Friedman TC | title = Decreased prevalence of diabetes in marijuana users: cross-sectional data from the National Health and Nutrition Examination Survey (NHANES) III | journal = BMJ Open | volume = 2 | issue = 1 | pages = e000494 | date = 1 January 2012 | pmid = 22368296 | pmc = 3289985 | doi = 10.1136/bmjopen-2011-000494 | doi-access = free }}</ref> and significantly reduced body mass index ([[Body mass index|BMI]]) and rates of obesity in ''Cannabis'' users,<ref>{{cite journal | vauthors = Clark TM, Jones JM, Hall AG, Tabner SA, Kmiec RL | title = Theoretical Explanation for Reduced Body Mass Index and Obesity Rates in ''Cannabis'' Users | journal = Cannabis and Cannabinoid Research | volume = 3 | issue = 1 | pages = 259–271 | date = 21 December 2018 | pmid = 30671538 | pmc = 6340377 | doi = 10.1089/can.2018.0045 }}</ref><ref>{{cite journal | vauthors = Danielsson AK, Lundin A, Yaregal A, Östenson CG, Allebeck P, Agardh EE | title = Cannabis Use as Risk or Protection for Type 2 Diabetes: A Longitudinal Study of 18 000 Swedish Men and Women | journal = Journal of Diabetes Research | volume = 2016 | pages = 6278709 | date = 2016 | pmid = 27843955 | pmc = 5098083 | doi = 10.1155/2016/6278709 | doi-access = free }}</ref> as endocannabinoids modulate [[pancreatic β-cell]]s function, [[Cell proliferation|proliferation]], and survival, as well as [[insulin]] production, [[Beta cell|secretion]], and [[Insulin resistance|resistance]], where animal and human research suggest that increased activity of the endocannabinoid system, may lead to [[insulin resistance]], [[glucose intolerance]] and obesity.<ref>{{cite journal | vauthors = Farokhnia M, McDiarmid GR, Newmeyer MN, Munjal V, Abulseoud OA, Huestis MA, Leggio L | title = Effects of oral, smoked, and vaporized cannabis on endocrine pathways related to appetite and metabolism: a randomized, double-blind, placebo-controlled, human laboratory study | journal = Translational Psychiatry | volume = 10 | issue = 1 | pages = 71 | date = February 2020 | pmid = 32075958 | pmc = 7031261 | doi = 10.1038/s41398-020-0756-3 }}</ref> |
||
Consistent with the associated reduced prevalence of [[non-alcoholic fatty liver disease]] (NAFLD) among [[Cannabis (drug)|cannabis]] users, that find significantly lower NAFLD prevalence compared to non-users, i.e. 15% lower in non-dependent users and 52% lower in dependent users, and dependent patients had 43% significantly lower prevalence of NAFLD compared to non-dependent patients.<ref>{{cite journal | vauthors = Adejumo AC, Alliu S, Ajayi TO, Adejumo KL, Adegbala OM, Onyeakusi NE, Akinjero AM, Durojaiye M, Bukong TN | display-authors = 6 | title = Cannabis use is associated with reduced prevalence of non-alcoholic fatty liver disease: A cross-sectional study | journal = PLOS ONE | volume = 12 | issue = 4 | pages = e0176416 | date = |
Consistent with the associated reduced prevalence of [[non-alcoholic fatty liver disease]] (NAFLD) among [[Cannabis (drug)|cannabis]] users, that find significantly lower NAFLD prevalence compared to non-users, i.e. 15% lower in non-dependent users and 52% lower in dependent users, and dependent patients had 43% significantly lower prevalence of NAFLD compared to non-dependent patients.<ref>{{cite journal | vauthors = Adejumo AC, Alliu S, Ajayi TO, Adejumo KL, Adegbala OM, Onyeakusi NE, Akinjero AM, Durojaiye M, Bukong TN | display-authors = 6 | title = Cannabis use is associated with reduced prevalence of non-alcoholic fatty liver disease: A cross-sectional study | journal = PLOS ONE | volume = 12 | issue = 4 | pages = e0176416 | date = 25 April 2017 | pmid = 28441459 | pmc = 5404771 | doi = 10.1371/journal.pone.0176416 | doi-access = free | bibcode = 2017PLoSO..1276416A }}</ref> And also by using [[Multivariable calculus|multivariable]] [[logistic regression]], and after adjusting for potential [[Confounding|confounders]], patients with cannabis abuse (daily consumption) is found 55% less likely to have [[hepatocellular carcinoma]] (adjusted [[odds ratio]], 0.45, 95% [[confidence interval]], 0.42–0.49) compared with patients without cannabis abuse in the periode 2002 – 2014.<ref name=":46">{{Cite journal |last=ElTelbany |first=Ahmed |date=28 April 2022 |title=Lower Rates of Hepatocellular Carcinoma Observed Among Cannabis Users: A Population-Based Study |journal=Cureus |volume=14 |issue=4|pages=e24576 |doi=10.7759/cureus.24576 |doi-access=free |pmid=35651376 |pmc=9138632 }}</ref> |
||
In addition to metabolism by FAAH, COX-2 and LOXs, NAE 20:4 (AEA) can also undergo oxidation by several of human [[cytochrome P450]] (CYPs) enzymes, resulting in various oxidized lipid species, some of which have biological relevance as CYP-derived [[epoxide]]s, that can act as a potent agonist of CB2 receptors.<ref name=":6" /> |
In addition to metabolism by FAAH, COX-2 and LOXs, NAE 20:4 (AEA) can also undergo oxidation by several of human [[cytochrome P450]] (CYPs) enzymes, resulting in various oxidized lipid species, some of which have biological relevance as CYP-derived [[epoxide]]s, that can act as a potent agonist of CB2 receptors.<ref name=":6" /> |
||
NAE 20:4 (AEA: C<sub>22</sub>H<sub>37</sub>NO<sub>2</sub>) which is similar in structure to [[N-Arachidonylglycine|N-arachidonoyl glycine]] (Nagly: C<sub>22</sub>H<sub>35</sub>NO<sub>3</sub> |
NAE 20:4 (AEA: C<sub>22</sub>H<sub>37</sub>NO<sub>2</sub>) which is similar in structure to [[N-Arachidonylglycine|N-arachidonoyl glycine]] (Nagly: C<sub>22</sub>H<sub>35</sub>NO<sub>3</sub> – a [[carboxylic acid]] [[C-terminus|COOH]]) are metabolically interconnected, as [[Redox|oxidation]] of the [[Hydroxy group|hydroxyl group]] of NAE 20:4 (AEA) leads to NAgly, preferring [[G protein-coupled receptor|G-protein coupled receptor]] (GPR) [[NAGly receptor|118]], with a molecular structure, that are found of pharmacological interest, as region one confers a high degree of specificity of action, as [[Polyunsaturated fatty acid|polyunsaturated]] residues produce molecules with [[analgesic]] and [[anti-inflammatory]] action, of which [[Saturated fat|saturated]] [[Saturated and unsaturated compounds|structures]], are inactive. Region two is related to metabolic stability as NAgly is degraded by FAAH activity. And last, region 3, the [[amino acid]] residue, can have an effect on the analgesic and anti-inflammatory activities depending on [[steric factor]]s and the [[Chirality|chiral]] nature of the amino acid.<ref name=":13">{{cite journal | vauthors = Burstein SH | title = The cannabinoid acids, analogs and endogenous counterparts | journal = Bioorganic & Medicinal Chemistry | volume = 22 | issue = 10 | pages = 2830–2843 | date = May 2014 | pmid = 24731541 | pmc = 4351512 | doi = 10.1016/j.bmc.2014.03.038 }}</ref> Also the amino acid residue at 296 and the hydroxyl groups of THC, 11-[[Hydroxy group|hydroxy]]-THC ([[11-Hydroxy-THC|11-OH-THC]]: C<sub>21</sub>H<sub>30</sub>O<sub>3</sub>) are critical for [[Potentiator|potentiation]] of [[glycine receptor]]s (GlyRs) and for some of the [[Cannabis (drug)|cannabis]]-induced analgesic and therapeutic effects.<ref name=":36" /> |
||
It is also found that [[Fatty acid|long-chain fatty acid]] [[Conjugation (biochemistry)|conjugates]] from the metabolic hydroxyl oxidation product of the phytocannabinoid, THC ([[Carbon|C]]<sub>21</sub>[[Hydrogen|H]]<sub>30</sub>[[Oxygen|O]]<sub>2</sub>), 11-[[Hydroxy group|hydroxy]]-THC ([[11-Hydroxy-THC|11-OH-THC]]: C<sub>21</sub>H<sub>30</sub>O<sub>3</sub>) are proposed to be a form in which THC may be stored within [[Tissue (biology)|tissues]].<ref>{{cite journal | vauthors = Grotenhermen F | title = Pharmacokinetics and pharmacodynamics of cannabinoids | journal = Clinical Pharmacokinetics | volume = 42 | issue = 4 | pages = 327–360 | date = 2003 | pmid = 12648025 | doi = 10.2165/00003088-200342040-00003 | s2cid = 25623600 }}</ref><ref>{{cite journal | vauthors = Grotenhermen F | title = Pharmacokinetics and pharmacodynamics of cannabinoids | journal = Clinical Pharmacokinetics | volume = 42 | issue = 4 | pages = 327–360 | date = 2003 |
It is also found that [[Fatty acid|long-chain fatty acid]] [[Conjugation (biochemistry)|conjugates]] from the metabolic hydroxyl oxidation product of the phytocannabinoid, THC ([[Carbon|C]]<sub>21</sub>[[Hydrogen|H]]<sub>30</sub>[[Oxygen|O]]<sub>2</sub>), 11-[[Hydroxy group|hydroxy]]-THC ([[11-Hydroxy-THC|11-OH-THC]]: C<sub>21</sub>H<sub>30</sub>O<sub>3</sub>) are proposed to be a form in which THC may be stored within [[Tissue (biology)|tissues]].<ref>{{cite journal | vauthors = Grotenhermen F | title = Pharmacokinetics and pharmacodynamics of cannabinoids | journal = Clinical Pharmacokinetics | volume = 42 | issue = 4 | pages = 327–360 | date = 2003 | pmid = 12648025 | doi = 10.2165/00003088-200342040-00003 | s2cid = 25623600 }}</ref><ref>{{cite journal | vauthors = Grotenhermen F | title = Pharmacokinetics and pharmacodynamics of cannabinoids | journal = Clinical Pharmacokinetics | volume = 42 | issue = 4 | pages = 327–360 | date = 1 April 2003 | pmid = 12648025 | doi = 10.2165/00003088-200342040-00003 | s2cid = 25623600 }}</ref> And the last cytochrome P450 oxidation product of THC afford the non-psychoactive and long-living 11-nor-9-[[Carboxylic acid|carboxy]]-THC ([[11-Nor-9-carboxy-THC|THC-COOH]]: C<sub>21</sub>H<sub>28</sub>O<sub>4</sub>) as main metabolite, that in some authors’ opinion, are insufficiently characterized, as an [[acid]] metabolite seen as a final product in both [[Cannabis|cannabis-plants]] and [[mammal]]s, with their main unanswered questions, "Could any of the pharmacological effects observed for THC be attributed to [[Tetrahydrocannabinolic acid|THCA]] (C<sub>22</sub>H<sub>30</sub>O<sub>4</sub>) and/or THC-COOH, and could THC also be a potential [[Prodrug|pro-drug]] to another pharmacological entity?".<ref name=":23">{{Cite web|vauthors=Ujváry I, Grotenhermen F|date=2014|title=11-Nor-9-carboxy-∆9-tetrahydrocannabinol – a ubiquitous yet under researched cannabinoid. A review of the literature|url=http://www.cannabis-med.org/data/pdf/en_2014_01_1.pdf|url-status=dead|website=cannabis-med.org|access-date=2021-04-05|archive-date=2017-04-20|archive-url=https://web.archive.org/web/20170420192452/http://www.cannabis-med.org/data/pdf/en_2014_01_1.pdf}}</ref><ref name=":13" /><ref>{{cite journal | vauthors = Purschke K, Heinl S, Lerch O, Erdmann F, Veit F | title = Development and validation of an automated liquid-liquid extraction GC/MS method for the determination of THC, 11-OH-THC, and free THC-carboxylic acid (THC-COOH) from blood serum | journal = Analytical and Bioanalytical Chemistry | volume = 408 | issue = 16 | pages = 4379–4388 | date = June 2016 | pmid = 27116418 | pmc = 4875941 | doi = 10.1007/s00216-016-9537-5 }}</ref><ref name=":15" /><ref name=":20">{{cite journal | vauthors = El-Gohary M, Eid MA | title = Effect of cannabinoid ingestion (in the form of bhang) on the immune system of high school and university students | journal = Human & Experimental Toxicology | volume = 23 | issue = 3 | pages = 149–156 | date = March 2004 | pmid = 15119535 | doi = 10.1191/0960327104ht426oa | bibcode = 2004HETox..23..149E | s2cid = 23909791 | doi-access = free }}</ref> |
||
[[Nonsteroidal anti-inflammatory drug|NSAIDs]] that [[COX-2 inhibitor|inhibit COX2]], may find its |
[[Nonsteroidal anti-inflammatory drug|NSAIDs]] that [[COX-2 inhibitor|inhibit COX2]], may find its medical influence from the cannabinoid system, either by inhibiting the breakdown of NAE 20:4 (AEA) by [[FAAH]] (i.e. [[ibuprofen]], [[Indometacin|indomethacin]], [[flurbiprofen]], ibu–am5), or by inhibiting a possible [[Intracellular transport|intracellular]] transporter of endocannabinoids (i.e. [[Paracetamol|acetaminophen]]).<ref>{{cite journal | vauthors = Păunescu H, Coman OA, Coman L, Ghiţă I, Georgescu SR, Drăghia F, Fulga I | title = Cannabinoid system and cyclooxygenases inhibitors | journal = Journal of Medicine and Life | volume = 4 | issue = 1 | pages = 11–20 | date = 15 February 2011 | pmid = 21505570 | pmc = 3056416 }}</ref> |
||
The phytocannabinoid THC is found to have twenty times the anti-inflammatory potency of [[aspirin]] and twice that of [[hydrocortisone]], but in contrast to NSAIDs, it demonstrates no COX inhibition at physiological concentrations.<ref>{{cite journal | vauthors = Russo EB | title = Cannabinoids in the management of difficult to treat pain | journal = Therapeutics and Clinical Risk Management | volume = 4 | issue = 1 | pages = 245–59 | date = February 2008 | pmid = 18728714 | pmc = 2503660 | doi = 10.2147/tcrm.s1928 }}</ref> |
The phytocannabinoid THC is found to have twenty times the anti-inflammatory potency of [[aspirin]] and twice that of [[hydrocortisone]], but in contrast to NSAIDs, it demonstrates no COX inhibition at physiological concentrations.<ref>{{cite journal | vauthors = Russo EB | title = Cannabinoids in the management of difficult to treat pain | journal = Therapeutics and Clinical Risk Management | volume = 4 | issue = 1 | pages = 245–59 | date = February 2008 | pmid = 18728714 | pmc = 2503660 | doi = 10.2147/tcrm.s1928 | doi-access = free }}</ref> |
||
Another of the main phytocannabinoids, [[cannabidiol]] (CBD: [[Carbon|C]]<sub>21</sub>[[Hydrogen|H]]<sub>30</sub>[[Oxygen|O]]<sub>2</sub>) is found to produce a significant increase in serum NAE 20:4 (AEA) levels, by inhibiting the [[Intracellular transport|intracellular]] degradation catalyzed by FAAH, suggest the inhibition of NAE 20:4 (AEA) deactivation may contribute to the [[Psychosis|antipsychotic]] effects of CBD, potentially representing a mechanism in the treatment of [[schizophrenia]], with a markedly superior [[Side effect|side-effect]] profile, compare to [[amisulpride]], a potent [[antipsychotic]]. CBD were also seen to elevate serum levels of the non-cannabimimetic lipid mediators, NAE 16:0 (PEA) and NAE 18:1 (OEA), but |
Another of the main phytocannabinoids, [[cannabidiol]] (CBD: [[Carbon|C]]<sub>21</sub>[[Hydrogen|H]]<sub>30</sub>[[Oxygen|O]]<sub>2</sub>) is found to produce a significant increase in serum NAE 20:4 (AEA) levels, by inhibiting the [[Intracellular transport|intracellular]] degradation catalyzed by FAAH, suggest the inhibition of NAE 20:4 (AEA) deactivation may contribute to the [[Psychosis|antipsychotic]] effects of CBD, potentially representing a mechanism in the treatment of [[schizophrenia]], with a markedly superior [[Side effect|side-effect]] profile, compare to [[amisulpride]], a potent [[antipsychotic]]. CBD were also seen to elevate serum levels of the non-cannabimimetic lipid mediators, NAE 16:0 (PEA) and NAE 18:1 (OEA), but amisulpride did not.<ref>{{cite journal | vauthors = Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, Klosterkötter J, Hellmich M, Koethe D | display-authors = 6 | title = Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia | journal = Translational Psychiatry | volume = 2 | issue = 3 | pages = e94 | date = March 2012 | pmid = 22832859 | pmc = 3316151 | doi = 10.1038/tp.2012.15 }}</ref><ref name=":14">{{Cite web| vauthors = Mechoulam R |date=2019|title=The Chemistry Behind Cannabinoid Acids (COOH)|url=https://www.youtube.com/watch?v=B76d3mGY5dg |archive-url=https://ghostarchive.org/varchive/youtube/20211215/B76d3mGY5dg |archive-date=2021-12-15|url-status=live|website=YouTube}}{{cbignore}}</ref> |
||
FAAH inhibitors are seen to both increase [[Alcoholic drink|alcohol]] consumption (NAE 20:4; AEA) and prevent against [[oxidative stress]] caused by [[Binge drinking|binge]] [[ethanol]] consumption, and as NAE 16:0 (PEA) and NAE 18:1 (OEA), through the endocannabinoidome-related peroxisome proliferator-activated receptor-α ([[Ppar |
FAAH inhibitors are seen to both increase [[Alcoholic drink|alcohol]] consumption (NAE 20:4; AEA) and prevent against [[oxidative stress]] caused by [[Binge drinking|binge]] [[ethanol]] consumption, and as NAE 16:0 (PEA) and NAE 18:1 (OEA), through the endocannabinoidome-related peroxisome proliferator-activated receptor-α ([[Ppar-α]]) is involved in the actions of NAEs with no endocannabinoid activity, have been reported to exhibit [[Neuroprotection|neuroprotective]] effects, suggest a strengthening of the [[Endocannabinoid system|ECS]] may reflect a [[Homeostasis|homeostatic]] [[Homeostatic plasticity|mechanism]] to prevent the [[Neurotoxicity|neurotoxic]] effects induced by [[Alcohol (drug)|alcohol]] with a relevant role of other non-cannabinoid [[Congener (chemistry)|congeners]] in the alcohol exposure, and the further activation in response to the negative [[Affect (psychology)|affective]] [[Affective neuroscience|state]], like the [[anxiety]],<ref name=":33">{{cite journal | vauthors = Kathuria S, Gaetani S, Fegley D, Valiño F, Duranti A, Tontini A, Mor M, Tarzia G, La Rana G, Calignano A, Giustino A, Tattoli M, Palmery M, Cuomo V, Piomelli D | display-authors = 6 | title = Modulation of anxiety through blockade of anandamide hydrolysis | journal = Nature Medicine | volume = 9 | issue = 1 | pages = 76–81 | date = January 2003 | pmid = 12461523 | doi = 10.1038/nm803 | s2cid = 20764484 | url = http://www.escholarship.org/uc/item/9vp7s85t }}</ref> associated to alcohol [[Alcohol withdrawal syndrome|withdrawal]].<ref>{{cite journal | vauthors = Sanchez-Marin L, Pavon FJ, Decara J, Suarez J, Gavito A, Castilla-Ortega E, Rodriguez de Fonseca F, Serrano A | display-authors = 6 | title = Effects of Intermittent Alcohol Exposure on Emotion and Cognition: A Potential Role for the Endogenous Cannabinoid System and Neuroinflammation | journal = Frontiers in Behavioral Neuroscience | volume = 11 | pages = 15 | date = 7 February 2017 | pmid = 28223925 | pmc = 5293779 | doi = 10.3389/fnbeh.2017.00015 | doi-access = free }}</ref> Or poorer [[Recall (memory)|recall]] of [[Speech|verbal]] and nonverbal information, as well as reduced [[Spatial–temporal reasoning|visuospatial]] [[Visuospatial function|skills]] related to alcohol [[hangover]] and withdrawal symptoms in youth, a relationship not seen in [[Adolescence|adolescents]] with similar levels of alcohol involvement if they are heavy users of marijuana.<ref>{{cite journal | vauthors = Mahmood OM, Jacobus J, Bava S, Scarlett A, Tapert SF | title = Learning and memory performances in adolescent users of alcohol and marijuana: interactive effects | journal = Journal of Studies on Alcohol and Drugs | volume = 71 | issue = 6 | pages = 885–894 | date = November 2010 | pmid = 20946746 | pmc = 2965487 | doi = 10.15288/jsad.2010.71.885 }}</ref> |
||
The cannabinoid [[CB1 receptor]] play a critical role in mediating the |
The cannabinoid [[CB1 receptor]] play a critical role in mediating the adolescent behavior, because enhanced CB1 density and endocannabinoid (eCB) signaling occur transiently during the periode from childhood to adolescence and reverse when [[adult]] and mature in normal phenotypes. Reports on enhanced adolescent CB1 signaling, suggest a pivotal role for the CB1 in an adolescent brain as an important molecular mediator of adolescent behavior, as adult CB1 mutant rats exhibit an adolescent-like phenotype with typical high [[risk]] seeking, [[impulsivity]], and augmented drug and nondrug [[Reward system|reward]] sensitivity, by an [[instinct]]ive need or call for activation, and [[Partial antagonist|partial]] inhibition of CB1 activity normalized behavior and led to an adult phenotype, is why it is concluded that the activity state and functionality of the CB1 is critical for mediating adolescent behavior and further turn to an adult phenotype, by normal CB1 downscaling.<ref>{{cite journal | vauthors = Schneider M, Kasanetz F, Lynch DL, Friemel CM, Lassalle O, Hurst DP, Steindel F, Monory K, Schäfer C, Miederer I, Leweke FM, Schreckenberger M, Lutz B, Reggio PH, Manzoni OJ, Spanagel R | display-authors = 6 | title = Enhanced Functional Activity of the Cannabinoid Type-1 Receptor Mediates Adolescent Behavior | journal = The Journal of Neuroscience | volume = 35 | issue = 41 | pages = 13975–13988 | date = October 2015 | pmid = 26468198 | pmc = 4604232 | doi = 10.1523/JNEUROSCI.1937-15.2015 }}</ref> This is also do to the cannabinoid system and its neurotransmitter NAE 20:4 (AEA), that highly participate in the modulation of human states and appropriate human [[emotion]]al responses by activation of the CB1 receptor,<ref name=":33" /><ref>{{cite journal | vauthors = Lutz B | title = Endocannabinoid signals in the control of emotion | journal = Current Opinion in Pharmacology | volume = 9 | issue = 1 | pages = 46–52 | date = February 2009 | pmid = 19157983 | doi = 10.1016/j.coph.2008.12.001 | series = Neurosciences }}</ref> also found in frontal [[Neocortex|neocortical]] areas, subserving higher [[Cognition|cognitive]] and [[Executive functions|executive]] functions, and in the [[Posterior cingulate cortex|posterior cingulate]], a region pivotal for [[consciousness]] and higher cognitive processing.<ref>{{cite journal | vauthors = Burns HD, Van Laere K, Sanabria-Bohórquez S, Hamill TG, Bormans G, Eng WS, Gibson R, Ryan C, Connolly B, Patel S, Krause S, Vanko A, Van Hecken A, Dupont P, De Lepeleire I, Rothenberg P, Stoch SA, Cote J, Hagmann WK, Jewell JP, Lin LS, Liu P, Goulet MT, Gottesdiener K, Wagner JA, de Hoon J, Mortelmans L, Fong TM, Hargreaves RJ | display-authors = 6 | title = [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 104 | issue = 23 | pages = 9800–9805 | date = June 2007 | pmid = 17535893 | pmc = 1877985 | doi = 10.1073/pnas.0703472104 | bibcode = 2007PNAS..104.9800B | doi-access = free }}</ref><ref name=":34">{{Cite web |date=2009 |title=A Cannabis Odyssey: To Smoke or Not To Smoke by Lester Grinspoon |url=http://marijuana-uses.com/to-smoke-or-not-to-smoke-a-cannabis-odyssey/ |website=marijuana-uses.com |vauthors=Grinspoon L}}</ref><ref>{{Cite journal |last=Garner |first=Emily |date=2016 |title=A phenomenology of marijuana use among graduate students |journal=Indo-Pacific Journal of Phenomenology |volume=16 |issue=1 |pages=1–17 |doi=10.1080/20797222.2016.1164997 |s2cid=148123749 |issn=1445-7377|doi-access=free }}</ref> |
||
Acute administration of [[Ethanol metabolism|ethanol]] inhibits receptor-mediated release of NAE 20:4 (AEA), whereas chronic ethanol administration |
Acute administration of [[Ethanol metabolism|ethanol]] inhibits receptor-mediated release of NAE 20:4 (AEA), whereas chronic ethanol administration increases levels of AEA that participates in the neuroadaptations associated with chronic ethanol exposure, as the inhibition of AEA release by acute ethanol administration, not derive from increased fatty acid ethanolamide degradation by FAAH.<ref>{{Cite journal |last=Ferrer |first=Belen |date=2007 |title=Regulation of brain anandamide by acute administration of ethanol |journal=The Biochemical Journal |volume=404 |issue=Pt 1 |pages=97–104 |doi=10.1042/BJ20061898 |pmid=17302558 |pmc=1868843 }}</ref><ref>{{Cite web |last=PubChem |title=Palmitoylethanolamide |url=https://pubchem.ncbi.nlm.nih.gov/compound/4671 |access-date=2023-03-05 |website=pubchem.ncbi.nlm.nih.gov |language=en}}</ref> |
||
However, [[Alcoholic drink|alcohol]] ([[Ethanol|EtOH]]) is seen to increase levels of NAE 20:4 (AEA), and its precursor ''N''‐arachidonoylphosphatidylethanolamine (N‐ArPE), a glycero-phospho-ethanolamine,<ref>{{Cite web|title=N-arachidonoylphosphatidylethanolamine (CHEBI:52571)|url=https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:52571|access-date=2021-04-07|website=www.ebi.ac.uk}}</ref> significantly, that may be a mechanism for [[neuron]]al adaptation and serve as a compensatory mechanism to counteract a continuous presence of EtOH, that together with previous results indicate the involvement of the endocannabinoid system in mediating some of the [[Pharmacology|pharmacological]] actions alleged of EtOH, also seen in [[red wine]] [[Resveratrol|components]],<ref name=":18">{{cite journal | vauthors = Hassanzadeh P, Arbabi E, Atyabi F, Dinarvand R | title = The endocannabinoid system and NGF are involved in the mechanism of action of resveratrol: a multi-target nutraceutical with therapeutic potential in neuropsychiatric disorders | journal = Psychopharmacology | volume = 233 | issue = 6 | pages = 1087–1096 | date = March 2016 | pmid = 26780936 | doi = 10.1007/s00213-015-4188-3 | s2cid = 15089814 }}</ref> and in [[Humulus lupulus]] to preserve and flavor |
However, [[Alcoholic drink|alcohol]] ([[Ethanol|EtOH]]) is seen to increase levels of NAE 20:4 (AEA), and its precursor ''N''‐arachidonoylphosphatidylethanolamine (N‐ArPE), a glycero-phospho-ethanolamine,<ref>{{Cite web|title=N-arachidonoylphosphatidylethanolamine (CHEBI:52571)|url=https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:52571|access-date=2021-04-07|website=www.ebi.ac.uk}}</ref> significantly, that may be a mechanism for [[neuron]]al adaptation and serve as a compensatory mechanism to counteract a continuous presence of EtOH, that together with previous results indicate the involvement of the endocannabinoid system in mediating some of the [[Pharmacology|pharmacological]] actions alleged of EtOH, also seen in [[red wine]] [[Resveratrol|components]],<ref name=":18">{{cite journal | vauthors = Hassanzadeh P, Arbabi E, Atyabi F, Dinarvand R | title = The endocannabinoid system and NGF are involved in the mechanism of action of resveratrol: a multi-target nutraceutical with therapeutic potential in neuropsychiatric disorders | journal = Psychopharmacology | volume = 233 | issue = 6 | pages = 1087–1096 | date = March 2016 | pmid = 26780936 | doi = 10.1007/s00213-015-4188-3 | s2cid = 15089814 }}</ref> and in [[Humulus lupulus]] to preserve and flavor beer, widely cultivated for use by the [[Brewing|brewing industry]], through [[caryophyllene]], a [[Diet (nutrition)|dietary]] cannabinoid,<ref>{{Cite journal |last1=Gertsch |first1=Jürg |last2=Leonti |first2=Marco |last3=Raduner |first3=Stefan |last4=Racz |first4=Ildiko |last5=Chen |first5=Jian-Zhong |last6=Xie |first6=Xiang-Qun |last7=Altmann |first7=Karl-Heinz |last8=Karsak |first8=Meliha |last9=Zimmer |first9=Andreas |date=1 July 2008 |title=Beta-caryophyllene is a dietary cannabinoid |journal=Proceedings of the National Academy of Sciences of the United States of America |volume=105 |issue=26 |pages=9099–9104 |doi=10.1073/pnas.0803601105 |issn=0027-8424 |pmc=2449371 |pmid=18574142 |bibcode=2008PNAS..105.9099G |doi-access=free }}</ref> that is a selective [[full agonist]] at [[Cannabinoid receptor type 2|CB2]] and also act through [[Peroxisome proliferator-activated receptor|PPAR nuclear receptors]] (i.e. [[Peroxisome proliferator-activated receptor alpha|PPARα]] and [[Peroxisome proliferator-activated receptor gamma|PPARγ]]), with countless beneficial and non-psychoactive effects,<ref>{{cite journal | vauthors = Russo EB | title = Beyond Cannabis: Plants and the Endocannabinoid System | journal = Trends in Pharmacological Sciences | volume = 37 | issue = 7 | pages = 594–605 | date = July 2016 | pmid = 27179600 | doi = 10.1016/j.tips.2016.04.005 }}</ref><ref>{{Cite web|title=Beyond Cannabis: Plants and the Endocannabinoid System|url=https://www.researchgate.net/publication/302979785|access-date=2021-04-07|website=ResearchGate|language=en}}</ref><ref>{{Cite journal |last=Scandiffio |first=Rosaria |date=23 March 2023 |title=Beta-Caryophyllene Modifies Intracellular Lipid Composition in a Cell Model of Hepatic Steatosis by Acting through CB2 and PPAR Receptors |journal=Int J Mol Sci |volume=24 |issue=7|page=6060 |doi=10.3390/ijms24076060 |pmid=37047034 |pmc=10094507 |doi-access=free }}</ref> that may constitute part of a common brain pathway mediating [[reinforcement]] of [[Substance abuse|drugs of abuse]] including EtOH,<ref name=":19">{{cite journal | vauthors = Basavarajappa BS, Hungund BL | title = Chronic ethanol increases the cannabinoid receptor agonist anandamide and its precursor N-arachidonoylphosphatidylethanolamine in SK-N-SH cells | journal = Journal of Neurochemistry | volume = 72 | issue = 2 | pages = 522–528 | date = February 1999 | pmid = 9930723 | doi = 10.1046/j.1471-4159.1999.0720522.x | s2cid = 10793743 | doi-access = free }}</ref> by elevated CB1.<ref>{{cite journal | vauthors = Neumeister A, Normandin MD, Murrough JW, Henry S, Bailey CR, Luckenbaugh DA, Tuit K, Zheng MQ, Galatzer-Levy IR, Sinha R, Carson RE, Potenza MN, Huang Y | display-authors = 6 | title = Positron emission tomography shows elevated cannabinoid CB1 receptor binding in men with alcohol dependence | journal = Alcoholism: Clinical and Experimental Research | volume = 36 | issue = 12 | pages = 2104–2109 | date = December 2012 | pmid = 22551199 | pmc = 3418442 | doi = 10.1111/j.1530-0277.2012.01815.x }}</ref> The CB1 receptor binding is 20-30% lower in patients with [[Alcoholism|alcohol dependence]] than in control subjects in all brain regions and is negatively correlated with years of alcohol abuse, and the CB1 receptor binding remain similarly reduced after 2–4 weeks of abstinence, suggests an involvement of CB1 receptors in alcohol dependence in humans.<ref>{{cite journal | vauthors = Hirvonen J, Zanotti-Fregonara P, Umhau JC, George DT, Rallis-Frutos D, Lyoo CH, Li CT, Hines CS, Sun H, Terry GE, Morse C, Zoghbi SS, Pike VW, Innis RB, Heilig M | display-authors = 6 | title = Reduced cannabinoid CB1 receptor binding in alcohol dependence measured with positron emission tomography | journal = Molecular Psychiatry | volume = 18 | issue = 8 | pages = 916–921 | date = August 2013 | pmid = 22776901 | pmc = 3594469 | doi = 10.1038/mp.2012.100 }}</ref> |
||
Similar pathways of hydrolysis or oxidation of NAEs are also found in plant cells.<ref>{{cite journal | vauthors = Van Der Stelt M, Noordermeer MA, Kiss T, Van Zadelhoff G, Merghart B, Veldink GA, Vliegenthart JF | title = Formation of a new class of oxylipins from N-acyl(ethanol)amines by the lipoxygenase pathway | journal = European Journal of Biochemistry | volume = 267 | issue = 7 | pages = 2000–7 | date = April 2000 | pmid = 10727939 | doi = 10.1046/j.1432-1327.2000.01203.x | hdl-access = free | hdl = 1874/5348 | s2cid = 42011572 }}</ref><ref>{{cite journal | vauthors = Gachet MS, Schubert A, Calarco S, Boccard J, Gertsch J | title = Targeted metabolomics shows plasticity in the evolution of signaling lipids and uncovers old and new endocannabinoids in the plant kingdom | journal = Scientific Reports | volume = 7 | pages = 41177 | date = January 2017 | pmid = 28120902 | pmc = 5264637 | doi = 10.1038/srep41177 | bibcode = 2017NatSR...741177G }}</ref> |
Similar pathways of hydrolysis or oxidation of NAEs are also found in plant cells.<ref>{{cite journal | vauthors = Van Der Stelt M, Noordermeer MA, Kiss T, Van Zadelhoff G, Merghart B, Veldink GA, Vliegenthart JF | title = Formation of a new class of oxylipins from N-acyl(ethanol)amines by the lipoxygenase pathway | journal = European Journal of Biochemistry | volume = 267 | issue = 7 | pages = 2000–7 | date = April 2000 | pmid = 10727939 | doi = 10.1046/j.1432-1327.2000.01203.x | hdl-access = free | hdl = 1874/5348 | s2cid = 42011572 }}</ref><ref>{{cite journal | vauthors = Gachet MS, Schubert A, Calarco S, Boccard J, Gertsch J | title = Targeted metabolomics shows plasticity in the evolution of signaling lipids and uncovers old and new endocannabinoids in the plant kingdom | journal = Scientific Reports | volume = 7 | pages = 41177 | date = January 2017 | issue = 1 | pmid = 28120902 | pmc = 5264637 | doi = 10.1038/srep41177 | bibcode = 2017NatSR...741177G }}</ref> |
||
== NAE system in plants == |
== NAE system in plants == |
||
N-acylethanolamines (NAEs), constitute a class of lipid compounds naturally present in both animal and |
N-acylethanolamines (NAEs), constitute a class of lipid compounds naturally present in both animal and plant [[Plant cell/membrane|membranes]], as constituents of the [[Plant cell|membrane]]-bound [[phospholipid]], [[N-Acylphosphatidylethanolamine]] (NAPE). NAPE is composed of a third fatty acid moiety linked to the [[Amino acid|amino]] head group of the commonly occurring membrane [[Phospholipid-derived fatty acids|phospholipid]], [[phosphatidylethanolamine]].<ref name=":3" /> |
||
A study in 2000 find, that [[Vascular plant|higher plants]] use defense signaling, to combat [[Cellular stress response|cellular stressful]] situations ([[homeostasis]]), like in [[Osmotic shock|osmotic stress]], where high levels of NAEs after a periode of [[dehydration]], are [[Metabolism|metabolized]] fast during the first few hours of [[imbibition]], and in response to [[Pathogen transmission|pathogen]] elicitors, that lead to [[signal transduction]] and [[membrane]] protection, in the same way as several [[mammal]]ian [[Cell membrane|cell]] types, coupled to [[Endocannabinoid system|endocannabinoid]] signaling, do, by releasing saturated and unsaturated long-chain NAEs, and saturated medium-chain NAEs, that can act as lipid mediators to modulate [[ion]] flux and activate defense [[gene expression]].<ref>{{cite journal | vauthors = Chapman KD | title = Emerging physiological roles for N-acylphosphatidylethanolamine metabolism in plants: signal transduction and membrane protection | journal = Chemistry and Physics of Lipids | volume = 108 | issue = 1–2 | pages = 221–229 | date = November 2000 | pmid = 11106793 | doi = 10.1016/s0009-3084(00)00198-5 }}</ref> |
A study in 2000 find, that [[Vascular plant|higher plants]] use defense signaling, to combat [[Cellular stress response|cellular stressful]] situations ([[homeostasis]]), like in [[Osmotic shock|osmotic stress]], where high levels of NAEs after a periode of [[dehydration]], are [[Metabolism|metabolized]] fast during the first few hours of [[imbibition]], and in response to [[Pathogen transmission|pathogen]] elicitors, that lead to [[signal transduction]] and [[membrane]] protection, in the same way as several [[mammal]]ian [[Cell membrane|cell]] types, coupled to [[Endocannabinoid system|endocannabinoid]] signaling, do, by releasing saturated and unsaturated long-chain NAEs, and saturated medium-chain NAEs, that can act as lipid mediators to modulate [[ion]] flux and activate defense [[gene expression]].<ref>{{cite journal | vauthors = Chapman KD | title = Emerging physiological roles for N-acylphosphatidylethanolamine metabolism in plants: signal transduction and membrane protection | journal = Chemistry and Physics of Lipids | volume = 108 | issue = 1–2 | pages = 221–229 | date = November 2000 | pmid = 11106793 | doi = 10.1016/s0009-3084(00)00198-5 }}</ref> |
||
The levels of NAEs increases 10- to 50-fold in tobacco (''[[Nicotiana tabacum]]'') [[Leaf|leaves]] treated with [[Fungus|fungal]] [[Fungicide|elicitors]], as a [[Crop protection|protection]] against it, by producing the ''N-''myristoylethanolamine (''Myristamide''-MEA: C<sub>16</sub>H<sub>33</sub>NO<sub>2</sub>; NAE 14:0), that specific binds to a [[protein]] in tobacco membranes with [[Biomolecule|biochemical]] properties appropriate for the [[Plant physiology|physiological]] responses, and it do not show identical binding properties to NAE-[[binding protein]]s in intact tobacco [[microsome]]s, compared to non-intact microsomes. In addition to this, [[Cannabinoid receptor antagonist|antagonists]] of mammalian CB receptors was seen to block both of the biological activities previously attributed to NAE 14:0, this endogenous NAE that is accumulated in tobacco [[cell suspension]]s and leaves after [[pathogen]] [[Pesticide|elicitor]] [[perception]], is why it is proposed, that plants possess an NAE-[[Signaling pathways|signaling pathway]] with functional similarities to the |
The levels of NAEs increases 10- to 50-fold in tobacco (''[[Nicotiana tabacum]]'') [[Leaf|leaves]] treated with [[Fungus|fungal]] [[Fungicide|elicitors]], as a [[Crop protection|protection]] against it, by producing the ''N-''myristoylethanolamine (''Myristamide''-MEA: C<sub>16</sub>H<sub>33</sub>NO<sub>2</sub>; NAE 14:0), that specific binds to a [[protein]] in tobacco membranes with [[Biomolecule|biochemical]] properties appropriate for the [[Plant physiology|physiological]] responses, and it do not show identical binding properties to NAE-[[binding protein]]s in intact tobacco [[microsome]]s, compared to non-intact microsomes. In addition to this, [[Cannabinoid receptor antagonist|antagonists]] of mammalian CB receptors was seen to block both of the biological activities previously attributed to NAE 14:0, this endogenous NAE that is accumulated in tobacco [[cell suspension]]s and leaves after [[pathogen]] [[Pesticide|elicitor]] [[perception]], is why it is proposed, that plants possess an NAE-[[Signaling pathways|signaling pathway]] with functional similarities to the "endocannabinoid" pathway of animal systems, and this pathway, in part, participates in [[xylanase]] elicitor [[Plant perception (physiology)|perception]] in the tobacco plant, as well as in the [[Arabidopsis]] and ''[[Medicago truncatula]]'' plant [[Vascular tissue|tissues]].<ref name=":3" /> |
||
== Medical values == |
== Medical values == |
||
N-acylethanolamines (NAEs), with its [[Cell membrane|cell]]-protective and [[Stress (biology)|stress]]-[[Stress management|combating]] action-response of organisms, also produced in [[neuron]]s, together with [[N-Acylphosphatidylethanolamine|N-acyl-phosphatidylethanolamine]] (NAPE), in response to the high [[Intracellular transport|intracellular]] [[Calcium in biology|Ca<sup>2+</sup>]] concentrations that occur in injured neurons,<ref>{{cite journal | vauthors = Castelli MP, Madeddu C, Casti A, Casu A, Casti P, Scherma M, Fattore L, Fadda P, Ennas MG | display-authors = 6 | title = Δ9-tetrahydrocannabinol prevents methamphetamine-induced neurotoxicity | journal = PLOS ONE | volume = 9 | issue = 5 | pages = e98079 | date = |
N-acylethanolamines (NAEs), with its [[Cell membrane|cell]]-protective and [[Stress (biology)|stress]]-[[Stress management|combating]] action-response of organisms, also produced in [[neuron]]s, together with [[N-Acylphosphatidylethanolamine|N-acyl-phosphatidylethanolamine]] (NAPE), in response to the high [[Intracellular transport|intracellular]] [[Calcium in biology|Ca<sup>2+</sup>]] concentrations that occur in injured neurons,<ref>{{cite journal | vauthors = Castelli MP, Madeddu C, Casti A, Casu A, Casti P, Scherma M, Fattore L, Fadda P, Ennas MG | display-authors = 6 | title = Δ9-tetrahydrocannabinol prevents methamphetamine-induced neurotoxicity | journal = PLOS ONE | volume = 9 | issue = 5 | pages = e98079 | date = 20 May 2014 | pmid = 24844285 | pmc = 4028295 | doi = 10.1371/journal.pone.0098079 | doi-access = free | bibcode = 2014PLoSO...998079C }}</ref> have shown promise as therapeutic potential in treating [[Bacterial infection|bacterial]], [[Mycosis|fungal]], and [[Viral disease|viral]] infections, as NAEs also exhibit [[anti-inflammatory]], [[Antibiotic|antibacterial]], and [[Antiviral drug|antiviral]] properties, which have considerable application potential.<ref name=":4" /> |
||
In [[Pediatrics|pediatric medicine]] for conditions including |
In [[Pediatrics|pediatric medicine]] for conditions including "non-organic [[Failure to thrive|failure-to-thrive]]" and [[cystic fibrosis]].<ref name=":8" /> A dysfunction of the endocannabinoid system is researched for a possible determining factor for causing [[infertility]] in cystic fibrosis (CF), as the illness is associated with an imbalance of [[fatty acid]]s, show that mild stimulation of the endocannabinoid system (CB1 and CB2) in [[Infant|infancy]] and adolescence, appears to normalize many reproductive processes and prevent infertility in CF males. The mild stimulated, were fully fertile, producing offspring comparable by the number of litters and the number of pups as the wild-type mice, and their counterparts, not treated, were shown completely infertile.<ref>{{cite journal | vauthors = Bregman T, Fride E | title = Treatment with tetrahydrocannabinol (THC) prevents infertility in male cystic fibrosis mice | journal = Journal of Basic and Clinical Physiology and Pharmacology | volume = 22 | issue = 1–2 | pages = 29–32 | date = June 2011 | pmid = 22865360 | doi = 10.1515/jbcpp.2011.004 | s2cid = 19335113 }}</ref> |
||
As NAE related Cannabis has an [[Ancient history|ancient]] |
As NAE related Cannabis has an [[Ancient history|ancient]] tradition of usage as a medicine in [[Obstetrics and gynaecology|obstetrics and gynecology]], its extracts, may represent an efficacious and safe alternative for treatment of a wide range of conditions in women including [[dysmenorrhea]], [[dysuria]], [[hyperemesis gravidarum]], and [[Menopause|menopausal]] symptoms.<ref>{{Cite web| vauthors = Russo E |date=2002|title=Cannabis Treatments in Obstetrics and Gynecology: A Historical Review|url=http://www.cannabis-med.org/membersonly/mo.php?aid=2002-03-04&fid=2002-03-04-1&mode=p&sid=|website=cannabis-med.org}}</ref> |
||
It has been found that [[Social relation|social]] [[Meeting|contact]] increases, whereas [[Social isolation|isolation]] decreases, the production of the [[Endogeny (biology)|endogenous]] [[Cannabis (drug)|marijuanna]]-like [[neurotransmitter]], NAE 20:4 (AEA), in [[nucleus accumbens]] (NAc), which regulate [[Motivation|motivated]] behavior, and this NAE 20:4 (AEA) production is via [[oxytocin]], the [[neuropeptide]] reinforcing |
It has been found that [[Social relation|social]] [[Meeting|contact]] increases, whereas [[Social isolation|isolation]] decreases, the production of the [[Endogeny (biology)|endogenous]] [[Cannabis (drug)|marijuanna]]-like [[neurotransmitter]], NAE 20:4 (AEA), in [[nucleus accumbens]] (NAc), which regulate [[Motivation|motivated]] behavior, and this NAE 20:4 (AEA) production is via [[oxytocin]], the [[neuropeptide]] reinforcing parental and social [[Human bonding|bonding]]. Activation of CB1 [[cannabinoid receptor]]s in NAc, are necessary and sufficient to express the [[Reward system|rewarding]] properties of social interactions, i.e. [[Interpersonal relationship|social contact]] reward.<ref name=":48">{{cite journal | vauthors = Wei D, Lee D, Cox CD, Karsten CA, Peñagarikano O, Geschwind DH, Gall CM, Piomelli D | display-authors = 6 | title = Endocannabinoid signaling mediates oxytocin-driven social reward | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 112 | issue = 45 | pages = 14084–14089 | date = November 2015 | pmid = 26504214 | pmc = 4653148 | doi = 10.1073/pnas.1509795112 | doi-access = free | bibcode = 2015PNAS..11214084W }}</ref><ref>{{cite journal | vauthors = Bossong MG, van Hell HH, Jager G, Kahn RS, Ramsey NF, Jansma JM | title = The endocannabinoid system and emotional processing: a pharmacological fMRI study with ∆9-tetrahydrocannabinol | journal = European Neuropsychopharmacology | volume = 23 | issue = 12 | pages = 1687–1697 | date = December 2013 | pmid = 23928295 | doi = 10.1016/j.euroneuro.2013.06.009 | s2cid = 4847188 | doi-access = free }}</ref><ref>{{cite journal | vauthors = Sano K, Mishima K, Koushi E, Orito K, Egashira N, Irie K, Takasaki K, Katsurabayashi S, Iwasaki K, Uchida N, Egawa T, Kitamura Y, Nishimura R, Fujiwara M | display-authors = 6 | title = Delta 9-tetrahydrocannabinol-induced catalepsy-like immobilization is mediated by decreased 5-HT neurotransmission in the nucleus accumbens due to the action of glutamate-containing neurons | journal = Neuroscience | volume = 151 | issue = 2 | pages = 320–328 | date = January 2008 | pmid = 18083311 | doi = 10.1016/j.neuroscience.2007.10.026 | s2cid = 45508434 }}</ref> In addition, CB1 activation also suppresses release of [[serotonin]], [[dopamine]], [[acetylcholine]] and [[Norepinephrine|noradrenaline]], which are mediating the characteristic [[Cognition|cognitive]] and [[antidepressant]] effects.<ref>{{cite journal | vauthors = Karhson DS, Hardan AY, Parker KJ | title = Endocannabinoid signaling in social functioning: an RDoC perspective | journal = Translational Psychiatry | volume = 6 | issue = 9 | pages = e905 | date = September 2016 | pmid = 27676446 | pmc = 5048207 | doi = 10.1038/tp.2016.169 }}</ref> As well as [[norepinephrine]] release,<ref name=":32">{{cite journal | vauthors = Hosking RD, Zajicek JP | title = Therapeutic potential of cannabis in pain medicine | language = English | journal = British Journal of Anaesthesia | volume = 101 | issue = 1 | pages = 59–68 | date = July 2008 | pmid = 18515270 | doi = 10.1093/bja/aen119 | doi-access = free }}</ref> as it is suggested that a major function of the ECS also lies in buffering the [[Sympathetic nervous system|symphatico]]-[[Adrenergic nerve fibre|adrenergic]] response to stress.<ref>{{cite journal | vauthors = Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG | display-authors = 6 | title = International Union of Pharmacology. XXVII. Classification of cannabinoid receptors | journal = Pharmacological Reviews | volume = 54 | issue = 2 | pages = 161–202 | date = June 2002 | pmid = 12037135 | doi = 10.1124/pr.54.2.161 | s2cid = 8259002 }}</ref> |
||
To use in expected [[Climate change|global heating]] scenario, in a catastrophic |
To use in expected [[Climate change|global heating]] scenario, in a catastrophic "hothouse Earth," possible well beyond the control of humans,<ref>{{Cite web| vauthors = Ripple W |date=2020|title=World Scientists' Warning of a Climate Emergency|url=https://academic.oup.com/bioscience/article/70/1/8/5610806|website=BioScience}}</ref><ref>{{Cite news | vauthors = Gillis J |date=9 October 2013 |title=By 2047, Coldest Years May Be Warmer Than Hottest in Past, Scientists Say |language=en-US |work=The New York Times |url=https://www.nytimes.com/2013/10/10/science/earth/by-2047-coldest-years-will-be-warmer-than-hottest-in-past.html |access-date=2022-09-22 |issn=0362-4331}}</ref><ref>{{Cite journal | vauthors = Mora C, Dousset B, Caldwell IR, Powell FE, Geronimo RC, Bielecki CR, Counsell CW, Dietrich BS, Johnston ET, Louis LV, Lucas MP | display-authors = 6 |date=19 June 2017 |title=Global risk of deadly heat |url=https://www.nature.com/articles/nclimate3322.epdf?author_access_token=-H1PjA2jcvfMCRnsav_1C9RgN0jAjWel9jnR3ZoTv0Nlcpopxh1V5GdQz8yAIWjC4EypI9XDfWqMBK8ZqTtVMSQZnmRB3fgQlPS2v1l3vZq4VLHM_7Sca48_uB-ccPQW |journal=Nature Climate Change |language=en |volume=7 |issue=7 |pages=501–506 |doi=10.1038/nclimate3322 |bibcode=2017NatCC...7..501M |s2cid=90219036 |issn=1758-678X}}</ref> where "[[Wet-bulb temperature|wet bulb temperatures]]," taken by a thermometer wrapped in a wet cloth, show temperatures of 35C or higher, and considered the limit to human survival and heighten [[humidity]] makes it harder for people to cool down via [[Perspiration|sweating]],<ref>{{Cite news | vauthors = Greenfield C, Dickie G |date=14 June 2022 |title=In hottest city on Earth, mothers bear brunt of climate change |language=en |work=Reuters |url=https://www.reuters.com/world/asia-pacific/hottest-city-earth-mothers-bear-brunt-climate-change-2022-06-14/ |access-date=2022-10-21}}</ref><ref name=":17" /> coursed by the [[Air pollution|pollution]] of the [[troposphere]], that tight holds 99% of human made solid [[Particulate pollution|particle pollution]], and keeps [[Carbon dioxide|CO<sub>2</sub>]] in it for more than 100 years,<ref>{{Cite web | vauthors = Zaelke D |date=2008 |title=Reducing Black Carbon May Be the Fastest Strategy for Slowing Climate Change |url=http://igsd.org/docs/IGSD%20BC%20Climate%20Briefing%20Note_clean.pdf |website=Institute for Governance & Sustainable Development}}</ref><ref>{{cite journal | vauthors = Meng L, Liu J, Tarasick DW, Randel WJ, Steiner AK, Wilhelmsen H, Wang L, Haimberger L | display-authors = 6 | title = Continuous rise of the tropopause in the Northern Hemisphere over 1980–2020 | journal = Science Advances | volume = 7 | issue = 45 | pages = eabi8065 | date = November 2021 | pmid = 34739322 | pmc = 8570593 | doi = 10.1126/sciadv.abi8065 | bibcode = 2021SciA....7R8065M }}</ref><ref>{{Cite web |title=Warming temperatures increasingly alter structure of atmosphere {{!}} NCAR & UCAR News |url=https://news.ucar.edu/132816/warming-temperatures-increasingly-alter-structure-atmosphere |access-date=2022-09-22 |website=news.ucar.edu |language=en}}</ref> for citizens who can't afford an [[Air conditioning|air-condition]] unit, to [[Cooling down|cool down]] and prevent [[Heat illness|heatstroke]] with an elevated core [[Thermoregulation|body temperature]] above 40 °C with [[Neurological disorder|neurologic]] dysfunctions, that can lead to a syndrome of multiple [[Organ (anatomy)|organ]] defect,<ref>{{cite journal | vauthors = Kim SY, Sung SA, Ko GJ, Boo CS, Jo SK, Cho WY, Kim HK | title = A case of multiple organ failure due to heat stoke following a warm bath | journal = The Korean Journal of Internal Medicine | volume = 21 | issue = 3 | pages = 210–212 | date = September 2006 | pmid = 17017675 | pmc = 3890729 | doi = 10.3904/kjim.2006.21.3.210 }}</ref> and [[Cellular stress response|cell stress]], as it is found, that the CB1 receptor activation, here by a phytocannabinoid Δ9-THC administration, induces profound [[hypothermia]], that is rapid in onset, persistent for 3–4 hours, dose-dependent and is accompanied by a reduction in [[oxygen]] (O) [[Breathing|consumption]], which indicate reduced heat production, as opposed to increased [[Heat transfer|heat loss]].<ref>{{cite journal | vauthors = Rawls SM, Benamar K | title = Effects of opioids, cannabinoids, and vanilloids on body temperature | journal = Frontiers in Bioscience | volume = 3 | issue = 3 | pages = 822–845 | date = June 2011 | pmid = 21622235 | pmc = 3979758 | doi = 10.2741/190 }}</ref><ref>{{cite journal | vauthors = Smirnov MS, Kiyatkin EA | title = Behavioral and temperature effects of delta 9-tetrahydrocannabinol in human-relevant doses in rats | journal = Brain Research | volume = 1228 | pages = 145–160 | date = September 2008 | pmid = 18619424 | pmc = 2613277 | doi = 10.1016/j.brainres.2008.06.069 }}</ref><ref>{{cite journal | vauthors = Devane WA, Dysarz FA, Johnson MR, Melvin LS, Howlett AC | title = Determination and characterization of a cannabinoid receptor in rat brain | journal = Molecular Pharmacology | volume = 34 | issue = 5 | pages = 605–613 | date = November 1988 | pmid = 2848184 | url = https://molpharm.aspetjournals.org/content/34/5/605 }}</ref> |
||
[[Planetary nebula|*]] [[Impact event|→]] [[Tetrahydrocannabinolic acid|THCA]]:[[Carboxylic acid|COOH]]: C<sub>22</sub>H<sub>30</sub>O<sub>4</sub> (heating/storage) → THC: [[Carbon|C]]<sub>21</sub>[[Hydrogen|H]]<sub>30</sub>[[Oxygen|O]]<sub>2</sub> → THC-OH: C<sub>21</sub>H<sub>30</sub>O<sub>3</sub> → THC:COOH: C<sub>21</sub>H<sub>28</sub>O<sub>4</sub> → profound hypothermia, a lowering of body temperature,<ref>{{Cite journal |last1=Gill |first1=E. W. |last2=Paton |first2=W. D. M. |last3=Pertwee |first3=R. G. |date=1970 |
[[Planetary nebula|*]] [[Impact event|→]] [[Tetrahydrocannabinolic acid|THCA]]:[[Carboxylic acid|COOH]]: C<sub>22</sub>H<sub>30</sub>O<sub>4</sub> (heating/storage) → THC: [[Carbon|C]]<sub>21</sub>[[Hydrogen|H]]<sub>30</sub>[[Oxygen|O]]<sub>2</sub> → THC-OH: C<sub>21</sub>H<sub>30</sub>O<sub>3</sub> → THC:COOH: C<sub>21</sub>H<sub>28</sub>O<sub>4</sub> → profound hypothermia, a lowering of body temperature,<ref>{{Cite journal |last1=Gill |first1=E. W. |last2=Paton |first2=W. D. M. |last3=Pertwee |first3=R. G. |date=10 October 1970 |title=Preliminary Experiments on the Chemistry and Pharmacology of Cannabis |url=https://www.nature.com/articles/228134a0 |journal=Nature |language=en |volume=228 |issue=5267 |pages=134–136 |doi=10.1038/228134a0 |pmid=5466704 |bibcode=1970Natur.228..134G |s2cid=4193316 |issn=1476-4687}}</ref> accompanied by a reduction in oxygen consumption. |
||
In metabolism of THCA from fresh plant [[Cannabis cultivation|material]] used [[Route of administration|orally]], is conversion to Delta9-THC not observed:<ref>{{cite journal | vauthors = Jung J, Meyer MR, Maurer HH, Neusüss C, Weinmann W, Auwärter V | title = Studies on the metabolism of the Delta9-tetrahydrocannabinol precursor Delta9-tetrahydrocannabinolic acid A (Delta9-THCA-A) in rat using LC-MS/MS, LC-QTOF MS and GC-MS techniques | journal = Journal of Mass Spectrometry | volume = 44 | issue = 10 | pages = 1423–1433 | date = October 2009 | pmid = 19728318 | doi = 10.1002/jms.1624 | bibcode = 2009JMSp...44.1423J }}</ref> |
In metabolism of THCA from fresh plant [[Cannabis cultivation|material]] used [[Route of administration|orally]], is conversion to Delta9-THC not observed:<ref>{{cite journal | vauthors = Jung J, Meyer MR, Maurer HH, Neusüss C, Weinmann W, Auwärter V | title = Studies on the metabolism of the Delta9-tetrahydrocannabinol precursor Delta9-tetrahydrocannabinolic acid A (Delta9-THCA-A) in rat using LC-MS/MS, LC-QTOF MS and GC-MS techniques | journal = Journal of Mass Spectrometry | volume = 44 | issue = 10 | pages = 1423–1433 | date = October 2009 | pmid = 19728318 | doi = 10.1002/jms.1624 | bibcode = 2009JMSp...44.1423J }}</ref> |
||
Line 170: | Line 171: | ||
THCA:[[Carboxylic acid|COOH]]: C<sub>22</sub>H<sub>30</sub>O<sub>4</sub> → [[11-Hydroxy-THC|THC]]-[[Hydroxy group|OH]]: C<sub>21</sub>H<sub>30</sub>O<sub>3</sub> → [[11-Nor-9-carboxy-THC|THC]]:COOH: C<sub>21</sub>H<sub>28</sub>O<sub>4</sub> |
THCA:[[Carboxylic acid|COOH]]: C<sub>22</sub>H<sub>30</sub>O<sub>4</sub> → [[11-Hydroxy-THC|THC]]-[[Hydroxy group|OH]]: C<sub>21</sub>H<sub>30</sub>O<sub>3</sub> → [[11-Nor-9-carboxy-THC|THC]]:COOH: C<sub>21</sub>H<sub>28</sub>O<sub>4</sub> |
||
To be protected where [[head injury]] is a possibility, as a positive THC screen is associated with significant decreased [[Death|mortality]] in adult patients sustaining [[traumatic brain injury]] (TBI), as research work, by a 3-year retrospective review of registry data at a [[Level I Trauma Center|Level I center]] of patients sustaining TBI, find mortality in the THC(+) group (2.4% [2 patients]) significantly decreased compared with the THC(-) group (11.5% [42]) in 446 cases meeting all inclusion criteria.<ref name=":15" /> And further have shorter hospital [[length of stay]] (LOS) and shorter [[ventilator]] days, than THC(-) patients sustaining TBI. For severely injured trauma patients |
To be protected where [[head injury]] is a possibility, as a positive THC screen is associated with significant decreased [[Death|mortality]] in adult patients sustaining [[traumatic brain injury]] (TBI), as research work, by a 3-year retrospective review of registry data at a [[Level I Trauma Center|Level I center]] of patients sustaining TBI, find mortality in the THC(+) group (2.4% [2 patients]) significantly decreased compared with the THC(-) group (11.5% [42]) in 446 cases meeting all inclusion criteria.<ref name=":15" /> And further have shorter hospital [[length of stay]] (LOS) and shorter [[ventilator]] days, than THC(-) patients sustaining TBI. For severely injured trauma patients with [[Injury Severity Score]] ≥16, a THC(+) screen show significantly lower [[Intensive care unit|intensive care]] unit LOS and mortality (19.3% versus 25.0%) than THC(-) patients, shown by 4849 patients included at two large regional trauma centers between 2014 and 2018.<ref>{{cite journal | vauthors = Taghavi S, Ramirez S, Duchesne J, Tatum D | title = Preinjury Use of Marijuana and Outcomes in Trauma Patients | language = English | journal = The Journal of Surgical Research | volume = 257 | pages = 42–49 | date = January 2021 | pmid = 32818783 | doi = 10.1016/j.jss.2020.07.011 | s2cid = 221219765 }}</ref> |
||
As the [[fatty acid amide hydrolase]] (FAAH) have showed significant decreased in [[bhang]] users as compared to controls, and indicating that the decrease in FAAH protein level is closely related to the duration of bhang use, and further revealed that the bhang–induced [[Immunosuppressive drug|immunotoxicity]], could be attributed to decrease in FAAH protein, bhang could also be a healthy drink/preparation to suppress an overactive [[immune response]].<ref name=":20" /><ref>{{cite journal | vauthors = Rieder SA, Chauhan A, Singh U, Nagarkatti M, Nagarkatti P | title = Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression | journal = Immunobiology | volume = 215 | issue = 8 | pages = 598–605 | date = August 2010 | pmid = 19457575 | pmc = 3005548 | doi = 10.1016/j.imbio.2009.04.001 }}</ref> |
As the [[fatty acid amide hydrolase]] (FAAH) have showed significant decreased in [[bhang]] users as compared to controls, and indicating that the decrease in FAAH protein level is closely related to the duration of bhang use, and further revealed that the bhang–induced [[Immunosuppressive drug|immunotoxicity]], could be attributed to decrease in FAAH protein, bhang could also be a healthy drink/preparation to suppress an overactive [[immune response]].<ref name=":20" /><ref>{{cite journal | vauthors = Rieder SA, Chauhan A, Singh U, Nagarkatti M, Nagarkatti P | title = Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression | journal = Immunobiology | volume = 215 | issue = 8 | pages = 598–605 | date = August 2010 | pmid = 19457575 | pmc = 3005548 | doi = 10.1016/j.imbio.2009.04.001 }}</ref> |
||
Fatty acid amide hydrolase (FAAH) inhibition has been found [[Neuroprotection|neuroprotective]] with therapeutic potential against [[Neuropathology|neuropathological]] states including traumatic brain injury, Alzheimer's, [[Huntington's disease|Huntington's]], and [[Parkinson's disease]]s, and |
Fatty acid amide hydrolase (FAAH) inhibition has been found [[Neuroprotection|neuroprotective]] with therapeutic potential against [[Neuropathology|neuropathological]] states including traumatic brain injury, Alzheimer's, [[Huntington's disease|Huntington's]], and [[Parkinson's disease]]s, and stroke.<ref>{{Cite journal |last=Hwang |first=Jeannie |date=13 June 2009 |title=Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: A neuroprotective therapeutic modality |journal=Life Sciences |volume=86 |issue=15–16 |pages=615–623 |doi=10.1016/j.lfs.2009.06.003 |pmid=19527737 |pmc=2848893 }}</ref> |
||
A [[Molecule|molecular]] mechanism through which NAE 20:4 (AEA) plant competitive substitute THC cannabinoid molecules can affect the development of [[Alzheimer's disease]], the leading cause of [[dementia]],<ref>{{Citation |title=Pollution Disease Link: Interview with neuroscience professor David Allsop from Lancaster University |url=https://www.youtube.com/watch?v=hPMRV9Ue0WE |language=en |access-date=2022-10-26}}</ref> or its impact: |
A [[Molecule|molecular]] mechanism through which NAE 20:4 (AEA) plant competitive substitute THC cannabinoid molecules can affect the development of [[Alzheimer's disease]], the leading cause of [[dementia]],<ref>{{Citation |title=Pollution Disease Link: Interview with neuroscience professor David Allsop from Lancaster University | date=6 September 2016 |url=https://www.youtube.com/watch?v=hPMRV9Ue0WE |language=en |access-date=2022-10-26}}</ref> or its impact: |
||
THC: [[Carbon|C]]<sub>21</sub>[[Hydrogen|H]]<sub>30</sub>[[Oxygen|O]]<sub>2</sub> → THC-OH: C<sub>21</sub>H<sub>30</sub>O<sub>3</sub> → THC:COOH: C<sub>21</sub>H<sub>28</sub>O<sub>4</sub> → a significantly superior inhibitor of [[Amyloid beta]] (Aβ) aggregation and [[Tau protein|tau]] [[Hyperphosphorylation|phosphorylation]], compared to [[approved drugs]] [[Acetylcholinesterase inhibitor|prescribed]] for the treatment of Alzheimer's disease in 2008, through which these molecules directly can affect the development by activation of both CB1 and CB2 receptors, which inhibit the enzyme [[acetylcholinesterase]] (AChE), which further prevent AChE-induced amyloid β-[[peptide]] (Aβ) aggregation, as they also are able to bind to the [[Ion|anionic]] site of AChE, a region involved in and critical for [[amyloid]] formation, as well as by promoting the brain's [[intrinsic]] repair mechanisms, and promote [[neurogenesis]], endocannabinoid signaling has demonstrated to modulate numerous concomitant pathological processes, including [[neuroinflammation]], [[excitotoxicity]], [[Mitochondrial disease|mitochondrial dysfunction]], and [[oxidative stress]].<ref>{{cite journal | vauthors = Eubanks LM, Rogers CJ, Beuscher AE, Koob GF, Olson AJ, Dickerson TJ, Janda KD | title = A molecular link between the active component of marijuana and Alzheimer's disease pathology | journal = Molecular Pharmaceutics | volume = 3 | issue = 6 | pages = 773–777 | date = 2006 | pmid = 17140265 | pmc = 2562334 | doi = 10.1021/mp060066m }}</ref><ref>{{Cite web |title=Cannabinoids as antioxidants and neuroprotectants - Patent US-6630507-B1 - PubChem |url=https://pubchem.ncbi.nlm.nih.gov/patent/US-6630507-B1#section=Abstract |access-date=2022-12-16 |website=pubchem.ncbi.nlm.nih.gov}}</ref><ref>{{Cite journal |last1=Aso |first1=Ester |last2=Ferrer |first2=Isidre |date=2014 |
THC: [[Carbon|C]]<sub>21</sub>[[Hydrogen|H]]<sub>30</sub>[[Oxygen|O]]<sub>2</sub> → THC-OH: C<sub>21</sub>H<sub>30</sub>O<sub>3</sub> → THC:COOH: C<sub>21</sub>H<sub>28</sub>O<sub>4</sub> → a significantly superior inhibitor of [[Amyloid beta]] (Aβ) aggregation and [[Tau protein|tau]] [[Hyperphosphorylation|phosphorylation]], compared to [[approved drugs]] [[Acetylcholinesterase inhibitor|prescribed]] for the treatment of Alzheimer's disease in 2008, through which these molecules directly can affect the development by activation of both CB1 and CB2 receptors, which inhibit the enzyme [[acetylcholinesterase]] (AChE), which further prevent AChE-induced amyloid β-[[peptide]] (Aβ) aggregation, as they also are able to bind to the [[Ion|anionic]] site of AChE, a region involved in and critical for [[amyloid]] formation, as well as by promoting the brain's [[intrinsic]] repair mechanisms, and promote [[neurogenesis]], endocannabinoid signaling has demonstrated to modulate numerous concomitant pathological processes, including [[neuroinflammation]], [[excitotoxicity]], [[Mitochondrial disease|mitochondrial dysfunction]], and [[oxidative stress]].<ref>{{cite journal | vauthors = Eubanks LM, Rogers CJ, Beuscher AE, Koob GF, Olson AJ, Dickerson TJ, Janda KD | title = A molecular link between the active component of marijuana and Alzheimer's disease pathology | journal = Molecular Pharmaceutics | volume = 3 | issue = 6 | pages = 773–777 | date = 2006 | pmid = 17140265 | pmc = 2562334 | doi = 10.1021/mp060066m }}</ref><ref>{{Cite web |title=Cannabinoids as antioxidants and neuroprotectants - Patent US-6630507-B1 - PubChem |url=https://pubchem.ncbi.nlm.nih.gov/patent/US-6630507-B1#section=Abstract |access-date=2022-12-16 |website=pubchem.ncbi.nlm.nih.gov}}</ref><ref>{{Cite journal |last1=Aso |first1=Ester |last2=Ferrer |first2=Isidre |date=5 March 2014 |title=Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic |journal=Frontiers in Pharmacology |volume=5 |pages=37 |doi=10.3389/fphar.2014.00037 |issn=1663-9812 |pmc=3942876 |pmid=24634659|doi-access=free }}</ref> However other [[phytochemical]]s that are present in ''[[Cannabis sativa]]'' is found to interact with each other in a [[Synergy|synergistic]] fashion, called the [[entourage effect]], that seems to have greater therapeutic potential when administered together, rather than individually.<ref>{{Cite journal |last1=Coles |first1=Madilyn |last2=Steiner-Lim |first2=Genevieve Z. |last3=Karl |first3=Tim |date=2022 |title=Therapeutic properties of multi-cannabinoid treatment strategies for Alzheimer's disease |journal=Frontiers in Neuroscience |volume=16 |page=962922 |doi=10.3389/fnins.2022.962922 |pmid=36117622 |pmc=9479694 |issn=1662-453X |doi-access=free }}</ref><ref name=":51">{{Cite web|title=Cannabis Our Key to the Endocannabinoid System|url=https://www.caymanchem.com/news/cannabis-our-key-to-the-endocannabinoid-system|access-date=2021-06-25|website=www.caymanchem.com|language=en}}</ref><ref name=":50" /><ref>{{Cite web |last1=Steiner-Lim |first1=Genevieve Z. |last2=Coles |first2=Madilyn |last3=Jaye |first3=Kayla |last4=Metri |first4=Najwa-Joelle |last5=Butt |first5=Ali S. |last6=Christofides |first6=Katerina |last7=McPartland |first7=Jackson |last8=Al-Modhefer |first8=Zainab |last9=Karamacoska |first9=Diana |date=2023 |title=Medicinal Cannabis for Alzheimer's Disease |url=https://www.researchgate.net/publication/369080435 |access-date=2023-08-13 |website=ResearchGate |language=English}}</ref> |
||
A synergistic outcome that also show different cannabinoids can be effective against harmful bacteria including those that are [[Antimicrobial resistance|resistant]] to common [[ |
A synergistic outcome that also show different cannabinoids can be effective against harmful bacteria including those that are [[Antimicrobial resistance|resistant]] to common [[antibiotic]]s, like [[Methicillin-resistant Staphylococcus aureus|Methicillin-resistant ''Staphylococcus aureus'']] (MRSA) causing various types of life-threatening infections, such as [[septic shock]], [[endocarditis]] and severe [[pneumonia]], coursed by the [[Antibiotic misuse|misuse of antibiotics]], which is the leading cause of the emergence of [[List of antibiotic-resistant bacteria|antibiotic-resistant bacteria]]. They do so by [[Biofilm prevention|inhibit]] the formation of [[biofilm]]s and also eradicate pre-existing ones, was showcased in 1976, where it was discovered that THC and CBD can be used as [[bacteriostatic agent]]s and are able to kill a panel of human pathogenic strains, and later a panel of cannabinoids are found able to do the same in different bacteria strains.<ref>{{Cite web |last1=Irenej |first1=Pečan Luka |last2=Francisco-Righoberto |first2=Barrios |last3=Marko |first3=Jeran |date=2023 |title=Cannabinoid Molecules from Cannabis Sativa L. as a {{sic|nolink=y|Promissing}} Solution for Methicillin-Resistant Staphylococcus Aureus (MRSA) |url=https://www.zf.uni-lj.si/images/knjiznica/Sokratska_8/15_Pe%C4%8Dan_Luka_Irenej.pdf |website=University of Ljubljana}}</ref><ref name=":52">{{Cite journal |last1=Farha |first1=Maya A. |last2=El-Halfawy |first2=Omar M. |last3=Gale |first3=Robert T. |last4=MacNair |first4=Craig R. |last5=Carfrae |first5=Lindsey A. |last6=Zhang |first6=Xiong |last7=Jentsch |first7=Nicholas G. |last8=Magolan |first8=Jakob |last9=Brown |first9=Eric D. |date=13 March 2020 |title=Uncovering the Hidden Antibiotic Potential of Cannabis |url=https://www.researchgate.net/publication/339033053 |journal=ACS Infectious Diseases |language=en |volume=6 |issue=3 |pages=338–346 |doi=10.1021/acsinfecdis.9b00419 |pmid=32017534 |s2cid=211035245 |issn=2373-8227 |via=ResearchGate}}</ref> |
||
Different |
Different medication and intervention regimes, and [[Lifestyle (social sciences)|lifestyle]] modifications, like [[Dietary supplement|diet]], [[Obesity|weight control]], exercise, [[mindfulness]] as [[Yoga as therapy|yoga]] and [[meditation]], and the use of [[Psychoactive drug|psychoactive substances]], like [[Alcoholic drink|alcohol]],<ref name=":19" /> [[Tobacco smoking|tobacco]], coffee,<ref>{{cite journal | vauthors = Rossi S, De Chiara V, Musella A, Mataluni G, Sacchetti L, Siracusano A, Bernardi G, Usiello A, Centonze D | display-authors = 6 | title = Caffeine drinking potentiates cannabinoid transmission in the striatum: interaction with stress effects | journal = Neuropharmacology | volume = 56 | issue = 3 | pages = 590–597 | date = March 2009 | pmid = 19027757 | doi = 10.1016/j.neuropharm.2008.10.013 | s2cid = 35191973 }}</ref><ref>{{cite journal | vauthors = Rossi S, De Chiara V, Musella A, Mataluni G, Sacchetti L, Siracusano A, Bernardi G, Usiello A, Centonze D | display-authors = 6 | title = Effects of caffeine on striatal neurotransmission: focus on cannabinoid CB1 receptors | journal = Molecular Nutrition & Food Research | volume = 54 | issue = 4 | pages = 525–531 | date = April 2010 | pmid = 20087854 | doi = 10.1002/mnfr.200900237 }}</ref> and [[cannabis]], beside [[general anaesthesia]] regimens (i.e. [[propofol]], [[etomidate]], [[sevoflurane]], [[isoflurane]], [[sufentanil]]),<ref>{{cite journal | vauthors = Schelling G, Hauer D, Azad SC, Schmoelz M, Chouker A, Schmidt M, Hornuss C, Rippberger M, Briegel J, Thiel M, Vogeser M | display-authors = 6 | title = Effects of general anesthesia on anandamide blood levels in humans | journal = Anesthesiology | volume = 104 | issue = 2 | pages = 273–277 | date = February 2006 | pmid = 16436846 | doi = 10.1097/00000542-200602000-00012 | s2cid = 27303365 | doi-access = free }}</ref><ref>{{cite journal | vauthors = Patel S, Wohlfeil ER, Rademacher DJ, Carrier EJ, Perry LJ, Kundu A, Falck JR, Nithipatikom K, Campbell WB, Hillard CJ | display-authors = 6 | title = The general anesthetic propofol increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase | journal = British Journal of Pharmacology | volume = 139 | issue = 5 | pages = 1005–1013 | date = July 2003 | pmid = 12839875 | doi = 10.1038/sj.bjp.0705334 | pmc = 1573928 }}</ref> and [[Insulin (medication)|Insulin medication]] and [[intraoperative]] doses of [[insulin]],<ref name=":29" /><ref name=":30" /> etc, do also modulate it, either by being a FAAH inhibitor, that blocks the breakdown of NAE 20:4 (AEA), and/or enhance or lowering its production, and/or by activate or inactivate the receptors connected, as [[arachidonic acid]] (C<sub>20</sub>H<sub>32</sub>[[Oxygen|O]]<sub>2</sub>; 20:4, ω-6), the precursor of NAE 20:4 (AEA) and other eCBs, is present in every [[Cell signaling|cell]] [[Cell membrane|membrane]] of the body, and their on demand [[Biosynthesis|synthesis]] is regulated by [[Membrane potential|electrical]] activity and [[calcium]] ([[Calcium in biology|Ca<sup>2+</sup>]]) shifts.<ref name=":9" /><ref name=":22">{{cite journal | vauthors = de Melo Reis RA, Isaac AR, Freitas HR, de Almeida MM, Schuck PF, Ferreira GC, Andrade-da-Costa BL, Trevenzoli IH | display-authors = 6 | title = Quality of Life and a Surveillant Endocannabinoid System | journal = Frontiers in Neuroscience | volume = 15 | pages = 747229 | date = 28 October 2021 | pmid = 34776851 | pmc = 8581450 | doi = 10.3389/fnins.2021.747229 | doi-access = free }}</ref><ref>{{cite journal | vauthors = Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K | title = GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 105 | issue = 7 | pages = 2699–2704 | date = February 2008 | pmid = 18263732 | pmc = 2268199 | doi = 10.1073/pnas.0711278105 | doi-access = free | bibcode = 2008PNAS..105.2699L }}</ref><ref>{{cite journal | vauthors = Berk K, Bzdega W, Konstantynowicz-Nowicka K, Charytoniuk T, Zywno H, Chabowski A | title = Phytocannabinoids-A Green Approach toward Non-Alcoholic Fatty Liver Disease Treatment | journal = Journal of Clinical Medicine | volume = 10 | issue = 3 | page = 393 | date = January 2021 | pmid = 33498537 | pmc = 7864168 | doi = 10.3390/jcm10030393 | doi-access = free }}</ref><ref>{{cite journal | vauthors = M Taalab Y, Mohammed WF, Helmy MA, Othman AA, Darwish M, Hassan I, Abbas M | title = Cannabis Influences the Putative Cytokines-Related Pathway of Epilepsy among Egyptian Epileptic Patients | journal = Brain Sciences | volume = 9 | issue = 12 | page = 332 | date = November 2019 | pmid = 31757102 | pmc = 6955862 | doi = 10.3390/brainsci9120332 | doi-access = free }}</ref><ref>{{cite journal | vauthors = Hampson AJ, Grimaldi M, Axelrod J, Wink D | title = Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 95 | issue = 14 | pages = 8268–8273 | date = July 1998 | pmid = 9653176 | pmc = 20965 | doi = 10.1073/pnas.95.14.8268 | doi-access = free | bibcode = 1998PNAS...95.8268H }}</ref><ref name=":15">{{cite journal | vauthors = Nguyen BM, Kim D, Bricker S, Bongard F, Neville A, Putnam B, Smith J, Plurad D | display-authors = 6 | title = Effect of marijuana use on outcomes in traumatic brain injury | journal = The American Surgeon | volume = 80 | issue = 10 | pages = 979–983 | date = October 2014 | pmid = 25264643 | doi = 10.1177/000313481408001015 | s2cid = 25797119 | doi-access = free }}</ref><ref>{{cite journal | vauthors = D'Souza DC, Cortes-Briones JA, Ranganathan M, Thurnauer H, Creatura G, Surti T, Planeta B, Neumeister A, Pittman B, Normandin M, Kapinos M, Ropchan J, Huang Y, Carson RE, Skosnik PD | display-authors = 6 | title = Rapid Changes in CB1 Receptor Availability in Cannabis Dependent Males after Abstinence from Cannabis | journal = Biological Psychiatry. Cognitive Neuroscience and Neuroimaging | volume = 1 | issue = 1 | pages = 60–67 | date = January 2016 | pmid = 26858993 | pmc = 4742341 | doi = 10.1016/j.bpsc.2015.09.008 }}</ref>{{Excessive citations inline|reason=Trim citations, this is excessive.|date=November 2023}} |
||
== The evolutionary harm reduction program == |
|||
The central [[Thesis statement|thesis]] is, that [[harm reduction]] is not only a [[social concept]],<ref>{{cite journal | vauthors = Ren M, Tang Z, Wu X, Spengler R, Jiang H, Yang Y, Boivin N | title = The origins of cannabis smoking: Chemical residue evidence from the first millennium BCE in the Pamirs | journal = Science Advances | volume = 5 | issue = 6 | pages = eaaw1391 | date = June 2019 | pmid = 31206023 | pmc = 6561734 | doi = 10.1126/sciadv.aaw1391 | bibcode = 2019SciA....5.1391R }}</ref> but also a [[biological]] one. More specifically, [[evolution]] does not make [[moral]] distinctions in the selection process, but utilizes a cannabis-based approach, seen from the oldest [[Pollination|pollen]], where ''[[Cannabis]]'' and ''[[Humulus]]'' [[Genetic divergence|diverged]] between 18.23 mya and 27.8 mya ago, and consistent with Cannabis dated to 19.6 ago ([[Million years ago|Ma]]), in [[Northwest China|northwestern China]], and converge on the northeastern [[Tibetan Plateau]], in the general vicinity of [[Qinghai Lake]], which is deduced as the Cannabis centre of origin, and co-localizes with the first [[Steppe people|steppe]] community that evolved in [[Asia]],<ref>{{Cite journal| vauthors = McPartland JM, Hegman W, Long|date=2019-11-01|title=Cannabis in Asia: its center of origin and early cultivation, based on a synthesis of subfossil pollen and archaeobotanical studies|url=https://doi.org/10.1007/s00334-019-00731-8|journal=Vegetation History and Archaeobotany|language=en|volume=28|issue=6|pages=691–702|doi=10.1007/s00334-019-00731-8|s2cid=181608199|issn=1617-6278}}</ref> or [[Yunnan]], in [[Southwest China|the southwest]] of [[China]], also identified as "the birthplace of [[tea]] ... the first area where humans [[Retrograde signaling|figured out]] that eating tea leaves or brewing a cup could be [[Pleasure|pleasant]]", and helpful, by its cannabimimetic bioactivity of [[catechin]] derivatives occurring in tea leaves, as the region of origin,<ref>{{Cite journal | vauthors = Osterberger E, Lohwasser U, Jovanovic D, Ruzicka J, Novak J |date=2022-04-01 |title=The origin of the genus Cannabis |journal=Genetic Resources and Crop Evolution |language=en |volume=69 |issue=4 |pages=1439–1449 |doi=10.1007/s10722-021-01309-y |s2cid=245589100 |issn=1573-5109|doi-access=free }}</ref><ref>{{cite journal | vauthors = Korte G, Dreiseitel A, Schreier P, Oehme A, Locher S, Geiger S, Heilmann J, Sand PG | display-authors = 6 | title = Tea catechins' affinity for human cannabinoid receptors | journal = Phytomedicine | volume = 17 | issue = 1 | pages = 19–22 | date = January 2010 | pmid = 19897346 | doi = 10.1016/j.phymed.2009.10.001 }}</ref> to harm reduction in order to promote [[survival of the fittest]]. Evidence provided from peer-reviewed scientific literature supports the hypothesis, that humans, and all [[animal]]s,<ref>{{cite journal | vauthors = Silver RJ | title = The Endocannabinoid System of Animals | journal = Animals | volume = 9 | issue = 9 | page = 686 | date = September 2019 | pmid = 31527410 | pmc = 6770351 | doi = 10.3390/ani9090686 | doi-access = free }}</ref> since the primordial [[Cannabinoid receptor|CB receptor]] evolved at least 600 million years ago; a date that broadly consistent with the [[Cambrian]] [[Cambrian explosion|explosion]],<ref>{{Cite web| vauthors = McPartland JM |date=2002|title=Sourcing the Code: Searching for the Evolutionary Origins of Cannabinoid Receptors, Vanilloid Receptors, and Anandamide|url=http://cannabis-med.org/data/pdf/2002-01-3.pdf|website=cannabis-med.org}}</ref> make and use internally produced cannabis-like products (endocannabinoids) as part of the evolutionary harm reduction program. More specifically, endocannabinoids [[Homeostasis|homeostatically]] regulate all [[Biological system|body systems]] ([[cardiovascular]], [[Digestive system|digestive]], [[Endocrine system|endocrine]], [[Excretory system|excretory]], [[Immune system|immune]], [[Nervous system|nervous]], [[Human musculoskeletal system|musculo-skeletal]], [[Reproductive system|reproductive]]),<ref name=":22" /> as a versatile tool available to [[organism]]s to fine-tune homeostasis,<ref>{{Cite journal |last1=Di Marzo |first1=Vincenzo |last2=De Petrocellis |first2=Luciano |date=2012-12-05 |title=Why do cannabinoid receptors have more than one endogenous ligand? |journal=Philosophical Transactions of the Royal Society B: Biological Sciences |volume=367 |issue=1607 |pages=3216–3228 |doi=10.1098/rstb.2011.0382 |issn=0962-8436 |pmc=3481524 |pmid=23108541}}</ref> and modulating endocannabinoid activity have therapeutic potential in almost all diseases affecting humans.<ref name=":16" /><ref>{{Cite web| vauthors = Mechoulam R |date=2019|title=Research on Cannabinoids Over the Decades and What's to Come - Raphael Mechoulam|url=https://www.youtube.com/watch?v=4-KQh0VrYyw |archive-url=https://ghostarchive.org/varchive/youtube/20211215/4-KQh0VrYyw |archive-date=2021-12-15|url-status=live|website=YouTube}}{{cbignore}}</ref><ref>{{cite journal | vauthors = Bachhuber MA, Saloner B, Cunningham CO, Barry CL | title = Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010 | journal = JAMA Internal Medicine | volume = 174 | issue = 10 | pages = 1668–1673 | date = October 2014 | pmid = 25154332 | pmc = 4392651 | doi = 10.1001/jamainternmed.2014.4005 | doi-access = free }}</ref><ref>{{cite journal | vauthors = Bradford AC, Bradford WD, Abraham A, Bagwell Adams G | title = Association Between US State Medical Cannabis Laws and Opioid Prescribing in the Medicare Part D Population | journal = JAMA Internal Medicine | volume = 178 | issue = 5 | pages = 667–672 | date = May 2018 | pmid = 29610897 | pmc = 6145794 | doi = 10.1001/jamainternmed.2018.0266 }}</ref><ref>{{Cite web| vauthors = Jeffries D |date=2006|title=Jeffrey's Journey - Healing a Child's Violent Rages With Pot|url=https://www.youtube.com/watch?v=4XM_TdmQ9lM |archive-url=https://ghostarchive.org/varchive/youtube/20211215/4XM_TdmQ9lM |archive-date=2021-12-15|url-status=live|website=YouTube}}{{cbignore}}</ref> Therefore, the health of each individual is dependent on this system are working appropriately,<ref name=":11" /><ref>{{Cite web|vauthors = Anderson DM, Rees DI, Sabia JJ |date=January 2012|title=High on Life? Medical Marijuana Laws and Suicide|url=http://ftp.iza.org/dp6280.pdf|website=Institute for the Study of Labor (IZA)}}</ref> and imagine what could be achieved if signaling through these receptors could be controlled: [[Happiness|happy]], [[Body shape index|slim]], and [[health]]y people who remember that they're pain-free,<ref>{{cite journal | vauthors = Lucas P, Boyd S, Milloy MJ, Walsh Z | title = Cannabis Significantly Reduces the Use of Prescription Opioids and Improves Quality of Life in Authorized Patients: Results of a Large Prospective Study | journal = Pain Medicine | volume = 22 | issue = 3 | pages = 727–739 | date = March 2021 | pmid = 33367882 | pmc = 7971472 | doi = 10.1093/pm/pnaa396 }}</ref><ref name=":32">{{cite journal | vauthors = Hosking RD, Zajicek JP | title = Therapeutic potential of cannabis in pain medicine | language = English | journal = British Journal of Anaesthesia | volume = 101 | issue = 1 | pages = 59–68 | date = July 2008 | pmid = 18515270 | doi = 10.1093/bja/aen119 | doi-access = free }}</ref> by [[forgetting]],<ref>{{cite journal | vauthors = Kruk-Slomka M, Dzik A, Budzynska B, Biala G | title = Endocannabinoid System: the Direct and Indirect Involvement in the Memory and Learning Processes-a Short Review | journal = Molecular Neurobiology | volume = 54 | issue = 10 | pages = 8332–8347 | date = December 2017 | pmid = 27924524 | pmc = 5684264 | doi = 10.1007/s12035-016-0313-5 }}</ref><ref>{{Cite web| vauthors = Mechoulam R |date=2007|title=Cannabinoid system in neuroprotection, and the importance of forgetting (9:08)|url=https://www.youtube.com/watch?v=ZI2VT2kOfnM |archive-url=https://ghostarchive.org/varchive/youtube/20211215/ZI2VT2kOfnM |archive-date=2021-12-15|url-status=live|website=YouTube}}{{cbignore}}</ref> and ignore it,<ref>{{Cite web|title=Cannabinoids To the Neurons and Beyond|url=https://www.caymanchem.com/news/cannabinoids-to-the-neurons-and-beyond|access-date=2021-04-11|website=www.caymanchem.com|language=en}}</ref> achieved though cannabis, the evolutionary byproduct of a plant that evolved as a [[Homeostatic capacity|systemic homeostasis]] to affect the [[Endocannabinoid system|ECS]] and to become its natural [[Lock and key|key]], stemming back to aquatic species 400 million years before the arrival of plants and trees.<ref name=":51">{{Cite web|title=Cannabis Our Key to the Endocannabinoid System|url=https://www.caymanchem.com/news/cannabis-our-key-to-the-endocannabinoid-system|access-date=2021-06-25|website=www.caymanchem.com|language=en}}</ref><ref name=":16" /> |
|||
== Cosmic birth of NAE elements by star death == |
|||
NAE 20:4 (AEA: [[Carbon|C]]<sub>22</sub>[[Hydrogen|H]]<sub>37</sub>[[Biological functions of nitric oxide|NO]]<sub>2</sub>; 20:[[Double bond|4]], [[Omega-6 fatty acid|ω-6]]) is the amide of [[arachidonic acid]] (C<sub>20</sub>H<sub>32</sub>[[Oxygen|O]]<sub>2</sub>; 20:4, ω-6) and [[ethanolamine]] (MEA: C<sub>2</sub>H<sub>7</sub>NO). |
|||
NAE 20:5 (EPEA: C<sub>22</sub>H<sub>35</sub>NO<sub>2</sub>; 20:5, ω-3) or Anandamide (20:5, n-3). It is the amide of [[eicosapentaenoic acid]] (EPA: C<sub>20</sub>H<sub>30</sub>O<sub>2</sub>; 20:5, ω-3) |
|||
NAE 22:6 (DHEA: C<sub>24</sub>H<sub>37</sub>NO<sub>2</sub>; 22:6, ω-3), or Anandamide (22:6, n-3) "synaptamide", is the amide of [[docosahexaenoic acid]] (DHA: C<sub>22</sub>H<sub>32</sub>O<sub>2</sub>; 22:6, [[Omega-3 fatty acid|ω-3]]) and ethanolamine (MEA: C<sub>2</sub>H<sub>7</sub>NO) |
|||
In the heart of a heavy [[star]], like [[Betelgeuse]], and in its [[Stellar core|core]], is where all the ingredients of [[life]] (and elements of NAEs) are found made. Deep in its core, the star will fight a futile battle against its own [[gravity]], as it tries to stop itself collapsing under its own weight, is where new [[Chemical element|elements]] are made in a sequence of separate stages. |
|||
Stage one, is while there is still a supply of [[hydrogen]] (H) to [[Combustion|burn]]. As the star burn in hydrogen to [[helium]] (He) in the core, are vast amounts of [[energy]] released and that energy escapes and thereby creating an outward [[pressure]], which balances the force of gravity, and holds the star off and keeps it stable. But the hydrogen (H) in the core will eventually run out, and the [[fusion reaction]]s will stop and no energy will be released, and the outward pressure will disappear, and the core will start to collapse and very rapidly leaving a [[Shell (structure)|shell]] of hydrogen (H) and helium (He) behind. |
|||
Beneath this shell, as the core collapses, the temperature rises again until at a hundred million [[Degree (temperature)|degrees]], the stage two stars and [[Helium-3 nuclear magnetic resonance|helium nuclear]] begin to fuse together. [[Triple-alpha process|Helium fusion]] does two things. First, it releases more energy so the collapse is halted, and secondly it produce two more elements in that process. [[Carbon]] (C) and [[oxygen]] (O), two elements vital for [[life]] (and molecules in the NAE structure), with further collapses until it eventually form [[iron]] (Fe). And when that happens, the star collapses around itself. And, through a [[Planetary nebula|nebula]], [[meteorite]]s and [[Impact event|comet impact]], this is where all the carbon, hydrogen, oxygen etc. in the NAE molecular structure come from, and every [[atom]] [[particle]] in every living thing on [[Earth]], was probably produced in and carried from the elements of a [[Stellar evolution|dying star]].<ref>{{Cite web| vauthors = Cox B |date=2011|title=Star Death and the Creation of Elements - Wonders of the Universe: Stardust|url=https://www.youtube.com/watch?v=DEw6X2BhIy8 |archive-url=https://ghostarchive.org/varchive/youtube/20211215/DEw6X2BhIy8 |archive-date=2021-12-15|url-status=live|website=YouTube}}{{cbignore}}</ref> |
|||
And due to the chemical ability to build [[Fatty acid|chains]] and [[Aromaticity|rings]], carbon (C) forms with quite a few other elements, like hydrogen (H), oxygen (O), nitrogen (N), [[phosphorus]] (P) and [[sulfur]] (S) the basis of the myriad of the chemical compounds, [[protein]]s, [[DNA]], [[carbohydrate]]s, [[lipid]]s, etc. of living organisms. |
|||
[[NASA]]-funded [[scientist]]s have evidenced, that some building blocks of DNA, a [[nucleic acid]], and the molecule that carry [[Genetic code|genetic]] instructions for life, found in meteorites, were likely created in [[Universe|space]]. The research supports the theory, that a "kit" of finished parts created in space and delivered to Earth by [[Meteorite fall|meteorite]] and [[Impact event|comet]] impact, has aided the [[Abiogenesis|origin of life]].<ref>{{Cite web| vauthors = Callahan MP |date=2011|title=DNA Building Blocks Can Be Made in Space|url=https://www.youtube.com/watch?v=1g7AKVZ3HC4 |archive-url=https://ghostarchive.org/varchive/youtube/20211215/1g7AKVZ3HC4 |archive-date=2021-12-15|url-status=live|website=YouTube}}{{cbignore}}</ref> |
|||
A simulated [[Comet]] impact on the surface of the Earth, as it probably would look like 3.8 [[billion]] [[Year|years]] ago (3800 [[Myr|MYA]]) at the [[Late Heavy Bombardment|late heavy bombardment]], show that [[amino acid]]s (i.e. [[Organic compound|organic]] compounds arisen from [[amine]] (-NH2) and [[carboxylic acid]] (-COOH) [[functional group]]s, producing [[protein]]s) in [[water]] is able to make [[peptide bond]]s (i.e. bonds from the carboxyl group of one amino acid to the amino group of the other amino acid), and [[peptide]]s from the heat of the impact through [[Earth's atmosphere]], and this could be a spark to early life on Earth.<ref>{{Cite web|title=New Evidence That Comets Deposited Building Blocks of Life on Primordial Earth|url=https://www.newswise.com/articles/new-evidence-that-comets-deposited-building-blocks-of-life-on-primordial-earth|access-date=2021-04-03|website=www.newswise.com|language=en}}</ref> |
|||
Using the samples returned by the [[spacecraft]] [[Stardust (spacecraft)|Stardust]], other scientists discovered the amino acid [[glycine]] (C<sub>2</sub>H<sub>5</sub>NO<sub>2</sub>) fully formed in a [[comet tail]], but this glycine was not like this on Earth; it was built with some subtle differences - traces of [[Carboxylic acid|COOH]]'s important presence and [[Interstellar medium|interstellar]] heritage, as well as strengthened the theory of [[panspermia]], which claims that these "seeds" of life are widespread throughout the [[universe]],<ref>{{Cite web| vauthors = Schultz C |date=2011|title=Amino Acids from Interstellar Space|url=https://www.youtube.com/watch?v=uAr6MbzRuEg |archive-url=https://ghostarchive.org/varchive/youtube/20211215/uAr6MbzRuEg |archive-date=2021-12-15|url-status=live|website=YouTube}}{{cbignore}}</ref> and among the most widespread and versatile signaling molecules ever discovered.<ref>{{cite journal | vauthors = Maccarrone M, Bab I, Bíró T, Cabral GA, Dey SK, Di Marzo V, Konje JC, Kunos G, Mechoulam R, Pacher P, Sharkey KA, Zimmer A | display-authors = 6 | title = Endocannabinoid signaling at the periphery: 50 years after THC | journal = Trends in Pharmacological Sciences | volume = 36 | issue = 5 | pages = 277–296 | date = May 2015 | pmid = 25796370 | pmc = 4420685 | doi = 10.1016/j.tips.2015.02.008 }}</ref> |
|||
Further other scientists have used the [[radio telescope]] ([[Green Bank Telescope|GBT]]) in [[West Virginia]] to study a giant [[Interstellar cloud|cloud of gas]] about 25,000 [[light-year]]s from Earth, near the center of the [[Milky Way]]. The chemicals found in the cloud include one [[molecule]] that is thought to be a precursor to a key element in DNA and another that may have a role in the formation of the [[amino acid]], [[alanine]] (Ala: C<sub>3</sub>H<sub>7</sub>NO<sub>2</sub>). |
|||
Cyanomethanimine (C<sub>2</sub>H<sub>2</sub>N<sub>2</sub>), is a step in the process that is believed to produce [[adenine]] (C<sub>5</sub>H<sub>5</sub>N<sub>5</sub>), one of the four [[nucleobase]]s that make up the "step" of the ladder-like structure of [[DNA]]. The second molecule, called ethanamine (C<sub>5</sub>H<sub>5</sub>N), is thought to play a role in the formation of [[alanine]] (Ala - C<sub>3</sub>H<sub>7</sub>NO<sub>2</sub>), one of the twenty [[amino acid]]s in the [[genetic code]].<ref>{{Cite journal| vauthors = Zaleski DP, Seifert NA, Steber AL, Muckle MT, Loomis RA, Corby JF, Martinez O, Crabtree KN, Jewell PR, Hollis JM, Lovas FJ | display-authors = 6 |date=2013-03-01|title=Detection of E-Cyanomethanimine toward Sagittarius B2(N) in the Green Bank Telescope PRIMOS Survey|url=http://adsabs.harvard.edu/abs/2013ApJ...765L..10Z|journal=The Astrophysical Journal Letters|volume=765|issue=1|pages=L10|doi=10.1088/2041-8205/765/1/L10|issn=0004-637X|arxiv=1302.0909|bibcode=2013ApJ...765L..10Z|s2cid=53552345}}</ref><ref>{{Cite web| vauthors = Remijan T |date=2013|title=DNA component found in interstellar space|url=https://www.youtube.com/watch?v=Ggm-vSfHiBQ&t=3s |archive-url=https://ghostarchive.org/varchive/youtube/20211215/Ggm-vSfHiBQ |archive-date=2021-12-15|url-status=live|website=YouTube}}{{cbignore}}</ref> |
|||
[[Big Bang|*]] → An [[atom]] consists of a nucleus, the atom nucleus, and a shell. The atom's [[Electric charge|positively charged]] [[Particle physics|particles]], [[proton]]s, lie in the nucleus and consist of the smallest building blocks we know of in the universe, called [[quark]]s, which are held together by [[gluon]]s, are everywhere. Along with the protons are [[neutron]]s, which are neutral. Outside the nucleus is the mantle, where the atom's negatively charged particles, [[electron]]s, interact (in the form of standing waves), and is the absolute smallest part of an element, that can exist independently, but is most often bound to other atoms that can either belong to the same element or other elements, thereby forming a [[molecule]].<ref>{{Cite web |title=atom {{!}} lex.dk |url=https://denstoredanske.lex.dk/atom |access-date=2022-12-18 |website=Den Store Danske |language=da}}</ref> |
|||
With a spike on a graph, an [[entourage effect]] and [[retrograde signaling]], by the motto “Science for Peace", and, also in the spirit of [[Niels Bohr]], the Danish [[physicist]] with the first relatively correct model of how an atom looks like, - an international group of about 6000 researchers connected at [[CERN]], by a [[particle accelerator]] located 100 meters underground, called LHC [[Large Hadron Collider|Large Hadron Collider 1]], which consists of a 27 km long tube in a circle, that can accelerate protons to near the [[speed of light]] and smash them together, demonstrated on 4 July 2012 the existence of the [[Higgs boson|Higgs particle]], a manifestation of the existence of the Higgs field - an [[Invisibility|invisible]] field in the entire [[Universe]] (symmetry breaking), believed to have emerge at about 1 [[picosecond]] (10<sup>−12</sup> s) after the [[Big Bang]], and required for [[atom]]s and other structures to form, as well as for [[nuclear reaction]]s in stars, such as the [[Sun]] and [[Betelgeuse]]. As so, the Higgs field is responsible for this symmetry breaking, and which all particles pass through, and which provide them their [[mass]] and thereby, [[weight]], and without this field, all particles and elements in the NAE-structure, would be moving around at the [[speed of light]], because they didn't have a mass, and they and living nature, wouldn't be able to exist. |
|||
== See also == |
== See also == |
Latest revision as of 15:16, 26 December 2024
An N-acylethanolamine (NAE) is a type of fatty acid amide where one of several types of acyl groups is linked to the nitrogen atom of ethanolamine, and highly metabolic formed by intake of essential fatty acids through diet by 20:4, n-6 and 22:6, n-3 fatty acids,[1][2] and when the body is physically and psychologically active,.[3][4] The endocannabinoid signaling system (ECS) is the major pathway by which NAEs exerts its physiological effects in animal cells with similarities in plants, and the metabolism of NAEs is an integral part of the ECS,[5] a very ancient signaling system, being clearly present from the divergence of the protostomian/deuterostomian,[6][7] and even further back in time, to the very beginning of bacteria, the oldest organisms on Earth known to express phosphatidylethanolamine, the precursor to endocannabinoids, in their cytoplasmic membranes. Fatty acid metabolites with affinity for CB receptors are produced by cyanobacteria, which diverged from eukaryotes at least 2000 Million years ago (MYA), by brown algae which diverged about 1500 MYA, by sponges, which diverged from eumetazoans about 930 MYA, and a lineages that predate the evolution of CB receptors, as CB1 – CB2 duplication event may have occurred prior to the lophotrochozoan-deuterostome divergence 590 MYA. Fatty acid amide hydrolase (FAAH) evolved relatively recently, either after the evolution of fish 400 MYA, or after the appearance of mammals 300 MYA, but after the appearance of vertebrates. Linking FAAH, vanilloid receptors (VR1) and anandamide (NAE 20:4) implies a coupling among the remaining ‘‘older’’ parts of the endocannabinoid system, monoglyceride lipase (MGL), CB receptors, that evolved prior to the metazoan–bilaterian divergence (ie, between extant Hydra and leech), but were secondarily lost in the Ecdysozoa, and 2-Arachidonoylglycerol (2-AG).[8]
These amides conceptually can be formed from a fatty acid and ethanolamine with the release of a molecule of water, but the known biological synthesis uses a specific phospholipase D to cleave the phospholipid unit from N-acylphosphatidylethanolamines.[9] Another route relies on the transesterification of acyl groups from phosphatidylcholine by an N-acyltransferase (NAT) activity.[citation needed] The suffixes -amine and -amide in these names each refer to the single nitrogen atom of ethanolamine that links the compound together: it is termed "amine" in ethanolamine because it is considered as a free terminal nitrogen in that subunit, while it is termed "amide" when it is considered in association with the adjacent carbonyl group of the acyl subunit. Names for these compounds may be encountered with either "amide" or "amine" varying by author.[10]
N-acylethanolamines (NAEs) are broken down, or hydrolysed, by fatty acid amide hydrolase (FAAH) to ethanolamine (MEA) and their corresponding fatty acid, arachidonic acid. FAAH is activated during stress exposure circumstances, which also raises the neuronal excitability in the amygdala, a critical brain area that mediates anxiety, and the anxiolytic outcome of CB1 receptor activation.[11] Inhibition of FAAH has been shown to increase the levels of NAEs in vivo and to produce desirable phenotypes, that produce analgesic, anxiolytic, neuroprotective, and anti-inflammatory effects,[12] like in high-level performance athletes (i.e., elite athletes) that present an extraordinary interindividual variability of physical, but also mental traits, that greatly influence their sports accomplishments and their career longevity, by an FAAH genetic polymorphism that produce the SNP rs324420 (C385A allele), associated with a higher sensitivity of FAAH to proteolytic degradation and a shorter half-life, as compared to the C variant, as the A variant displays normal catalytic properties, but an enhanced sensitivity to degradation, leading to increased NAE and anandamide (AEA) signaling.[11] Activation of the cannabinoid receptor CB1 or CB2 in different tissues, including skin, inhibit FAAH, and thereby increases endocannabinoid levels.[13]
Examples
[edit]Examples of N-acylethanolamines include:[14]
- Anandamide (N-arachidonoylethanolamine; NAE) or arachidonoylethanolamine (AEA: C22H37NO2; 20:4, ω-6) is the amide of arachidonic acid (C20H32O2; 20:4, ω-6) and ethanolamine (MEA: C2H7NO).[15] It is the ligand of both cannabinoid receptors and vanilloid receptor that attenuates pain sensation.[16][17][18][19] Where binding to cannabinoid receptors is coupled to nitric oxide (NO) release in the central nervous system of invertebrates and in peripheral immune cells of both invertebrates and humans.[20]
- N-Palmitoylethanolamine (PEA: C18H37NO2; 16:0) is the amide of palmitic acid (C16H32O2; 16:0) and ethanolamine. It is a ligand at CB2 receptors,[21][22] and PPAR-α.[23] It has anti-inflammatory activity and also attenuates pain sensation in mammals, whose levels are increased following neuroinflammatory or neuropathic conditions in both animals and humans, possibly to exert a local anti-inflammatory and analgesic action.[19][24][25][26] NAE 16:0 has also been identified in plants including corn, and seeds of cotton, okra, tomato, castor bean, soya bean and peanuts,[27] but its physiological functions remain unknown,[28]
- N-alpha-Linoleoylethanolamide (ALEA: C20H35NO2; 18:3, ω-3) or Anandamide (18:3, n-3),[29] is a metabolic product of the omega-3 fat α-linoleic acid (ALA: C18H30O2; 18:3, ω-3) and ethanolamine (MEA: C2H7NO).[30]
- N-Oleoylethanolamine (OEA: C20H39NO2; 18:1, ω-9) is the amide of oleic acid (C18H34O2; 18:1) and ethanolamine. It has anorexic effects and enables fat breakdown by stimulating PPAR-alpha.[31] In plants, NAE 18:1 is present abundantly in dry seeds and levels decline during seed imbibition,[27][32] but its physiological functions are yet to be elucidated. In humans, plasma OEA levels are also found positively correlated with positive mood and emotions.[4] OEA acting mostly at peroxisome proliferator‐activated receptor‐α (PPAR‐α) nuclear receptors and, to some extent, TRPV1 channels.[33]
- N-Stearoylethanolamine (SEA: C20H41NO2; 18:0) is the amide of stearic acid (C18H36O2) and ethanolamine (MEA: C2H7NO). It has pro-apoptotic activity. It operates independently of the known cannabinoid and vanilloid receptors targeted by anandamide.[31] It is an inhibitor of the sphingolipid signaling pathway, via specific ceramidase inhibition (ceramidase converts ceramide to sphingosine) and blocks the effects of TNF- and arachidonic acid on intracellular Ca2+ concentration.[34][35][36]
- N-Linoleoyl ethanolamide (MEA: C20H37NO2; 18:2, ω-6) or Anandamide (18:2, n-6) is the ethanolamide of linoleic acid (LA: C18H32O2; 18:2, ω-6) and its metabolized incorporated ethanolamine (MEA: C2H7NO),[37] is the first natural inhibitor of fatty acid amide hydrolase (FAAH) discovered, also derives from hydroperoxides of NAE 20:4 (AEA) or its linoleoyl analogues by lipoxygenase action.[20]
- N-Docosahexaenoyl ethanolamine (DHEA: C24H37NO2; 22:6, ω-3), or Anandamide (22:6, n-3) "synaptamide", is the non-oxidative produced amide of the mainly fish oil derived, docosahexaenoic acid (DHA: C22H32O2; 22:6, ω-3), that is the most abundant polyunsaturated fatty acid (PUFA) in the brain and the retina,[38] and ethanolamine (MEA: C2H7NO).[39] It can act at CB1 and CB2 receptors,[40][41] and have anti-proliferative effects on prostate cancer cell lines and promotes synaptogenesis, neurogenesis and neuritogenesis,[42][43] and as an endogenous metabolite of DHA, it promotes brain development and function.[44]
- N-Docosatetraenoylethanolamine (DEA: C24H41NO2; 22:4,ω-6) act on the CB1 receptor,[21] and possible CB2.[34]
- N-Eicosapentaenoylethanolamide (EPEA: C22H35NO2; 20:5, ω-3) or Anandamide (20:5, n-3). It is the amide of eicosapentaenoic acid (EPA: C20H30O2; 20:5, n-3),[45] that can act on CB1 and CB2 receptors in combination with PPAR-gamma to decrease LPS induced adipocyte IL-6 and MCP-1 levels.[40][41]
- N-homo-gamma-linolenoylethanolamine, or Anandamide (20:3,n-6) (HGLEA: C22H39NO2; 20:3,ω-6).[46]
These bioactive lipid amides are generated by the membrane enzyme NAPE-PLD, and natural bile acids regulate this essential process.[47] An in vivo active NAPE-PLD inhibitor called LEI-401 was found to be CNS-active and modulated NAE biosynthesis. It had similar effects as a cannabinoid CB1 receptor antagonist, which could be reversed by co-treatment with a FAAH inhibitor.[48]
At least two pathways distinct from NAPE-PLD have been proposed as metabolic pathways for NAE 20:4 (AEA) formation. One pathway involves the double-O-deacylation of NAPEs by α,β-hydrolase (ABHD4) to form glycerophospho-N-acylethanolamines (GP-NAEs),[49] followed by conversion of these intermediates to NAEs by glycerophosphodiesterase-1 (GDE1). Another pathway uses a phospholipase C (PLC) to produce phopho-N-arachidonoylethanolamine (pAEA) from NAPE, widely found in phospholipids,[50] followed by conversion of pAEA into NAE 20:4 (AEA) by phosphatases such as PTPN22 and SHIP1.[51]
The effects of NAE 20:4 (AEA) and another endocannabinoid 2-Arachidonoylglycerol (2-AG: C23H38O4; 20:4, ω-6), with tissue levels of 2-AG usually several tens to several hundreds of times those of AEA,[52] is found to be enhanced by "entourage compounds", NAEs that inhibit their hydrolysis via substrate competition, and thereby prolong their action. These compounds include N-palmitylethanolamide (PEA, NAE 16:0), N-oleoylethanolamide (SEA, NAE 18:0), and cis-9-octadecenoamide (OEA, oleamide, NAE 18:1).[53]
All are members of the endocannabinoidome, a complex lipid signaling system composed of more than 100 of fatty acid-derived mediators and their receptors, its anabolic and catabolic enzymes of more than 50 proteins, which are deeply involved in the control of energy metabolism and its pathological deviations,[54] as well as immunosuppression,[55] and some NAE members, do not activate the CB1 and CB2 receptors efficiently, but instead activate other receptors (e.g. peroxisome proliferator-activated receptors (PPAR)-α/γ, G-protein coupled receptors (GPR) 55, 110, 118, 119, TRPV1 channels), known to counteract metabolic disorders in animal models, by gut bacterial families (e.g. Veillonellaceae, Peptostreptococcaceae and Akkermansiaceae) associated with variations in most NAEs and omega3-derived 2-monoacylglycerols (2‑MAGs), congeners of 2-AG, as gut microbiota communities and the host endocannabinoidome also seem to be interrelated in a mutual crosstalk controlling whole body metabolism,[56][57] and onset and development of chronic intestinal inflammation.[58]
NAE's are also involved in modulation of different physiological processes such as pain, stress, anxiety, appetite, cardiovascular function and inflammation. A study suggests the presence of an endogenous NAE tone control emotional behavior.[48]
Raphael Mechoulam that described and named Anandamide in 1992. He said:
Look, I believe there are 8 billion people on this planet, and I believe there are 8 billion different personalities. One way of explaining it is, there are several hundred compounds, endocannabinoid-like compounds. They are like anandamide in their chemical structure, that are present in the brain, and it is quite possible that each one of us, has a different, slightly different level of these compounds. And it is quite possible that differences in the endocannabinoid system, endocannabinoid-like system, can have something to do with the different personalities, and that ratios of 10 of these to 10 of others and so on will cause that.[16] in the YouTube video The Scientist, released in 2015.[59]
Beyond vertebrates NAEs are also found to have signaling roles in more primitive organism, implicated as metabolic signals that coordinate nutrient status and lifespan determination in Caenorhabditis elegans, and detected in organisms as diverse as yeast (Saccharomyces cerevisiae), freshwater fish (Esox lucius and Cyprinus carpio), bivalve mollusc (Mytilus galloprovincialis), protists (Tetrahymena thermophila), slime mold (Dictyostelium discoideum), microbes such as bacteria, fungi, and viruses, are all organisms that appear to regulate their endogenous NAE levels via similar enzymatic machinery as mammalian vertebrates, show a widespread occurrence of NAEs, from single-celled organisms to humans, and a highly conserved role for this group of lipids in cell signaling.[60][22] Studies in amphibians and birds show that endocannabinoid signaling may function as a behavioral switch, allowing redirection from less- to more-essential behaviors in response to emergent environmental changes,[61][62] and provide evidence of cannabinoid modulation of aggression, emesis, feeding behavior, locomotor activity, reproductive behaviors, vocal learning, sensory perception and stress responses.[63][64]
NAE and the reproductive system
[edit]Several researchers have found, that NAE, and especially 20:4 anandamide (AEA: C22H37NO2; 20:4, ω-6), is a part of the reproductive system,[65] and play a fundamental role for a healthy and successful pregnancy.
A 2006 report from the Pediatrics Department at Vanderbilt University characterized NAE 20:4 (AEA) as "an emerging concept in female reproduction", because they found a "cannabinoid sensor" mechanism to influence several crucial steps during early pregnancy.
The Vanderbilt research team termed this "endocannabinoid signaling in preimplantation embryo development and activation", because one of the first things the fertilized embryo must do, is to attach itself to the lining of the uterus, and without becoming attached to the uterine wall, which forms the umbilical cord, there will be no pregnancy. NAE 20:4 (AEA) plays a key role, because, for the embryo to become attached to the lining of the uterus, a particular amount (temporary reduction by high Fatty acid amide hydrolase FAAH) of NAE 20:4 (AEA),[66] present at the uterine lining (uterine epithelium), is necessary for the fertilized embryo can attach itself to the uterine wall, i.e. implantation. NAE 20:4 (AEA) uses the CB1 receptors, that are at high levels on the blastocyst (fertilized egg), to this attachment. So, the amount of NAE 20:4 (AEA) directs the outcome of the attachment to the uterine wall via CB1, and thereby, the outcome to pregnancy,[67][68] by synchronizing trophoblast differentiation and uterine preparation to the receptive state.
However, low FAAH expression and high NAE 20:4 (AEA) levels at the interimplantation sites, prior to successful implantation, have been reported, and a later possible miscarriage, as AEA levels are inversely correlated with FAAH levels in peripheral blood mononuclear cells (PMNCs) and FAAH levels are found lower in women who consequently miscarry compared with those who progress beyond the first trimester. A consequence also found in women undergoing in vitro fertilization and embryo transfer, as low activity of FAAH in PMNCs and high plasma AEA levels after embryo transfer show failure to achieve a successful pregnancy. As well, high AEA level also inhibits BeWo trophoblast cell proliferation, in a dose-dependent manner, via the CB2 receptor, suggest that FAAH acts as a barrier to the AEA maternal-fetal transfer. So, high plasma AEA levels can be used as a marker of early pregnancy loss in patients with threatened miscarriage, as altered modulation of the ECS contribute to the spontaneous pregnancy loss.[69]
This is in line with a study of 50 women, where NAE 20:4 (AEA) hydrolase activity was lower in the seven women who miscarried than in the 43 who did not (60.43 pmol/min per mg protein [SD 29.34] vs 169.60 pmol/min per mg protein [30.20], and another study showing that all 15 women in the low AEA hydrolase group had miscarriages, compared with one of the 105 women with high concentrations at or above the threshold of hydrolase.[70]
An earlier 2004 research into the course of ectopic pregnancy, a result of embryo retention in the fallopian tube, found that decoupled cannabinoid receptor CB1, can cause retention of embryos in the mouse oviduct, and lead to pregnancy failure, as either silencing or amplification of NAE 20:4 (AEA) signaling via CB1 receptors causes oviductal retention or blastocyst incompetence for implantation. The report estimates that aberrant cannabinoid signaling impedes coordinated oviductal smooth muscle contraction and relaxation, which are crucial to normal oviductal embryo transport. This was also seen in wild-type mice treated with methanandamide (AM-356; C23H39NO2, 20:4, n6), and thereby concluded, that a colocalization of CB1 in the oviduct muscularis implicate a basal endocannabinoid tone of NAE 20:4 (AEA) is needed for oviductal motility and for normal journey of embryos into the uterus.[71]
Another 2004 study published in the American Journal of Obstetrics and Gynecology find NAE 20:4 (AEA) and the phytocannabinoid Δ9-tetrahydrocannabinol (THC: C21H30O2), that can mimic NAE 20:4 (AEA) by direct activation at CB1, as the CB1 carboxyl-terminus have critical structures important for CB1 activity and regulation in the receptor life cycle including activation, desensitization, and internalization,[72] the CB2 receptors,[73][74] and markedly lowering AEA content levels,[75] enhance the function of glycine receptors (GlyRs),[76] activate the nuclear receptor family, peroxisome proliferator-activated receptors (PPARs),[77] able to switch from agonist to antagonist depending on firing rate,[78] and to protect neonatal cardiac cells against hypoxia via CB2 receptor activation by induction of NO production,[79][80] to exert a direct relaxant effect on human pregnant myometrium in vitro, with equal potency for both compounds, which was mediated through the CB1 receptor. This means that the middle layer of the uterine wall, where also CB2 reseptors are expressed, is modulated by NAE 20:4 (AEA) as well.[81]
Likewise, there is also demonstrated CB1 expression in the first trimester placenta characterized by a spatial-temporal modulation. But, at term, there is found lack of FAAH and high CB1 expression at placental villous tissue of non-laboring compared with laboring.[69]
After birth, CB1 receptors appears to be critical for milk sucking by newborn, as it apparently activate oral-motor musculature, by 2-AG (C23H38O4; 20:4 ω-6) in the breast milk, activation, as elevated levels of 2-AG modulate infant appetite and health,[82] as well as NAE 20:4 (AEA) act as a neuroprotectant, also by providing retrograde signaling in the developing postnatal brain, with observations suggest that children may be less prone to psychoactive side effects of Δ9-tetrahydrocannabinol (THC: C21H30O2) or endocannabinoids than adults, as very low density of CB1, and neonatal cardiac cells express CB2, but not CB1 receptors,[80] suggest a promising future for cannabinoids in pediatric medicine for conditions including non-organic failure-to-thrive and cystic fibrosis.[68][83]
Mood
[edit]As the euphoric feeling described after running, called the "runners high" is, at least in part, due to increased circulating endocannabinoids (eCBs), and these lipid signaling molecules are involved in reward, appetite, mood, memory and neuroprotection, an analysis of endocannabinoid concentrations and moods after singing, dancing, exercise and reading in healthy volunteers, showed that singing increased plasma levels of anandamide (AEA) by 42%, palmitoylethanolamine (PEA) by 53% and oleoylethanolamine (OEA) by 34%, and improved positive mood and emotions. Dancing did not affect eCB levels but decreased negative mood and emotions. Cycling increased OEA levels by 26% and reading increased OEA levels by 28%. All the ethanolamines were positively correlated with heart rate. As so, the plasma OEA levels were positively correlated with positive mood and emotions, and AEA levels were seen positively correlated with satiation.[4]
However in posttraumatic stress disorder (PTSD), circulating NAE 20:4 (AEA) are found associated with overall mood states and exercise-induced improvements in women with and without PTSD, as AEA significantly increased following aerobic exercise for both groups, whereas the circulation of the endocannabinoid 2-AG only increased in women without PTSD, thereby AEA was associated with lower depressive mood, confusion, and total mood disturbance within the PTSD group and consistent with the discovery of a greater eCB tone, and particularly AEA, following pharmacological and/or non-pharmacological manipulations that may be beneficial for improving psychological outcomes, as mood and cognition among PTSD and possibly other psychiatric populations.[84]
NAE and endocannabinoids is an integral component of stress recovery, both centrally and peripherally, through regulation of the HPA axis, and reduction in circulating NAE 20:4 (AEA) content in major depression, and exposure to stress, is found to increase inflammatory markers by down-regulating the circulating content of the endogenous anti-inflammatory molecules, through their activation of PPAR-α, palmitoylethanolamine (PEA: C18H37NO2; 16:0) and Oleoylethanolamine (OEA: C20H39NO2; 18:1, ω-9), as NAE catabolism is accelerated by stress and by the same FAAH catabolic pathway.[85]
Administration of CB1 receptor antagonists to humans has been found to increase indices of depression and anxiety. Accordingly, the deficit in circulating endocannabinoids and activation of CB1, documented in individuals with major depression, may contribute to the emotional sequelae associated with this disease. And it is therefore speculated, that this reduction in circulating endocannabinoid and NAE content in depression may be associated with the increased rates of inflammation, cardiovascular disease and autoimmune dysfunction seen in this disease.[85] And in other stress-associated psychiatric disorders, like posttraumatic stress disorder (PTSD) and borderline personality disorder (BPD), characterized by intense and rapidly changing mood states as well as chronic feelings of emptiness, impulsivity, fear of abandonment, unstable relationships, and unstable self-image, showing significantly and cronically reduced content of the NAE 20:4 (AEA) that attenuate depressive and anxious symptoms, by elevated fatty acid amide hydrolase (FAAH) in the amygdala-prefrontal cortex (PFC), that subserves emotion regulation and used to measures of hostility and aggression, provide preliminary evidence of elevated FAAH binding in PFC in any psychiatric condition,[86] may be of great therapeutic interest to psychiatry.[87][88] And consistent with the model that lower endocannabinoid tone could perturb PFC circuitry that regulates emotion and aggression,[89] and the feeling of loneliness, as social contact increases, whereas isolation decreases, the production of the endogenous marijuanna-like neurotransmitter, NAE 20:4 (AEA) in nucleus accumbens (NAc), where activation of CB1 are necessary and sufficient to express the rewarding properties of social interactions, i.e. social contact reward.[90]
And possible why cannabinoids are seen highly used in the prison population, and among those who have been imprisoned, and is clearly involved in daily life in prison, where detainees in some prisons estimated the current use of cannabis/hashish to be as high as 80%, and staff estimate 50%, described analgesic, calming, self-help to go through the prison experience, relieve stress, facilitate sleep, prevent violence, and a social peacemaker, where the introduction of a more restrictive regulation induced fear of violence, increased trafficking and a shift to other drug use.[91][92] As seen in the Danish prisons that reflect a ‘treatment guarantee’ embedded in a policy of zero tolerance and intensified disciplinary sanctions, launched by the Danish Government (Regeringen, 2003) and inspired by US drug policy called The Fight against Drugs, with introduction of better fence systems, more sniffer-dogs, and cell and body search of inmates, with an increasingly repressive response to drugs, including zero tolerance and harsher punishment like isolation, that reflects the same chain of destruction as the steps seen to the Holocaust,[93] to make clients drug free and preparing them for a life without crime.[94]
Released to a daily life environment, where the highest scores for quality of life is observed among habitual cannabis users, followed by occasional users, whereas both non-users and dysfunctional users present less favorable score, and non-users reported more depression or anxiety symptoms and a lower quality of life, than occasional and habitual users, found in a Brazilian cross-sectional study involving more than 7400 adults (6620 recreational cannabis users and 785 non-users), even illegal.[95][96] And other findings imply that a causal link between marijuana use and violence is primarily due to its illegality, and thus would not exist in an environment in which marijuana use, at least medicinally (MML), as a first choice in any situation, is legalized, to correct the injustices of cannabis prohibition, as the legalization of cannabis for adult use is found being increasingly embraced in several countries and local entities, coursed by the economic and human suffering of cannabis prohibition, which have fallen most heavily upon disadvantaged minority populations, and for countries, in which cannabis consumption before constituted a traditional habit, also in religion, and practiced for hundreds or thousands of years,[97][98][99] without being subject to any social opprobrium, as no correlation between Marijuana use and criminal behavior are found, correlates with a reduction in homicide and assault rates, after introduction of state MML.[100][101][102] Followed by an almost 5% estimated reduction in the total suicide rate, for the period 1990 through 2007, with an 11% percent reduction for 20- through 29-year-old males, and a 9% reduction in the suicide rate of 30- through 39-year-old males.[103] And the secondary mortality attributing to herbal cannabis is found extremely rare, and usually associated with misadventures with law enforcement, and the prison experience and of solitary confinements.[104][105]
Longevity
[edit]A study of 42 eighty years old (octogenarians) humans living in the east-central mountain area of Sardinia, a High-Longevity Zone (HLZ) in Italy, have found, that the endocannabinoidome related circulating NAEs and familiar fatty acids are associated with a longer human life or longevity, as increased conjugated linoleic acid (CLA: C18H32O2; 18:2, n-6) and heptadecanoic acid (C17H34O2; 17:0), elevated palmitoleic acid (POA; C16H30O2; 16:1, n-7), a conjugate acid of a palmitoleate (C16H29O2; 16:1, n-7),[106] where n-7 fatty acids are precursors for the production of omega-4 fatty acids like palmitolinoleic acid (16:2),[107] and a significantly increased level of NAE 22:6 (DHEA: C24H37NO2; 22:6, n-3), the metabolite of DHA (C22H32O2; 22:6, n-3), and the two endocannabinoids NAE 20:4 (AEA: C22H37NO2; 20:4, ω-6) and 2-arachidonoyl-glycerol (2-AG: C23H38O4; 20:4, n-6), as well of increased NAE 18:1 (OEA: C20H39NO2; 18:1, ω-9), the amide of palmitic acid (C16H32O2; 16:0) and ethanolamine (MEA: C2H7NO), and increase of 2-linoleoyl-glycerol (2-LG; C21H38O4; 18:2, n-6),[108] derived from linoleic acid (LA: C18H32O2; 18:2, n-6), can indicate a metabolic pattern potentially protective from adverse chronic conditions, and show a suitable physiological metabolic pattern, that may counteract the adverse stimuli leading to age-related disorders such as neurodegenerative and metabolic diseases.[109]
It is found that 3T3-L1 adipocytes convert eicosapentaenoic acid (EPA: C20H30O2; 20:5, ω-3) to NAE 20:5 (EPEA: C22H35NO2; 20:5, ω-3) or Anandamide (20:5, n-3) and docosahexaenoic acid (DHA: C22H32O2; 22:6, ω-3) to NAE 22:6 (DHEA: C24H37NO2; 22:6, ω-3), or Anandamide (22:6, n-3). This conversion to EPEA and DHEA decrease IL-6 and MCP-1 levels, and the combined incubations with PPAR-gamma and CB2 antagonists, suggest a role of these receptors in mediating the reduction of IL-6 by DHEA. These results are in line with the hypothesis, that in addition to other pathways, this formation of NAEs may contribute to the biological activity of n-3 PUFAs, and different targets, including the endocannabinoid system, may be involved in the immune-modulating activity of fish-oil derived NAEs.[40]
The importance of a low ratio of omega-6 to omega-3 essential fatty acids
[edit]Studies have found that humans evolved on a diet with a ratio of omega-6 (n-6) to omega-3 (n-3) essential fatty acids (EFA) of about 1:1, whereas in today's Western diets the ratio is 15/1–16.7/1, or even more. The excessive amounts of n-6 polyunsaturated fatty acids (PUFA) and a very high n-6/n-3 ratio, promote the pathogenesis of many diseases, including cardiovascular disease, cancer, and inflammatory and autoimmune diseases, whereas a low n-6/n-3 ratio exert suppressive effects. However, it is found impotent, that this low ratio, should change a bit, depending on disease, as the ratio of 2.5/1 reduce rectal cell proliferation in patients with colorectal cancer, and 2–3/1 suppress inflammation in patients with rheumatoid arthritis, 4/1 is optimum for prevention of cardiovascular disease, showing a 70% decrease in total mortality, and 5/1 have a beneficial effect on patients with asthma, whereas 10/1 have adverse consequences, indicate, that the optimal ‘low ratio’, may vary with the specific disease.[110][61]
The World Health Organization (WHO) estimate hemp, a culture CO2 negative, - a crop that is capable in the carbon cycle of removing more CO2 from the ambient than it emits, where production of biomass produce between 8 and 12 tons of CO2, but seize between 10 and 15 tons per hectare, with the possibility to sequester up to 22 tons of CO2 from the increased dry matter of the stem, where 80% of atmospheric carbon is sequestered and stored, by a nitrogen fertilization between 0 and 120 kg per hectare,[61] with roots that by various physicians and herbalists in the latter part of the 17th century, was recommended to treat fever, inflammation, gout, arthritis, and joint pain, as well as skin burns and hard tumors, beside more,[111] as well as to have modest antimicrobial activity against Cryptococcus neoformans by ergost-5-en-3-ol,[112] and potent antimicrobial activity against Escherichia coli by p-coumaroyltyramine,[113][114] as having what is considered to be an optimal 3:1 balance of omega 6 to omega 3 essential fatty acids, and where hempseed oil, of which 80% are polyunsaturated fatty acids, of which 60% are omega-6 linoleic acid (LA: C18H32O2), the precursor of NAE 20:4 (AEA) and other NAEs, and 20% are omega-3 alpha-linolenic acid (ALA: C18H30O2), the precursor of NAE 18:3 (ALEA: C20H35NO2; 18:3, ω-3) or Anandamide (18:3, n-3),[29][30] is the only one that is in perfect balance according to what the human body needs – 3:1, and a pound (454 gram) of hemp seed, of which 43% are protein, can provide all the protein, essential fatty acids, and dietary fiber necessary for human survival for two weeks, or 33 gram a day.[2][115][116][117][118][119]
And their absence has been found responsible for the development of a wide range of diseases such as metabolic disorders,[3] cardiovascular disorders, inflammatory processes, viral infections, certain types of cancer and autoimmune disorders,[120] as well as skin disorders, as cutaneous cannabinoid ("c[ut]annabinoid") signaling is deeply involved in the maintenance of skin homeostasis, barrier formation and regeneration, and its dysregulation is implicated to contribute to several diseases and disorders, e.g., atopic dermatitis, psoriasis, scleroderma, acne, hair growth and pigmentation disorders, keratin diseases, various tumors, and itch, as the endocannabinoids (eCBs; e.g., NAE 20:4; AEA), the eCB-responsive receptors (e.g., CB1, CB2), as well as the complex enzyme and transporter apparatus involved in the metabolism of the ligands, show to be expressed in several tissues, including the skin,[121] where 18 prostanoids, 12 hydroxy-fatty acids, 9 endocannabinoids and N-acyl ethanolamides (NAEs), and 21 non-hydroxylated ceramides and sphingoid bases, of which several demonstrating significantly different expression in the tissues assayed, demonstrate the diversity of lipid mediators involved in maintaining tissue homeostasis in resting skin and hint at their contribution to signaling, cross-support, and functions of different skin compartments.[122]
The NAE substitutes, the phytocannabinoids from the flowers and fruits, like the psychoactive compound Δ9-tetrahydrocannabinol (THC: C21H30O2) and the nonpsychotropic compounds cannabidiol (CBD: C21H30O2), and leaves (THCA/CBDA: C22H30O4),[123] from the plant, are also potent PPARγ agonist with neuroprotective activity,[124][125][126] and found to modulate inflammatory responses by regulating the production of cytokines from keratinocytes in several experimental models of skin inflammation, by CB2 and TRPV1 activation, where CBD dose-dependently elevates the levels of NAE 20:4 (AEA) and inhibits poly-(I:C)-induced release of MCP-2, interleukin-6 (IL-6), IL-8, and tumor necrosis factor-α, in allergic contact dermatitis (ACD),[127] through the endocannabinoid system (ECS), and where FAAH–deficient mice, which have increased levels of NAE 20:4, displayed reduced allergic responses in the skin,[128] as the activation of CB1 or CB2 increases endocannabinoid levels by inhibiting fatty acid amide hydrolase (FAAH) or adenylyl cyclase, and activation of CB1 is tightly associated with the generation of cellular ceramides.[13]
Beside the CB1 receptors being triggers of the generation of ceramides that mediate neuronal cell fate, the skin CB1 receptor aktivation also increases ceramides, with long-chain fatty acids (FAs) (C22–C24), which mainly account for the formation of the epidermal barrier, through activation of ceramide synthase, CerS 2 and CerS 3, thereby resulting in the enhancement of epidermal permeability barrier function in IL-4 inflamed skin.[13]
Synthesis of LC-PUFAs in humans and many other eukaryotes starts with:
* Linoleic acid (LA: C18H32O2; 18:2-n6) → Δ6-desaturation (removing two hydrogen atoms, creating a double bond and a bend in the fatty acid) → γ-linolenic acid (GLA: C18H30O2; 18:3-n6) → Δ6-specific elongase (introducing two carbons and four hydrogens) → Dihomo-gamma-linolenic acid DGLA: C20H34O2; 20:3-n6) → Δ5-desaturase → arachidonic acid (AA: C20H32O2; 20:4-n6) → also endocannabinoids.
* α-Linolenic acid (ALA: C18H30O2; 18:3-n3) → Δ6-desaturation → stearidonic acid (SDA: C18H28O2; 18:4-n3) and/or → Δ6-specific elongase → eicosatetraenoic acid (ETA: C20H32O2; 20:4-n3) → Δ5-desaturase → eicosapentaenoic acid (EPA: C20H30O2; 20:5-n3) → elongation and Δ6-desaturation (FADS2) → docosahexaenoic acid (DHA: C22H32O2; 22:6-n3) → + ethanolamine (MEA: C2H7NO) → N-Docosahexaenoyl ethanolamine (DHEA: C24H37NO2; 22:6, ω-3), or Anandamide (22:6, n-3) "synaptamide", is the non-oxidative produced amide, NAE 22:6.[129][38][39]
By a Δ17-desaturase, gamma-Linolenic acid (GLA: C18H30O2; 18:3-n6) can be further converted to stearidonic acid (SDA: C18H28O2; 18:4-n3), dihomo-gamma-linolenic acid (DHGLA/DGLA: C20H34O2; 20:3-n6) to eicosatetraenoic acid (ETA: C20H32O2; 20:4-n3; omega-3 Arachidonic acid)[130] and arachidonic acid (AA: C20H32O2; 20:4-n6) to eicosapentaenoic acid (EPA: C20H30O2; 20:5-n3), respectively.[131]
- Fatty acids with at least 20 carbons (C20) and three double bonds (20:3) bind to CB1 receptors.[1]
- Arachidonic acid (AA) is also the catalyst to the formation of the two main endocannabinoids, Anandamide (AEA) and 2-Arachidonoylglycerol (2-AG).
* Anandamide (AEA: C22H37NO2; 20:4,n-6) is an N-acylethanolamine resulting from the formal condensation of the carboxy group of arachidonic acid (AA: C20H32O2; 20:4-n6) with the amino group of ethanolamine (C2H7NO), bind preferably to CB1 receptors.[132]
* 2-Arachidonoylglycerol (2-AG: C23H38O4; 20:4-n6) is an endogenous agonist of the cannabinoid receptors (CB1 and CB2), and the physiological ligand for the cannabinoid CB2 receptor.[133] It is an ester formed from omega-6-arachidonic acid (AA: C20H32O2; 20:4-n6) and glycerol (C3H8O3),[134] and tissue levels of 2-AG is usually several tens to several hundreds of times those of AEA.[52]
The N-acylethanolamine synthesis pathway is one of the non-oxidative pathways in which the mainly fish oil derived n−3 long-chain polyunsaturated fatty acids (n−3 LCPUFA, C18 to C22), ω-3 FAs docosahexaenoic acid (DHA: C22H32O2; 22:6, n-3) and eicosapentaenoic acid (EPA: C20H30O2; 20:5, n-3) are converted to NAE 22:6 docosahexaenoyl ethanolamide (DHEA: C24H37NO2; 22:6, ω-3)[39] and NAE 20:5 eicosapentaenoyl ethanolamide (EPEA: C22H35NO2; 20:5, ω-3), or Anandamid (20:5, n-3),[45] by incorporated ethanolamine (MEA: C2H7NO), respectively. On common diseases including cancers, this conversion show beneficial synergistic effect, when administered with the NAE-fatty acid familiar cannabinoids,[41] like delta(9)-tetrahydrocannabinol (THC: C21H30O2), – a metabolite of delta9-tetrahydrocannabinolic acid (THCA: C22H30O4), a diterpenoid, with a carboxyl group (–COOH) at one end, like 11-Nor-9-carboxy-THC (THC-COOH: C21H28O4), the secondary metabolite of THC, which is formed in the body after cannabis is consumed, that has a role as an anti-inflammatory and a neuroprotective agent,[135] – and a non-narcotic analgesic, a hallucinogen, a cannabinoid receptor agonist and an epitope.[136] As Cannabis sativa and their derivatives act in the organism by mimicking endogenous substances, the endocannabinoids, that activate specific cannabinoid receptors, is why cannabinoids are found to be selective antitumour compounds, that can kill tumour cells, by growth arrest or apoptosis, without affecting their non-transformed counterparts, is probably because, cannabinoid receptors regulate cell-survival and cell-death pathways differently in tumour and non-tumour cells.[137][138][139][140][141]
Metabolic production of NAEs
[edit]Diets in mammals, containing 20:4,n−6 and 22:6,n−3, are found to increase several biologically active NAEs in brain homogenates as metabolic products, like 20:4,n−6 NAE (4-fold), 20:5,n−3 NAE (5-fold), and 22:5,n−3 and 22:6,n−3 NAE (9- to 10-fold). The increase in all of the metabolic NAEs is regarded biologically important, because NAEs having fatty acids with at least 20 carbons and three double bonds bind to CB1 receptors,[1] and endogenously released NAE 20:4 and 2-arachidonylglycerol (2-AG: C23H38O4; 20:4,n-6), the ester metabolic formed from omega-6-arachidonic acid (AA: C20H32O2; 20:4, n-6) and glycerol (C3H8O3), are also found to activate CB2 receptors in addition,[34] where 2-AG is the physiological ligand.[133]
The hydrolysis of NAE to free fatty acid (FFA) and ethanolamine (MEA) in animals, is catalyzed by fatty acid amide hydrolase (FAAH) or by a N-acylethanolamine-hydrolyzing acid amidase (NAAA), and the polyunsaturated NAEs such as NAE 18:2, NAE 18:3, or NAE 20:4 can also be oxygenated via lipoxygenase (LOX) or cyclooxygenase (COX), to produce ethanolamide oxylipins, like prostaglandin ethanolamides (prostamide) by COX-2, with various potential bioactivities that may have enhanced affinity with cannabinoid receptors in comparison to their respective non-oxygenated NAEs,[142][55][143] as well as to oxygenated eicosanoid ethanolamides, prostaglandins, and leukotrienes, all believed to be important signaling compounds.[144]
The major COX-2 derived prostanoid product from NAE 20:4 (AEA) are prostaglandin E2 (PGE2) ethanolamide (PGE2-EA; prostamide E2) and PGD2 ethanolamide (PGD2-EA; prostamide D2), might have many important functions,[145] as PGE2 and PGD2 are pro-inflammatory mediators responsible for the induction of inflammation,[142] PGE2-EA and PGD2-EA are contrary both growth inhibitory and can induce apoptosis,[146] as well as that NAE 20:4 (AEA) and/or its prostamide metabolites in the renal medulla, may represent medullipin and function as a regulator of body fluid and the mean arterial pressure (MAP).[147]
Fatty acid amide hydrolase (FAAH) is the main degrading enzyme of NAE 20:4 (AEA) and NAE 18:1 (OEA), which have opposite effects on food intake and energy balance. AEA, an endogenous ligand of CB1 cannabinoid receptors, enhances food intake and energy storage, whereas OEA binds to peroxisome proliferator-activated receptors-α to reduce food intake and promoting lipolysis, thereby FAAH deficiency promotes energy storage and enhances the motivation for food, through the enhancement of AEA levels rather than promoting the anorexic effects of OEA.[148] Tetrahydrocannabinol (THC: C21H30O2) is found to lower production of NAE 20:4 (AEA) and 2-AG, that is synthesized in an on-demand manner when needed for activation,[149] by a biphasic response after THC injection reaching maximal values at 30 min., where AEA increased slightly from 0.58 ± 0.21 ng/ml at baseline to 0.64 ± 0.24 ng/ml, and 2-AG from 7,60 ± 4,30 ng/ml to 9,50 ± 5,90 ng/ml, and after reaching maximal concentrations, EC plasma levels decreased markedly to a nadir of 300 min after THC administration to 0.32 ± 0.15 ng/ml for AEA, and 5,50 ± 3,01 ng/ml for 2-AG, and returned to near baseline levels until 48 hours after the experiment, in 25 healthy volunteers who received a large intravenous dose of THC (0.10 mg/kg).[75]
Insulin medication and intraoperative doses of insulin is also found, but not recognized by companies producing and selling medication to general public also as a slimming formula like Wegovy, to get its anorectic effect by the involvement of FAAH activity, which, beside of other NAE's, degrade NAE 20:4 (AEA),[150] suggest that insulin may play a key role in the obesity-linked dysregulation of the adipose ECS at the gene level.[151] And is possible why the European Medicines Agency (EMA) in 2023 are investigating several reports from European countries about suicidal thoughts and thoughts of self-harm in patients, who have been treated with Novo Nordisk's popular medicines for obesity and diabetes.[152] An outcome also seen in the CB1 receptor blocker rimonabant, an anorectic antiobesity drug that was first approved in Europe in 2006 but was withdrawn worldwide in 2008 due to serious psychiatric side effects,[123][87] and happening at the same time as EMA, has raised a safety alert for Wegovy, that also applies to the companies diabetes medication Ozempic, based on a study that suggests that the active substance in the two preparations, can increase the risk of thyroid cancer in patients with type 2 diabetes.[153]
FAAH expression, that metabolizes NAE 20:4 (AEA) involved in the regulation of emotional reactivity, into ethanolamine and arachidonic acid, is found significantly increased in depressive-like phenotypes, where knockout or pharmacological inhibition of FAAH effectively reduces depressive-like behavior, with a dose-dependent effect, that elicits anxiolytic and antidepressant-like effects, like the NAE 20:4 (AEA) substitutes ∆9-THC and other cannabinoids that may contribute to the overall mood-elevating properties of cannabis,[96][154][155] and differences in FAAH expression in depressive-like phenotypes were largely localized to animal prefrontal cortex (PFC), hippocampus and striatum, containing high densities of CB1 receptors.[156][157] As well as FAAH levels in amygdala and PFC are elevated in borderline personality disorder, which relates to the hostility and aggression, are consistent with the model, that lower endocannabinoid tone perturb PFC circuitry that regulates emotion and aggression, provide preliminary evidence of elevated PFC FAAH binding in any psychiatric condition.[89]
A FAAH 385A mutant alleles have been found to have a direct effect on elevated plasma levels of NAE 20:4 (AEA) and related NAEs in humans, and biomarkers that may indicate risk for severe obesity that suggest novel ECS obesity treatment strategies,[158] as leptin increases the FAAH activity and reduces NAE 20:4 (AEA) signaling, particularly within the hypothalamus, to promote a suppression of food intake, a mechanism that is lost in diet-induced obesity and modulated by a human genetic variant (C385A) of the FAAH gene.[159] The cannabinoid type 1 receptors (CB1) and their endogenous ligands, the endocannabinoids, present in peripheral organs, such as liver, white adipose tissue, muscle, and pancreas, where it regulate lipid and glucose homeostasis, and dysregulation of it, has been associated with the development of obesity, characterized by chronic mild inflammation,[160] and its sequelae, such as dyslipidemia and diabetes, are involved in modulating food intake and the motivation to consume palatable food.[161]
NAE 20:4 related THC treatment have shown to increase culture protein content and reduced methyl-(3)H-thymidine incorporation, and cells treated with THC underwent adipogenesis shown by the expression of PPARγ and had increased lipid accumulation. Basal and IP-stimulated lipolyses were also inhibited by THC, and the effects on methyl-(3)H-thymidine incorporation and lipolysis seem to be mediated through CB1- and CB2-dependent pathways. THC did also decrease NAPE-PLD, the enzyme that catalyzes and converts ordinary lipids into chemical signals like NAE 20:4 (AEA) and NAE 18:1 (OEA), in preadipocytes and increased adiponectin and TGFβ transcription in adipocytes, results that show the ECS interferes with adipocyte biology and may contribute to adipose tissue (AT) remodeling. And this stimulation of adiponectin production and inhibition of lipolysis from THC may be in favor of improved insulin sensitivity under cannabinoid influence.[162]
A full agonist at the CB1 receptor is found able to up-regulate PPARy, and increased (+50%) glucose uptake, the translocation of glucose transporter 4, and intracellular calcium in fat cells, that indicate a role for the local endocannabinoids in the regulation of glucose metabolism in human adipocytes and suggest a role in channelling excess energy fuels to adipose tissue in obese humans.[163] This is consistent with the decreased prevalence of diabetes seen in marijuana users,[164] and significantly reduced body mass index (BMI) and rates of obesity in Cannabis users,[165][166] as endocannabinoids modulate pancreatic β-cells function, proliferation, and survival, as well as insulin production, secretion, and resistance, where animal and human research suggest that increased activity of the endocannabinoid system, may lead to insulin resistance, glucose intolerance and obesity.[167]
Consistent with the associated reduced prevalence of non-alcoholic fatty liver disease (NAFLD) among cannabis users, that find significantly lower NAFLD prevalence compared to non-users, i.e. 15% lower in non-dependent users and 52% lower in dependent users, and dependent patients had 43% significantly lower prevalence of NAFLD compared to non-dependent patients.[168] And also by using multivariable logistic regression, and after adjusting for potential confounders, patients with cannabis abuse (daily consumption) is found 55% less likely to have hepatocellular carcinoma (adjusted odds ratio, 0.45, 95% confidence interval, 0.42–0.49) compared with patients without cannabis abuse in the periode 2002 – 2014.[140]
In addition to metabolism by FAAH, COX-2 and LOXs, NAE 20:4 (AEA) can also undergo oxidation by several of human cytochrome P450 (CYPs) enzymes, resulting in various oxidized lipid species, some of which have biological relevance as CYP-derived epoxides, that can act as a potent agonist of CB2 receptors.[144]
NAE 20:4 (AEA: C22H37NO2) which is similar in structure to N-arachidonoyl glycine (Nagly: C22H35NO3 – a carboxylic acid COOH) are metabolically interconnected, as oxidation of the hydroxyl group of NAE 20:4 (AEA) leads to NAgly, preferring G-protein coupled receptor (GPR) 118, with a molecular structure, that are found of pharmacological interest, as region one confers a high degree of specificity of action, as polyunsaturated residues produce molecules with analgesic and anti-inflammatory action, of which saturated structures, are inactive. Region two is related to metabolic stability as NAgly is degraded by FAAH activity. And last, region 3, the amino acid residue, can have an effect on the analgesic and anti-inflammatory activities depending on steric factors and the chiral nature of the amino acid.[169] Also the amino acid residue at 296 and the hydroxyl groups of THC, 11-hydroxy-THC (11-OH-THC: C21H30O3) are critical for potentiation of glycine receptors (GlyRs) and for some of the cannabis-induced analgesic and therapeutic effects.[76]
It is also found that long-chain fatty acid conjugates from the metabolic hydroxyl oxidation product of the phytocannabinoid, THC (C21H30O2), 11-hydroxy-THC (11-OH-THC: C21H30O3) are proposed to be a form in which THC may be stored within tissues.[170][171] And the last cytochrome P450 oxidation product of THC afford the non-psychoactive and long-living 11-nor-9-carboxy-THC (THC-COOH: C21H28O4) as main metabolite, that in some authors’ opinion, are insufficiently characterized, as an acid metabolite seen as a final product in both cannabis-plants and mammals, with their main unanswered questions, "Could any of the pharmacological effects observed for THC be attributed to THCA (C22H30O4) and/or THC-COOH, and could THC also be a potential pro-drug to another pharmacological entity?".[172][169][173][174][175]
NSAIDs that inhibit COX2, may find its medical influence from the cannabinoid system, either by inhibiting the breakdown of NAE 20:4 (AEA) by FAAH (i.e. ibuprofen, indomethacin, flurbiprofen, ibu–am5), or by inhibiting a possible intracellular transporter of endocannabinoids (i.e. acetaminophen).[176]
The phytocannabinoid THC is found to have twenty times the anti-inflammatory potency of aspirin and twice that of hydrocortisone, but in contrast to NSAIDs, it demonstrates no COX inhibition at physiological concentrations.[177]
Another of the main phytocannabinoids, cannabidiol (CBD: C21H30O2) is found to produce a significant increase in serum NAE 20:4 (AEA) levels, by inhibiting the intracellular degradation catalyzed by FAAH, suggest the inhibition of NAE 20:4 (AEA) deactivation may contribute to the antipsychotic effects of CBD, potentially representing a mechanism in the treatment of schizophrenia, with a markedly superior side-effect profile, compare to amisulpride, a potent antipsychotic. CBD were also seen to elevate serum levels of the non-cannabimimetic lipid mediators, NAE 16:0 (PEA) and NAE 18:1 (OEA), but amisulpride did not.[178][179]
FAAH inhibitors are seen to both increase alcohol consumption (NAE 20:4; AEA) and prevent against oxidative stress caused by binge ethanol consumption, and as NAE 16:0 (PEA) and NAE 18:1 (OEA), through the endocannabinoidome-related peroxisome proliferator-activated receptor-α (Ppar-α) is involved in the actions of NAEs with no endocannabinoid activity, have been reported to exhibit neuroprotective effects, suggest a strengthening of the ECS may reflect a homeostatic mechanism to prevent the neurotoxic effects induced by alcohol with a relevant role of other non-cannabinoid congeners in the alcohol exposure, and the further activation in response to the negative affective state, like the anxiety,[180] associated to alcohol withdrawal.[181] Or poorer recall of verbal and nonverbal information, as well as reduced visuospatial skills related to alcohol hangover and withdrawal symptoms in youth, a relationship not seen in adolescents with similar levels of alcohol involvement if they are heavy users of marijuana.[182]
The cannabinoid CB1 receptor play a critical role in mediating the adolescent behavior, because enhanced CB1 density and endocannabinoid (eCB) signaling occur transiently during the periode from childhood to adolescence and reverse when adult and mature in normal phenotypes. Reports on enhanced adolescent CB1 signaling, suggest a pivotal role for the CB1 in an adolescent brain as an important molecular mediator of adolescent behavior, as adult CB1 mutant rats exhibit an adolescent-like phenotype with typical high risk seeking, impulsivity, and augmented drug and nondrug reward sensitivity, by an instinctive need or call for activation, and partial inhibition of CB1 activity normalized behavior and led to an adult phenotype, is why it is concluded that the activity state and functionality of the CB1 is critical for mediating adolescent behavior and further turn to an adult phenotype, by normal CB1 downscaling.[183] This is also do to the cannabinoid system and its neurotransmitter NAE 20:4 (AEA), that highly participate in the modulation of human states and appropriate human emotional responses by activation of the CB1 receptor,[180][184] also found in frontal neocortical areas, subserving higher cognitive and executive functions, and in the posterior cingulate, a region pivotal for consciousness and higher cognitive processing.[185][186][187]
Acute administration of ethanol inhibits receptor-mediated release of NAE 20:4 (AEA), whereas chronic ethanol administration increases levels of AEA that participates in the neuroadaptations associated with chronic ethanol exposure, as the inhibition of AEA release by acute ethanol administration, not derive from increased fatty acid ethanolamide degradation by FAAH.[188][189]
However, alcohol (EtOH) is seen to increase levels of NAE 20:4 (AEA), and its precursor N‐arachidonoylphosphatidylethanolamine (N‐ArPE), a glycero-phospho-ethanolamine,[190] significantly, that may be a mechanism for neuronal adaptation and serve as a compensatory mechanism to counteract a continuous presence of EtOH, that together with previous results indicate the involvement of the endocannabinoid system in mediating some of the pharmacological actions alleged of EtOH, also seen in red wine components,[191] and in Humulus lupulus to preserve and flavor beer, widely cultivated for use by the brewing industry, through caryophyllene, a dietary cannabinoid,[192] that is a selective full agonist at CB2 and also act through PPAR nuclear receptors (i.e. PPARα and PPARγ), with countless beneficial and non-psychoactive effects,[193][194][195] that may constitute part of a common brain pathway mediating reinforcement of drugs of abuse including EtOH,[196] by elevated CB1.[197] The CB1 receptor binding is 20-30% lower in patients with alcohol dependence than in control subjects in all brain regions and is negatively correlated with years of alcohol abuse, and the CB1 receptor binding remain similarly reduced after 2–4 weeks of abstinence, suggests an involvement of CB1 receptors in alcohol dependence in humans.[198]
Similar pathways of hydrolysis or oxidation of NAEs are also found in plant cells.[199][200]
NAE system in plants
[edit]N-acylethanolamines (NAEs), constitute a class of lipid compounds naturally present in both animal and plant membranes, as constituents of the membrane-bound phospholipid, N-Acylphosphatidylethanolamine (NAPE). NAPE is composed of a third fatty acid moiety linked to the amino head group of the commonly occurring membrane phospholipid, phosphatidylethanolamine.[34]
A study in 2000 find, that higher plants use defense signaling, to combat cellular stressful situations (homeostasis), like in osmotic stress, where high levels of NAEs after a periode of dehydration, are metabolized fast during the first few hours of imbibition, and in response to pathogen elicitors, that lead to signal transduction and membrane protection, in the same way as several mammalian cell types, coupled to endocannabinoid signaling, do, by releasing saturated and unsaturated long-chain NAEs, and saturated medium-chain NAEs, that can act as lipid mediators to modulate ion flux and activate defense gene expression.[201]
The levels of NAEs increases 10- to 50-fold in tobacco (Nicotiana tabacum) leaves treated with fungal elicitors, as a protection against it, by producing the N-myristoylethanolamine (Myristamide-MEA: C16H33NO2; NAE 14:0), that specific binds to a protein in tobacco membranes with biochemical properties appropriate for the physiological responses, and it do not show identical binding properties to NAE-binding proteins in intact tobacco microsomes, compared to non-intact microsomes. In addition to this, antagonists of mammalian CB receptors was seen to block both of the biological activities previously attributed to NAE 14:0, this endogenous NAE that is accumulated in tobacco cell suspensions and leaves after pathogen elicitor perception, is why it is proposed, that plants possess an NAE-signaling pathway with functional similarities to the "endocannabinoid" pathway of animal systems, and this pathway, in part, participates in xylanase elicitor perception in the tobacco plant, as well as in the Arabidopsis and Medicago truncatula plant tissues.[34]
Medical values
[edit]N-acylethanolamines (NAEs), with its cell-protective and stress-combating action-response of organisms, also produced in neurons, together with N-acyl-phosphatidylethanolamine (NAPE), in response to the high intracellular Ca2+ concentrations that occur in injured neurons,[202] have shown promise as therapeutic potential in treating bacterial, fungal, and viral infections, as NAEs also exhibit anti-inflammatory, antibacterial, and antiviral properties, which have considerable application potential.[22]
In pediatric medicine for conditions including "non-organic failure-to-thrive" and cystic fibrosis.[68] A dysfunction of the endocannabinoid system is researched for a possible determining factor for causing infertility in cystic fibrosis (CF), as the illness is associated with an imbalance of fatty acids, show that mild stimulation of the endocannabinoid system (CB1 and CB2) in infancy and adolescence, appears to normalize many reproductive processes and prevent infertility in CF males. The mild stimulated, were fully fertile, producing offspring comparable by the number of litters and the number of pups as the wild-type mice, and their counterparts, not treated, were shown completely infertile.[203]
As NAE related Cannabis has an ancient tradition of usage as a medicine in obstetrics and gynecology, its extracts, may represent an efficacious and safe alternative for treatment of a wide range of conditions in women including dysmenorrhea, dysuria, hyperemesis gravidarum, and menopausal symptoms.[204]
It has been found that social contact increases, whereas isolation decreases, the production of the endogenous marijuanna-like neurotransmitter, NAE 20:4 (AEA), in nucleus accumbens (NAc), which regulate motivated behavior, and this NAE 20:4 (AEA) production is via oxytocin, the neuropeptide reinforcing parental and social bonding. Activation of CB1 cannabinoid receptors in NAc, are necessary and sufficient to express the rewarding properties of social interactions, i.e. social contact reward.[90][205][206] In addition, CB1 activation also suppresses release of serotonin, dopamine, acetylcholine and noradrenaline, which are mediating the characteristic cognitive and antidepressant effects.[207] As well as norepinephrine release,[208] as it is suggested that a major function of the ECS also lies in buffering the symphatico-adrenergic response to stress.[209]
To use in expected global heating scenario, in a catastrophic "hothouse Earth," possible well beyond the control of humans,[210][211][212] where "wet bulb temperatures," taken by a thermometer wrapped in a wet cloth, show temperatures of 35C or higher, and considered the limit to human survival and heighten humidity makes it harder for people to cool down via sweating,[213][62] coursed by the pollution of the troposphere, that tight holds 99% of human made solid particle pollution, and keeps CO2 in it for more than 100 years,[214][215][216] for citizens who can't afford an air-condition unit, to cool down and prevent heatstroke with an elevated core body temperature above 40 °C with neurologic dysfunctions, that can lead to a syndrome of multiple organ defect,[217] and cell stress, as it is found, that the CB1 receptor activation, here by a phytocannabinoid Δ9-THC administration, induces profound hypothermia, that is rapid in onset, persistent for 3–4 hours, dose-dependent and is accompanied by a reduction in oxygen (O) consumption, which indicate reduced heat production, as opposed to increased heat loss.[218][219][220]
* → THCA:COOH: C22H30O4 (heating/storage) → THC: C21H30O2 → THC-OH: C21H30O3 → THC:COOH: C21H28O4 → profound hypothermia, a lowering of body temperature,[221] accompanied by a reduction in oxygen consumption.
In metabolism of THCA from fresh plant material used orally, is conversion to Delta9-THC not observed:[222]
THCA:COOH: C22H30O4 → THC-OH: C21H30O3 → THC:COOH: C21H28O4
To be protected where head injury is a possibility, as a positive THC screen is associated with significant decreased mortality in adult patients sustaining traumatic brain injury (TBI), as research work, by a 3-year retrospective review of registry data at a Level I center of patients sustaining TBI, find mortality in the THC(+) group (2.4% [2 patients]) significantly decreased compared with the THC(-) group (11.5% [42]) in 446 cases meeting all inclusion criteria.[174] And further have shorter hospital length of stay (LOS) and shorter ventilator days, than THC(-) patients sustaining TBI. For severely injured trauma patients with Injury Severity Score ≥16, a THC(+) screen show significantly lower intensive care unit LOS and mortality (19.3% versus 25.0%) than THC(-) patients, shown by 4849 patients included at two large regional trauma centers between 2014 and 2018.[223]
As the fatty acid amide hydrolase (FAAH) have showed significant decreased in bhang users as compared to controls, and indicating that the decrease in FAAH protein level is closely related to the duration of bhang use, and further revealed that the bhang–induced immunotoxicity, could be attributed to decrease in FAAH protein, bhang could also be a healthy drink/preparation to suppress an overactive immune response.[175][224]
Fatty acid amide hydrolase (FAAH) inhibition has been found neuroprotective with therapeutic potential against neuropathological states including traumatic brain injury, Alzheimer's, Huntington's, and Parkinson's diseases, and stroke.[225]
A molecular mechanism through which NAE 20:4 (AEA) plant competitive substitute THC cannabinoid molecules can affect the development of Alzheimer's disease, the leading cause of dementia,[226] or its impact:
THC: C21H30O2 → THC-OH: C21H30O3 → THC:COOH: C21H28O4 → a significantly superior inhibitor of Amyloid beta (Aβ) aggregation and tau phosphorylation, compared to approved drugs prescribed for the treatment of Alzheimer's disease in 2008, through which these molecules directly can affect the development by activation of both CB1 and CB2 receptors, which inhibit the enzyme acetylcholinesterase (AChE), which further prevent AChE-induced amyloid β-peptide (Aβ) aggregation, as they also are able to bind to the anionic site of AChE, a region involved in and critical for amyloid formation, as well as by promoting the brain's intrinsic repair mechanisms, and promote neurogenesis, endocannabinoid signaling has demonstrated to modulate numerous concomitant pathological processes, including neuroinflammation, excitotoxicity, mitochondrial dysfunction, and oxidative stress.[227][228][229] However other phytochemicals that are present in Cannabis sativa is found to interact with each other in a synergistic fashion, called the entourage effect, that seems to have greater therapeutic potential when administered together, rather than individually.[230][231][136][232]
A synergistic outcome that also show different cannabinoids can be effective against harmful bacteria including those that are resistant to common antibiotics, like Methicillin-resistant Staphylococcus aureus (MRSA) causing various types of life-threatening infections, such as septic shock, endocarditis and severe pneumonia, coursed by the misuse of antibiotics, which is the leading cause of the emergence of antibiotic-resistant bacteria. They do so by inhibit the formation of biofilms and also eradicate pre-existing ones, was showcased in 1976, where it was discovered that THC and CBD can be used as bacteriostatic agents and are able to kill a panel of human pathogenic strains, and later a panel of cannabinoids are found able to do the same in different bacteria strains.[233][234]
Different medication and intervention regimes, and lifestyle modifications, like diet, weight control, exercise, mindfulness as yoga and meditation, and the use of psychoactive substances, like alcohol,[196] tobacco, coffee,[235][236] and cannabis, beside general anaesthesia regimens (i.e. propofol, etomidate, sevoflurane, isoflurane, sufentanil),[237][238] and Insulin medication and intraoperative doses of insulin,[150][151] etc, do also modulate it, either by being a FAAH inhibitor, that blocks the breakdown of NAE 20:4 (AEA), and/or enhance or lowering its production, and/or by activate or inactivate the receptors connected, as arachidonic acid (C20H32O2; 20:4, ω-6), the precursor of NAE 20:4 (AEA) and other eCBs, is present in every cell membrane of the body, and their on demand synthesis is regulated by electrical activity and calcium (Ca2+) shifts.[53][239][240][241][242][243][174][244][excessive citations]
See also
[edit]- Fatty acid desaturase
- Retrograde signaling
- Endocannabinoid system
- Cannabis in pregnancy
- Evolutionary history of life
- Evolutionary history of plants
- Hemp seed oil
- Hemp seed protein
- COX-2 inhibitors
References
[edit]- ^ a b c Berger A, Crozier G, Bisogno T, Cavaliere P, Innis S, Di Marzo V (May 2001). "Anandamide and diet: inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets". Proceedings of the National Academy of Sciences of the United States of America. 98 (11): 6402–6406. Bibcode:2001PNAS...98.6402B. doi:10.1073/pnas.101119098. PMC 33480. PMID 11353819.
- ^ a b Galasso I, Russo R, Mapelli S, Ponzoni E, Brambilla IM, Battelli G, Reggiani R (20 May 2016). "Variability in Seed Traits in a Collection of Cannabis sativa L. Genotypes". Frontiers in Plant Science. 7: 688. doi:10.3389/fpls.2016.00688. PMC 4873519. PMID 27242881.
- ^ a b Charytoniuk T, Zywno H, Berk K, Bzdega W, Kolakowski A, Chabowski A, Konstantynowicz-Nowicka K (March 2022). "The Endocannabinoid System and Physical Activity-A Robust Duo in the Novel Therapeutic Approach against Metabolic Disorders". International Journal of Molecular Sciences. 23 (6): 3083. doi:10.3390/ijms23063083. PMC 8948925. PMID 35328503.
- ^ a b c Stone NL, Millar SA, Herrod PJ, Barrett DA, Ortori CA, Mellon VA, O'Sullivan SE (26 November 2018). "An Analysis of Endocannabinoid Concentrations and Mood Following Singing and Exercise in Healthy Volunteers". Frontiers in Behavioral Neuroscience. 12: 269. doi:10.3389/fnbeh.2018.00269. PMC 6275239. PMID 30534062. Material was copied from this source, which is available under a Creative Commons Attribution 4.0 International License.
- ^ Blancaflor EB, Chapman KD (2006). "Similarities Between Endocannabinoid Signaling in Animal Systems and N-Acylethanolamine Metabolism in Plants". In Baluška F, Mancuso S, Volkmann D (eds.). Communication in Plants: Neuronal Aspects of Plant Life. Berlin, Heidelberg: Springer. pp. 205–219. doi:10.1007/978-3-540-28516-8_14. ISBN 978-3-540-28516-8.
- ^ Fasano, Silvia; Meccariello, Rosaria; Cobellis, Gilda; Chianese, Rosanna; Cacciola, Giovanna; Chioccarelli, Teresa; Pierantoni, Riccardo (April 2009). "The Endocannabinoid System: An Ancient Signaling Involved in the Control of Male Fertility". Annals of the New York Academy of Sciences. 1163 (1): 112–124. Bibcode:2009NYASA1163..112F. doi:10.1111/j.1749-6632.2009.04437.x. PMID 19456333. S2CID 6304998.
- ^ Elphick, M. R.; Egertová, M. (2005), Pertwee, Roger G. (ed.), "The Phylogenetic Distribution and Evolutionary Origins of Endocannabinoid Signalling", Cannabinoids, Handbook of Experimental Pharmacology, no. 168, Berlin, Heidelberg: Springer, pp. 283–297, doi:10.1007/3-540-26573-2_9, ISBN 978-3-540-26573-3, PMID 16596778
- ^ McPartland, John M (1 April 2004). "Phylogenomic and chemotaxonomic analysis of the endocannabinoid system". Brain Research Reviews. 45 (1): 18–29. doi:10.1016/j.brainresrev.2003.11.005. ISSN 0165-0173. PMID 15063097. S2CID 25038370.
- ^ Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N (February 2004). "Molecular characterization of a phospholipase D generating anandamide and its congeners". The Journal of Biological Chemistry. 279 (7): 5298–5305. doi:10.1074/jbc.M306642200. PMID 14634025.
- ^ For example, note synonyms in PubChem for oleoylethanolamine.
- ^ a b Silva, Hugo-Henrique; Tavares, Valéria; Silva, Maria-Raquel G.; Neto, Beatriz Vieira; Cerqueira, Fátima; Medeiros, Rui (26 March 2023). "Association of FAAH rs324420 (C385A) Polymorphism with High-Level Performance in Volleyball Players". Genes. 14 (6): 1164. doi:10.3390/genes14061164. ISSN 2073-4425. PMC 10298391. PMID 37372343. This article incorporates text from this source, which is available under the CC BY 4.0 license.
- ^ Hayes, Alexander C. (2013). "Identification of N-acylethanolamines in Dictyostelium discoideum and confirmation of their hydrolysis by fatty acid amide hydrolase". J. Lipid Res. 54 (2): 457–466. doi:10.1194/jlr.M032219. PMC 3588872. PMID 23187822.
- ^ a b c Shin, Kyong-Oh (2 August 2021). "N-Palmitoyl Serinol Stimulates Ceramide Production through a CB1-Dependent Mechanism in In Vitro Model of Skin Inflammation". Int J Mol Sci. 22 (15): 8302. doi:10.3390/ijms22158302. PMC 8348051. PMID 34361066. This article incorporates text from this source, which is available under the CC BY 4.0 license.
- ^ The list and references provided are based on background discussion in Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N (February 2004). "Molecular characterization of a phospholipase D generating anandamide and its congeners". The Journal of Biological Chemistry. 279 (7): 5298–305. doi:10.1074/jbc.M306642200. PMID 14634025.
- ^ PubChem. "Anandamide". pubchem.ncbi.nlm.nih.gov. Retrieved 29 June 2023.
- ^ a b Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. (December 1992). "Isolation and structure of a brain constituent that binds to the cannabinoid receptor". Science. 258 (5090): 1946–9. Bibcode:1992Sci...258.1946D. doi:10.1126/science.1470919. PMID 1470919.
- ^ Di Marzo V (June 1998). "'Endocannabinoids' and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance". Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism. 1392 (2–3): 153–75. doi:10.1016/s0005-2760(98)00042-3. PMID 9630590.
- ^ Di Marzo V, De Petrocellis L, Fezza F, Ligresti A, Bisogno T (2002). "Anandamide receptors". Prostaglandins, Leukotrienes, and Essential Fatty Acids. 66 (2–3): 377–91. doi:10.1054/plef.2001.0349. PMID 12052051.
- ^ a b Calignano A, La Rana G, Giuffrida A, Piomelli D (July 1998). "Control of pain initiation by endogenous cannabinoids". Nature. 394 (6690): 277–81. Bibcode:1998Natur.394..277C. doi:10.1038/28393. PMID 9685157. S2CID 4418082.
- ^ a b Maccarrone M, van der Stelt M, Rossi A, Veldink GA, Vliegenthart JF, Agrò AF (November 1998). "Anandamide hydrolysis by human cells in culture and brain". The Journal of Biological Chemistry. 273 (48): 32332–32339. doi:10.1074/jbc.273.48.32332. hdl:1887/50863. PMID 9822713.
- ^ a b Walter L, Franklin A, Witting A, Moller T, Stella N (June 2002). "Astrocytes in culture produce anandamide and other acylethanolamides". The Journal of Biological Chemistry. 277 (23): 20869–76. doi:10.1074/jbc.M110813200. PMID 11916961.
- ^ a b c Kamlekar RK, Swamy MJ (July 2006). "Molecular packing and intermolecular interactions in two structural polymorphs of N-palmitoylethanolamine, a type 2 cannabinoid receptor agonist". Journal of Lipid Research. 47 (7): 1424–33. doi:10.1194/jlr.M600043-JLR200. PMID 16609146.
- ^ Verme, Jesse Lo; Fu, Jin; Astarita, Giuseppe; Rana, Giovanna La; Russo, Roberto; Calignano, Antonio; Piomelli, Daniele (1 January 2005). "The Nuclear Receptor Peroxisome Proliferator-Activated Receptor-α Mediates the Anti-Inflammatory Actions of Palmitoylethanolamide". Molecular Pharmacology. 67 (1): 15–19. doi:10.1124/mol.104.006353. ISSN 0026-895X. PMID 15465922. S2CID 12671741.
- ^ Lambert DM, Vandevoorde S, Jonsson KO, Fowler CJ (March 2002). "The palmitoylethanolamide family: a new class of anti-inflammatory agents?". Current Medicinal Chemistry. 9 (6): 663–74. doi:10.2174/0929867023370707. PMID 11945130.
- ^ Rahman IA, Tsuboi K, Uyama T, Ueda N (August 2014). "New players in the fatty acyl ethanolamide metabolism". Pharmacological Research. Lipid amide signaling: regulation, physiological roles and pathological implications. 86: 1–10. doi:10.1016/j.phrs.2014.04.001. PMID 24747663.
- ^ Darmani, Nissar A.; Izzo, Angelo A.; Degenhardt, Brian; Valenti, Marta; Scaglione, Giuseppe; Capasso, Raffaele; Sorrentini, Italo; Di Marzo, Vincenzo (1 June 2005). "Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: Review of the available pre-clinical data, and first human studies". Neuropharmacology. Future Directions in Cannabinoid Therapeutics: “From the Bench to the Clinic”. 48 (8): 1154–1163. doi:10.1016/j.neuropharm.2005.01.001. ISSN 0028-3908. PMID 15910891. S2CID 14828175.
- ^ a b Chapman KD, Venables B, Markovic R, Bettinger C (August 1999). "N-Acylethanolamines in seeds. Quantification Of molecular species and their degradation upon imbibition". Plant Physiology. 120 (4): 1157–64. doi:10.1104/pp.120.4.1157. PMC 59349. PMID 10444099.
- ^ Motes CM, Pechter P, Yoo CM, Wang YS, Chapman KD, Blancaflor EB (December 2005). "Differential effects of two phospholipase D inhibitors, 1-butanol and N-acylethanolamine, on in vivo cytoskeletal organization and Arabidopsis seedling growth". Protoplasma. 226 (3–4): 109–23. doi:10.1007/s00709-005-0124-4. PMID 16333570. S2CID 19838345.
- ^ a b PubChem. "Alpha-Linolenoyl ethanolamide". pubchem.ncbi.nlm.nih.gov. Retrieved 3 August 2023.
- ^ a b Jones, Peter J. H.; Lin, Lin; Gillingham, Leah G.; Yang, Haifeng; Omar, Jaclyn M. (1 December 2014). "Modulation of plasma N-acylethanolamine levels and physiological parameters by dietary fatty acid composition in humans". Journal of Lipid Research. 55 (12): 2655–2664. doi:10.1194/jlr.P051235. ISSN 0022-2275. PMC 4242457. PMID 25262934.
- ^ a b Rodríguez de Fonseca F, Navarro M, Gómez R, Escuredo L, Nava F, Fu J, et al. (November 2001). "An anorexic lipid mediator regulated by feeding". Nature. 414 (6860): 209–212. Bibcode:2001Natur.414..209R. doi:10.1038/35102582. PMID 11700558. S2CID 4430005.
- ^ Kilaru A, Tamura P, Isaac G, Welti R, Venables BJ, Seier E, Chapman KD (September 2012). "Lipidomic analysis of N-acylphosphatidylethanolamine molecular species in Arabidopsis suggests feedback regulation by N-acylethanolamines". Planta. 236 (3): 809–824. Bibcode:2012Plant.236..809K. doi:10.1007/s00425-012-1669-z. PMC 3579225. PMID 22673881.
- ^ Di Marzo V, Piscitelli F (May 2011). "Gut feelings about the endocannabinoid system". Neurogastroenterology and Motility. 23 (5): 391–398. doi:10.1111/j.1365-2982.2011.01689.x. PMID 21481098.
- ^ a b c d e Tripathy S, Kleppinger-Sparace K, Dixon RA, Chapman KD (April 2003). "N-acylethanolamine signaling in tobacco is mediated by a membrane-associated, high-affinity binding protein". Plant Physiology. 131 (4): 1781–91. doi:10.1104/pp.102.014936. PMC 166934. PMID 12692337.
- ^ Hofmann U, Domeier E, Frantz S, Laser M, Weckler B, Kuhlencordt P, et al. (June 2003). "Increased myocardial oxygen consumption by TNF-alpha is mediated by a sphingosine signaling pathway". American Journal of Physiology. Heart and Circulatory Physiology. 284 (6): H2100-5. doi:10.1152/ajpheart.00888.2002. PMID 12560208.
- ^ Amadou A, Nawrocki A, Best-Belpomme M, Pavoine C, Pecker F (June 2002). "Arachidonic acid mediates dual effect of TNF-alpha on Ca2+ transients and contraction of adult rat cardiomyocytes". American Journal of Physiology. Cell Physiology. 282 (6): C1339-47. doi:10.1152/ajpcell.00471.2001. PMID 11997249.
- ^ "Linoleoyl ethanolamide". PubChem. U.S. National Library of Medicine. Retrieved 29 October 2022.
- ^ a b Simón, María Victoria; Agnolazza, Daniela L.; German, Olga Lorena; Garelli, Andrés; Politi, Luis E.; Agbaga, Martin-Paul; Anderson, Robert E.; Rotstein, Nora P. (2016). "Synthesis of docosahexaenoic acid from eicosapentaenoic acid in retina neurons protects photoreceptors from oxidative stress". Journal of Neurochemistry. 136 (5): 931–946. doi:10.1111/jnc.13487. ISSN 0022-3042. PMC 4755815. PMID 26662863.
- ^ a b c "Docosahexaenoyl Ethanolamide". PubChem. U.S. National Library of Medicine. Retrieved 19 November 2022.
- ^ a b c Balvers MG, Verhoeckx KC, Plastina P, Wortelboer HM, Meijerink J, Witkamp RF (October 2010). "Docosahexaenoic acid and eicosapentaenoic acid are converted by 3T3-L1 adipocytes to N-acyl ethanolamines with anti-inflammatory properties". Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1801 (10): 1107–14. doi:10.1016/j.bbalip.2010.06.006. PMID 20601112.
- ^ a b c Brown, Iain; Cascio, Maria G.; Rotondo, Dino; Pertwee, Roger G.; Heys, Steven D.; Wahle, Klaus W. J. (1 January 2013). "Cannabinoids and omega-3/6 endocannabinoids as cell death and anticancer modulators". Progress in Lipid Research. 52 (1): 80–109. doi:10.1016/j.plipres.2012.10.001. ISSN 0163-7827. PMID 23103355.
- ^ Brown I, Cascio MG, Wahle KW, Smoum R, Mechoulam R, Ross RA, et al. (September 2010). "Cannabinoid receptor-dependent and -independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines". Carcinogenesis. 31 (9): 1584–91. doi:10.1093/carcin/bgq151. PMC 2930808. PMID 20660502.
- ^ Kim HY, Spector AA, Xiong ZM (November 2011). "A synaptogenic amide N-docosahexaenoylethanolamide promotes hippocampal development". Prostaglandins & Other Lipid Mediators. 96 (1–4): 114–20. doi:10.1016/j.prostaglandins.2011.07.002. PMC 3215906. PMID 21810478.
- ^ Lee JW, Huang BX, Kwon H, Rashid MA, Kharebava G, Desai A, et al. (October 2016). "Orphan GPR110 (ADGRF1) targeted by N-docosahexaenoylethanolamine in development of neurons and cognitive function". Nature Communications. 7 (1): 13123. Bibcode:2016NatCo...713123L. doi:10.1038/ncomms13123. PMC 5075789. PMID 27759003.
- ^ a b PubChem. "Eicosapentaenoyl Ethanolamide". pubchem.ncbi.nlm.nih.gov. Retrieved 5 August 2023.
- ^ Walter L, Franklin A, Witting A, Wade C, Xie Y, Kunos G, et al. (February 2003). "Nonpsychotropic cannabinoid receptors regulate microglial cell migration". The Journal of Neuroscience. 23 (4): 1398–405. doi:10.1523/JNEUROSCI.23-04-01398.2003. PMC 6742252. PMID 12598628.
- ^ Magotti P, Bauer I, Igarashi M, Babagoli M, Marotta R, Piomelli D, Garau G (March 2015). "Structure of human N-acylphosphatidylethanolamine-hydrolyzing phospholipase D: regulation of fatty acid ethanolamide biosynthesis by bile acids". Structure. 23 (3): 598–604. doi:10.1016/j.str.2014.12.018. PMC 4351732. PMID 25684574.
- ^ a b Mock ED, Mustafa M, Gunduz-Cinar O, Cinar R, Petrie GN, Kantae V, et al. (June 2020). "Discovery of a NAPE-PLD inhibitor that modulates emotional behavior in mice". Nature Chemical Biology. 16 (6): 667–675. doi:10.1038/s41589-020-0528-7. PMC 7468568. PMID 32393901.
- ^ Tsuboi K, Okamoto Y, Ikematsu N, Inoue M, Shimizu Y, Uyama T, et al. (October 2011). "Enzymatic formation of N-acylethanolamines from N-acylethanolamine plasmalogen through N-acylphosphatidylethanolamine-hydrolyzing phospholipase D-dependent and -independent pathways". Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1811 (10): 565–577. doi:10.1016/j.bbalip.2011.07.009. PMID 21801852.
- ^ Wellner N, Diep TA, Janfelt C, Hansen HS (March 2013). "N-acylation of phosphatidylethanolamine and its biological functions in mammals". Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1831 (3): 652–662. doi:10.1016/j.bbalip.2012.08.019. PMID 23000428.
- ^ Serrano A, Parsons LH (December 2011). "Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors". Pharmacology & Therapeutics. 132 (3): 215–241. doi:10.1016/j.pharmthera.2011.06.005. PMC 3209522. PMID 21798285.
- ^ a b Oka, Saori (2006). "Involvement of the Cannabinoid CB2 Receptor and Its Endogenous Ligand 2-Arachidonoylglycerol in Oxazolone-Induced Contact Dermatitis in Mice". Journal of Immunology. 177 (12): 8796–9505. doi:10.4049/jimmunol.177.12.8796. PMID 17142782. S2CID 11946479. Retrieved 24 March 2023.
- ^ a b McPartland JM, Guy GW, Di Marzo V (12 March 2014). "Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system". PLOS ONE. 9 (3): e89566. Bibcode:2014PLoSO...989566M. doi:10.1371/journal.pone.0089566. PMC 3951193. PMID 24622769. Text was copied from this source, which is available under a Creative Commons Attribution 4.0 International License.
- ^ Di Marzo V, Silvestri C (August 2019). "Lifestyle and Metabolic Syndrome: Contribution of the Endocannabinoidome". Nutrients. 11 (8). 1956. doi:10.3390/nu11081956. PMC 6722643. PMID 31434293.
- ^ a b Surowiec I, Gouveia-Figueira S, Orikiiriza J, Lindquist E, Bonde M, Magambo J, et al. (September 2017). "The oxylipin and endocannabidome responses in acute phase Plasmodium falciparum malaria in children". Malaria Journal. 16 (1): 358. doi:10.1186/s12936-017-2001-y. PMC 5591560. PMID 28886714.
- ^ Lacroix S (2020). "Dietary fatty acid intake and gut microbiota determine circulating endocannabinoidome signaling beyond the effect of body fat" (PDF). Scientific Reports. 10 (1): 15975. Bibcode:2020NatSR..1015975C. doi:10.1038/s41598-020-72861-3. PMC 7524791. PMID 32994521.
- ^ Manca, Claudia (2020). "Germ-free mice exhibit profound gut microbiota-dependent alterations of intestinal endocannabinoidome signaling". J Lipid Res. 61 (1): 70–85. doi:10.1194/jlr.RA119000424. PMC 6939599. PMID 31690638.
- ^ Venneri, Tommaso (15 May 2023). "Altered endocannabinoidome bioactive lipid levels accompany reduced DNBS-induced colonic inflammation in germ-free mice". Lipids in Health and Disease. 22 (1): 63. doi:10.1186/s12944-023-01823-1. PMC 10186685. PMID 37189092.
- ^ The Scientist, 23 July 2015, archived from the original on 15 December 2021, retrieved 14 March 2021
- ^ Blancaflor EB, Kilaru A, Keereetaweep J, Khan BR, Faure L, Chapman KD (August 2014). "N-Acylethanolamines: lipid metabolites with functions in plant growth and development". The Plant Journal. 79 (4): 568–83. doi:10.1111/tpj.12427. PMID 24397856.
- ^ a b c Sorrentino G (March 2021). "Introduction to emerging industrial applications of cannabis (Cannabis sativa L.)". Rendiconti Lincei. Scienze Fisiche e Naturali. 32 (2): 233–243. doi:10.1007/s12210-021-00979-1. PMC 7978457. PMID 33777341.
- ^ a b Rockström J, Steffen W, Noone K, Persson Å, Chapin III FS, Lambin E, et al. (18 November 2009). "Planetary Boundaries: Exploring the Safe Operating Space for Humanity". Ecology and Society. 14 (2). doi:10.5751/ES-03180-140232. hdl:10535/5421. ISSN 1708-3087.
- ^ Soderstrom K (2009). "Lessons from Nonmammalian Species". In Kendall D, Alexander S (eds.). Behavioral Neurobiology of the Endocannabinoid System. Current Topics in Behavioral Neurosciences. Vol. 1. Berlin, Heidelberg: Springer. pp. 173–98. doi:10.1007/978-3-540-88955-7_7. ISBN 978-3-540-88955-7. PMID 21104384.
- ^ DeVries MS, Cordes MA, Rodriguez JD, Stevenson SA, Riters LV (August 2016). "Neural endocannabinoid CB1 receptor expression, social status, and behavior in male European starlings". Brain Research. 1644: 240–8. doi:10.1016/j.brainres.2016.05.031. PMC 4904780. PMID 27206544.
- ^ Melamede R (September 2005). "Harm reduction—the cannabis paradox". Harm Reduction Journal. 2 (1): 17. doi:10.1186/1477-7517-2-17. PMC 1261530. PMID 16179090. Text was copied from this source, which is available under a Creative Commons Attribution 2.0 Generic (CC BY 2.0) license.
- ^ Wang H, Matsumoto H, Guo Y, Paria BC, Roberts RL, Dey SK (December 2003). "Differential G protein-coupled cannabinoid receptor signaling by anandamide directs blastocyst activation for implantation". Proceedings of the National Academy of Sciences of the United States of America. 100 (25): 14914–14919. Bibcode:2003PNAS..10014914W. doi:10.1073/pnas.2436379100. PMC 299852. PMID 14645706.
- ^ Wang H, Xie H, Dey SK (2006). "Endocannabinoid signaling directs periimplantation events". The AAPS Journal. 8 (2): E425 – E432. doi:10.1007/BF02854916. PMC 3231559. PMID 16808046.
- ^ a b c Fride E (October 2004). "The endocannabinoid-CB(1) receptor system in pre- and postnatal life". European Journal of Pharmacology. SPECIAL CELEBRATORY VOLUME 500 Dedicated to Professor David de Wied Honorary and Founding Editor. 500 (1–3): 289–297. doi:10.1016/j.ejphar.2004.07.033. PMID 15464041.
- ^ a b Trabucco E, Acone G, Marenna A, Pierantoni R, Cacciola G, Chioccarelli T, et al. (June 2009). "Endocannabinoid system in first trimester placenta: low FAAH and high CB1 expression characterize spontaneous miscarriage". Placenta. 30 (6): 516–522. doi:10.1016/j.placenta.2009.03.015. PMID 19419760.
- ^ Maccarrone M, Valensise H, Bari M, Lazzarin N, Romanini C, Finazzi-Agrò A (April 2000). "Relation between decreased anandamide hydrolase concentrations in human lymphocytes and miscarriage". Lancet. 355 (9212): 1326–1329. doi:10.1016/S0140-6736(00)02115-2. PMID 10776746. S2CID 39733100.
- ^ Wang H, Guo Y, Wang D, Kingsley PJ, Marnett LJ, Das SK, et al. (October 2004). "Aberrant cannabinoid signaling impairs oviductal transport of embryos". Nature Medicine. 10 (10): 1074–80. doi:10.1038/nm1104. PMID 15378054. S2CID 29106466.
- ^ Stadel, Rebecca; Ahn, Kwang H.; Kendall, Debra A. (2011). "The Cannabinoid Type-1 Receptor Carboxyl-Terminus, More Than Just a Tail". Journal of Neurochemistry. 117 (1): 1–18. doi:10.1111/j.1471-4159.2011.07186.x. ISSN 0022-3042. PMC 3055937. PMID 21244428.
- ^ Pertwee RG (January 2008). "The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin". British Journal of Pharmacology. 153 (2): 199–215. doi:10.1038/sj.bjp.0707442. PMC 2219532. PMID 17828291.
- ^ Morales P, Hurst DP, Reggio PH (2017). "Molecular Targets of the Phytocannabinoids: A Complex Picture". Phytocannabinoids. Progress in the Chemistry of Organic Natural Products. Vol. 103. Cham: Springer. pp. 103–131. doi:10.1007/978-3-319-45541-9_4. ISBN 978-3-319-45539-6. PMC 5345356. PMID 28120232.
- ^ a b Thieme U, Schelling G, Hauer D, Greif R, Dame T, Laubender RP, et al. (2014). "Quantification of anandamide and 2-arachidonoylglycerol plasma levels to examine potential influences of tetrahydrocannabinol application on the endocannabinoid system in humans". Drug Testing and Analysis. 6 (1–2): 17–23. doi:10.1002/dta.1561. PMID 24424856.
- ^ a b Xiong, Wei (2011). "Cannabinoid potentiation of glycine receptors contributes to cannabis-induced analgesia". Nature Chemical Biology. 7 (5): 296–303. doi:10.1038/nchembio.552. PMC 3388539. PMID 21460829.
- ^ O'Sullivan, S E (2007). "Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors". British Journal of Pharmacology. 152 (5): 576–582. doi:10.1038/sj.bjp.0707423. ISSN 0007-1188. PMC 2190029. PMID 17704824.
- ^ Roloff AM, Thayer SA (April 2009). "Modulation of excitatory synaptic transmission by Delta 9-tetrahydrocannabinol switches from agonist to antagonist depending on firing rate". Molecular Pharmacology. 75 (4): 892–900. doi:10.1124/mol.108.051482. PMC 2684930. PMID 19118122.
- ^ Lipina, Christopher (24 January 2017). "The endocannabinoid system: 'NO' longer anonymous in the control of nitrergic signalling?". J Mol Cell Biol. 9 (2): 91–103. doi:10.1093/jmcb/mjx008. PMC 5439392. PMID 28130308.
- ^ a b Shmist, Yelena A.; Goncharov, Igor; Eichler, Maor; Shneyvays, Vladimir; Isaac, Ahuva; Vogel, Zvi; Shainberg, Asher (1 February 2006). "Delta-9-tetrahydrocannabinol protects cardiac cells from hypoxia via CB2 receptor activation and nitric oxide production". Molecular and Cellular Biochemistry. 283 (1): 75–83. doi:10.1007/s11010-006-2346-y. ISSN 1573-4919. PMID 16444588. S2CID 24074568.
- ^ Dennedy MC, Friel AM, Houlihan DD, Broderick VM, Smith T, Morrison JJ (January 2004). "Cannabinoids and the human uterus during pregnancy" (PDF). American Journal of Obstetrics and Gynecology. 190 (1): 2–9, discussion 3A. doi:10.1016/j.ajog.2003.07.013. PMID 14749627.
- ^ Datta P, Melkus MW, Rewers-Felkins K, Patel D, Bateman T, Baker T, Hale TW (July 2021). "Human Milk Endocannabinoid Levels as a Function of Obesity and Diurnal Rhythm". Nutrients. 13 (7): 2297. doi:10.3390/nu13072297. PMC 8308542. PMID 34371807.
- ^ Fride E, Suris R, Weidenfeld J, Mechoulam R (September 2005). "Differential response to acute and repeated stress in cannabinoid CB1 receptor knockout newborn and adult mice". Behavioural Pharmacology. 16 (5–6): 431–440. doi:10.1097/00008877-200509000-00016. PMID 16148448. S2CID 25548954.
- ^ Botsford, Chloe; Brellenthin, Angelique G.; Cisler, Josh M.; Hillard, Cecilia J.; Koltyn, Kelli F.; Crombie, Kevin M. (1 January 2023). "Circulating endocannabinoids and psychological outcomes in women with PTSD". Journal of Anxiety Disorders. 93: 102656. doi:10.1016/j.janxdis.2022.102656. ISSN 0887-6185. PMC 9839585. PMID 36469982.
- ^ a b Hill, Matthew N. (2009). "Circulating Endocannabinoids and N-Acyl Ethanolamines Are Differentially Regulated in Major Depression and Following Exposure to Social Stress". Psychoneuroendocrinology. 34 (8): 1257–1262. doi:10.1016/j.psyneuen.2009.03.013. PMC 2716432. PMID 19394765.
- ^ Wingenfeld, Katja; Dettenborn, Lucia; Kirschbaum, Clemens; Gao, Wei; Otte, Christian; Roepke, Stefan (4 July 2018). "Reduced levels of the endocannabinoid arachidonylethanolamide (AEA) in hair in patients with borderline personality disorder – a pilot study". Stress. 21 (4): 366–369. doi:10.1080/10253890.2018.1451837. ISSN 1025-3890. PMID 29546791. S2CID 3929753.
- ^ a b Crippa, José; Zuardi, Antonio; Hallak, Jaime (2010). "Therapeutical use of the cannabinoids in psychiatry". Braz J Psychiatry. 32: 56–66. PMID 20512271 – via PubMed Central.
- ^ Cousens, Kenneth; DiMascio, Alberto (1 December 1973). "(−)δ9 THC as an hypnotic". Psychopharmacologia. 33 (4): 355–364. doi:10.1007/BF00437513. ISSN 1432-2072. PMID 4776660. S2CID 8775767.
- ^ a b Kolla, Nathan J. (10 June 2020). "Elevated fatty acid amide hydrolase in the prefrontal cortex of borderline personality disorder: a [11C]CURB positron emission tomography study". Neuropsychopharmacology. 45 (11): 1834–1841. doi:10.1038/s41386-020-0731-y. PMC 7608329. PMID 32521537.
- ^ a b Wei D, Lee D, Cox CD, Karsten CA, Peñagarikano O, Geschwind DH, et al. (November 2015). "Endocannabinoid signaling mediates oxytocin-driven social reward". Proceedings of the National Academy of Sciences of the United States of America. 112 (45): 14084–14089. Bibcode:2015PNAS..11214084W. doi:10.1073/pnas.1509795112. PMC 4653148. PMID 26504214.
- ^ Ritter, Catherine; Broers, Barbara; Elger, Bernice S. (1 November 2013). "Cannabis use in a Swiss male prison: Qualitative study exploring detainees' and staffs' perspectives". International Journal of Drug Policy. 24 (6): 573–578. doi:10.1016/j.drugpo.2013.05.001. ISSN 0955-3959. PMID 23773686.
- ^ Jiménez-Vinaja, R. (31 March 2022). "Jailhouse rock: Health status, patterns of use, and subjective benefits of cannabis use in a sample of inmates in Spanish prisons". Rev Esp Sanid Penit. 24 (1): 9–14. doi:10.18176/resp.00044. PMC 9017606. PMID 35411912.
- ^ Excerpt: The House I Live In – The Chain of Destruction, 24 January 2013, retrieved 15 August 2023
- ^ Kolind, Torsten; Frank, Vibeke Asmussen; Dahl, Helle (1 January 2010). "Drug treatment or alleviating the negative consequences of imprisonment? A critical view of prison-based drug treatment in Denmark". International Journal of Drug Policy. 21 (1): 43–48. doi:10.1016/j.drugpo.2009.03.002. ISSN 0955-3959. PMID 19427186.
- ^ de Lima e Silva Surjus, Luciana Togni (5 April 2023). "Use of Marijuana to Promote Well-Being: Effects of Use and Prohibition in the Daily Lives of Brazilian Adults". Subst Abuse. 17. doi:10.1177/11782218231162469. PMC 10084564. PMID 37051015.
- ^ a b El-Alfy, Abir T. (21 March 2010). "Antidepressant-like effect of Δ9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L". Pharmacol Biochem Behav. 95 (4): 434–442. doi:10.1016/j.pbb.2010.03.004. PMC 2866040. PMID 20332000.
- ^ His Majesty's, Government of Nepal (8 August 1975). "CHAPTER VI NARCOTIC DRUGS AND PSYCHOTROPIC SUBSTANCES – Declarations and Reservations for Nepal". un.org.
- ^ Hamayun, Muhammad; Shinwari, Zabta Khan (22 December 2004). "Folk Methodology of Charas (Hashish) Production and Its Marketing at Afridi Tirah, Federally Administered Tribal Areas (FATA), Pakistan". Journal of Industrial Hemp. 9 (2): 41–50. doi:10.1300/J237v09n02_04. ISSN 1537-7881. S2CID 85423253.
- ^ "The Science of Marijuana, 2nd edn". British Journal of Clinical Pharmacology. 67 (2): 268. 23 February 2009. doi:10.1111/j.1365-2125.2008.03355.x. PMC 2670388.
- ^ Adinoff, Bryon; Reiman, Amanda (2 November 2019). "Implementing social justice in the transition from illicit to legal cannabis". The American Journal of Drug and Alcohol Abuse. 45 (6): 673–688. doi:10.1080/00952990.2019.1674862. ISSN 0095-2990. PMID 31634005. S2CID 204834660.
- ^ Iōakeimoglou, Geōrgios; Wolstenholme, G. E. W.; Knight, Julie (1965). "Hashish its chemistry and pharmacology. In honor of Professor Dr. G. Joachimoglu | WorldCat.org". www.worldcat.org. Retrieved 13 August 2023.
- ^ Morris, Robert G.; TenEyck, Michael; Barnes, J. C.; Kovandzic, Tomislav V. (26 March 2014). "The Effect of Medical Marijuana Laws on Crime: Evidence from State Panel Data, 1990–2006". PLOS ONE. 9 (3): e92816. Bibcode:2014PLoSO...992816M. doi:10.1371/journal.pone.0092816. PMC 3966811. PMID 24671103.
- ^ Anderson DM, Rees DI, Sabia JJ (January 2012). "High on Life? Medical Marijuana Laws and Suicide" (PDF). Institute for the Study of Labor (IZA).
- ^ Russo, Ethan B. (2 January 2023). "When The Pharmacopoeia Fails: Cannabis for Pain". Pain Medicine (Malden, Mass.). 24 (7): 912–913. doi:10.1093/pm/pnac208. PMID 36592031. Retrieved 13 August 2023.
- ^ Bojesen, Bo (6 April 1979). "Title: Tremmeværk/latticework - Situation: Prisoner in solitary confinement gets a visit, where the official visits the prisoner, who sits alone in the dark – Subtitle: The Human Rights Commission must now take a closer look at the long-term isolation of Danish remand prisoners.- Dialogue: You can try to talk to him, but he's been so strangely withdrawn over the last seven months. – Digitale samlinger". www5.kb.dk. Retrieved 13 August 2023.
- ^ Subramanian C, Frank MW, Batte JL, Whaley SG, Rock CO (June 2019). "Oleate hydratase from Staphylococcus aureus protects against palmitoleic acid, the major antimicrobial fatty acid produced by mammalian skin". The Journal of Biological Chemistry. 294 (23): 9285–9294. doi:10.1074/jbc.RA119.008439. PMC 6556589. PMID 31018965.
- ^ Vanhoutte K, Vanhoutte J (22 June 2009). "Composition comprising omega-7 and/or omega-4 fatty acids". Google Patents.
- ^ Compton DL, Laszlo JA, Appell M, Vermillion KE, Evans KO (2012). "Influence of Fatty Acid Desaturation on Spontaneous Acyl Migration in 2-Monoacylglycerols". Journal of the American Oil Chemists' Society. 89 (12): 2259–2267. doi:10.1007/s11746-012-2113-z. ISSN 1558-9331. S2CID 83629022.
- ^ Manca C, Carta G, Murru E, Abolghasemi A, Ansar H, Errigo A, et al. (March 2021). "Circulating fatty acids and endocannabinoidome-related mediator profiles associated to human longevity". GeroScience. 43 (4): 1783–1798. doi:10.1007/s11357-021-00342-0. PMC 8492808. PMID 33650014.
- ^ Simopoulos AP (October 2002). "The importance of the ratio of omega-6/omega-3 essential fatty acids". Biomedicine & Pharmacotherapy. 56 (8): 365–379. doi:10.1016/S0753-3322(02)00253-6. PMID 12442909.
- ^ Ryz, Natasha R.; Remillard, David J.; Russo, Ethan B. (1 August 2017). "Cannabis Roots: A Traditional Therapy with Future Potential for Treating Inflammation and Pain". Cannabis and Cannabinoid Research. 2 (1): 210–216. doi:10.1089/can.2017.0028. ISSN 2378-8763. PMC 5628559. PMID 29082318.
- ^ PubChem. "Ergost-5-en-3-ol". pubchem.ncbi.nlm.nih.gov. Retrieved 26 March 2023.
- ^ PubChem. "p-Coumaroyltyramine". pubchem.ncbi.nlm.nih.gov. Retrieved 26 March 2023.
- ^ Elhendawy, Mostafa A.; Wanas, Amira S.; Radwan, Mohamed M.; Azzaz, Nabil A.; Toson, ElShahat S.; ElSohly, Mahmoud A. (2018). "Chemical and Biological Studies of Cannabis sativa Roots". Medical Cannabis and Cannabinoids. 1 (2): 104–111. doi:10.1159/000495582. ISSN 2504-3889. PMC 7158750. PMID 32296742.
- ^ Iftikhar, Amna (20 December 2021). "Applications of Cannabis Sativa L. in Food and Its Therapeutic Potential: From a Prohibited Drug to a Nutritional Supplement". Molecules. 26 (24): 7699. doi:10.3390/molecules26247699. PMC 8708517. PMID 34946779.
- ^ "Hemp Seed Protein". Innvista. Retrieved 31 October 2022.
- ^ "Omega Oils". Innvista. Retrieved 31 October 2022.
- ^ "Hampefrøolie". www.nyborggaard.dk (in Danish). Retrieved 22 July 2023.
- ^ "Hampeprotein". www.nyborggaard.dk (in Danish). Retrieved 20 August 2023.
- ^ Guil-Guerrero JL, Rincón-Cervera MÁ, Venegas-Venegas E (2010). "Gamma-linolenic and stearidonic acids: Purification and upgrading of C18-PUFA oils". European Journal of Lipid Science and Technology. 112 (10): 1068–1081. doi:10.1002/ejlt.200900294. ISSN 1438-7697.
- ^ Tóth, Kinga Fanni; Ádám, Dorottya; Bíró, Tamás; Oláh, Attila (6 March 2019). "Cannabinoid Signaling in the Skin: Therapeutic Potential of the "C(ut)annabinoid" System". Molecules. 24 (5): 918. doi:10.3390/molecules24050918. ISSN 1420-3049. PMC 6429381. PMID 30845666.
- ^ Kendall, Alexandra C.; Pilkington, Suzanne M.; Massey, Karen A.; Sassano, Gary; Rhodes, Lesley E.; Nicolaou, Anna (1 June 2015). "Distribution of Bioactive Lipid Mediators in Human Skin". Journal of Investigative Dermatology. 135 (6): 1510–1520. doi:10.1038/jid.2015.41. ISSN 0022-202X. PMID 25668241. S2CID 2385238.
- ^ a b Courtney W (2008). "Marijuana Symposium Mendocino Sept 11 '08". YouTube. Archived from the original on 15 December 2021.
- ^ PubChem. "(6aR,10aR)-1-Hydroxy-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-dibenzo[b,d]pyran-4-carboxylic acid". pubchem.ncbi.nlm.nih.gov. Retrieved 24 March 2023.
- ^ PubChem. "Cannabidiolic acid". pubchem.ncbi.nlm.nih.gov. Retrieved 24 March 2023.
- ^ Nadal, Xavier; del Río, Carmen; Casano, Salvatore; Palomares, Belén; Ferreiro-Vera, Carlos; Navarrete, Carmen; Sánchez-Carnerero, Carolina; Cantarero, Irene; Bellido, Maria Luz; Meyer, Stefan; Morello, Gaetano; Appendino, Giovanni; Muñoz, Eduardo (December 2017). "Tetrahydrocannabinolic acid is a potent PPARγ agonist with neuroprotective activity". British Journal of Pharmacology. 174 (23): 4263–4276. doi:10.1111/bph.14019. ISSN 0007-1188. PMC 5731255. PMID 28853159.
- ^ Petrosino, Stefania; Verde, Roberta; Vaia, Massimo; Allarà, Marco; Iuvone, Teresa; Marzo, Vincenzo Di (1 June 2018). "Anti-inflammatory Properties of Cannabidiol, a Nonpsychotropic Cannabinoid, in Experimental Allergic Contact Dermatitis". Journal of Pharmacology and Experimental Therapeutics. 365 (3): 652–663. doi:10.1124/jpet.117.244368. ISSN 0022-3565. PMID 29632236. S2CID 4739468.
- ^ Karsak, Meliha (8 June 2007). "Attenuation of Allergic Contact Dermatitis Through the Endocannabinoid System". Science. 316 (5830): 1494–1497. Bibcode:2007Sci...316.1494K. doi:10.1126/science.1142265. PMID 17556587. S2CID 37611370.
- ^ Mukerjee, Souvik; Saeedan, Abdulaziz S.; Ansari, Mohd Nazam; Singh, Manjari (2021). "Polyunsaturated Fatty Acids Mediated Regulation of Membrane Biochemistry and Tumor Cell Membrane Integrity". Membranes. 11 (7): 479. doi:10.3390/membranes11070479. ISSN 2077-0375. PMC 8304949. PMID 34203433.
- ^ "8,11,14,17-Eicosatetraenoic acid". PubChem. U.S. National Library of Medicine. Retrieved 28 November 2022.
- ^ Abedi E, Sahari MA (September 2014). "Long-chain polyunsaturated fatty acid sources and evaluation of their nutritional and functional properties". Food Science & Nutrition. 2 (5): 443–463. doi:10.1002/fsn3.121. PMC 4237475. PMID 25473503.
- ^ "Anandamide". PubChem. U.S. National Library of Medicine. Retrieved 28 November 2022.
- ^ a b Sugiura T, Kondo S, Kishimoto S, Miyashita T, Nakane S, Kodaka T, et al. (January 2000). "Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells". The Journal of Biological Chemistry. 275 (1): 605–612. doi:10.1074/jbc.275.1.605. PMID 10617657.
- ^ "2-Arachidonoylglycerol". PubChem. U.S. National Library of Medicine. Retrieved 28 November 2022.
- ^ PubChem. "delta9-Tetrahydrocannabinolic acid". pubchem.ncbi.nlm.nih.gov. Retrieved 5 August 2023.
- ^ a b PubChem. "Dronabinol". pubchem.ncbi.nlm.nih.gov. Retrieved 5 August 2023.
- ^ Guzmán, Manuel (2003). "Cannabinoids: potential anticancer agents". Nature Reviews Cancer. 3 (10): 745–755. doi:10.1038/nrc1188. ISSN 1474-1768. PMID 14570037. S2CID 7868655.
- ^ Guzmán, Manuel; Sánchez, Cristina; Galve-Roperh, Ismael (1 January 2001). "Control of the cell survival/death decision by cannabinoids". Journal of Molecular Medicine. 78 (11): 613–625. doi:10.1007/s001090000177. ISSN 1432-1440. PMID 11269508. S2CID 12278192.
- ^ Munson, A. E.; Harris, L. S.; Friedman, M. A.; Dewey, W. L.; Carchman, R. A. (1 September 1975). "Antineoplastic Activity of Cannabinoids". Journal of the National Cancer Institute. 55 (3): 597–602. doi:10.1093/jnci/55.3.597. PMID 1159836.
- ^ a b ElTelbany, Ahmed (28 April 2022). "Lower Rates of Hepatocellular Carcinoma Observed Among Cannabis Users: A Population-Based Study". Cureus. 14 (4): e24576. doi:10.7759/cureus.24576. PMC 9138632. PMID 35651376.
- ^ Clark, Thomas M. (13 October 2021). "Scoping Review and Meta-Analysis Suggests that Cannabis Use May Reduce Cancer Risk in the United States". Cannabis Cannabinoid Res. 6 (5): 413–434. doi:10.1089/can.2019.0095. PMC 8612444. PMID 33998861.
- ^ a b Dyall SC (November 2017). "Interplay Between n-3 and n-6 Long-Chain Polyunsaturated Fatty Acids and the Endocannabinoid System in Brain Protection and Repair". Lipids. 52 (11): 885–900. doi:10.1007/s11745-017-4292-8. PMC 5656721. PMID 28875399.
- ^ Gaitán AV, Wood JT, Solomons NW, Donohue JA, Ji L, Liu Y, et al. (June 2019). "Endocannabinoid Metabolome Characterization of Milk from Guatemalan Women Living in the Western Highlands". Current Developments in Nutrition. 3 (6): nzz018. doi:10.1093/cdn/nzz018. PMC 6517780. PMID 31111118.
- ^ a b Keereetaweep J, Chapman KD (2016). "Lipidomic Analysis of Endocannabinoid Signaling: Targeted Metabolite Identification and Quantification". Neural Plasticity. 2016: 2426398. doi:10.1155/2016/2426398. PMC 4709765. PMID 26839710.
- ^ Yu M, Ives D, Ramesha CS (August 1997). "Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2". The Journal of Biological Chemistry. 272 (34): 21181–6. doi:10.1074/jbc.272.34.21181. PMID 9261124.
- ^ Patsos HA, Hicks DJ, Dobson RR, Greenhough A, Woodman N, Lane JD, et al. (December 2005). "The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2". Gut. 54 (12): 1741–50. doi:10.1136/gut.2005.073403. PMC 1774787. PMID 16099783.
- ^ Ritter JK, Li C, Xia M, Poklis JL, Lichtman AH, Abdullah RA, et al. (September 2012). "Production and actions of the anandamide metabolite prostamide E2 in the renal medulla". The Journal of Pharmacology and Experimental Therapeutics. 342 (3): 770–9. doi:10.1124/jpet.112.196451. PMC 3422528. PMID 22685343.
- ^ Touriño C, Oveisi F, Lockney J, Piomelli D, Maldonado R (March 2010). "FAAH deficiency promotes energy storage and enhances the motivation for food". International Journal of Obesity. 34 (3): 557–568. doi:10.1038/ijo.2009.262. PMC 3709605. PMID 20029375.
- ^ Filipiuc LE, Ababei DC, Alexa-Stratulat T, Pricope CV, Bild V, Stefanescu R, et al. (November 2021). "Major Phytocannabinoids and Their Related Compounds: Should We Only Search for Drugs That Act on Cannabinoid Receptors?". Pharmaceutics. 13 (11): 1823. doi:10.3390/pharmaceutics13111823. PMC 8625816. PMID 34834237.
- ^ a b Weis F, Beiras-Fernandez A, Hauer D, Hornuss C, Sodian R, Kreth S, et al. (August 2010). "Effect of anaesthesia and cardiopulmonary bypass on blood endocannabinoid concentrations during cardiac surgery". British Journal of Anaesthesia. 105 (2): 139–144. doi:10.1093/bja/aeq117. PMID 20525978.
- ^ a b Murdolo G, Kempf K, Hammarstedt A, Herder C, Smith U, Jansson PA (September 2007). "Insulin differentially modulates the peripheral endocannabinoid system in human subcutaneous abdominal adipose tissue from lean and obese individuals". Journal of Endocrinological Investigation. 30 (8): RC17 – RC21. doi:10.1007/BF03347440. PMID 17923791. S2CID 39337082.
- ^ Journalist, Vibeke Lyngklip Svansø; Journalist, Signe Westermann Kühn (23 June 2023). "Ny bekymring om populære Novo Nordisk-lægemidler – undersøger om de kan give selvmordstanker". Berlingske.dk (in Danish). Retrieved 4 July 2023.
- ^ Weber, Cordelia (21 June 2023). "Novo Nordisk-slankemiddel undersøges for at øge kræftrisiko". www.bt.dk (in Danish). Retrieved 4 July 2023.
- ^ Fokos, S.; Panagis, G. (2010). "Effects of delta9-tetrahydrocannabinol on reward and anxiety in rats exposed to chronic unpredictable stress". Journal of Psychopharmacology. 24 (5): 767–777. doi:10.1177/0269881109104904. ISSN 1461-7285. PMID 19406854. S2CID 8855238.
- ^ Sharpe, Lara; Sinclair, Justin; Kramer, Andrew; de Manincor, Michael; Sarris, Jerome (2 October 2020). "Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties". Journal of Translational Medicine. 18 (1): 374. doi:10.1186/s12967-020-02518-2. ISSN 1479-5876. PMC 7531079. PMID 33008420.
- ^ Rafiei, Dorsa; Kolla, Nathan J. (21 January 2021). "Elevated Brain Fatty Acid Amide Hydrolase Induces Depressive-Like Phenotypes in Rodent Models: A Review". International Journal of Molecular Sciences. 22 (3): 1047. doi:10.3390/ijms22031047. ISSN 1422-0067. PMC 7864498. PMID 33494322.
- ^ Viveros, M. P.; Marco, Eva M.; File, Sandra E. (2005). "Endocannabinoid system and stress and anxiety responses". Pharmacology, Biochemistry, and Behavior. 81 (2): 331–342. doi:10.1016/j.pbb.2005.01.029. ISSN 0091-3057. PMID 15927244. S2CID 25052842.
- ^ Sipe JC, Scott TM, Murray S, Harismendy O, Simon GM, Cravatt BF, Waalen J (January 2010). "Biomarkers of endocannabinoid system activation in severe obesity". PLOS ONE. 5 (1): e8792. Bibcode:2010PLoSO...5.8792S. doi:10.1371/journal.pone.0008792. PMC 2808340. PMID 20098695.
- ^ Balsevich G, Sticht M, Bowles NP, Singh A, Lee TT, Li Z, et al. (July 2018). "Role for fatty acid amide hydrolase (FAAH) in the leptin-mediated effects on feeding and energy balance". Proceedings of the National Academy of Sciences of the United States of America. 115 (29): 7605–7610. Bibcode:2018PNAS..115.7605B. doi:10.1073/pnas.1802251115. PMC 6055171. PMID 29967158.
- ^ Trayhurn P, Bing C, Wood IS (July 2006). "Adipose tissue and adipokines—energy regulation from the human perspective". The Journal of Nutrition. 136 (7 Suppl): 1935S – 1939S. doi:10.1093/jn/136.7.1935S. PMID 16772463.
- ^ Cota D (2008). "Role of the endocannabinoid system in energy balance regulation and obesity". Obesity and Metabolism. Frontiers of Hormone Research. Vol. 36. Basel: KARGER. pp. 135–145. doi:10.1159/000115362. ISBN 978-3-8055-8429-6. PMID 18230900.
- ^ Teixeira D, Pestana D, Faria A, Calhau C, Azevedo I, Monteiro R (November 2010). "Modulation of adipocyte biology by δ(9)-tetrahydrocannabinol". Obesity. 18 (11): 2077–2085. doi:10.1038/oby.2010.100. PMID 20467421.
- ^ Pagano C, Pilon C, Calcagno A, Urbanet R, Rossato M, Milan G, et al. (December 2007). "The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms". The Journal of Clinical Endocrinology and Metabolism. 92 (12): 4810–4819. doi:10.1210/jc.2007-0768. PMID 17785353.
- ^ Rajavashisth TB, Shaheen M, Norris KC, Pan D, Sinha SK, Ortega J, Friedman TC (1 January 2012). "Decreased prevalence of diabetes in marijuana users: cross-sectional data from the National Health and Nutrition Examination Survey (NHANES) III". BMJ Open. 2 (1): e000494. doi:10.1136/bmjopen-2011-000494. PMC 3289985. PMID 22368296.
- ^ Clark TM, Jones JM, Hall AG, Tabner SA, Kmiec RL (21 December 2018). "Theoretical Explanation for Reduced Body Mass Index and Obesity Rates in Cannabis Users". Cannabis and Cannabinoid Research. 3 (1): 259–271. doi:10.1089/can.2018.0045. PMC 6340377. PMID 30671538.
- ^ Danielsson AK, Lundin A, Yaregal A, Östenson CG, Allebeck P, Agardh EE (2016). "Cannabis Use as Risk or Protection for Type 2 Diabetes: A Longitudinal Study of 18 000 Swedish Men and Women". Journal of Diabetes Research. 2016: 6278709. doi:10.1155/2016/6278709. PMC 5098083. PMID 27843955.
- ^ Farokhnia M, McDiarmid GR, Newmeyer MN, Munjal V, Abulseoud OA, Huestis MA, Leggio L (February 2020). "Effects of oral, smoked, and vaporized cannabis on endocrine pathways related to appetite and metabolism: a randomized, double-blind, placebo-controlled, human laboratory study". Translational Psychiatry. 10 (1): 71. doi:10.1038/s41398-020-0756-3. PMC 7031261. PMID 32075958.
- ^ Adejumo AC, Alliu S, Ajayi TO, Adejumo KL, Adegbala OM, Onyeakusi NE, et al. (25 April 2017). "Cannabis use is associated with reduced prevalence of non-alcoholic fatty liver disease: A cross-sectional study". PLOS ONE. 12 (4): e0176416. Bibcode:2017PLoSO..1276416A. doi:10.1371/journal.pone.0176416. PMC 5404771. PMID 28441459.
- ^ a b Burstein SH (May 2014). "The cannabinoid acids, analogs and endogenous counterparts". Bioorganic & Medicinal Chemistry. 22 (10): 2830–2843. doi:10.1016/j.bmc.2014.03.038. PMC 4351512. PMID 24731541.
- ^ Grotenhermen F (2003). "Pharmacokinetics and pharmacodynamics of cannabinoids". Clinical Pharmacokinetics. 42 (4): 327–360. doi:10.2165/00003088-200342040-00003. PMID 12648025. S2CID 25623600.
- ^ Grotenhermen F (1 April 2003). "Pharmacokinetics and pharmacodynamics of cannabinoids". Clinical Pharmacokinetics. 42 (4): 327–360. doi:10.2165/00003088-200342040-00003. PMID 12648025. S2CID 25623600.
- ^ Ujváry I, Grotenhermen F (2014). "11-Nor-9-carboxy-∆9-tetrahydrocannabinol – a ubiquitous yet under researched cannabinoid. A review of the literature" (PDF). cannabis-med.org. Archived from the original (PDF) on 20 April 2017. Retrieved 5 April 2021.
- ^ Purschke K, Heinl S, Lerch O, Erdmann F, Veit F (June 2016). "Development and validation of an automated liquid-liquid extraction GC/MS method for the determination of THC, 11-OH-THC, and free THC-carboxylic acid (THC-COOH) from blood serum". Analytical and Bioanalytical Chemistry. 408 (16): 4379–4388. doi:10.1007/s00216-016-9537-5. PMC 4875941. PMID 27116418.
- ^ a b c Nguyen BM, Kim D, Bricker S, Bongard F, Neville A, Putnam B, et al. (October 2014). "Effect of marijuana use on outcomes in traumatic brain injury". The American Surgeon. 80 (10): 979–983. doi:10.1177/000313481408001015. PMID 25264643. S2CID 25797119.
- ^ a b El-Gohary M, Eid MA (March 2004). "Effect of cannabinoid ingestion (in the form of bhang) on the immune system of high school and university students". Human & Experimental Toxicology. 23 (3): 149–156. Bibcode:2004HETox..23..149E. doi:10.1191/0960327104ht426oa. PMID 15119535. S2CID 23909791.
- ^ Păunescu H, Coman OA, Coman L, Ghiţă I, Georgescu SR, Drăghia F, Fulga I (15 February 2011). "Cannabinoid system and cyclooxygenases inhibitors". Journal of Medicine and Life. 4 (1): 11–20. PMC 3056416. PMID 21505570.
- ^ Russo EB (February 2008). "Cannabinoids in the management of difficult to treat pain". Therapeutics and Clinical Risk Management. 4 (1): 245–59. doi:10.2147/tcrm.s1928. PMC 2503660. PMID 18728714.
- ^ Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, et al. (March 2012). "Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia". Translational Psychiatry. 2 (3): e94. doi:10.1038/tp.2012.15. PMC 3316151. PMID 22832859.
- ^ Mechoulam R (2019). "The Chemistry Behind Cannabinoid Acids (COOH)". YouTube. Archived from the original on 15 December 2021.
- ^ a b Kathuria S, Gaetani S, Fegley D, Valiño F, Duranti A, Tontini A, et al. (January 2003). "Modulation of anxiety through blockade of anandamide hydrolysis". Nature Medicine. 9 (1): 76–81. doi:10.1038/nm803. PMID 12461523. S2CID 20764484.
- ^ Sanchez-Marin L, Pavon FJ, Decara J, Suarez J, Gavito A, Castilla-Ortega E, et al. (7 February 2017). "Effects of Intermittent Alcohol Exposure on Emotion and Cognition: A Potential Role for the Endogenous Cannabinoid System and Neuroinflammation". Frontiers in Behavioral Neuroscience. 11: 15. doi:10.3389/fnbeh.2017.00015. PMC 5293779. PMID 28223925.
- ^ Mahmood OM, Jacobus J, Bava S, Scarlett A, Tapert SF (November 2010). "Learning and memory performances in adolescent users of alcohol and marijuana: interactive effects". Journal of Studies on Alcohol and Drugs. 71 (6): 885–894. doi:10.15288/jsad.2010.71.885. PMC 2965487. PMID 20946746.
- ^ Schneider M, Kasanetz F, Lynch DL, Friemel CM, Lassalle O, Hurst DP, et al. (October 2015). "Enhanced Functional Activity of the Cannabinoid Type-1 Receptor Mediates Adolescent Behavior". The Journal of Neuroscience. 35 (41): 13975–13988. doi:10.1523/JNEUROSCI.1937-15.2015. PMC 4604232. PMID 26468198.
- ^ Lutz B (February 2009). "Endocannabinoid signals in the control of emotion". Current Opinion in Pharmacology. Neurosciences. 9 (1): 46–52. doi:10.1016/j.coph.2008.12.001. PMID 19157983.
- ^ Burns HD, Van Laere K, Sanabria-Bohórquez S, Hamill TG, Bormans G, Eng WS, et al. (June 2007). "[18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor". Proceedings of the National Academy of Sciences of the United States of America. 104 (23): 9800–9805. Bibcode:2007PNAS..104.9800B. doi:10.1073/pnas.0703472104. PMC 1877985. PMID 17535893.
- ^ Grinspoon L (2009). "A Cannabis Odyssey: To Smoke or Not To Smoke by Lester Grinspoon". marijuana-uses.com.
- ^ Garner, Emily (2016). "A phenomenology of marijuana use among graduate students". Indo-Pacific Journal of Phenomenology. 16 (1): 1–17. doi:10.1080/20797222.2016.1164997. ISSN 1445-7377. S2CID 148123749.
- ^ Ferrer, Belen (2007). "Regulation of brain anandamide by acute administration of ethanol". The Biochemical Journal. 404 (Pt 1): 97–104. doi:10.1042/BJ20061898. PMC 1868843. PMID 17302558.
- ^ PubChem. "Palmitoylethanolamide". pubchem.ncbi.nlm.nih.gov. Retrieved 5 March 2023.
- ^ "N-arachidonoylphosphatidylethanolamine (CHEBI:52571)". www.ebi.ac.uk. Retrieved 7 April 2021.
- ^ Hassanzadeh P, Arbabi E, Atyabi F, Dinarvand R (March 2016). "The endocannabinoid system and NGF are involved in the mechanism of action of resveratrol: a multi-target nutraceutical with therapeutic potential in neuropsychiatric disorders". Psychopharmacology. 233 (6): 1087–1096. doi:10.1007/s00213-015-4188-3. PMID 26780936. S2CID 15089814.
- ^ Gertsch, Jürg; Leonti, Marco; Raduner, Stefan; Racz, Ildiko; Chen, Jian-Zhong; Xie, Xiang-Qun; Altmann, Karl-Heinz; Karsak, Meliha; Zimmer, Andreas (1 July 2008). "Beta-caryophyllene is a dietary cannabinoid". Proceedings of the National Academy of Sciences of the United States of America. 105 (26): 9099–9104. Bibcode:2008PNAS..105.9099G. doi:10.1073/pnas.0803601105. ISSN 0027-8424. PMC 2449371. PMID 18574142.
- ^ Russo EB (July 2016). "Beyond Cannabis: Plants and the Endocannabinoid System". Trends in Pharmacological Sciences. 37 (7): 594–605. doi:10.1016/j.tips.2016.04.005. PMID 27179600.
- ^ "Beyond Cannabis: Plants and the Endocannabinoid System". ResearchGate. Retrieved 7 April 2021.
- ^ Scandiffio, Rosaria (23 March 2023). "Beta-Caryophyllene Modifies Intracellular Lipid Composition in a Cell Model of Hepatic Steatosis by Acting through CB2 and PPAR Receptors". Int J Mol Sci. 24 (7): 6060. doi:10.3390/ijms24076060. PMC 10094507. PMID 37047034.
- ^ a b Basavarajappa BS, Hungund BL (February 1999). "Chronic ethanol increases the cannabinoid receptor agonist anandamide and its precursor N-arachidonoylphosphatidylethanolamine in SK-N-SH cells". Journal of Neurochemistry. 72 (2): 522–528. doi:10.1046/j.1471-4159.1999.0720522.x. PMID 9930723. S2CID 10793743.
- ^ Neumeister A, Normandin MD, Murrough JW, Henry S, Bailey CR, Luckenbaugh DA, et al. (December 2012). "Positron emission tomography shows elevated cannabinoid CB1 receptor binding in men with alcohol dependence". Alcoholism: Clinical and Experimental Research. 36 (12): 2104–2109. doi:10.1111/j.1530-0277.2012.01815.x. PMC 3418442. PMID 22551199.
- ^ Hirvonen J, Zanotti-Fregonara P, Umhau JC, George DT, Rallis-Frutos D, Lyoo CH, et al. (August 2013). "Reduced cannabinoid CB1 receptor binding in alcohol dependence measured with positron emission tomography". Molecular Psychiatry. 18 (8): 916–921. doi:10.1038/mp.2012.100. PMC 3594469. PMID 22776901.
- ^ Van Der Stelt M, Noordermeer MA, Kiss T, Van Zadelhoff G, Merghart B, Veldink GA, Vliegenthart JF (April 2000). "Formation of a new class of oxylipins from N-acyl(ethanol)amines by the lipoxygenase pathway". European Journal of Biochemistry. 267 (7): 2000–7. doi:10.1046/j.1432-1327.2000.01203.x. hdl:1874/5348. PMID 10727939. S2CID 42011572.
- ^ Gachet MS, Schubert A, Calarco S, Boccard J, Gertsch J (January 2017). "Targeted metabolomics shows plasticity in the evolution of signaling lipids and uncovers old and new endocannabinoids in the plant kingdom". Scientific Reports. 7 (1): 41177. Bibcode:2017NatSR...741177G. doi:10.1038/srep41177. PMC 5264637. PMID 28120902.
- ^ Chapman KD (November 2000). "Emerging physiological roles for N-acylphosphatidylethanolamine metabolism in plants: signal transduction and membrane protection". Chemistry and Physics of Lipids. 108 (1–2): 221–229. doi:10.1016/s0009-3084(00)00198-5. PMID 11106793.
- ^ Castelli MP, Madeddu C, Casti A, Casu A, Casti P, Scherma M, et al. (20 May 2014). "Δ9-tetrahydrocannabinol prevents methamphetamine-induced neurotoxicity". PLOS ONE. 9 (5): e98079. Bibcode:2014PLoSO...998079C. doi:10.1371/journal.pone.0098079. PMC 4028295. PMID 24844285.
- ^ Bregman T, Fride E (June 2011). "Treatment with tetrahydrocannabinol (THC) prevents infertility in male cystic fibrosis mice". Journal of Basic and Clinical Physiology and Pharmacology. 22 (1–2): 29–32. doi:10.1515/jbcpp.2011.004. PMID 22865360. S2CID 19335113.
- ^ Russo E (2002). "Cannabis Treatments in Obstetrics and Gynecology: A Historical Review". cannabis-med.org.
- ^ Bossong MG, van Hell HH, Jager G, Kahn RS, Ramsey NF, Jansma JM (December 2013). "The endocannabinoid system and emotional processing: a pharmacological fMRI study with ∆9-tetrahydrocannabinol". European Neuropsychopharmacology. 23 (12): 1687–1697. doi:10.1016/j.euroneuro.2013.06.009. PMID 23928295. S2CID 4847188.
- ^ Sano K, Mishima K, Koushi E, Orito K, Egashira N, Irie K, et al. (January 2008). "Delta 9-tetrahydrocannabinol-induced catalepsy-like immobilization is mediated by decreased 5-HT neurotransmission in the nucleus accumbens due to the action of glutamate-containing neurons". Neuroscience. 151 (2): 320–328. doi:10.1016/j.neuroscience.2007.10.026. PMID 18083311. S2CID 45508434.
- ^ Karhson DS, Hardan AY, Parker KJ (September 2016). "Endocannabinoid signaling in social functioning: an RDoC perspective". Translational Psychiatry. 6 (9): e905. doi:10.1038/tp.2016.169. PMC 5048207. PMID 27676446.
- ^ Hosking RD, Zajicek JP (July 2008). "Therapeutic potential of cannabis in pain medicine". British Journal of Anaesthesia. 101 (1): 59–68. doi:10.1093/bja/aen119. PMID 18515270.
- ^ Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al. (June 2002). "International Union of Pharmacology. XXVII. Classification of cannabinoid receptors". Pharmacological Reviews. 54 (2): 161–202. doi:10.1124/pr.54.2.161. PMID 12037135. S2CID 8259002.
- ^ Ripple W (2020). "World Scientists' Warning of a Climate Emergency". BioScience.
- ^ Gillis J (9 October 2013). "By 2047, Coldest Years May Be Warmer Than Hottest in Past, Scientists Say". The New York Times. ISSN 0362-4331. Retrieved 22 September 2022.
- ^ Mora C, Dousset B, Caldwell IR, Powell FE, Geronimo RC, Bielecki CR, et al. (19 June 2017). "Global risk of deadly heat". Nature Climate Change. 7 (7): 501–506. Bibcode:2017NatCC...7..501M. doi:10.1038/nclimate3322. ISSN 1758-678X. S2CID 90219036.
- ^ Greenfield C, Dickie G (14 June 2022). "In hottest city on Earth, mothers bear brunt of climate change". Reuters. Retrieved 21 October 2022.
- ^ Zaelke D (2008). "Reducing Black Carbon May Be the Fastest Strategy for Slowing Climate Change" (PDF). Institute for Governance & Sustainable Development.
- ^ Meng L, Liu J, Tarasick DW, Randel WJ, Steiner AK, Wilhelmsen H, et al. (November 2021). "Continuous rise of the tropopause in the Northern Hemisphere over 1980–2020". Science Advances. 7 (45): eabi8065. Bibcode:2021SciA....7R8065M. doi:10.1126/sciadv.abi8065. PMC 8570593. PMID 34739322.
- ^ "Warming temperatures increasingly alter structure of atmosphere | NCAR & UCAR News". news.ucar.edu. Retrieved 22 September 2022.
- ^ Kim SY, Sung SA, Ko GJ, Boo CS, Jo SK, Cho WY, Kim HK (September 2006). "A case of multiple organ failure due to heat stoke following a warm bath". The Korean Journal of Internal Medicine. 21 (3): 210–212. doi:10.3904/kjim.2006.21.3.210. PMC 3890729. PMID 17017675.
- ^ Rawls SM, Benamar K (June 2011). "Effects of opioids, cannabinoids, and vanilloids on body temperature". Frontiers in Bioscience. 3 (3): 822–845. doi:10.2741/190. PMC 3979758. PMID 21622235.
- ^ Smirnov MS, Kiyatkin EA (September 2008). "Behavioral and temperature effects of delta 9-tetrahydrocannabinol in human-relevant doses in rats". Brain Research. 1228: 145–160. doi:10.1016/j.brainres.2008.06.069. PMC 2613277. PMID 18619424.
- ^ Devane WA, Dysarz FA, Johnson MR, Melvin LS, Howlett AC (November 1988). "Determination and characterization of a cannabinoid receptor in rat brain". Molecular Pharmacology. 34 (5): 605–613. PMID 2848184.
- ^ Gill, E. W.; Paton, W. D. M.; Pertwee, R. G. (10 October 1970). "Preliminary Experiments on the Chemistry and Pharmacology of Cannabis". Nature. 228 (5267): 134–136. Bibcode:1970Natur.228..134G. doi:10.1038/228134a0. ISSN 1476-4687. PMID 5466704. S2CID 4193316.
- ^ Jung J, Meyer MR, Maurer HH, Neusüss C, Weinmann W, Auwärter V (October 2009). "Studies on the metabolism of the Delta9-tetrahydrocannabinol precursor Delta9-tetrahydrocannabinolic acid A (Delta9-THCA-A) in rat using LC-MS/MS, LC-QTOF MS and GC-MS techniques". Journal of Mass Spectrometry. 44 (10): 1423–1433. Bibcode:2009JMSp...44.1423J. doi:10.1002/jms.1624. PMID 19728318.
- ^ Taghavi S, Ramirez S, Duchesne J, Tatum D (January 2021). "Preinjury Use of Marijuana and Outcomes in Trauma Patients". The Journal of Surgical Research. 257: 42–49. doi:10.1016/j.jss.2020.07.011. PMID 32818783. S2CID 221219765.
- ^ Rieder SA, Chauhan A, Singh U, Nagarkatti M, Nagarkatti P (August 2010). "Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression". Immunobiology. 215 (8): 598–605. doi:10.1016/j.imbio.2009.04.001. PMC 3005548. PMID 19457575.
- ^ Hwang, Jeannie (13 June 2009). "Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: A neuroprotective therapeutic modality". Life Sciences. 86 (15–16): 615–623. doi:10.1016/j.lfs.2009.06.003. PMC 2848893. PMID 19527737.
- ^ Pollution Disease Link: Interview with neuroscience professor David Allsop from Lancaster University, 6 September 2016, retrieved 26 October 2022
- ^ Eubanks LM, Rogers CJ, Beuscher AE, Koob GF, Olson AJ, Dickerson TJ, Janda KD (2006). "A molecular link between the active component of marijuana and Alzheimer's disease pathology". Molecular Pharmaceutics. 3 (6): 773–777. doi:10.1021/mp060066m. PMC 2562334. PMID 17140265.
- ^ "Cannabinoids as antioxidants and neuroprotectants - Patent US-6630507-B1 - PubChem". pubchem.ncbi.nlm.nih.gov. Retrieved 16 December 2022.
- ^ Aso, Ester; Ferrer, Isidre (5 March 2014). "Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic". Frontiers in Pharmacology. 5: 37. doi:10.3389/fphar.2014.00037. ISSN 1663-9812. PMC 3942876. PMID 24634659.
- ^ Coles, Madilyn; Steiner-Lim, Genevieve Z.; Karl, Tim (2022). "Therapeutic properties of multi-cannabinoid treatment strategies for Alzheimer's disease". Frontiers in Neuroscience. 16: 962922. doi:10.3389/fnins.2022.962922. ISSN 1662-453X. PMC 9479694. PMID 36117622.
- ^ "Cannabis Our Key to the Endocannabinoid System". www.caymanchem.com. Retrieved 25 June 2021.
- ^ Steiner-Lim, Genevieve Z.; Coles, Madilyn; Jaye, Kayla; Metri, Najwa-Joelle; Butt, Ali S.; Christofides, Katerina; McPartland, Jackson; Al-Modhefer, Zainab; Karamacoska, Diana (2023). "Medicinal Cannabis for Alzheimer's Disease". ResearchGate. Retrieved 13 August 2023.
- ^ Irenej, Pečan Luka; Francisco-Righoberto, Barrios; Marko, Jeran (2023). "Cannabinoid Molecules from Cannabis Sativa L. as a Promissing [sic] Solution for Methicillin-Resistant Staphylococcus Aureus (MRSA)" (PDF). University of Ljubljana.
- ^ Farha, Maya A.; El-Halfawy, Omar M.; Gale, Robert T.; MacNair, Craig R.; Carfrae, Lindsey A.; Zhang, Xiong; Jentsch, Nicholas G.; Magolan, Jakob; Brown, Eric D. (13 March 2020). "Uncovering the Hidden Antibiotic Potential of Cannabis". ACS Infectious Diseases. 6 (3): 338–346. doi:10.1021/acsinfecdis.9b00419. ISSN 2373-8227. PMID 32017534. S2CID 211035245 – via ResearchGate.
- ^ Rossi S, De Chiara V, Musella A, Mataluni G, Sacchetti L, Siracusano A, et al. (March 2009). "Caffeine drinking potentiates cannabinoid transmission in the striatum: interaction with stress effects". Neuropharmacology. 56 (3): 590–597. doi:10.1016/j.neuropharm.2008.10.013. PMID 19027757. S2CID 35191973.
- ^ Rossi S, De Chiara V, Musella A, Mataluni G, Sacchetti L, Siracusano A, et al. (April 2010). "Effects of caffeine on striatal neurotransmission: focus on cannabinoid CB1 receptors". Molecular Nutrition & Food Research. 54 (4): 525–531. doi:10.1002/mnfr.200900237. PMID 20087854.
- ^ Schelling G, Hauer D, Azad SC, Schmoelz M, Chouker A, Schmidt M, et al. (February 2006). "Effects of general anesthesia on anandamide blood levels in humans". Anesthesiology. 104 (2): 273–277. doi:10.1097/00000542-200602000-00012. PMID 16436846. S2CID 27303365.
- ^ Patel S, Wohlfeil ER, Rademacher DJ, Carrier EJ, Perry LJ, Kundu A, et al. (July 2003). "The general anesthetic propofol increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase". British Journal of Pharmacology. 139 (5): 1005–1013. doi:10.1038/sj.bjp.0705334. PMC 1573928. PMID 12839875.
- ^ de Melo Reis RA, Isaac AR, Freitas HR, de Almeida MM, Schuck PF, Ferreira GC, et al. (28 October 2021). "Quality of Life and a Surveillant Endocannabinoid System". Frontiers in Neuroscience. 15: 747229. doi:10.3389/fnins.2021.747229. PMC 8581450. PMID 34776851.
- ^ Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K (February 2008). "GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current". Proceedings of the National Academy of Sciences of the United States of America. 105 (7): 2699–2704. Bibcode:2008PNAS..105.2699L. doi:10.1073/pnas.0711278105. PMC 2268199. PMID 18263732.
- ^ Berk K, Bzdega W, Konstantynowicz-Nowicka K, Charytoniuk T, Zywno H, Chabowski A (January 2021). "Phytocannabinoids-A Green Approach toward Non-Alcoholic Fatty Liver Disease Treatment". Journal of Clinical Medicine. 10 (3): 393. doi:10.3390/jcm10030393. PMC 7864168. PMID 33498537.
- ^ M Taalab Y, Mohammed WF, Helmy MA, Othman AA, Darwish M, Hassan I, Abbas M (November 2019). "Cannabis Influences the Putative Cytokines-Related Pathway of Epilepsy among Egyptian Epileptic Patients". Brain Sciences. 9 (12): 332. doi:10.3390/brainsci9120332. PMC 6955862. PMID 31757102.
- ^ Hampson AJ, Grimaldi M, Axelrod J, Wink D (July 1998). "Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants". Proceedings of the National Academy of Sciences of the United States of America. 95 (14): 8268–8273. Bibcode:1998PNAS...95.8268H. doi:10.1073/pnas.95.14.8268. PMC 20965. PMID 9653176.
- ^ D'Souza DC, Cortes-Briones JA, Ranganathan M, Thurnauer H, Creatura G, Surti T, et al. (January 2016). "Rapid Changes in CB1 Receptor Availability in Cannabis Dependent Males after Abstinence from Cannabis". Biological Psychiatry. Cognitive Neuroscience and Neuroimaging. 1 (1): 60–67. doi:10.1016/j.bpsc.2015.09.008. PMC 4742341. PMID 26858993.
External links
[edit]- N-Acylphosphatidylethanolamines (NAPEs), N-acylethanolamines (NAEs) and Other Acylamides: Metabolism, Occurrence and Functions in Plants; Center for Plant Lipid Research, Department of Biological Sciences, University of North Texas, Denton, TX, USA